{
  "file_name": "백신+위해성+관리+계획+사례집.pdf",
  "total_pages": 80,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "29.457735061645508": 1,
      "23.747718811035156": 1,
      "23.98040008544922": 2,
      "20.02363395690918": 3,
      "17.02608299255371": 3,
      "11.030982971191406": 4092,
      "14.028532981872559": 8,
      "12.94941520690918": 103,
      "11.99020004272461": 66,
      "14.987749099731445": 14,
      "9.951866149902344": 81,
      "15.946965217590332": 34,
      "7.074217319488525": 10
    },
    "heading_sizes": [
      23.98040008544922,
      20.02363395690918,
      17.02608299255371,
      15.946965217590332,
      14.987749099731445,
      14.028532981872559,
      12.94941520690918,
      11.99020004272461
    ]
  },
  "table_analysis": {
    "total_tables": 18,
    "tables_info": [
      {
        "bbox": [
          69.44236755371094,
          183.86337280273438,
          535.5504760742188,
          584.5095825195312
        ],
        "num_rows": 7,
        "num_cols": 2
      },
      {
        "bbox": [
          65.12470245361328,
          509.7953796386719,
          536.7084350585938,
          700.6305541992188
        ],
        "num_rows": 4,
        "num_cols": 3
      },
      {
        "bbox": [
          61.64658737182617,
          107.1553955078125,
          536.9486694335938,
          558.2261962890625
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          61.76652526855469,
          294.1510314941406,
          538.5078125,
          386.69366455078125
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          61.64658737182617,
          184.95037841796875,
          519.4381103515625,
          721.7799682617188
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          61.64658737182617,
          463.16632080078125,
          433.20489501953125,
          585.1967163085938
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          61.64658737182617,
          207.96522521972656,
          533.2306518554688,
          734.19384765625
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          61.64658737182617,
          195.4988555908203,
          527.7139892578125,
          651.3643798828125
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          61.76652526855469,
          200.0538787841797,
          533.2306518554688,
          552.951904296875
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          61.64658737182617,
          227.62374877929688,
          532.9916381835938,
          423.2536926269531
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          63.08580780029297,
          367.5108642578125,
          545.5839233398438,
          676.17724609375
        ],
        "num_rows": 4,
        "num_cols": 2
      },
      {
        "bbox": [
          63.08580780029297,
          144.19491577148438,
          545.5839233398438,
          725.5632934570312
        ],
        "num_rows": 14,
        "num_cols": 4
      },
      {
        "bbox": [
          63.08580780029297,
          215.7567138671875,
          545.5839233398438,
          726.0427856445312
        ],
        "num_rows": 13,
        "num_cols": 5
      },
      {
        "bbox": [
          61.76652526855469,
          485.5818176269531,
          532.9907836914062,
          733.4746704101562
        ],
        "num_rows": 3,
        "num_cols": 4
      },
      {
        "bbox": [
          61.76652526855469,
          143.3558349609375,
          527.47412109375,
          739.7078247070312
        ],
        "num_rows": 6,
        "num_cols": 3
      },
      {
        "bbox": [
          217.5620880126953,
          235.77484130859375,
          532.9925537109375,
          411.38665771484375
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          61.76652526855469,
          170.9257049560547,
          527.2342529296875,
          736.7111206054688
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          85.0339126586914,
          375.5720520019531,
          523.3960571289062,
          674.8737182617188
        ],
        "num_rows": 6,
        "num_cols": 2
      }
    ]
  },
  "text_blocks": [
    {
      "text": "백신 위해성 관리 계획 사례집",
      "font_size": 29.457735061645508,
      "font_name": "H2hdrM",
      "bbox": [
        98.34669494628906,
        227.83831787109375,
        496.072265625,
        253.84988403320312
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-일본, 유럽연합-",
      "font_size": 23.747718811035156,
      "font_name": "H2hdrM",
      "bbox": [
        191.89599609375,
        272.4359130859375,
        402.82989501953125,
        293.4129943847656
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[민원인 안내서]",
      "font_size": 23.98040008544922,
      "font_name": "H2hdrM",
      "bbox": [
        219.12124633789062,
        309.0606689453125,
        383.74420166015625,
        333.0344543457031
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018. 11.",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        252.58309936523438,
        409.43023681640625,
        342.3465881347656,
        429.4483642578125
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오생약심사부 생물제제과",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        157.4746551513672,
        669.5459594726562,
        437.4027099609375,
        689.5640869140625
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침·안내서 제‧개정 점검표",
      "font_size": 17.02608299255371,
      "font_name": "H2hdrM",
      "bbox": [
        186.25904846191406,
        107.41549682617188,
        410.0584716796875,
        124.43689727783203
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.95449829101562,
        140.71051025390625,
        443.4034423828125,
        155.37855529785156
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 위해성관리계획 사례집(민원인 안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        83.95449829101562,
        140.71051025390625,
        443.4034423828125,
        155.37855529785156
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        167.7890625,
        164.924072265625,
        429.0168762207031,
        179.59210205078125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        72.20086669921875,
        310.2052917480469,
        116.2166748046875,
        324.8733215332031
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여부",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.2348861694336,
        327.8260192871094,
        105.30292510986328,
        342.4940490722656
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침·안내서 중 동일·유사한 내용의",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        183.86337280273438,
        395.4665832519531,
        198.53140258789062
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침·안내서가 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        151.238037109375,
        200.285400390625,
        278.0503234863281,
        214.9534454345703
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        184.34283447265625,
        507.804443359375,
        214.47398376464844
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        184.34283447265625,
        507.804443359375,
        214.47398376464844
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        219.82406616210938,
        535.55029296875,
        234.49209594726562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고려하시기 바랍니다. 그럼에도 불구하고 동 지침·안내서의 제정이 필요한",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        236.24612426757812,
        535.5506591796875,
        267.4560546875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        236.24612426757812,
        535.5506591796875,
        267.4560546875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(사유 :                                                                 )",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        269.3299560546875,
        526.6383666992188,
        283.99798583984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        287.310302734375,
        436.1248779296875,
        301.97833251953125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용을 단순 편집 또는 나열한 것입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        151.238037109375,
        303.85223388671875,
        355.40838623046875,
        318.520263671875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        287.9096374511719,
        507.804443359375,
        317.9208984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        287.9096374511719,
        507.804443359375,
        317.9208984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        317.63714599609375,
        507.804443359375,
        347.7682800292969
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        317.63714599609375,
        507.804443359375,
        347.7682800292969
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        317.63714599609375,
        507.804443359375,
        347.7682800292969
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        346.88519287109375,
        443.0807800292969,
        361.55322265625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        362.2284240722656,
        210.643798828125,
        376.8964538574219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        346.88519287109375,
        507.804443359375,
        376.8964538574219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        346.88519287109375,
        507.804443359375,
        376.8964538574219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 번역하거나 설명하는 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        376.01336669921875,
        507.804443359375,
        406.1445007324219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        376.01336669921875,
        507.804443359375,
        406.1445007324219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        376.01336669921875,
        507.804443359375,
        406.1445007324219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        405.26141357421875,
        440.0824279785156,
        419.929443359375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        420.6046447753906,
        252.8642120361328,
        435.2726745605469
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        405.26141357421875,
        507.804443359375,
        435.2726745605469
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        405.26141357421875,
        507.804443359375,
        435.2726745605469
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        436.7869567871094,
        530.2739868164062,
        467.8770446777344
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침·안내서 제·개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        436.7869567871094,
        530.2739868164062,
        467.8770446777344
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침·안내서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        65.48451232910156,
        494.3240661621094,
        126.81218719482422,
        508.9920959472656
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.2348861694336,
        511.9447937011719,
        105.30292510986328,
        526.6128540039062
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        471.6688232421875,
        448.0770263671875,
        486.33685302734375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        487.1319274902344,
        432.84918212890625,
        501.7999572753906
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        471.6688232421875,
        531.1958618164062,
        501.7999572753906
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        471.6688232421875,
        531.1958618164062,
        501.7999572753906
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        504.6327819824219,
        451.9553527832031,
        519.3008422851562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        519.97607421875,
        451.9564514160156,
        549.9873046875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식약처의 입장을 기술하는 것입니까? (민원인용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        519.97607421875,
        451.9564514160156,
        549.9873046875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        512.304443359375,
        535.5504760742188,
        542.3157348632812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        512.304443359375,
        535.5504760742188,
        542.3157348632812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 확인",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        69.44236755371094,
        569.841552734375,
        118.97551727294922,
        584.5095825195312
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.2348861694336,
        587.3424682617188,
        105.30292510986328,
        602.010498046875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        554.2586059570312,
        426.0497131347656,
        568.9266357421875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        569.7216796875,
        337.0552978515625,
        584.3897094726562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        554.2586059570312,
        507.804443359375,
        584.3897094726562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        554.2586059570312,
        507.804443359375,
        584.3897094726562
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        588.6610107421875,
        531.6868286132812,
        603.3290405273438
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서 제·개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        605.2029418945312,
        375.1716613769531,
        619.8709716796875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        216.0029296875,
        627.378662109375,
        381.7624816894531,
        642.0466918945312
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018  년  11  월     일",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        228.47616577148438,
        664.418212890625,
        357.88604736328125,
        679.0862426757812
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "담당자",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        330.4209289550781,
        693.06689453125,
        496.6508483886719,
        721.9993286132812
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        330.4209289550781,
        693.06689453125,
        496.6508483886719,
        721.9993286132812
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백 선 영",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        330.4209289550781,
        693.06689453125,
        496.6508483886719,
        721.9993286132812
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        127.49981689453125,
        511.88232421875,
        146.1537322998047
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고자 작성하였습니다.",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        152.6723175048828,
        225.42906188964844,
        171.32623291015625
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        177.8448028564453,
        516.8158569335938,
        196.49871826171875
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        203.0172882080078,
        516.8158569335938,
        221.67120361328125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "준수하셔야 하는 사항이 아님을 알려드립니다. 또한, 본 안내서는",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        228.18978881835938,
        516.8165283203125,
        246.8437042236328
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        253.36227416992188,
        516.6959228515625,
        272.01617431640625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        278.5347595214844,
        516.8165283203125,
        297.18865966796875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        303.7072448730469,
        398.79949951171875,
        322.36114501953125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.9950180053711,
        354.3872985839844,
        516.4368896484375,
        371.6062927246094
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        106.98201751708984,
        377.76177978515625,
        511.7615051269531,
        394.98077392578125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        106.98201751708984,
        401.13623046875,
        516.4368896484375,
        418.355224609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관한 규정 제2조)",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        106.98201751708984,
        425.3497619628906,
        209.03546142578125,
        442.5687561035156
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        633.874755859375,
        544.1450805664062,
        646.5172119140625
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물제제과로 문의하시기 바랍니다.",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.47313690185547,
        653.0537719726562,
        279.5628662109375,
        665.6962280273438
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화번호 : 043-719-3452",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        672.2328491210938,
        221.7598114013672,
        684.8753051757812
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "팩스번호 : 043-719-3450",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        691.411865234375,
        221.7598114013672,
        704.0543212890625
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목  차",
      "font_size": 23.98040008544922,
      "font_name": "H2hdrM",
      "bbox": [
        260.9785461425781,
        112.35565185546875,
        328.14215087890625,
        136.32945251464844
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 서 론 ································································································   1",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        167.45132446289062,
        525.848876953125,
        187.38072204589844
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 백신별 위해성 관리계획 공개 현황 ··········································   2",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        206.4087371826172,
        525.848876953125,
        226.338134765625
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 일본 ····································································································· 3",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        245.36618041992188,
        525.848876953125,
        265.2955627441406
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.1. 폐렴구균 백신(프리베나13주) ·····················································  3",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        284.3236083984375,
        525.848876953125,
        304.25299072265625
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 유럽연합 ··························································································· 19",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        323.281005859375,
        525.848876953125,
        343.21038818359375
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.1. 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        362.2384338378906,
        525.848876953125,
        382.1678161621094
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.2. 폐렴구균 백신 ··········································································  29",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        401.19586181640625,
        525.848876953125,
        421.125244140625
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.3. 수막구균 백신 ··········································································  38",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        440.1532897949219,
        525.848876953125,
        460.0826721191406
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.4. 수두바이러스 백신 ··································································  46",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        479.1107177734375,
        525.848876953125,
        499.04010009765625
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.5. 일본뇌염 백신 ··········································································  56",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        518.0681762695312,
        525.848876953125,
        537.99755859375
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.6. 로타바이러스 백신 ··································································  59",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        557.0255737304688,
        525.848876953125,
        576.9549560546875
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.7. 홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        595.9829711914062,
        525.848876953125,
        615.912353515625
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.8. 인유두종바이러스 백신 ··························································  67",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.68548583984375,
        634.9404296875,
        525.848876953125,
        654.8698120117188
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제․개정 이력",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        240.7095489501953,
        118.1485824584961,
        354.1680603027344,
        138.1667022705078
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        66.08418273925781,
        182.10043334960938,
        434.6444396972656,
        198.0439453125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정번호",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        66.08418273925781,
        182.10043334960938,
        434.6444396972656,
        198.0439453125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인일자",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        66.08418273925781,
        182.10043334960938,
        434.6444396972656,
        198.0439453125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요내용",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        66.08418273925781,
        182.10043334960938,
        434.6444396972656,
        198.0439453125
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        74.83943939208984,
        219.49957275390625,
        422.65093994140625,
        235.44308471679688
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서-0909-01",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        74.83943939208984,
        219.49957275390625,
        422.65093994140625,
        235.44308471679688
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018.11.",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        74.83943939208984,
        219.49957275390625,
        422.65093994140625,
        235.44308471679688
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제정",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        74.83943939208984,
        219.49957275390625,
        422.65093994140625,
        235.44308471679688
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 1 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 6,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 서론",
      "font_size": 17.02608299255371,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        96.49454498291016,
        121.13434600830078,
        116.92022705078125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        70.52178192138672,
        142.04476928710938,
        544.6248168945312,
        157.56683349609375
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        166.16091918945312,
        544.6253662109375,
        179.8147430419922
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        185.07774353027344,
        544.7453002929688,
        200.61276245117188
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        205.93495178222656,
        544.6248168945312,
        221.469970703125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출 대상이 확대되었다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        226.6722869873047,
        202.66424560546875,
        242.19435119628906
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        270.08734130859375,
        544.7453002929688,
        283.74114990234375
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        289.004150390625,
        544.6248168945312,
        304.5262451171875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        309.7414855957031,
        544.6248168945312,
        325.2635803222656
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        330.59869384765625,
        544.6248168945312,
        346.12078857421875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        351.3360290527344,
        416.98809814453125,
        366.8581237792969
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        392.9305725097656,
        544.745849609375,
        408.4526672363281
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        413.66790771484375,
        544.6259155273438,
        429.20294189453125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다. 일부 백신에",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        434.4052429199219,
        544.6253662109375,
        449.9273376464844
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있어서 유효성(efficacy)",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        456.2214050292969,
        544.745849609375,
        470.7367858886719
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 수행할 수 없거나 장기적인 면역원성이",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        456.2214050292969,
        544.745849609375,
        470.7367858886719
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        476.958740234375,
        544.745849609375,
        491.47412109375
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출하고 그 수행한 결과를 보고하도록 하고 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        496.73712158203125,
        358.5797424316406,
        512.2592163085938
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        538.3316650390625,
        544.6253662109375,
        553.853759765625
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        560.8895263671875,
        544.6253662109375,
        574.5433959960938
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        579.9262084960938,
        544.6248168945312,
        595.4483032226562
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        602.4840698242188,
        544.6253662109375,
        616.137939453125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마련하게 되었다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        621.40087890625,
        157.20887756347656,
        636.9229736328125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 7,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 국가별 위해성 관리 계획 공개 현황",
      "font_size": 17.02608299255371,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        96.49454498291016,
        367.36163330078125,
        116.92022705078125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 일본",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        56.609317779541016,
        151.973876953125,
        117.81065368652344,
        167.9164581298828
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본의 경우,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        68.24301147460938,
        179.92337036132812,
        544.6234130859375,
        195.4454345703125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        68.24301147460938,
        179.92337036132812,
        544.6234130859375,
        195.4454345703125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        203.29783630371094,
        538.1224365234375,
        218.8199005126953
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        226.6722869873047,
        538.1224365234375,
        242.19435119628906
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        250.04673767089844,
        538.2423706054688,
        265.5688171386719
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        273.4211730957031,
        544.6253662109375,
        288.9432678222656
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        273.4211730957031,
        544.6253662109375,
        288.9432678222656
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성을",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        273.4211730957031,
        544.6253662109375,
        288.9432678222656
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        296.7956237792969,
        544.745849609375,
        312.3177185058594
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        320.17010498046875,
        494.9458312988281,
        335.69219970703125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<프리베나13주>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        56.609317779541016,
        430.5494384765625,
        185.704345703125,
        446.4920349121094
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 품목개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        459.34552001953125,
        122.57357025146484,
        471.9879455566406
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인연월일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        490.0169982910156,
        429.2473449707031,
        501.6480407714844
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2013년 6월 18일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        490.0169982910156,
        429.2473449707031,
        501.6480407714844
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약효분류",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        490.0169982910156,
        429.2473449707031,
        501.6480407714844
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "876311",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        490.0169982910156,
        429.2473449707031,
        501.6480407714844
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재심사기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        539.7625732421875,
        116.69641876220703,
        551.3936157226562
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아: 8년",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        518.3060302734375,
        279.32861328125,
        572.8501586914062
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고연령층: 1차 승인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        518.3060302734375,
        279.32861328125,
        572.8501586914062
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 관계된 재심사기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        518.3060302734375,
        279.32861328125,
        572.8501586914062
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간의 잔여기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        518.3060302734375,
        279.32861328125,
        572.8501586914062
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        289.5230712890625,
        539.7625732421875,
        491.61273193359375,
        551.3936157226562
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "22500AMX00917000",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        289.5230712890625,
        539.7625732421875,
        491.61273193359375,
        551.3936157226562
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국제발매일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        589.5082397460938,
        256.4210205078125,
        601.1392822265625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2009년 7월 10일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        589.5082397460938,
        256.4210205078125,
        601.1392822265625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판매명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        623.43115234375,
        292.4012145996094,
        635.0621948242188
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프리베나13®수성현탁주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        623.43115234375,
        292.4012145996094,
        635.0621948242188
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성분",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        657.4739379882812,
        400.1031494140625,
        669.10498046875
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐렴구균협막 폴리사카라이드-CRM197결합체",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        657.4739379882812,
        400.1031494140625,
        669.10498046875
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함량 및 제형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        704.8222045898438,
        127.61050415039062,
        716.4532470703125
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1 시린지   중에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        683.3656616210938,
        540.5467529296875,
        737.9097900390625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        683.3656616210938,
        540.5467529296875,
        737.9097900390625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 2.2µg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        683.3656616210938,
        540.5467529296875,
        737.9097900390625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폴리사카라이드혈청형6B: 4.4µg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        683.3656616210938,
        540.5467529296875,
        737.9097900390625
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐렴구균 백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        103.86370849609375,
        377.3276062011719,
        215.7630615234375,
        393.27020263671875
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 3 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CRM197:약 34µg(단백질량으로)을 함유하는 주사제.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        117.58399963378906,
        429.9425964355469,
        129.2150421142578
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용법 및 용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        193.10147094726562,
        127.61050415039062,
        204.73251342773438
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 고연령층",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        143.1160888671875,
        343.2295837402344,
        169.0115509033203
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1회 0.5mL를 근육 내에 주사한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        143.1160888671875,
        343.2295837402344,
        169.0115509033203
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 소아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        186.02920532226562,
        535.0297241210938,
        254.83775329589844
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        186.02920532226562,
        535.0297241210938,
        254.83775329589844
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피하에   주사한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        186.02920532226562,
        535.0297241210938,
        254.83775329589844
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다. 단, 3차 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        186.02920532226562,
        535.0297241210938,
        254.83775329589844
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부터 60일 이상의 간격을   둔다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        186.02920532226562,
        535.0297241210938,
        254.83775329589844
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능 또는 효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        289.47613525390625,
        138.64486694335938,
        301.107177734375
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 고연령층",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        275.21173095703125,
        534.9100952148438,
        315.3716125488281
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        275.21173095703125,
        534.9100952148438,
        315.3716125488281
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "23F)에 의한 감염증의   예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        275.21173095703125,
        534.9100952148438,
        315.3716125488281
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 소아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        329.87200927734375,
        534.9100952148438,
        384.4161376953125
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        329.87200927734375,
        534.9100952148438,
        384.4161376953125
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "23F)에 의한 침습성   감염증의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        329.87200927734375,
        534.9100952148438,
        384.4161376953125
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인조건",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        399.5158996582031,
        195.85385131835938,
        411.1469421386719
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        399.5158996582031,
        195.85385131835938,
        411.1469421386719
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        445.06610107421875,
        83.71463012695312,
        456.6971435546875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        430.68182373046875,
        535.0291748046875,
        470.9615783691406
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        430.68182373046875,
        535.0291748046875,
        470.9615783691406
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "능·효과로 승인사항 일부변경 승인을 취득.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.7858123779297,
        430.68182373046875,
        535.0291748046875,
        470.9615783691406
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변경 내역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        502.1237487792969,
        111.17974090576172,
        513.7547607421875
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전회 제출일:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        552.1090698242188,
        144.28179931640625,
        578.1244506835938
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2015년 9월 20일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        552.1090698242188,
        144.28179931640625,
        578.1244506835938
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경내용의 개요:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        604.6116943359375,
        534.9097900390625,
        673.5401611328125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        604.6116943359375,
        534.9097900390625,
        673.5401611328125
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관해서 실시상황을 갱신했다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        604.6116943359375,
        534.9097900390625,
        673.5401611328125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        604.6116943359375,
        534.9097900390625,
        673.5401611328125
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        604.6116943359375,
        534.9097900390625,
        673.5401611328125
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        687.680908203125,
        460.6459655761719,
        727.960693359375
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        687.680908203125,
        460.6459655761719,
        727.960693359375
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        687.680908203125,
        460.6459655761719,
        727.960693359375
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 4 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 의약품 위해성 관리계획의 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        99.03427124023438,
        249.9445343017578,
        112.68810272216797
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 안전성 검토사항",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        119.75662231445312,
        170.5475616455078,
        132.3990478515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 특정 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        143.3558349609375,
        160.59262084960938,
        154.98687744140625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쇼크, 아나필락시스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        163.13421630859375,
        158.07363891601562,
        174.7652587890625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 특정 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        181.35430908203125,
        530.7123413085938,
        235.89845275878906
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        181.35430908203125,
        530.7123413085938,
        235.89845275878906
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        181.35430908203125,
        530.7123413085938,
        235.89845275878906
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        181.35430908203125,
        530.7123413085938,
        235.89845275878906
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        241.76828002929688,
        530.5924072265625,
        324.96112060546875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        241.76828002929688,
        530.5924072265625,
        324.96112060546875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 일반   의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        241.76828002929688,
        530.5924072265625,
        324.96112060546875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        241.76828002929688,
        530.5924072265625,
        324.96112060546875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        241.76828002929688,
        530.5924072265625,
        324.96112060546875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        241.76828002929688,
        530.5924072265625,
        324.96112060546875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        332.2693786621094,
        536.2293701171875,
        429.72662353515625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        332.2693786621094,
        536.2293701171875,
        429.72662353515625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        332.2693786621094,
        536.2293701171875,
        429.72662353515625
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        332.2693786621094,
        536.2293701171875,
        429.72662353515625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        332.2693786621094,
        536.2293701171875,
        429.72662353515625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        332.2693786621094,
        536.2293701171875,
        429.72662353515625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이해를 촉구하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        332.2693786621094,
        536.2293701171875,
        429.72662353515625
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주사부위   국소반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        437.6342468261719,
        166.10964965820312,
        449.2652893066406
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 특정 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "39.0%~46.5%였다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다. 피",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은 경향이었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요한 특정 위해성으로는 설정하지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        467.36175537109375,
        547.1431274414062,
        664.9096069335938
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        682.6464233398438,
        379.449951171875,
        737.1906127929688
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        682.6464233398438,
        379.449951171875,
        737.1906127929688
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        682.6464233398438,
        379.449951171875,
        737.1906127929688
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        682.6464233398438,
        379.449951171875,
        737.1906127929688
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 5 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용성적조사(소아)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        107.03553009033203,
        530.7123413085938,
        161.5796661376953
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        107.03553009033203,
        530.7123413085938,
        161.5796661376953
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        107.03553009033203,
        530.7123413085938,
        161.5796661376953
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "황을 집계, 검토하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        107.03553009033203,
        530.7123413085938,
        161.5796661376953
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화(완화) 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        177.3986358642578,
        530.7123413085938,
        260.5914611816406
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        177.3986358642578,
        530.7123413085938,
        260.5914611816406
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        177.3986358642578,
        530.7123413085938,
        260.5914611816406
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        177.3986358642578,
        530.7123413085938,
        260.5914611816406
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        177.3986358642578,
        530.7123413085938,
        260.5914611816406
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        177.3986358642578,
        530.7123413085938,
        260.5914611816406
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과민증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        275.57135009765625,
        94.74864959716797,
        287.202392578125
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 특정 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        298.586181640625,
        536.1098022460938,
        353.1303405761719
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        298.586181640625,
        536.1098022460938,
        353.1303405761719
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        298.586181640625,
        536.1098022460938,
        353.1303405761719
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 외 국가에서 시판 후의 자발보고가 있기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        298.586181640625,
        536.1098022460938,
        353.1303405761719
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 최소화(완화) 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        359.0001525878906,
        530.7123413085938,
        527.4198608398438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        537.485107421875,
        83.71463012695312,
        549.1161499023438
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 특정 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.4178466796875,
        530.7119750976562,
        645.6106567382812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.4178466796875,
        530.7119750976562,
        645.6106567382812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.4178466796875,
        530.7119750976562,
        645.6106567382812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내외에서 시판 후 자발보고가 있었기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.4178466796875,
        530.7119750976562,
        645.6106567382812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.4178466796875,
        530.7119750976562,
        645.6106567382812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.4178466796875,
        530.7119750976562,
        645.6106567382812
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        653.8778686523438,
        379.449951171875,
        737.0707397460938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        653.8778686523438,
        379.449951171875,
        737.0707397460938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        653.8778686523438,
        379.449951171875,
        737.0707397460938
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        653.8778686523438,
        379.449951171875,
        737.0707397460938
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        653.8778686523438,
        379.449951171875,
        737.0707397460938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        653.8778686523438,
        379.449951171875,
        737.0707397460938
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로 설정하고 발현상황을 집계, 검토하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 이해를 촉진한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2293701171875,
        226.7884063720703
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무호흡",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        236.97352600097656,
        94.74864959716797,
        248.6045684814453
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 특정 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        272.5746154785156,
        530.7123413085938,
        355.7674560546875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        272.5746154785156,
        530.7123413085938,
        355.7674560546875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        272.5746154785156,
        530.7123413085938,
        355.7674560546875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        272.5746154785156,
        530.7123413085938,
        355.7674560546875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        272.5746154785156,
        530.7123413085938,
        355.7674560546875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        272.5746154785156,
        530.7123413085938,
        355.7674560546875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        536.109130859375,
        461.6117858886719
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        536.109130859375,
        461.6117858886719
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        536.109130859375,
        461.6117858886719
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        536.109130859375,
        461.6117858886719
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        536.109130859375,
        461.6117858886719
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사의 증례도 포함해 폭넓게 수집하기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        536.109130859375,
        461.6117858886719
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        477.3108825683594,
        536.2290649414062,
        560.503662109375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        477.3108825683594,
        536.2290649414062,
        560.503662109375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        477.3108825683594,
        536.2290649414062,
        560.503662109375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        477.3108825683594,
        536.2290649414062,
        560.503662109375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        477.3108825683594,
        536.2290649414062,
        560.503662109375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        477.3108825683594,
        536.2290649414062,
        560.503662109375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        578.0007934570312,
        171.62664794921875,
        589.6318359375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른  폐렴구균백신과의 접종과오",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        607.6084594726562,
        232.07388305664062,
        619.239501953125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        638.414794921875,
        465.56329345703125,
        678.6945190429688
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        638.414794921875,
        465.56329345703125,
        678.6945190429688
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        638.414794921875,
        465.56329345703125,
        678.6945190429688
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        694.8731079101562,
        335.9135437011719,
        735.15283203125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        694.8731079101562,
        335.9135437011719,
        735.15283203125
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        694.8731079101562,
        335.9135437011719,
        735.15283203125
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        429.3429260253906,
        126.33818054199219
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        429.3429260253906,
        126.33818054199219
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        140.11936950683594,
        530.7123413085938,
        237.5766143798828
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        140.11936950683594,
        530.7123413085938,
        237.5766143798828
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 위해성 최소화 활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        140.11936950683594,
        530.7123413085938,
        237.5766143798828
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴모박스®NP와의 접종과오 방지의 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        140.11936950683594,
        530.7123413085938,
        237.5766143798828
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        140.11936950683594,
        530.7123413085938,
        237.5766143798828
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        140.11936950683594,
        530.7123413085938,
        237.5766143798828
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        140.11936950683594,
        530.7123413085938,
        237.5766143798828
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종대상 및 접종경로 선택에 관한 과오",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        259.2691650390625,
        265.05633544921875,
        270.90020751953125
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        291.87353515625,
        530.7123413085938,
        360.80194091796875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        291.87353515625,
        530.7123413085938,
        360.80194091796875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        291.87353515625,
        530.7123413085938,
        360.80194091796875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로: 근육 내(고연령층), 피하(소아)). 또, 고연령층(65세 이상의 성인) 및 소아를 대상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        291.87353515625,
        530.7123413085938,
        360.80194091796875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        291.87353515625,
        530.7123413085938,
        360.80194091796875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        467.72210693359375,
        447.4672546386719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        467.72210693359375,
        447.4672546386719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        467.72210693359375,
        447.4672546386719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        467.72210693359375,
        447.4672546386719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        378.538818359375,
        467.72210693359375,
        447.4672546386719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받는 사람을 위한 가이드에 기재하고 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 위해성 최소화 활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종대상 및 접종경로 선택에 관한 과오방지의 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하고, 적정 사용에 관한 이해를 촉진한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        454.2960205078125,
        536.109130859375,
        609.0505981445312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판감소성  자반병",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        621.8728637695312,
        171.62664794921875,
        633.50390625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        651.600341796875,
        536.109130859375,
        734.793212890625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        651.600341796875,
        536.109130859375,
        734.793212890625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        651.600341796875,
        536.109130859375,
        734.793212890625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시판 후의 자발보고가 있기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        651.600341796875,
        536.109130859375,
        734.793212890625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        651.600341796875,
        536.109130859375,
        734.793212890625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        651.600341796875,
        536.109130859375,
        734.793212890625
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 8 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        102.8401107788086,
        160.0888671875,
        114.47114562988281
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보를 폭넓게 수집하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        130.52984619140625,
        530.7123413085938,
        242.3713836669922
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        256.0326843261719,
        536.2293701171875,
        353.48992919921875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        256.0326843261719,
        536.2293701171875,
        353.48992919921875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        256.0326843261719,
        536.2293701171875,
        353.48992919921875
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        256.0326843261719,
        536.2293701171875,
        353.48992919921875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        256.0326843261719,
        536.2293701171875,
        353.48992919921875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        256.0326843261719,
        536.2293701171875,
        353.48992919921875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이해를 촉진한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        256.0326843261719,
        536.2293701171875,
        353.48992919921875
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "돌연사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        364.9936218261719,
        94.74864959716797,
        376.6246643066406
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토회’가 개최되었다. 본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다. 13vPnC의 일본",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        393.7621765136719,
        536.2290649414062,
        605.5744018554688
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보를 폭넓게 수집하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        613.4820556640625,
        530.7123413085938,
        739.4680786132812
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        774.4439697265625,
        311.57611083984375,
        784.3931274414062
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        169.25128173828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        169.25128173828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        169.25128173828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        169.25128173828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        169.25128173828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "천식",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        178.59732055664062,
        83.71463012695312,
        190.22836303710938
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        211.20169067382812,
        530.7119750976562,
        294.39453125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        211.20169067382812,
        530.7119750976562,
        294.39453125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        211.20169067382812,
        530.7119750976562,
        294.39453125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가에서 시판 후 자발보고가 있었기 때문.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        211.20169067382812,
        530.7119750976562,
        294.39453125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        211.20169067382812,
        530.7119750976562,
        294.39453125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        211.20169067382812,
        530.7119750976562,
        294.39453125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 포함한 충분한 정보수집에 노력하여 감시를 강화한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        308.05584716796875,
        530.7123413085938,
        419.8973693847656
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        430.92156982421875,
        536.2290649414062,
        514.1143798828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        430.92156982421875,
        536.2290649414062,
        514.1143798828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        430.92156982421875,
        536.2290649414062,
        514.1143798828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        430.92156982421875,
        536.2290649414062,
        514.1143798828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        430.92156982421875,
        536.2290649414062,
        514.1143798828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        430.92156982421875,
        536.2290649414062,
        514.1143798828125
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부적절한   접종 스케줄의 사용(접종간격간 차이)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        533.0499267578125,
        310.3617858886719,
        544.6809692382812
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성으로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.0582275390625,
        536.2290649414062,
        659.5154418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로   지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.0582275390625,
        536.2290649414062,
        659.5154418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.0582275390625,
        536.2290649414062,
        659.5154418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1명 보고되었다. 현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.0582275390625,
        536.2290649414062,
        659.5154418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "줄의 사용(접종간격간 차이)이 보고되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.0582275390625,
        536.2290649414062,
        659.5154418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.0582275390625,
        536.2290649414062,
        659.5154418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성으로는 설정하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        562.0582275390625,
        536.2290649414062,
        659.5154418945312
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        670.1800537109375,
        379.449951171875,
        738.9886474609375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        670.1800537109375,
        379.449951171875,
        738.9886474609375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        670.1800537109375,
        379.449951171875,
        738.9886474609375
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        670.1800537109375,
        379.449951171875,
        738.9886474609375
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        670.1800537109375,
        379.449951171875,
        738.9886474609375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 10 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재해   주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이해를 촉진한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        101.04207611083984,
        536.2290649414062,
        256.03643798828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        266.3414306640625,
        144.16152954101562,
        277.97247314453125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역억제상태인 사람에 대한 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        295.9490661621094,
        243.10824584960938,
        307.5801086425781
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족정보로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        321.8407897949219,
        547.1427612304688,
        419.29803466796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        321.8407897949219,
        547.1427612304688,
        419.29803466796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        321.8407897949219,
        547.1427612304688,
        419.29803466796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없기 때문에 부족정보로 설정했다. 또한, 일본 외 국가에서 18세 이상의 HIV 감염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        321.8407897949219,
        547.1427612304688,
        419.29803466796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        321.8407897949219,
        547.1427612304688,
        419.29803466796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        321.8407897949219,
        547.1427612304688,
        419.29803466796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험(6115A1-3003)이 완료되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        321.8407897949219,
        547.1427612304688,
        419.29803466796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아 및 고연령층(65세이상의 성인))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상약물반응 발현상황에 관해서 기술하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        425.7672119140625,
        536.2290649414062,
        551.8731079101562
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        568.1715698242188,
        547.1427612304688,
        665.6287841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        568.1715698242188,
        547.1427612304688,
        665.6287841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        568.1715698242188,
        547.1427612304688,
        665.6287841796875
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        568.1715698242188,
        547.1427612304688,
        665.6287841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        568.1715698242188,
        547.1427612304688,
        665.6287841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        568.1715698242188,
        547.1427612304688,
        665.6287841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 이해를 촉진하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        568.1715698242188,
        547.1427612304688,
        665.6287841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 백신과의 동시접종 시의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        687.680908203125,
        248.50497436523438,
        699.3119506835938
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족정보로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        710.69580078125,
        428.2876892089844,
        736.5912475585938
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        710.69580078125,
        428.2876892089844,
        736.5912475585938
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 11 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다. 소아에 대해서는 DPT 이외",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보로 설정했다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용성적조사(소아 및 고연령층(65세 이상의 성인))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 이해를 촉진하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.109130859375,
        397.12225341796875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임신 37주 미만에 출생한 조산아의 접종에 대한 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        406.8279113769531,
        341.9343566894531,
        418.4589538574219
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족정보로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        443.867431640625,
        536.109130859375,
        527.0602416992188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 소아>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        443.867431640625,
        536.109130859375,
        527.0602416992188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        443.867431640625,
        536.109130859375,
        527.0602416992188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        443.867431640625,
        536.109130859375,
        527.0602416992188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "했다. 또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        443.867431640625,
        536.109130859375,
        527.0602416992188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조산아의 접종이므로 고연령층은 대상이 되지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        443.867431640625,
        536.109130859375,
        527.0602416992188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        551.869384765625,
        530.7123413085938,
        677.9752807617188
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        693.4346313476562,
        396.36077880859375,
        733.71435546875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        693.4346313476562,
        396.36077880859375,
        733.71435546875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        693.4346313476562,
        396.36077880859375,
        733.71435546875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        140.60260009765625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        140.60260009765625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        140.60260009765625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        150.4281005859375,
        407.17901611328125,
        162.05914306640625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족 정보로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 예상되므로, 부족정보로 설정했다. 일본 외 국가는 13vPnC의 1차 접종(접종 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(고연령층(65세 이상의 성인))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현시점에서 위해성 최소화 활동은 실시하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        171.76478576660156,
        536.2290649414062,
        525.7416381835938
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        538.2042846679688,
        536.109130859375,
        564.0997314453125
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13vPnC를 접종했을 때의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        538.2042846679688,
        536.109130859375,
        564.0997314453125
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족정보로 지정한 이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물반응의 보고는 없다. 또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        576.5623779296875,
        547.1431274414062,
        731.3170166015625
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 13 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 유효성에 관련된 검토사항: 해당 사항 없음",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        346.0693054199219,
        311.7110595703125,
        358.71173095703125
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 의약품 안전성 감시계획의 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        382.86907958984375,
        248.50531005859375,
        395.5115051269531
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 추가 의약품 안전성 감시활동으로 다음을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용성적 조사(고연령층(65세 이상의 성인))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술하기 위해.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용 및 선택이유:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【내용】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현시점에서 위해성 최소화 활동은 실시하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【선택이유】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        107.58169555664062,
        100.44273376464844,
        536.2290649414062,
        326.0399475097656
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 의약품 안전성  감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        414.259765625,
        237.59088134765625,
        425.89080810546875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 의약품 안전성 감시활동의 개요:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        437.5143737792969,
        535.7493286132812,
        477.7940979003906
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        437.5143737792969,
        535.7493286132812,
        477.7940979003906
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전대책의 검토",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        437.5143737792969,
        535.7493286132812,
        477.7940979003906
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        489.4176330566406,
        210.12579345703125,
        501.0486755371094
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용  성적 조사(소아)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        509.1960144042969,
        172.91629028320312,
        520.8270263671875
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【안전성 검토사항】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출생된 조산아에게 접종 했을 때의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【목적】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 사항을 파악하는 것을 목적으로 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 사용실태의 파악",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 이상반응의 발현상황의 파악",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        525.9776611328125,
        535.7493286132812,
        666.3480224609375
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【실시계획】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        683.3656616210938,
        334.5886535644531,
        737.9097900390625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사기간: 2014년 3월~2016년 6월(2년 4개월)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        683.3656616210938,
        334.5886535644531,
        737.9097900390625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록기간: 2014년 3월~2015년 2월(1년)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        683.3656616210938,
        334.5886535644531,
        737.9097900390625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사대상:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        683.3656616210938,
        334.5886535644531,
        737.9097900390625
      ],
      "page_num": 18,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 14 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예정증례수: 1000명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시방법: 연속조사방식",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관찰기간:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 평가기간으로 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28일차까지. 도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "까지).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중점조사항목:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주사부위 국소반응, 발열, 경련 및 열성경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【실시계획의 근거】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예정(목표) 증례수의 설정근거:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "례 수를 산출하면, 600례가 필요하다. 또, 미국에서 실시된 주요 시험인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다. 0.3% 발",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산출하면, 1000례가 필요하다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상으로 등록예정 증례수를 1000례로 설정했다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        100.44273376464844,
        546.6630249023438,
        455.37860107421875
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "*일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        472.2763671875,
        530.2326049804688,
        555.4691772460938
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        472.2763671875,
        530.2326049804688,
        555.4691772460938
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        472.2763671875,
        530.2326049804688,
        555.4691772460938
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        472.2763671875,
        530.2326049804688,
        555.4691772460938
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(0.52%)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        472.2763671875,
        530.2326049804688,
        555.4691772460938
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6096A1-3024 시험: 주사부위 경결 1건(0.55%)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        472.2763671875,
        530.2326049804688,
        555.4691772460938
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "【전환점이 되는 예정 시기   및 근거】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치 및 시작의 결정기준】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관해 검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        110.22026062011719,
        572.48681640625,
        535.7496337890625,
        727.12158203125
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 15 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용성적조사(고연령층(65세 이상의 성인))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        103.439453125,
        273.421630859375,
        115.07048797607422
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【안전성 검토사항】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13vPnC를 접종했을 때의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【목적】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 사용실태의 파악",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 이상반응의 발현상황 파악",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사기간: 2015년 4월~2016년 10월(1년 7개월)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록기간: 2015년 4월~2016년 9월(1년 6개월)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사대상: 고연령층(65세 이상의 성인)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예정증례수: 600례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시방법: 연속조사방식",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관찰기간: 본 제제 접종 후 28일차까지로 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사항목:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        120.22111511230469,
        541.1460571289062,
        374.5868835449219
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【실시계획의 근거】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예정증례수의 설정근거:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다. 또, 두 시험에서 본 제제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        565.054931640625,
        535.7496337890625,
        733.9541015625
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Table.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        382.4945068359375,
        509.12371826171875,
        394.12554931640625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        382.4945068359375,
        509.12371826171875,
        394.12554931640625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조사목적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        396.2794189453125,
        316.8679504394531,
        407.91046142578125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 조사항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        396.2794189453125,
        316.8679504394531,
        407.91046142578125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용실태의 파악",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        452.97747802734375,
        202.69015502929688,
        464.6085205078125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종대상자 배경(성별, 연령, 병력 등)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        410.0643615722656,
        515.0009155273438,
        507.5216064453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 제제 접종 이전의 폐렴구균백신 접종이력, 기타",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        410.0643615722656,
        515.0009155273438,
        507.5216064453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 백신 접종이력",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        410.0643615722656,
        515.0009155273438,
        507.5216064453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 제제의 접종기록(접종량, 접종부위, 접종경로, 로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        410.0643615722656,
        515.0009155273438,
        507.5216064453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트 번호)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        410.0643615722656,
        515.0009155273438,
        507.5216064453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동시 접종백신(동시 접종백신명, 접종부위), 본 제제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        410.0643615722656,
        515.0009155273438,
        507.5216064453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종 후의 다른     백신 접종상황",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        410.0643615722656,
        515.0009155273438,
        507.5216064453125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        516.8676147460938,
        240.5889434814453,
        528.4986572265625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발현상황의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        516.8676147460938,
        240.5889434814453,
        528.4986572265625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파악",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        120.17486572265625,
        531.1320190429688,
        142.242919921875,
        542.7630615234375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국소반응 및 전신반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        509.6755065917969,
        355.2471618652344,
        549.9552001953125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그 밖의 이상반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        509.6755065917969,
        355.2471618652344,
        549.9552001953125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중점조사항목: 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.3870086669922,
        509.6755065917969,
        355.2471618652344,
        549.9552001953125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 16 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        375.1974792480469,
        368.8001403808594,
        387.83990478515625
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 위해성 최소화 계획의 개요",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        413.5555419921875,
        212.04507446289062,
        426.1979675292969
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        100.44273376464844,
        535.7493286132812,
        183.5157012939453
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        100.44273376464844,
        535.7493286132812,
        183.5157012939453
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        100.44273376464844,
        535.7493286132812,
        183.5157012939453
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        100.44273376464844,
        535.7493286132812,
        183.5157012939453
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        100.44273376464844,
        535.7493286132812,
        183.5157012939453
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로 본 조사의 예정증례수 600례를 설정했다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        100.44273376464844,
        535.7493286132812,
        183.5157012939453
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【전환점이 되는 예정 시기   및 근거】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 시작의 결정기준】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관해 검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(조사의 계속·추가조사의 실시 등)에 관해 검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.50390625,
        200.53334045410156,
        535.7496337890625,
        355.1681213378906
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 위해성 최소화 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.88483428955078,
        438.5931701660156,
        213.24407958984375,
        450.2242126464844
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 위해성 최소화 활동의 개요:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.88483428955078,
        455.4947204589844,
        405.6198425292969,
        481.3901672363281
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.88483428955078,
        455.4947204589844,
        405.6198425292969,
        481.3901672363281
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가의 위해성 최소화 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.88483428955078,
        486.540771484375,
        202.33035278320312,
        498.17181396484375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뉴모박스®NP와의 접종과오 방지의 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.88483428955078,
        506.4390563964844,
        268.77435302734375,
        518.070068359375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【안전성 검토사항】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 폐렴구균백신과의 접종과오",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【목적】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【구체적인 방법】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "를 직접 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포장 차이 등이 명확하도록 정보를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조치】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        525.6180419921875,
        538.6281127929688,
        737.5501708984375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 17 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        397.2683410644531,
        537.308837890625,
        410.9221496582031
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 의약품 안전성 감시계획의 목록",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        418.1105651855469,
        242.50856018066406,
        430.75299072265625
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 유효성에 관련된 조사・시험 계획의 일람",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        721.8585815429688,
        302.47607421875,
        734.5010375976562
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        440.9905700683594,
        235.552001953125,
        452.6216125488281
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        457.89208984375,
        536.7088012695312,
        483.78753662109375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전대책의 검토",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        457.89208984375,
        536.7088012695312,
        483.78753662109375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가 의약품 안전성 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        488.93817138671875,
        213.48394775390625,
        500.5692138671875
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가 의약품 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        509.7953796386719,
        171.266845703125,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감시활동의 명칭",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        509.7953796386719,
        171.266845703125,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전환점이 되는 증례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        509.7953796386719,
        276.6900634765625,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수/목표증례수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        509.7953796386719,
        276.6900634765625,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전환점이 되는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        509.7953796386719,
        512.2420043945312,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예정 시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        509.7953796386719,
        512.2420043945312,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시상황",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        509.7953796386719,
        512.2420043945312,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        509.7953796386719,
        512.2420043945312,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성예정일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        509.7953796386719,
        512.2420043945312,
        535.6907958984375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 직후 조사(소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 사항 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "판매시작부터 2, 4,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6개월 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성완료(2014",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년 6월 제출)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        542.7593383789062,
        531.1913452148438,
        568.774658203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용 성적 조사(소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        580.158447265625,
        165.8701171875,
        606.0538940429688
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        580.158447265625,
        165.8701171875,
        606.0538940429688
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기보고에 수집된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        572.96630859375,
        282.20672607421875,
        613.2460327148438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증례수/최종목표증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        572.96630859375,
        282.20672607421875,
        613.2460327148438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "례수: 1000례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        572.96630859375,
        282.20672607421875,
        613.2460327148438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 정기보고의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        580.158447265625,
        436.2035827636719,
        606.0538940429688
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        580.158447265625,
        436.2035827636719,
        606.0538940429688
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시 중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        580.158447265625,
        436.2035827636719,
        606.0538940429688
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 정기보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        457.19219970703125,
        572.96630859375,
        536.7084350585938,
        613.2460327148438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고로 보고서를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        457.19219970703125,
        572.96630859375,
        536.7084350585938,
        613.2460327148438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성한다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        457.19219970703125,
        572.96630859375,
        536.7084350585938,
        613.2460327148438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 직후 조사(고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        616.5986328125,
        171.266845703125,
        656.8783569335938
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연령층(65세 이상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        616.5986328125,
        171.266845703125,
        656.8783569335938
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        616.5986328125,
        171.266845703125,
        656.8783569335938
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 사항 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        623.790771484375,
        531.1913452148438,
        649.6862182617188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인부터 2, 4, 6개",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        623.790771484375,
        531.1913452148438,
        649.6862182617188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "월 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        623.790771484375,
        531.1913452148438,
        649.6862182617188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        623.790771484375,
        531.1913452148438,
        649.6862182617188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성완료(2015",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        623.790771484375,
        531.1913452148438,
        649.6862182617188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년 2월 제출)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        623.790771484375,
        531.1913452148438,
        649.6862182617188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용 성적 조사(고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        660.350830078125,
        171.266845703125,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연령층(65세 이상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        660.350830078125,
        171.266845703125,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        65.12470245361328,
        660.350830078125,
        171.266845703125,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기보고에 수집된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        660.350830078125,
        282.20672607421875,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증례수/최종목표증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        660.350830078125,
        282.20672607421875,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "례수: 600례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.94464111328125,
        660.350830078125,
        282.20672607421875,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 정기보고의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        667.54296875,
        436.2035827636719,
        693.4384155273438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        667.54296875,
        436.2035827636719,
        693.4384155273438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시 중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        286.884521484375,
        667.54296875,
        436.2035827636719,
        693.4384155273438
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 정기보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        457.19219970703125,
        660.350830078125,
        536.7084350585938,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고로 보고서를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        457.19219970703125,
        660.350830078125,
        536.7084350585938,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성한다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        457.19219970703125,
        660.350830078125,
        536.7084350585938,
        700.6305541992188
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성 등)를 검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        100.44273376464844,
        351.52947998046875,
        126.33818054199219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가, 보고의 예정시기: 안전성 정기보고 제출 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        100.44273376464844,
        351.52947998046875,
        126.33818054199219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종대상 및 접종경로 선택에 관한 과오방지의 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        64.88483428955078,
        131.48880004882812,
        328.62158203125,
        143.11984252929688
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【안전성 검토사항】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종대상 및 접종경로 선택에 관한 과오",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【목적】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【구체적인 방법】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "를 직접 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은 자재를 작성하고 정보를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조치】",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재작성 등)를 검토한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가, 보고의 예정시기: 안전성 정기보고 제출 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        103.86370849609375,
        148.3903350830078,
        538.6281127929688,
        374.5868835449219
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 18 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 위해성 최소화 계획의 일람",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        176.69439697265625,
        224.518310546875,
        189.33682250976562
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성에 관련된 조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        107.1553955078125,
        162.39199829101562,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사·시험의 명칭",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        107.1553955078125,
        162.39199829101562,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전환점이 되는 증례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        172.58645629882812,
        107.1553955078125,
        273.21160888671875,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수/목표증례수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        172.58645629882812,
        107.1553955078125,
        273.21160888671875,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전환점이 되는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        283.4064025878906,
        107.1553955078125,
        508.88385009765625,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예정 시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        283.4064025878906,
        107.1553955078125,
        508.88385009765625,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시상황",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        283.4064025878906,
        107.1553955078125,
        508.88385009765625,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        283.4064025878906,
        107.1553955078125,
        508.88385009765625,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성예정일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        283.4064025878906,
        107.1553955078125,
        508.88385009765625,
        133.05084228515625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 사항 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        142.1571502685547,
        138.64486694335938,
        153.78819274902344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 위해성 최소화   활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        203.4102020263672,
        222.599365234375,
        215.04124450683594
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        223.30845642089844,
        398.3038024902344,
        234.9394989013672
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가 위해성 최소화   활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        243.0868377685547,
        200.53097534179688,
        254.71788024902344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가 위해성 최소화   활동의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        263.9440612792969,
        434.6441345214844,
        289.8395080566406
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        263.9440612792969,
        434.6441345214844,
        289.8395080566406
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전환점이 되는 예정   시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        263.9440612792969,
        434.6441345214844,
        289.8395080566406
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시상황",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        263.9440612792969,
        434.6441345214844,
        289.8395080566406
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 직후 조사(소아)에 의한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        321.96063232421875,
        217.9215545654297,
        347.8561096191406
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정보제공",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        321.96063232421875,
        217.9215545654297,
        347.8561096191406
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시기간: 판매시작 후 6개월간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        300.50408935546875,
        385.9501647949219,
        369.3126525878906
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가 예정 시기: 판매시작부터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        300.50408935546875,
        385.9501647949219,
        369.3126525878906
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2, 4, 6개월 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        300.50408935546875,
        385.9501647949219,
        369.3126525878906
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고 예정시기: 판매시작부터 8",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        300.50408935546875,
        385.9501647949219,
        369.3126525878906
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개월 이내",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        300.50408935546875,
        385.9501647949219,
        369.3126525878906
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        329.0329284667969,
        412.69635009765625,
        340.6639709472656
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 직후 조사(고연령층(65",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        390.1661071777344,
        217.92137145996094,
        430.4458312988281
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세이상의 성인))에 의한 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        390.1661071777344,
        217.92137145996094,
        430.4458312988281
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제공",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        390.1661071777344,
        217.92137145996094,
        430.4458312988281
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시기간: 승인 후 6개월간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        375.9017028808594,
        385.9508056640625,
        444.71026611328125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가 예정시기: 승인부터 2, 4,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        375.9017028808594,
        385.9508056640625,
        444.71026611328125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6개월 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        375.9017028808594,
        385.9508056640625,
        444.71026611328125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고 예정시기: 승인부터 8개월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        375.9017028808594,
        385.9508056640625,
        444.71026611328125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이내",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        375.9017028808594,
        385.9508056640625,
        444.71026611328125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        404.5503845214844,
        412.69635009765625,
        416.1814270019531
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뉴모박스®NP와의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        461.2484130859375,
        217.9212188720703,
        472.87945556640625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종과오",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        461.2484130859375,
        217.9212188720703,
        472.87945556640625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방지의 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        475.5128479003906,
        123.65264892578125,
        487.1438903808594
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소아 및 고연령층의 시판 직후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        446.8641357421875,
        385.95050048828125,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조사기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        446.8641357421875,
        385.95050048828125,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고연령층의 추가 승인 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        446.8641357421875,
        385.95050048828125,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 정기보고의 시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        446.8641357421875,
        385.95050048828125,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종과오 상황을 확인하고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        446.8641357421875,
        536.9486694335938,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필요에 따라‘적정사용’의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        446.8641357421875,
        536.9486694335938,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알림 문서의 배포 등에 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        446.8641357421875,
        536.9486694335938,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 정보제공을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        446.8641357421875,
        536.9486694335938,
        501.4082946777344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종대상 및 접종경로 선택에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        517.9464111328125,
        211.56500244140625,
        543.8418579101562
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련된 과오방지의 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.205745697021484,
        517.9464111328125,
        211.56500244140625,
        543.8418579101562
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소아 및 고연령층의 시판 직후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        503.6820373535156,
        385.95050048828125,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조사기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        503.6820373535156,
        385.95050048828125,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고연령층의 추가 승인 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        503.6820373535156,
        385.95050048828125,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 정기보고의 시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        222.71929931640625,
        503.6820373535156,
        385.95050048828125,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종과오 상황을 확인하고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        503.6820373535156,
        536.9486694335938,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필요에 따라 ‘적정사용’",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        503.6820373535156,
        536.9486694335938,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 알림 문서의 배포 등에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        503.6820373535156,
        536.9486694335938,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의한 정보제공을 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        390.6282958984375,
        503.6820373535156,
        536.9486694335938,
        558.2261962890625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 19 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 유럽연합",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        56.609317779541016,
        98.99178314208984,
        144.4014434814453,
        114.93435668945312
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유럽연합의",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이미",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2006년",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획을",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도입하였으며",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        148.3978271484375,
        544.745849609375,
        163.91989135742188
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "홈페이지(www.ema.europa.eu)에서",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        168.53582763671875,
        544.7453002929688,
        184.0708465576172
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디프테리아·파상풍·백일해(DTaP)",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        168.53582763671875,
        544.7453002929688,
        184.0708465576172
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        168.53582763671875,
        544.7453002929688,
        184.0708465576172
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        188.67381286621094,
        544.6253662109375,
        204.1958770751953
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인할 수 있다. 제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        208.81179809570312,
        544.1450805664062,
        224.3338623046875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적 위해성,",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        228.94979858398438,
        544.745849609375,
        244.47186279296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족정보)",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        228.94979858398438,
        544.745849609375,
        244.47186279296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 의약품감시계획, 위해성 완화 조치방법에",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        228.94979858398438,
        544.745849609375,
        244.47186279296875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 개략적인 내용이 공개되어 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        249.08778381347656,
        280.6219787597656,
        264.60986328125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 사례집은 DTaP",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        289.36376953125,
        538.1224365234375,
        304.8858642578125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반 혼합백신,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        289.36376953125,
        538.1224365234375,
        304.8858642578125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐렴구균 백신,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        289.36376953125,
        538.1224365234375,
        304.8858642578125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수막구균 백신,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        289.36376953125,
        538.1224365234375,
        304.8858642578125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수두바이러스",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        309.5017395019531,
        538.2423706054688,
        325.0238342285156
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        309.5017395019531,
        538.2423706054688,
        325.0238342285156
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일본뇌염",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        309.5017395019531,
        538.2423706054688,
        325.0238342285156
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        309.5017395019531,
        538.2423706054688,
        325.0238342285156
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로타바이러스",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        309.5017395019531,
        538.2423706054688,
        325.0238342285156
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        309.5017395019531,
        538.2423706054688,
        325.0238342285156
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "홍역·유행성이하선염·풍진(MMR)",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        329.6397399902344,
        544.7453002929688,
        345.1747741699219
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼합백신,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        329.6397399902344,
        544.7453002929688,
        345.1747741699219
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인유두종바이러스 백신의 총 14개",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        329.6397399902344,
        544.7453002929688,
        345.1747741699219
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품별 유럽 공공 평가 보고서(European",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        350.7366943359375,
        544.6253662109375,
        365.2520751953125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Public",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        350.7366943359375,
        544.6253662109375,
        365.2520751953125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assessment",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        350.7366943359375,
        544.6253662109375,
        365.2520751953125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Report)의 위해성",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        350.7366943359375,
        544.6253662109375,
        365.2520751953125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리 계획 항목을 기반으로 작성되었다. 백신의 경우 여러 제품에서 중요한",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        369.9157409667969,
        544.6253662109375,
        385.4378356933594
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부족정보는 면역기능이 저하된 사람,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        390.0537109375,
        538.1224365234375,
        405.5758056640625
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소아대상 백신은 미숙아였다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        390.0537109375,
        538.1224365234375,
        405.5758056640625
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        390.0537109375,
        538.1224365234375,
        405.5758056640625
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다. 예를",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        410.19171142578125,
        544.6253662109375,
        425.71380615234375
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "들면 로타바이러스 백신의 장중첩증,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        430.3297119140625,
        538.2423706054688,
        445.851806640625
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수막구균 백신의 길랑바레증후군,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        430.3297119140625,
        538.2423706054688,
        445.851806640625
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "급성파종성 뇌척수염,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        450.4676818847656,
        538.1224365234375,
        466.0027160644531
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DTaP",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        450.4676818847656,
        538.1224365234375,
        466.0027160644531
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반 혼합백신의 저긴장성·저반응성 에피소드,",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        450.4676818847656,
        538.1224365234375,
        466.0027160644531
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        470.6056823730469,
        544.6253662109375,
        486.1277770996094
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당된다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        490.7436828613281,
        111.7535171508789,
        506.2657775878906
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        69.56230163574219,
        532.8401489257812,
        544.745849609375,
        546.4940185546875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다. 자세한 내용은",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        551.1576538085938,
        544.6253662109375,
        566.6797485351562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        572.254638671875,
        544.6253662109375,
        586.77001953125
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 등 연구 설계시 도움이 될 것으로 사료된다.",
      "font_size": 12.94941520690918,
      "font_name": "T10",
      "bbox": [
        56.609317779541016,
        593.9508666992188,
        351.9833068847656,
        609.4729614257812
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 20 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-1",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        489.3345031738281,
        125.00334930419922
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디프테리아·파상풍·백일해(DTaP) 기반 혼합백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        489.3345031738281,
        125.00334930419922
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<Hexacima>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        160.00509643554688,
        172.39096069335938,
        175.9476776123047
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        189.5203857421875,
        128.5703125,
        202.16281127929688
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        639.5086059570312,
        260.4988098144531,
        652.1510620117188
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.71300506591797,
        217.0752716064453,
        496.1400451660156,
        228.70631408691406
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sanofi Pasteur",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.71300506591797,
        217.0752716064453,
        496.1400451660156,
        228.70631408691406
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.71300506591797,
        217.0752716064453,
        496.1400451660156,
        228.70631408691406
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2013.04.17(EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.71300506591797,
        217.0752716064453,
        496.1400451660156,
        228.70631408691406
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.71300506591797,
        259.3890380859375,
        256.0286560058594,
        271.02008056640625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Hexacima",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        86.71300506591797,
        259.3890380859375,
        256.0286560058594,
        271.02008056640625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        322.1454162597656,
        245.00474548339844,
        388.10931396484375,
        256.6357727050781
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        327.66241455078125,
        259.3890380859375,
        377.1955871582031,
        271.02008056640625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        337.9768371582031,
        273.6534423828125,
        366.8511657714844,
        285.28448486328125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver 8.0",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        441.9604797363281,
        259.3890380859375,
        478.9007873535156,
        271.02008056640625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        358.88031005859375,
        138.64486694335938,
        370.5113525390625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디프테리아 톡소이드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파상풍 톡소시드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백일해 톡소이드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필라멘트 헤마글루티닌",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불활화 폴리오 바이러스 제1형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불활화 폴리오 바이러스 제2형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불활화 폴리오 바이러스 제3형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정제B형 간염 표면단백항원",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        301.7027893066406,
        454.7939453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20 IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40 IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40 DU",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8 DU",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32 DU",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        467.9863586425781,
        301.7027893066406,
        522.31689453125,
        427.8087158203125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        458.4914245605469,
        105.66239929199219,
        470.1224670410156
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        444.1071472167969,
        532.0313110351562,
        484.38690185546875
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        444.1071472167969,
        532.0313110351562,
        484.38690185546875
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        444.1071472167969,
        532.0313110351562,
        484.38690185546875
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        550.79052734375,
        105.66239929199219,
        562.4215698242188
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종(최소 4주 간격) 스케줄로 투여한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가접종한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근육주사(IM) 한다. 권장되는 주사부위는 대퇴부 전외측 또는 보다 높은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연령의 소아(15개월 이상부터)의 경우 삼각근이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.95602416992188,
        500.6853332519531,
        532.0313110351562,
        612.406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 문제 요약",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        661.4296264648438,
        149.67886352539062,
        673.0606689453125
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        691.0372924804688,
        171.62664794921875,
        702.6683349609375
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표시사항에 기재된 이상사례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        676.6530151367188,
        368.20013427734375,
        702.8406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        676.6530151367188,
        368.20013427734375,
        702.8406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저긴장성-저반응성 에피소드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        676.6530151367188,
        368.20013427734375,
        702.8406982421875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        704.8655395507812,
        335.21832275390625,
        717.1051025390625
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "광범위한 팔다리 부기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        704.8655395507812,
        335.21832275390625,
        717.1051025390625
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        719.0866088867188,
        502.9830017089844,
        730.7176513671875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        719.0866088867188,
        502.9830017089844,
        730.7176513671875
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 21 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        100.0065689086914,
        247.30596923828125,
        112.24608612060547
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        100.0065689086914,
        247.30596923828125,
        112.24608612060547
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        114.27098083496094,
        291.2015380859375,
        126.510498046875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아나필락시스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        114.27098083496094,
        291.2015380859375,
        126.510498046875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        143.3558349609375,
        529.2728271484375,
        183.68800354003906
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상사례:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        143.3558349609375,
        529.2728271484375,
        183.68800354003906
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        143.3558349609375,
        529.2728271484375,
        183.68800354003906
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무호흡",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        143.3558349609375,
        529.2728271484375,
        183.68800354003906
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        185.832763671875,
        288.6835632324219,
        198.07228088378906
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌병증, 뇌염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        185.832763671875,
        288.6835632324219,
        198.07228088378906
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        214.79776000976562,
        529.2720336914062,
        283.7261962890625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상인 이상사례:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        214.79776000976562,
        529.2720336914062,
        283.7261962890625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        214.79776000976562,
        529.2720336914062,
        283.7261962890625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS),",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        214.79776000976562,
        529.2720336914062,
        283.7261962890625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        214.79776000976562,
        529.2720336914062,
        283.7261962890625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Apparent Life-Threatening Event, ALTE)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        214.79776000976562,
        529.2720336914062,
        283.7261962890625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        335.8654479980469,
        149.67886352539062,
        347.4964904785156
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        285.88006591796875,
        529.2728271484375,
        326.2122497558594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않았다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        285.88006591796875,
        529.2728271484375,
        326.2122497558594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        285.88006591796875,
        529.2728271484375,
        326.2122497558594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미숙아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        285.88006591796875,
        529.2728271484375,
        326.2122497558594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        328.3570251464844,
        484.8968811035156,
        340.5965270996094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(질병 또는 치료로 인해) 면역기능이 저하된 대상자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        328.3570251464844,
        484.8968811035156,
        340.5965270996094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        342.6214294433594,
        523.756103515625,
        368.9530334472656
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        342.6214294433594,
        523.756103515625,
        368.9530334472656
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진 대상자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        342.6214294433594,
        523.756103515625,
        368.9530334472656
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        371.2701110839844,
        351.64910888671875,
        383.5096130371094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발작 병력이 있는 대상자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        371.2701110839844,
        351.64910888671875,
        383.5096130371094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        208.8068389892578,
        385.5345458984375,
        521.9567260742188,
        397.7740478515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        208.8068389892578,
        385.5345458984375,
        521.9567260742188,
        397.7740478515625
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        417.4962463378906,
        459.23046875,
        429.1272888183594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        417.4962463378906,
        459.23046875,
        429.1272888183594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        417.4962463378906,
        459.23046875,
        429.1272888183594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        437.0348815917969,
        177.26358032226562,
        448.6659240722656
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저긴장성-저반응성 에피소드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        475.0333557128906,
        210.2457275390625,
        486.6643981933594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발적보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        546.3554077148438,
        344.69287109375,
        600.8995361328125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기안전성보고(PSUR)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        546.3554077148438,
        344.69287109375,
        600.8995361328125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실마리정보 확인 체계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        546.3554077148438,
        344.69287109375,
        600.8995361328125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특별관심",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        546.3554077148438,
        344.69287109375,
        600.8995361328125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상사례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        546.3554077148438,
        344.69287109375,
        600.8995361328125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Adverse",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        603.5328979492188,
        361.12420654296875,
        615.1639404296875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Event",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        603.5328979492188,
        361.12420654296875,
        615.1639404296875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        603.5328979492188,
        361.12420654296875,
        615.1639404296875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Special Interest, AESI)로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        617.9171752929688,
        350.0899353027344,
        643.8126220703125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규명된 사례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        617.9171752929688,
        350.0899353027344,
        643.8126220703125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.8항 [부작용]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        453.5768127441406,
        534.9097900390625,
        508.1209411621094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신경계 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        453.5768127441406,
        534.9097900390625,
        508.1209411621094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "매우 드물게: 저긴장성 반응 또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        453.5768127441406,
        534.9097900390625,
        508.1209411621094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저긴장성-저반응성 에피소드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        453.5768127441406,
        534.9097900390625,
        508.1209411621094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "광범위한 팔다리 부기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        617.6774291992188,
        177.263916015625,
        629.3084716796875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.8항 [부작용]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전신 이상 및 투여 부위 상태",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "드물게: 광범위한 팔다리 부기. 주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사부위에서 확대되어 한쪽 또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양쪽 관절을 침범하는 광범위한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "팔다리 부기를 포함하여 큰 주사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부위 반응(50 mm 초과)이 소아에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 보고되었다. 이러한 반응은 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종 후 24~72시간 이내에 발생하고,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주사부위의 홍반, 열감, 압통 또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통증이 관련될 수 있으며, 3~5일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이내에 자연적으로 소실된다. 이러",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 반응은 4차 및 5차 접종 시 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "험이 증가하며, 과거 무세포 백일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해 포함 백신의 접종 횟수에 좌우",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 것으로 보인다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        510.3947448730469,
        545.823486328125,
        736.5912475585938
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 22 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        103.19972229003906,
        177.26358032226562,
        114.83075714111328
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아나필락시스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        341.6191711425781,
        133.36737060546875,
        353.2502136230469
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발적보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        405.74908447265625,
        344.69287109375,
        460.293212890625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기안전성보고(PSUR)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        405.74908447265625,
        344.69287109375,
        460.293212890625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실마리정보 확인 체계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        405.74908447265625,
        344.69287109375,
        460.293212890625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특별관심",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        405.74908447265625,
        344.69287109375,
        460.293212890625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상사례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        405.74908447265625,
        344.69287109375,
        460.293212890625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Adverse",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        462.9266052246094,
        361.12420654296875,
        474.5576477050781
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Event",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        462.9266052246094,
        361.12420654296875,
        474.5576477050781
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        462.9266052246094,
        361.12420654296875,
        474.5576477050781
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Special Interest, AESI)로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        477.1910095214844,
        350.0899353027344,
        503.2063293457031
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규명된 사례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        220.92027282714844,
        477.1910095214844,
        350.0899353027344,
        503.2063293457031
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아나필락시스는 SmPC 다음 항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        119.86151123046875,
        534.9097900390625,
        145.7569580078125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        119.86151123046875,
        534.9097900390625,
        145.7569580078125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.3항 [금기]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "헥사심주(Hexacima)를 이전에 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 후 아나필락시스 반응의 이력",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 있는 자.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분, Section 6.1에 열거된 첨가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제, 미량의 잔류물질 (글루타르알",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데히드, 포름알데히드, 네오마이신,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스트렙토마이신, 폴리믹신 B), 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일해 백신에 대해, 또는 이전에 헥",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사심주(Hexacima) 또는 동일한 성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분 또는 구성성분이 포함된 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 투여한 후 과민반응이 있었던",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        162.7746124267578,
        534.9097900390625,
        346.0580749511719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.4항 [특수 경고 및 사용상의 주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의사항]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생물학적제제를 주사하기 전에, 투",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여를 담당하는 사람은 알레르기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응 또는 기타 반응의 예방을 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해 알려진 모든 주의조치를 실시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해야 한다. 모든 주사형 백신의 경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우와 마찬가지로, 백신을 투여한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후 아나필락시스 반응이 발생하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우 적절한 의학적 치료 및 관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가 항상 신속히 이루어질 수 있도",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "록 준비되어야 한다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.8항 [부작용]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피부 및 피하조직 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "드물게: 발진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        363.0757141113281,
        534.9097900390625,
        574.887939453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        648.6036376953125,
        89.35157012939453,
        660.2346801757812
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경련은 SmPC 다음 항에 기술되었",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        577.0418701171875,
        529.3927001953125,
        603.0571899414062
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        577.0418701171875,
        529.3927001953125,
        603.0571899414062
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.3항 [금기]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백일해 백신은 조절되지 않는 신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경계 장애 또는 조절되지 않는 간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질이 있는 사람의 경우 그러한 상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "태에 대한 치료가 확립되고, 상태",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가 안정화되고, 백신 접종에 따른",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유익성이 위해성을 명백하게 상회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기 전에는 투여해서는 안 된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        619.9549560546875,
        534.9097900390625,
        731.7965087890625
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 23 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.4항 [특수 경고 및 사용상의 주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의사항]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백일해 포함 백신을 투여 받은 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다음의 사례가 발생된 것으로 알",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "려진 경우, 백일해 포함 백신의 추",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가 접종 여부에 대한 결정은 신중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하게 결정해야 한다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신접종 후 3일 이내에 발생된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발열을 동반하거나 동반하지 않는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "열성 경련 병력, 가족력에 경련 또",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 영아 돌연사 증후군이 있더라",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도 DTaP-IPV-HepB-PRP-T 투여의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "금기사항은 아니다. 열성 경련의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병력이 있는 자는 접종 후 2~3일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이내에 그러한 이상사례가 발생될",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수도 있으므로 면밀하게 추적관찰",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되어야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        369.5523986816406
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.8항 [부작용]",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 이상사례 (즉, 헥사심주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Hexacima)의 구성요소 또는 성분",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 1개 이상 포함된 다른 백신 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종 시 보고되었으나 헥사심주 투",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여와는 직접적인 관련이 없는 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상사례):",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신경계 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발열을 동반하거나 동반하지 않는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경련.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        386.4501647949219,
        534.9097900390625,
        526.8204956054688
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무호흡",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        621.9927368164062,
        100.38558959960938,
        633.623779296875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무호흡은 SmPC 다음 항에 기술되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        528.974365234375,
        529.3927001953125,
        554.9896850585938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        528.974365234375,
        529.3927001953125,
        554.9896850585938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.4항 [사용상의 주의사항]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "극미숙아(very premature infants)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(출생시 재태기간 28주 이하)와 호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흡계 미성숙 기왕력이 있는 영아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 대해 기초접종을 실시할 경우",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무호흡의 잠재적 위험과 48-72시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간 동안 호흡 모니터링의 필요성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 고려해야 한다. 이러한 영아에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 예방접종의 유익성이 높으므로,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방접종을 보류하거나 지연해서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 안 된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        571.8875122070312,
        540.4266967773438,
        726.64208984375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.8항 [부작용]",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 이상사례 (즉, 헥사심주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Hexacima)의 구성요소 또는 성분",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 1개 이상 포함된 다른 백신 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종 시 보고되었으나 헥사심주 투",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여와는 직접적인 관련이 없는 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상사례):",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "호흡, 흉부 및 종격동 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "극미숙아 (출생시 재태기간 28주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이하)에서의 무호흡 (4.4항 참조)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        114.70714569091797,
        534.9100952148438,
        255.07749938964844
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌병증/ 뇌염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        436.075927734375,
        131.20855712890625,
        447.70697021484375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌병증, 뇌염은 SmPC 다음 항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        257.23138427734375,
        534.9097900390625,
        283.1268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        257.23138427734375,
        534.9097900390625,
        283.1268310546875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.3항 [금기]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백일해 포함 백신(전세포 또는 무",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포 백일해 백신)으로 이전에 예",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방접종을 실시한 후 7일 이내에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생된 병인을 알 수 없는 뇌병증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 경험한 경우, DTaP-IPV-Hep",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "B-PRP-T 백신접종을 실시해서는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안 된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 경우 백일해 예방접종을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중단하여야 하며, 디프테리아-파상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "풍, B형 간염, 폴리오 및 Hib 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 사용하여 접종을 실시해야 한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        300.1445007324219,
        545.8231201171875,
        483.4279479980469
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.8항 [부작용]:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적 이상사례 (즉, 헥사심주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Hexacima)의 구성요소 또는 성분",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 1개 이상 포함된 다른   백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종 시 보고되었으나 헥사심주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여와는 직접적인 관련이 없는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례):",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신경계 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "뇌병증, 뇌염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        500.4455871582031,
        534.9097900390625,
        626.431640625
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영아 돌연사 증후군(SIDS)/돌",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        657.2341918945312,
        210.72579956054688,
        697.513916015625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연사(SUD)/생명 위협 사건",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        657.2341918945312,
        210.72579956054688,
        697.513916015625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ALTE)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.28353118896484,
        657.2341918945312,
        210.72579956054688,
        697.513916015625
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영아 돌연사 증후군(SIDS) 및 돌연",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        628.7053833007812,
        534.9100952148438,
        726.1626586914062
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사(SUD)의 모니터링에 대한 강화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        628.7053833007812,
        534.9100952148438,
        726.1626586914062
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된 약물감시 활동의 일환으로, 사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        628.7053833007812,
        534.9100952148438,
        726.1626586914062
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "노피파스퇴르는 가능한 경우 관찰",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        628.7053833007812,
        534.9100952148438,
        726.1626586914062
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값:예상값 비율 평가방법을 사용하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        628.7053833007812,
        534.9100952148438,
        726.1626586914062
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여 이러한 이상사례에 대한 정기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        628.7053833007812,
        534.9100952148438,
        726.1626586914062
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석을 실시하고 결과를 PSUR에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        628.7053833007812,
        534.9100952148438,
        726.1626586914062
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 25 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        260.7225646972656,
        390.02862548828125,
        273.364990234375
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Category 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.",
      "font_size": 9.951866149902344,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        421.18035888671875,
        537.0689086914062,
        470.6309814453125
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Category 2는 고유한 의무이다",
      "font_size": 9.951866149902344,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        421.18035888671875,
        537.0689086914062,
        470.6309814453125
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Category 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수",
      "font_size": 9.951866149902344,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        421.18035888671875,
        537.0689086914062,
        470.6309814453125
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적으로 요구되는 추가 PhV 활동이다",
      "font_size": 9.951866149902344,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        421.18035888671875,
        537.0689086914062,
        470.6309814453125
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 안전성 문제가 확인된 경우",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        100.44273376464844,
        534.9097900390625,
        126.33818054199219
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 전에 제공할 계획이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        100.44273376464844,
        534.9097900390625,
        126.33818054199219
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "엄밀히 말하면, 이는 위해성 완화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        143.3558349609375,
        534.9097900390625,
        240.81307983398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조치방법이 아니라 약물감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        143.3558349609375,
        534.9097900390625,
        240.81307983398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이다. 계획된 정기적인 관찰값 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        143.3558349609375,
        534.9097900390625,
        240.81307983398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비 예상값(OvE) 분석을 실시하면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        143.3558349609375,
        534.9097900390625,
        240.81307983398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신뢰할 수 있는 실마리정보 확인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        143.3558349609375,
        534.9097900390625,
        240.81307983398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 가능하다. 제안된 OvE 실시 방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        143.3558349609375,
        534.9097900390625,
        240.81307983398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "법이 승인되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        354.7677307128906,
        143.3558349609375,
        534.9097900390625,
        240.81307983398438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험/활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        286.9588928222656,
        136.126220703125,
        327.2386169433594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유형, 제목 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        286.9588928222656,
        136.126220703125,
        327.2386169433594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "카테고리 (1-3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        286.9588928222656,
        136.126220703125,
        327.2386169433594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        165.0305633544922,
        294.1510314941406,
        369.39947509765625,
        312.8543395996094
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검토된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        165.0305633544922,
        294.1510314941406,
        369.39947509765625,
        312.8543395996094
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        165.0305633544922,
        294.1510314941406,
        369.39947509765625,
        312.8543395996094
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        294.1510314941406,
        538.5078125,
        320.0464782714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진행상황",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        294.1510314941406,
        538.5078125,
        320.0464782714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간 또는 최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        294.1510314941406,
        538.5078125,
        320.0464782714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고서 제출일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        294.1510314941406,
        538.5078125,
        320.0464782714844
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역기능이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        332.1495056152344,
        154.83609008789062,
        343.7805480957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        332.1495056152344,
        154.83609008789062,
        343.7805480957031
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "된 사람에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        346.5337829589844,
        160.3531036376953,
        386.69366455078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구*",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        346.5337829589844,
        160.3531036376953,
        386.69366455078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Category 3",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        346.5337829589844,
        160.3531036376953,
        386.69366455078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역기능이 저하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        165.0305633544922,
        339.3416442871094,
        249.46478271484375,
        379.62139892578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "된 유아에서  유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        165.0305633544922,
        339.3416442871094,
        249.46478271484375,
        379.62139892578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효성과 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        165.0305633544922,
        339.3416442871094,
        249.46478271484375,
        379.62139892578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역기능이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        339.3416442871094,
        352.9687194824219,
        350.9726867675781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        339.3416442871094,
        352.9687194824219,
        350.9726867675781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "된 유아에   대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        353.6060485839844,
        358.3654479980469,
        379.62139892578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        259.6592712402344,
        353.6060485839844,
        358.3654479980469,
        379.62139892578125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        363.0432434082031,
        346.5337829589844,
        438.84259033203125,
        358.1648254394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "류",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        363.0432434082031,
        346.5337829589844,
        438.84259033203125,
        358.1648254394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        363.0432434082031,
        346.5337829589844,
        438.84259033203125,
        358.1648254394531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Pending)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        363.0432434082031,
        360.7981872558594,
        408.1084289550781,
        372.4292297363281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2013년 제4분기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        449.03662109375,
        346.5337829589844,
        526.0345458984375,
        372.4292297363281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(요약 및 개요)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        449.03662109375,
        346.5337829589844,
        526.0345458984375,
        372.4292297363281
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        394.60125732421875,
        468.6816101074219,
        406.2322998046875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 26 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<Vaxelis>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        98.99178314208984,
        146.00579833984375,
        114.93435668945312
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        128.62693786621094,
        128.5703125,
        141.2693634033203
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        544.0928344726562,
        188.53781127929688,
        556.7352905273438
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        154.024169921875,
        462.798095703125,
        165.65521240234375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MCM Vaccine B.V.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        154.024169921875,
        462.798095703125,
        165.65521240234375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        154.024169921875,
        462.798095703125,
        165.65521240234375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2016.02.15(EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        154.024169921875,
        462.798095703125,
        165.65521240234375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        184.95037841796875,
        186.10708618164062,
        196.5814208984375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Vaxelis",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        184.95037841796875,
        186.10708618164062,
        196.5814208984375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        317.8277587890625,
        170.6859588623047,
        386.7900390625,
        210.8458251953125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        317.8277587890625,
        170.6859588623047,
        386.7900390625,
        210.8458251953125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        317.8277587890625,
        170.6859588623047,
        386.7900390625,
        210.8458251953125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver 2.1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        391.46783447265625,
        184.95037841796875,
        428.5273132324219,
        196.5814208984375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        284.5615234375,
        138.64486694335938,
        296.19256591796875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디프테리아 톡소이드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파상풍 톡소시드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백일해 톡소이드(PT)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필라멘트 헤마글루티닌(FHA)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pertactin(PRN)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Fimbriae Types 2+3 (FIM)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불활화 폴리오 바이러스 제1형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불활화 폴리오 바이러스 제2형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불활화 폴리오 바이러스 제3형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정제B형 간염 표면단백항원",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        212.99972534179688,
        453.35382080078125,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20 IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40 IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40 DU",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8 DU",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32 DU",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        465.22784423828125,
        212.99972534179688,
        519.4381103515625,
        367.7543640136719
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        384.17266845703125,
        105.66239929199219,
        395.8037109375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        369.9082336425781,
        529.2728271484375,
        410.18798828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        369.9082336425781,
        529.2728271484375,
        410.18798828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        369.9082336425781,
        529.2728271484375,
        410.18798828125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        462.3272399902344,
        105.66239929199219,
        473.9582824707031
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "격) 스케줄로 투여한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가접종한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "근육주사(IM) 한다. 권장되는 주사부위는 대퇴부 전외측 또는 보다 높은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연령의 소아(15개월 이상부터)의 경우 삼각근이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        412.34185791015625,
        529.1528930664062,
        524.0634765625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 문제 요약",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        568.7708740234375,
        149.67886352539062,
        580.4019165039062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        588.3095092773438,
        213.8441162109375,
        599.9405517578125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        588.3095092773438,
        213.8441162109375,
        599.9405517578125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        640.6922607421875,
        171.62664794921875,
        652.3233032226562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        604.53515625,
        400.7025146484375,
        616.7747192382812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아나필락시스 반응을 포함한 과민반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        604.53515625,
        400.7025146484375,
        616.7747192382812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        618.799560546875,
        334.73858642578125,
        631.0391235351562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "열성 경련을 포함한 경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        618.799560546875,
        334.73858642578125,
        631.0391235351562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        633.06396484375,
        518.5684204101562,
        645.3035278320312
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        633.06396484375,
        518.5684204101562,
        645.3035278320312
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        647.4482421875,
        266.7354431152344,
        659.6878051757812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌병증/뇌염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        647.4482421875,
        266.7354431152344,
        659.6878051757812
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        661.7127075195312,
        434.9742431640625,
        673.9522705078125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무호흡 (재태기간이 28주 이하인 미숙아에서)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        661.7127075195312,
        434.9742431640625,
        673.9522705078125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        675.9771118164062,
        433.564697265625,
        688.2166748046875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신 접종을 실시한 팔다리의 광범위한 부종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        675.9771118164062,
        433.564697265625,
        688.2166748046875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        709.9765625,
        111.17974090576172,
        721.6076049804688
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        695.2760009765625,
        384.15179443359375,
        707.5155639648438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주 미만의 영아에 대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        695.2760009765625,
        384.15179443359375,
        707.5155639648438
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        709.5404052734375,
        472.0638427734375,
        721.7799682617188
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출생시 재태기간이 28주 미만인 미숙아에 대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        709.5404052734375,
        472.0638427734375,
        721.7799682617188
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        723.9246826171875,
        395.1858215332031,
        736.1642456054688
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역기능이 저하된 환자에 대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        723.9246826171875,
        395.1858215332031,
        736.1642456054688
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 27 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        100.0065689086914,
        400.7028503417969,
        112.24608612060547
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생후 15개월 이후의 유아에 대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        100.0065689086914,
        400.7028503417969,
        112.24608612060547
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        191.77606201171875,
        114.27098083496094,
        378.6341552734375,
        126.510498046875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백일해 항원에 의한 방어면역기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        191.77606201171875,
        114.27098083496094,
        378.6341552734375,
        126.510498046875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성   중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        155.4626007080078,
        524.5953369140625,
        181.35806274414062
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인   위해성 완화 조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        155.4626007080078,
        524.5953369140625,
        181.35806274414062
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가적인   위해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        155.4626007080078,
        524.5953369140625,
        181.35806274414062
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 완화 조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        155.4626007080078,
        524.5953369140625,
        181.35806274414062
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한   규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        184.95037841796875,
        183.380615234375,
        196.5814208984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        201.61216735839844,
        84.43389892578125,
        213.2432098388672
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한   잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        218.27395629882812,
        183.380615234375,
        229.90499877929688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아나필락시스 반응을 포",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        276.4104309082031,
        185.17962646484375,
        302.3058776855469
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함한 과민반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        276.4104309082031,
        185.17962646484375,
        302.3058776855469
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응을 포함한 과민반응의 잠재적 가능성은 SmPC",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 기술되어 있다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4.3항 금기: 이 백신의 성분 또는 구성성분에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해 과민반응을 보이는 환자에게 백신을 투여해서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 안 된다;",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.4항 특수 경고 및 사용상의 주의사항: 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완화를 위해 적절한 의학적 치료 및 관리가 항상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신속히 이루어질 수 있도록 준비되어야 한다).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        233.49732971191406,
        451.3153991699219,
        359.4833984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        290.6748352050781,
        478.0609130859375,
        302.3058776855469
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "열성 경련을 포함한 경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        397.4781188964844,
        185.17962646484375,
        423.3735656738281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        397.4781188964844,
        185.17962646484375,
        423.3735656738281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        361.75714111328125,
        451.3150634765625,
        459.21441650390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함한 경련에 대한 잠재적인 가능성은 SmPC에 기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        361.75714111328125,
        451.3150634765625,
        459.21441650390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "술되어 있다 (4.4항 특수 경고 및 사용상의 주의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        361.75714111328125,
        451.3150634765625,
        459.21441650390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항과 4.8항/c 바람직하지 못한 효과/기재된 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        361.75714111328125,
        451.3150634765625,
        459.21441650390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상약물반응의 개요). 열성 경련을 포함한 경련의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        361.75714111328125,
        451.3150634765625,
        459.21441650390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병력이 있는 환자는 면밀하게 추적조사를 실시해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        361.75714111328125,
        451.3150634765625,
        459.21441650390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        361.75714111328125,
        451.3150634765625,
        459.21441650390625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        404.6702575683594,
        478.0609130859375,
        416.3013000488281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저긴장성-저반응성 에피",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        482.8248596191406,
        185.17929077148438,
        508.7203063964844
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소드",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        482.8248596191406,
        185.17929077148438,
        508.7203063964844
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        461.3682861328125,
        445.79840087890625,
        530.1768188476562
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 에피소드의 잠재적 가능성은 SmPC에 기술되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        461.3682861328125,
        445.79840087890625,
        530.1768188476562
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        461.3682861328125,
        445.79840087890625,
        530.1768188476562
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상약물반응의 개요) (4.4항 특수 경고 및 사용상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        461.3682861328125,
        445.79840087890625,
        530.1768188476562
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 주의사항).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        461.3682861328125,
        445.79840087890625,
        530.1768188476562
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        489.8971252441406,
        478.0609130859375,
        501.5281677246094
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "뇌병증/ 뇌염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        575.2438354492188,
        126.41149139404297,
        586.8748779296875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        532.3306884765625,
        456.8317565917969,
        629.7879638671875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 가능성은 SmPC에 기술되어 있다 (4.3항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        532.3306884765625,
        456.8317565917969,
        629.7879638671875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "금기). 위해성 완화를 위해 백일해 항원 포함 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        532.3306884765625,
        456.8317565917969,
        629.7879638671875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신으로 이전에 예방접종을 실시한 후 7일 이내에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        532.3306884765625,
        456.8317565917969,
        629.7879638671875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병인을 알 수 없는 뇌병증이 발생된 환자에게 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        532.3306884765625,
        456.8317565917969,
        629.7879638671875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신을 투여해서는 안 된다는 정보를 처방의사에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        532.3306884765625,
        456.8317565917969,
        629.7879638671875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        532.3306884765625,
        456.8317565917969,
        629.7879638671875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        575.2438354492188,
        478.0609130859375,
        586.8748779296875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무호흡 (재태기간이 28",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        653.3983764648438,
        185.1796417236328,
        679.4136962890625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주 이하인 미숙아에서)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        653.3983764648438,
        185.1796417236328,
        679.4136962890625
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        631.9418334960938,
        451.3153991699219,
        700.8703002929688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간이 28주 이하인 미숙아에서)의 잠재적인 가능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        631.9418334960938,
        451.3153991699219,
        700.8703002929688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        631.9418334960938,
        451.3153991699219,
        700.8703002929688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용상의 주의사항과 4.8항/d 바람직하지 못한 효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        631.9418334960938,
        451.3153991699219,
        700.8703002929688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과/기타 특수환자군).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        631.9418334960938,
        451.3153991699219,
        700.8703002929688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        660.5905151367188,
        478.0609130859375,
        672.2215576171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "광범위한 팔다리 부종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        703.024169921875,
        478.0609130859375,
        728.9196166992188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백셀리스(Vaxelis) 또는 구성성분 투여와 관련된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        703.024169921875,
        478.0609130859375,
        728.9196166992188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "광범위한 팔다리 부종의 잠재적 가능성은 SmPC",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        703.024169921875,
        478.0609130859375,
        728.9196166992188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        703.024169921875,
        478.0609130859375,
        728.9196166992188
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 28 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        100.44273376464844,
        445.7684020996094,
        126.33818054199219
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재된 이상약물반응의 개요).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        100.44273376464844,
        445.7684020996094,
        126.33818054199219
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        128.49208068847656,
        106.50193786621094,
        140.1231231689453
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주 미만의 영아에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        192.38226318359375,
        190.69631958007812,
        218.2777099609375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        192.38226318359375,
        190.69631958007812,
        218.2777099609375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주 이상 경과된 영유아에게 디프테리아, 파",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필루스 인플루엔자균)에 의해 발생되는 침습성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질병에 대한 기초접종 및 추가접종을 위해 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하도록 되어 있다고 기술되어 있다. 백셀리스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Vaxelis)의 생후 6주령 미만의 영아에 대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 연구되지 않았으며 그에 따라 이 연령군의 영",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아에게 투여해서는 안 된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        142.27700805664062,
        451.3153991699219,
        268.3829650878906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        199.57440185546875,
        478.0609130859375,
        211.2054443359375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출생시 재태기간이 28주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        349.1708984375,
        190.6966552734375,
        389.4506530761719
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미만인 미숙아에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        349.1708984375,
        190.6966552734375,
        389.4506530761719
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        349.1708984375,
        190.6966552734375,
        389.4506530761719
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC (4.4항 특수 경고 및 사용상의 주의사항)에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 임상시험을 통해 조산아에서의 투여에 대해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 미숙아에게 투여할 수 있다고 기술되어 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그러나, 보다 낮은 수준의 면역반응이 관찰될 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있고 임상적 방어 수준도 알려져 있지 않다. 극미",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "숙아(very premature infants) (출생시 재태기간이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28주 미만)와 특히 호흡계 미성숙 기왕력이 있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영유아에 대한 기초접종을 실시할 경우 SmPC",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4.4항 특수 경고 및 사용상의 주의사항)에 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "된 무호흡의 잠재적 위험과 48-72시간 동안 호흡",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모니터링의 필요성을 고려해야 한다. 이러한 영아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 예방접종의 유익성이 높으므로, 예방접종을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보류하거나 지연해서는 안 된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        270.5368347167969,
        451.3153991699219,
        468.084716796875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        363.55517578125,
        478.0609130859375,
        375.18621826171875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역기능이 저하된 환자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        513.2715454101562,
        185.17929077148438,
        539.1669921875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        513.2715454101562,
        185.17929077148438,
        539.1669921875
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC (4.4항 특수 경고 및 사용상의 주의사항)에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 백신의 면역원성이 면역억제치료 또는 면역결",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "핍상태에 의해 감소될 수 있다고 기술되어 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그러한 치료가 종료되거나 질병이 치유될 때까지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예방접종을 연기하도록 권장된다. 그럼에도 불구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고, HIV 감염 등 만성 면역결핍이 있는 환자에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 예방접종은 항체반응이 제한적일 수 있기는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지만 권장된다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        470.35845947265625,
        451.3150634765625,
        582.080078125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        520.3438110351562,
        478.0609130859375,
        531.974853515625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        619.9549560546875,
        201.6100616455078,
        631.5859985351562
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15개월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        619.9549560546875,
        201.6100616455078,
        631.5859985351562
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이후의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        619.9549560546875,
        201.6100616455078,
        631.5859985351562
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유아에 대한 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        634.3392333984375,
        150.39849853515625,
        645.9702758789062
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC (4.2항 용법용량)에는 생후 6주 미만의 영",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        584.2340087890625,
        451.3150634765625,
        681.6912231445312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        584.2340087890625,
        451.3150634765625,
        681.6912231445312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용 가능한 데이터가 없으므로 확립되지 않았다고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        584.2340087890625,
        451.3150634765625,
        681.6912231445312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술되어 있다. SmPC 4.8항과 5.1항에 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        584.2340087890625,
        451.3150634765625,
        681.6912231445312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 통한 생후 15개월 이후의 유아에서 백셀리스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        584.2340087890625,
        451.3150634765625,
        681.6912231445312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Vaxelis)의 안전성과 면역원성은 연구되지 않았다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        584.2340087890625,
        451.3150634765625,
        681.6912231445312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고 기술되어 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.37411499023438,
        584.2340087890625,
        451.3150634765625,
        681.6912231445312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        455.99285888671875,
        627.1470947265625,
        478.0609130859375,
        638.7781372070312
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백일해 항원에 의한 방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        683.8451538085938,
        478.0609130859375,
        709.8604736328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어면역기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        683.8451538085938,
        478.0609130859375,
        709.8604736328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        683.8451538085938,
        478.0609130859375,
        709.8604736328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        62.48613357543945,
        683.8451538085938,
        478.0609130859375,
        709.8604736328125
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 29 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-2",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        220.08042907714844,
        125.00334930419922
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴구균 백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        220.08042907714844,
        125.00334930419922
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<Prevenar 13>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        158.20706176757812,
        191.2225341796875,
        174.14964294433594
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        187.72235107421875,
        128.5703125,
        200.36477661132812
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        222.34950256347656,
        510.0535583496094,
        233.9805450439453
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pfizer Limited",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        222.34950256347656,
        510.0535583496094,
        233.9805450439453
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        222.34950256347656,
        510.0535583496094,
        233.9805450439453
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2009.12.09(EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        222.34950256347656,
        510.0535583496094,
        233.9805450439453
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        253.63531494140625,
        337.46710205078125,
        279.53076171875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prevenar   13 suspension for injection",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        253.63531494140625,
        337.46710205078125,
        279.53076171875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴구균 다당류 접합 백신 (13가 흡착)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        253.63531494140625,
        337.46710205078125,
        279.53076171875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        356.9265441894531,
        246.44317626953125,
        434.16436767578125,
        258.07421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        356.9265441894531,
        246.44317626953125,
        434.16436767578125,
        258.07421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획   번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        356.9265441894531,
        260.70758056640625,
        434.1646728515625,
        286.722900390625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        356.9265441894531,
        260.70758056640625,
        434.1646728515625,
        286.722900390625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver. 3.2",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        438.8421630859375,
        260.70758056640625,
        478.7800598144531,
        272.338623046875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        315.00823974609375,
        127.97064208984375,
        340.9036865234375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        315.00823974609375,
        127.97064208984375,
        340.9036865234375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        138.1651153564453,
        293.55169677734375,
        538.6281127929688,
        333.8314208984375
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2.2 μg",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        138.1651153564453,
        293.55169677734375,
        538.6281127929688,
        333.8314208984375
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CRM197 단백질 접합, 알루미늄 포스페이트에 흡착",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        138.1651153564453,
        293.55169677734375,
        538.6281127929688,
        333.8314208984375
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        138.1651153564453,
        350.7292175292969,
        494.97174072265625,
        362.3602600097656
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능 효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        393.162841796875,
        111.17974090576172,
        404.79388427734375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        139.84420776367188,
        364.1978454589844,
        538.747314453125,
        404.79388427734375
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        364.1978454589844,
        538.747314453125,
        404.79388427734375
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        364.1978454589844,
        538.747314453125,
        404.79388427734375
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동 면역)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        364.1978454589844,
        538.747314453125,
        404.79388427734375
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        139.84420776367188,
        407.1109619140625,
        538.748046875,
        433.44256591796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        407.1109619140625,
        538.748046875,
        433.44256591796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐렴에 대한 예방(예방에 대한 능동 면역)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        407.1109619140625,
        538.748046875,
        433.44256591796875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용법 용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        578.6001586914062,
        111.17974090576172,
        590.231201171875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 생후 6주에서 만5세까지의 영아 및 어린이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        435.5964660644531,
        364.2422790527344,
        447.2275085449219
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        449.8608703613281,
        538.7476806640625,
        475.8761901855469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마치는 것이 권장된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        449.8608703613281,
        538.7476806640625,
        475.8761901855469
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 생후 6주에서 생후 6개월 사이의 영아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        492.77398681640625,
        342.29449462890625,
        504.405029296875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3회 기초접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다. 기초 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고, 접종 간격은 최소 1개월 이상이어야 한다. 첫번째 접종은 생후 6주에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진행할 수도 있다. 4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이에 하는 것이 권장된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2회 기초접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3회 접종으로 구성될 수 있다. 첫번째 접종은 생후 2개월부터 접종이 가능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, (첫번째 접종) 2달 후 두번째 접종을 한다. 세번째 접종(추가 접종)은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        507.1582336425781,
        538.748046875,
        661.79296875
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 조산아 (임신 37주 미만)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        678.8106079101562,
        272.2224426269531,
        690.441650390625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        693.0750732421875,
        538.748046875,
        733.3547973632812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성된다. 기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        693.0750732421875,
        538.748046875,
        733.3547973632812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 접종 간격은 최소 1개월 이상으로 한다. 첫번째 접종은 생후 6주에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        693.0750732421875,
        538.748046875,
        733.3547973632812
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 30 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 안전성 중점 검토 항목 및 조치 계획 – ver. 3.2",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        377.9544677734375,
        337.7369384765625,
        390.5968933105469
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 것도 가능하다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        100.44273376464844,
        538.7476806640625,
        154.98687744140625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        100.44273376464844,
        538.7476806640625,
        154.98687744140625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        100.44273376464844,
        538.7476806640625,
        154.98687744140625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4.4항 및 5.1항 참고).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        100.44273376464844,
        538.7476806640625,
        154.98687744140625
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        171.88465881347656,
        446.5176696777344,
        183.5157012939453
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 7개월에서 생후 11개월 사이의 영아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 세번째 접종은 그 다음 해에 하는 것이 권장된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생후 12개월에서 생후 23개월 사이의 어린이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(SmPC 5.1항 참고).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만2세에서 만17세까지의 어린이 및 청소년",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.5mL을 1회 접종한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        153.39883422851562,
        186.26893615722656,
        538.7476806640625,
        297.9906005859375
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 18 이상의 성인 및 고령자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        139.84420776367188,
        315.00823974609375,
        281.8472595214844,
        326.6392822265625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.5mL을 1회 접종한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        329.27264404296875,
        530.68798828125,
        355.1681213378906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        154.11647033691406,
        329.27264404296875,
        530.68798828125,
        355.1681213378906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점 검토   항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        405.74908447265625,
        503.96685791015625,
        417.380126953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        405.74908447265625,
        503.96685791015625,
        417.380126953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화 조치 방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        405.74908447265625,
        503.96685791015625,
        417.380126953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.445613861083984,
        425.1678466796875,
        173.30572509765625,
        436.79888916015625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가적인 F/U이 필요한 중요",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        456.09405517578125,
        214.92352294921875,
        482.109375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 규명된 위해성은 없다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        456.09405517578125,
        214.92352294921875,
        482.109375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프리베나13의 안전성 프로파",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        441.82965087890625,
        383.7916564941406,
        496.373779296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일을 모니터하기 위한 시판후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        441.82965087890625,
        383.7916564941406,
        496.373779296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 관찰 연구와 일상적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        441.82965087890625,
        383.7916564941406,
        496.373779296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        441.82965087890625,
        383.7916564941406,
        496.373779296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        463.28619384765625,
        410.53717041015625,
        474.917236328125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.445613861083984,
        501.404541015625,
        173.30572509765625,
        513.0355834960938
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프리베나13 임상시험에서 발",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        603.7726440429688,
        220.44053649902344,
        644.0523681640625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "견되지 않은 예상하지 못한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        603.7726440429688,
        220.44053649902344,
        644.0523681640625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 실마리 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        603.7726440429688,
        220.44053649902344,
        644.0523681640625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프리베나13의 안전성 프로파일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 모니터링하기 위해 프리베",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나13을 접종한 최소 43,000",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명의 어린이에서 실시되는 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판후 안전성 관찰 연구 4002.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 연구는 병원 및 응급실 환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경에서 일어나는 모든 의학적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사례와 병원, 응급실 및 외래",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "클리닉 환경에서 일어나는 사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전에 정해놓은 안전성 정보의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율을 평가하기 위해 디자인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되었다. 아나필락시스, 과민증,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발작, 경련, 천명, 무호흡과 같",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은 사례가 이 연구에서 사전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 정해놓은 평가변수이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.9464111328125,
        394.8249206542969,
        729.8786010742188
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        618.1569213867188,
        410.53717041015625,
        629.7879638671875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 31 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각국의 권고사항에 따라 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        114.70714569091797,
        225.83726501464844,
        154.98687744140625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종을 모두 받은 어린이에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        114.70714569091797,
        225.83726501464844,
        154.98687744140625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서 발생한 백신 실패",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        114.70714569091797,
        225.83726501464844,
        154.98687744140625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신 실패에 대한 시판 후 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.7913513183594,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상사례 보고서.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.7913513183594,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈청형 정보가 수집되었는지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.7913513183594,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인하기 위한 백신 실패 보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.7913513183594,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고서의 F/U 질문지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.7913513183594,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 백신과 마찬가지로 프",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        100.44273376464844,
        538.7476806640625,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리베나13이 접종 받는 모두",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        100.44273376464844,
        538.7476806640625,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에게 효과가 있지는 않다는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        100.44273376464844,
        538.7476806640625,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 SmPC의 사용상의 주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        100.44273376464844,
        538.7476806640625,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의사항에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        100.44273376464844,
        538.7476806640625,
        169.25128173828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.445613861083984,
        174.28204345703125,
        151.35797119140625,
        185.9130859375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프리베나의 높은 유효성와 프",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        219.47265625,
        214.92352294921875,
        259.75238037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리베나13의 유효성의 동등 여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        219.47265625,
        214.92352294921875,
        259.75238037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        219.47265625,
        214.92352294921875,
        259.75238037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프랑스, 독일, 네덜란드, 노르",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨이 및 영국의 국가 감시 체",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계를 사용하여 5년 동안 5개",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유럽 국가의 침습성 질환 발",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생률, 영국과 네덜란드의 폐렴",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생률 및 5년간 영국의 급성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중이염 발생률에 대한 인구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기반 조사.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        190.82395935058594,
        383.7916564941406,
        302.6654968261719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        233.737060546875,
        410.53717041015625,
        245.36810302734375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신 혈청형의 감소와 연관된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        319.08380126953125,
        220.44020080566406,
        359.363525390625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "非백신 폐렴구균 혈청형의 역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        319.08380126953125,
        220.44020080566406,
        359.363525390625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학에서의 잠재적 변화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        319.08380126953125,
        220.44020080566406,
        359.363525390625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5년 동안 프리베나 13 혈청형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        304.8193664550781,
        383.7916564941406,
        373.6279296875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서의 잠재적 변화를 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        304.8193664550781,
        383.7916564941406,
        373.6279296875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위해 5개의 유럽 인구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        304.8193664550781,
        383.7916564941406,
        373.6279296875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기반 감시 체계가 사용될 것",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        304.8193664550781,
        383.7916564941406,
        373.6279296875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        304.8193664550781,
        383.7916564941406,
        373.6279296875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        326.27593994140625,
        410.53717041015625,
        337.906982421875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 백신 유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        390.1661071777344,
        149.67886352539062,
        401.7971496582031
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 유효성을 모니터하기 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        375.7818298339844,
        378.3949279785156,
        416.0615539550781
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해 유럽, 캐나다 및 미국의 감",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        375.7818298339844,
        378.3949279785156,
        416.0615539550781
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시 체계가 사용될 것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        375.7818298339844,
        378.3949279785156,
        416.0615539550781
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        382.9739685058594,
        410.53717041015625,
        394.6050109863281
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고위험 소아 인구군에서의 안",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        418.2154541015625,
        214.92352294921875,
        458.66748046875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전성과 면역원성:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        418.2154541015625,
        214.92352294921875,
        458.66748046875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        61.64658737182617,
        418.2154541015625,
        214.92352294921875,
        458.66748046875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HIV에 감염된 어린이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        418.2154541015625,
        214.92352294921875,
        458.66748046875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        61.64658737182617,
        460.6924133300781,
        177.14364624023438,
        472.9319152832031
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "37개월 미만 조산아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        460.6924133300781,
        177.14364624023438,
        472.9319152832031
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        61.64658737182617,
        475.0766906738281,
        214.92352294921875,
        515.6726684570312
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이전에 23가 폐렴구균 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        475.0766906738281,
        214.92352294921875,
        515.6726684570312
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신을 접종한 겸형 적혈구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        475.0766906738281,
        214.92352294921875,
        515.6726684570312
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증을 가진 어린이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        475.0766906738281,
        214.92352294921875,
        515.6726684570312
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HIV 양성 어린이, 조숙아 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        432.5997314453125,
        394.82568359375,
        501.4082946777344
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이전에 12가 폐렴구균 백신을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        432.5997314453125,
        394.82568359375,
        501.4082946777344
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종한 겸형 적혈구증을 가진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        432.5997314453125,
        394.82568359375,
        501.4082946777344
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어린이에서의 안전성 및 면역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        432.5997314453125,
        394.82568359375,
        501.4082946777344
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원성에 대한  임상 시험.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        432.5997314453125,
        394.82568359375,
        501.4082946777344
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역 반응 장애가 있는 어린",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        439.6719970703125,
        538.8679809570312,
        494.2161560058594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에서 항체 반응이 감소할",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        439.6719970703125,
        538.8679809570312,
        494.2161560058594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다는 내용을 SmPC의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        439.6719970703125,
        538.8679809570312,
        494.2161560058594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용상의 주의사항에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        439.6719970703125,
        538.8679809570312,
        494.2161560058594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어린이의 비인두 세균총에 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        532.2108154296875,
        220.44020080566406,
        601.0194091796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 비-폐렴구균성 세균 치환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        532.2108154296875,
        220.44020080566406,
        601.0194091796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 모니터링하는 것을 포함한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        532.2108154296875,
        220.44020080566406,
        601.0194091796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비인두 집락에 대한 프리베나",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        532.2108154296875,
        220.44020080566406,
        601.0194091796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13의 영향",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        532.2108154296875,
        220.44020080566406,
        601.0194091796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ACTIV 프로그램을 통한 프랑",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스에서의 폐렴구균의 비인두",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "집락에 대한 진행 중인 조사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "와 이스라엘에서의 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Study 3006). ACTIV 프로그램",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을   통한 프랑스에서의 어린",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 비인두 세균총의 비-폐렴",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구균성 세균 치환을 모니터링",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        517.8265380859375,
        383.7916564941406,
        629.6680908203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        560.7396850585938,
        410.53717041015625,
        572.3707275390625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이전에 프리베나로 기초접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        631.8219604492188,
        220.44053649902344,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 한 어린이에서 6개의 추가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        631.8219604492188,
        220.44053649902344,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈청형에 대한 예방을 위해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        631.8219604492188,
        220.44053649902344,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프리베나13이 접종되었을 때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        631.8219604492188,
        220.44053649902344,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CRM 기반 폐렴구균 접합 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        631.8219604492188,
        220.44053649902344,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신의 4회 이상 접종에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        631.8219604492188,
        220.44053649902344,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        631.8219604492188,
        220.44053649902344,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개의 연구(미국에서의 Study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        631.8219604492188,
        383.792724609375,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3011과 알라스카에서의 Study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        631.8219604492188,
        383.792724609375,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3010)에서 (추가 혈청형의 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        631.8219604492188,
        383.792724609375,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역원성 획득에 대한) 격차 해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        631.8219604492188,
        383.792724609375,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소 프로그램 고려를 위한 프",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        631.8219604492188,
        383.792724609375,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리베나13의 4회 이상 접종의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        631.8219604492188,
        383.792724609375,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성을 평가할 것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        631.8219604492188,
        383.792724609375,
        729.2792358398438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        674.735107421875,
        410.53717041015625,
        686.3661499023438
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 32 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프리베나로 기초 접종 후 프",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        121.89927673339844,
        220.44053649902344,
        176.44342041015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리베나13으로 추가 접종했을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        121.89927673339844,
        220.44053649902344,
        176.44342041015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "때 6개의 추가 혈청형에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        121.89927673339844,
        220.44053649902344,
        176.44342041015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        121.89927673339844,
        220.44053649902344,
        176.44342041015625
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프리베나로 기초 접종 3회를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.792724609375,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받은 어린이에게 프리베나13",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.792724609375,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 추가 접종을 하면 6개의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.792724609375,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가 혈청형에 대해 적절한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.792724609375,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성을   보인다는 Study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.792724609375,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "008의 결과를 확증하기 위한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.792724609375,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Study   3011 catch-up study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        100.44273376464844,
        383.792724609375,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        100.44273376464844,
        538.868896484375,
        112.07376861572266
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항목(posology",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        100.44273376464844,
        538.868896484375,
        112.07376861572266
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "section)에 기술된 것처럼 6",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        114.70714569091797,
        538.7476806640625,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개의 새로운 혈청형에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        114.70714569091797,
        538.7476806640625,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방어 면역을 얻기 위해서는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        114.70714569091797,
        538.7476806640625,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연령에 맞는 접종이 필요하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        114.70714569091797,
        538.7476806640625,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다고 SmPC 항목 4.2에서 기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        114.70714569091797,
        538.7476806640625,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        114.70714569091797,
        538.7476806640625,
        197.8999786376953
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전환 (접종) 계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        321.6010437011719,
        213.69418334960938,
        347.4964904785156
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(프리베나에서 프리베나13으로)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        321.6010437011719,
        213.69418334960938,
        347.4964904785156
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2-3개월의 전환 기간에 일어",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        235.77484130859375,
        383.7913513183594,
        304.5834045410156
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나는 백신 실패는 영국, 프란",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        235.77484130859375,
        383.7913513183594,
        304.5834045410156
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스, 독일, 네덜란드 및 노르웨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        235.77484130859375,
        383.7913513183594,
        304.5834045410156
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이의 국가 감시 프로그램에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        235.77484130859375,
        383.7913513183594,
        304.5834045410156
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의해 평가될 것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        235.77484130859375,
        383.7913513183594,
        304.5834045410156
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일상적인 약물감시 활동을 통",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해 회사로 보고된 백신 실패",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 검토할 것이다. 정기적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최신 안전성 보고서 분석을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통해 프리베나에서 프리베나",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전환하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        321.6010437011719,
        394.8253479003906,
        404.79388427734375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생하는 백신 실패의 모든",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        407.42724609375,
        383.7916564941406,
        433.32269287109375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고서를 확인할 것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.1179962158203,
        407.42724609375,
        383.7916564941406,
        433.32269287109375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가권자는 의약전문인에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "a) 프리베나13과 프리베나의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차별점, 예를 들어 포장, 제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품 라벨과 시린지 및 바늘",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "덮개의 색상 차이와 b) 프리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "베나로 백신 접종을 시작하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 어린이들에게 프리베나13",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 전환하는 방법에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를 알릴 것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        200.0538787841797,
        538.8679809570312,
        326.0399475097656
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "앞으로 수집될 이상사례 보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        343.0575866699219,
        538.8676147460938,
        411.86614990234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고서가 접종된 백신의 종류",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        343.0575866699219,
        538.8676147460938,
        411.86614990234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "와 명확하게 연결될 수 있도",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        343.0575866699219,
        538.8676147460938,
        411.86614990234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "록 허가권자는 두 백신이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        343.0575866699219,
        538.8676147460938,
        411.86614990234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "batch",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        343.0575866699219,
        538.8676147460938,
        411.86614990234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "no.(체계),",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        343.0575866699219,
        538.8676147460938,
        411.86614990234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시린지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        343.0575866699219,
        538.8676147460938,
        411.86614990234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "plunger 및 바늘 덮개의 색",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        414.619384765625,
        533.3508911132812,
        469.1635437011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상 및 carton 포장과 라벨에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        414.619384765625,
        533.3508911132812,
        469.1635437011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서 차이를 가지도록 할 것이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        414.619384765625,
        533.3508911132812,
        469.1635437011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.5893859863281,
        414.619384765625,
        533.3508911132812,
        469.1635437011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 33 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<Sinflorix>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        98.99178314208984,
        151.88232421875,
        114.93435668945312
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        128.62693786621094,
        128.5703125,
        141.2693634033203
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        151.9864044189453,
        516.64892578125,
        163.61744689941406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GlaxoSmithKline Biologicals S.A.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        151.9864044189453,
        516.64892578125,
        163.61744689941406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        151.9864044189453,
        516.64892578125,
        163.61744689941406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2009.03.30(EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        151.9864044189453,
        516.64892578125,
        163.61744689941406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        218.63356018066406,
        100.14572143554688,
        230.2646026611328
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Synflorix suspension for injection in",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "pre-filled syringe",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Synflorix suspension for injection",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Synflorix suspension for injection in",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "multidose container (2 doses)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Synflorix suspension for injection in",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "multidose container (4 doses)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴구균 다당류 접합 백신 (흡착)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        168.648193359375,
        326.2223205566406,
        280.3698425292969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        358.9654541015625,
        204.36915588378906,
        424.9293518066406,
        244.64889526367188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획   번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        358.9654541015625,
        204.36915588378906,
        424.9293518066406,
        244.64889526367188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        358.9654541015625,
        204.36915588378906,
        424.9293518066406,
        244.64889526367188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver. 3",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        445.4385986328125,
        218.63356018066406,
        476.8615417480469,
        230.2646026611328
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        285.4006042480469,
        122.09382629394531,
        311.2960510253906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        285.4006042480469,
        122.09382629394531,
        311.2960510253906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CRM197 단백질 접합, 알루미늄 포스페이트 흡착",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        285.4006042480469,
        514.0413818359375,
        311.2960510253906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        285.4006042480469,
        514.0413818359375,
        311.2960510253906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능 효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        344.8556213378906,
        116.57682037353516,
        356.4866638183594
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        316.3268127441406,
        531.791748046875,
        385.1353454589844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        316.3268127441406,
        531.791748046875,
        385.1353454589844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        316.3268127441406,
        531.791748046875,
        385.1353454589844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        316.3268127441406,
        531.791748046875,
        385.1353454589844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "렴에 대한 예방 (예방에 대한 능동 면역)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        316.3268127441406,
        531.791748046875,
        385.1353454589844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법 용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        557.86279296875,
        116.57682037353516,
        569.4938354492188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ 생후 6주에서 생후 6개월까지의 영아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        142.48277282714844,
        393.04296875,
        339.4160461425781,
        404.67401123046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3회 기초접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종으로 구성된다. 기초 접종은 3회 접종으로 구성되고, 첫번째 접종은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다. 첫번째",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종은 생후 6주에도 할 수 있다. 추가(4번째) 접종은 마지막 기초 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. (생후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2회 기초접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.5mL씩 3회 접종된다. 첫번째 접종은 생후 6주에도 가능하며, 접종 2개월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후 두번째 접종을 한다. 추가(세번째) 접종은 최소한 마지막 기초 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. (생후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        155.91746520996094,
        412.34185791015625,
        538.5081787109375,
        595.6253051757812
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 조산아 (임신 27-36주 사이 출생)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        142.48277282714844,
        612.5230712890625,
        318.7572326660156,
        624.1541137695312
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        631.8219604492188,
        538.5081787109375,
        686.3661499023438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        631.8219604492188,
        538.5081787109375,
        686.3661499023438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종 간격은 최소 1개월로 한다. 추가(4번째) 접종은 기초 접종 이후 최소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        631.8219604492188,
        538.5081787109375,
        686.3661499023438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6개월 이후에 하는 것이 권장된다. (4.4항과 5.1항 참고).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        631.8219604492188,
        538.5081787109375,
        686.3661499023438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        142.48277282714844,
        703.3837890625,
        443.7594909667969,
        715.0148315429688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        722.6826782226562,
        538.5081787109375,
        734.313720703125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 34 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 안전성 중점 검토 항목 및 조치 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        238.7865447998047,
        284.48583984375,
        251.42897033691406
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되며 접종 간격은 최소 1개월로 한다. 추가(세번째) 접종은 그 다음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        103.67919158935547,
        538.5078125,
        172.6076202392578
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        103.67919158935547,
        538.5078125,
        172.6076202392578
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진행한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        103.67919158935547,
        538.5078125,
        172.6076202392578
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        103.67919158935547,
        538.5078125,
        172.6076202392578
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종 간격은 최소 2개월로 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        156.63510131835938,
        103.67919158935547,
        538.5078125,
        172.6076202392578
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        189.50540161132812,
        532.9907836914062,
        215.52072143554688
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 것이 권장된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        140.80369567871094,
        189.50540161132812,
        532.9907836914062,
        215.52072143554688
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점 검토   항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        262.1460266113281,
        514.6410522460938,
        273.7770690917969
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        262.1460266113281,
        514.6410522460938,
        273.7770690917969
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화 조치   방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        262.1460266113281,
        514.6410522460938,
        273.7770690917969
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        281.6846618652344,
        177.02371215820312,
        293.3157043457031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "열성 경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        448.4224548339844,
        116.57682037353516,
        460.0534973144531
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상 자료를 추가적으로 통합",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        369.78839111328125,
        383.5517883300781,
        424.33251953125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 결과가 위해성 관리계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        369.78839111328125,
        383.5517883300781,
        424.33251953125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "버전 3에 기재되어 있다. (자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        369.78839111328125,
        383.5517883300781,
        424.33251953125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료 마감 시점 2018-06-15)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        369.78839111328125,
        383.5517883300781,
        424.33251953125
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "COMPAS 임상시험의 추가 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        441.35015869140625,
        383.5517883300781,
        481.5100402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종 기간 동안 경련(열성 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        441.35015869140625,
        383.5517883300781,
        481.5100402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비열성)을 수집",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        441.35015869140625,
        383.5517883300781,
        481.5100402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기적인 최신 안전성 보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        498.5276794433594,
        378.1550598144531,
        538.807373046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 통한 열성 경련 발생 사례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        498.5276794433594,
        378.1550598144531,
        538.807373046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 모니터링",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        498.5276794433594,
        378.1550598144531,
        538.807373046875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "열성 경련에 대한 내용은 EU",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 제출한 SmPC의 4.8항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 의약전문인은 신플로릭",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스 접종 후 열성 경련이 일어",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "날 수 있다는 정보를 얻을 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 열성 경련은 고위험군",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 확인된 일부 인구집단에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 발생하는 매우 드문 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사례이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EU에 제출된 SmPC의 4.4항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 다음과 같이 기술하고 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“백일해 균이 포함된 백신과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신플로릭스를 동시에 접종 받",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 모든 어린이와 이전에 열",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성 경련 경험이 있거나 경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성 질환을 가진 어린이에게는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열반응이 나타날 가능성이 높",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으므로 예방적 해열제가 권장",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된다(4.8항 참고).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해열제 처방은 각국의 지침에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 이루어져야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        298.2265930175781,
        544.1450805664062,
        610.2493286132812
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "격리 질환의 혈청형 치환 가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        655.3162841796875,
        217.442138671875,
        681.3316040039062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "능성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        655.3162841796875,
        217.442138671875,
        681.3316040039062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ GSK는 침습성 질환/돌발 감",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        612.4031982421875,
        378.0351257324219,
        624.0342407226562
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "염/백신 실패/혈청형 치환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능성/집단 면역/항생제 내",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성 균주를 모니터할 시판후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조사 연구 수행의 타당성을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토 중이다. 연구 기간은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5년이며, 신플로릭스의 연",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구가 수행되는 지역에서 사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용 지속 여부에 달렸다. 회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        626.7874755859375,
        383.5517883300781,
        738.5091552734375
      ],
      "page_num": 39,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        669.7005615234375,
        437.76275634765625,
        681.3316040039062
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 35 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사는 다음의 조건들이 충족",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        100.44273376464844,
        383.5517883300781,
        183.5157012939453
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "될 때 신플로릭스를 사용하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        100.44273376464844,
        383.5517883300781,
        183.5157012939453
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 국가에서 침습성 질환의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        100.44273376464844,
        383.5517883300781,
        183.5157012939453
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인과 모니터링을 위한 역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        100.44273376464844,
        383.5517883300781,
        183.5157012939453
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 조사의 강화를 지원할",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        100.44273376464844,
        383.5517883300781,
        183.5157012939453
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.79058837890625,
        100.44273376464844,
        383.5517883300781,
        183.5157012939453
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 해당 국가의 접종 권역이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.9105224609375,
        189.83229064941406,
        383.5517883300781,
        203.06539916992188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시기절적하게 시판후 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        205.56784057617188,
        378.15472412109375,
        245.7277069091797
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 주 목적을 만족시키기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        205.56784057617188,
        378.15472412109375,
        245.7277069091797
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 충분할 때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        205.56784057617188,
        378.15472412109375,
        245.7277069091797
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 해당 국가가 전국적인 폐",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.9105224609375,
        252.04429626464844,
        378.0351257324219,
        265.27740478515625
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "렴구균성 질환 감시 체계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        267.77984619140625,
        378.1550598144531,
        293.6753234863281
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 갖추고 있을 때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        267.77984619140625,
        378.1550598144531,
        293.6753234863281
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 국가가 시기절적하게 돌",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        301.3431701660156,
        383.5517883300781,
        370.1517333984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발 감염/백신 실패/혈청형 치",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        301.3431701660156,
        383.5517883300781,
        370.1517333984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환 가능성의 조사가 가능할",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        301.3431701660156,
        383.5517883300781,
        370.1517333984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만큼의 최소한의 폐렴구균성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        301.3431701660156,
        383.5517883300781,
        370.1517333984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환 발생이 발생할 때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        301.3431701660156,
        383.5517883300781,
        370.1517333984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만삭 및 조산아의 무호흡증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        486.780517578125,
        204.48883056640625,
        498.41156005859375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "study 10PN-PD-DIT- 015의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        408.1464538574219,
        383.5517883300781,
        462.69061279296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 결과가 위해성 관리 계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        408.1464538574219,
        383.5517883300781,
        462.69061279296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획 버전 3 1.2.2.2.1항과 별첨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        408.1464538574219,
        383.5517883300781,
        462.69061279296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7에 기재되어 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        408.1464538574219,
        383.5517883300781,
        462.69061279296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study 10PN-PD-DIT-016 BST:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        479.58837890625,
        383.55145263671875,
        505.60369873046875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "015",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        479.58837890625,
        383.55145263671875,
        505.60369873046875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조산아/저체중아 및 만삭 아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        522.50146484375,
        383.5514831542969,
        577.0455932617188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기의 시판후 사례는 정기적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        522.50146484375,
        383.5514831542969,
        577.0455932617188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최신 안전성 보고서에서 논의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        522.50146484375,
        383.5514831542969,
        577.0455932617188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "될 것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        522.50146484375,
        383.5514831542969,
        577.0455932617188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU에 제출한 SmPC의 4.4항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음과 같이 기술하고 있다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“기초 접종이 아주 조산아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(28주 이하), 특히 호흡 미숙",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 대한 이력을 가지고 있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조산아에게 접종되었을 때 무",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "호흡의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        372.3056335449219,
        544.144775390625,
        469.76287841796875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "48-72시간 동안 호흡 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "링의 필요성이 고려되어야 한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.이 영아군에서의 접종으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인한 이익이 크기 때문에 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종을 보류하거나 지연해서는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안된다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 내용은 의사에게 적절히",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려질 것이고, 이 내용이 취",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약한 어린이 집단에서의 무호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "흡 위험을 관리할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        472.51611328125,
        544.144775390625,
        612.8864135742188
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "돌발 감염/백신 실패 가능성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        665.1455688476562,
        207.96728515625,
        676.776611328125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일상적인 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        615.0403442382812,
        383.5534362792969,
        698.233154296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능 부족을 의심하게 하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        615.0403442382812,
        383.5534362792969,
        698.233154296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례들은 별도로 정기적인 최",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        615.0403442382812,
        383.5534362792969,
        698.233154296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신 안전성 보고서에서 논의될",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        615.0403442382812,
        383.5534362792969,
        698.233154296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        615.0403442382812,
        383.5534362792969,
        698.233154296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        615.0403442382812,
        383.5534362792969,
        698.233154296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        615.0403442382812,
        383.5534362792969,
        698.233154296875
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10PN-PD-DIT-043",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        700.8665161132812,
        378.1550598144531,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "• GSK는 침습성 질환/돌발 감",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        700.8665161132812,
        378.1550598144531,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EU에 제출한 SmPC의 4.4항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음과 같이 기술하고 있다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“다른 백신과 마찬가지로,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신플로릭스가 접종한 모든 사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "람에게 백신이 포함한 혈청형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 의한 침습성 질환 또는 중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이염에 대한 면역 효과가 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 것은 아니다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        615.0403442382812,
        544.1454467773438,
        726.761962890625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 36 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "염/백신 실패/혈청형 치환 가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "능성/집단 면역/항생제 내성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "균주를 모니터할 시판후조사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 수행의 타당성을 검토",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중이다. 연구 기간은 5년이며,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신플로릭스의 연구가 수행되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 지역에서 사용 지속 여부",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 달렸다. 회사는 다음의 조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "건들이 충족될 때 신플로릭스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "를 사용하는 국가에서 침습성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환의 확인과 모니터링을 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 역할 조사의 강화를 지원",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할 것이다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        100.44273376464844,
        383.5517883300781,
        283.7261962890625
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 해당 국가의 접종 권역이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.9105224609375,
        285.0082702636719,
        383.5517883300781,
        298.24139404296875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시기절적하게 시판후 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        300.62396240234375,
        378.15472412109375,
        340.9036865234375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 주 목적을 만족시키기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        300.62396240234375,
        378.15472412109375,
        340.9036865234375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 충분할 때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        300.62396240234375,
        378.15472412109375,
        340.9036865234375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 해당 국가가 전국적인 폐",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        238.9105224609375,
        347.22027587890625,
        378.0351257324219,
        360.4533996582031
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "렴구균성 질환 감시 체계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        362.8359680175781,
        378.1550598144531,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 갖추고 있을 때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        245.8667449951172,
        362.8359680175781,
        378.1550598144531,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 국가가 시기절적하게 돌",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        396.5191650390625,
        383.5517883300781,
        465.3277282714844
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발 감염/백신 실패/혈청형 치",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        396.5191650390625,
        383.5517883300781,
        465.3277282714844
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환 가능성의 조사가 가능할",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        396.5191650390625,
        383.5517883300781,
        465.3277282714844
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만큼의 최소한의 폐렴구균성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        396.5191650390625,
        383.5517883300781,
        465.3277282714844
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환 발생이 발생할 때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        396.5191650390625,
        383.5517883300781,
        465.3277282714844
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신의 폐렴구균 혈청형으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인한 중이염에 대한 예방은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "침습적 질환에 대한 예방 효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과보다 대체로 낮을 것으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예상된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "게다가 중이염은 백신에 있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐렴구균 혈청형들보다 많은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미생물에 의해 발생하기 때문",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 중이염에 대한 전반적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방 효과는 제한적이다. (5.1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항 참고)”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 내용은 의사에게 적절히",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려질 것이고, 이 내용이 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "러한 환자군에서의 위험을 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        176.91915893554688,
        544.144775390625,
        388.8512878417969
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시판후 기간 동안 발생하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        539.0433959960938,
        222.95883178710938,
        579.2032470703125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예기치 않은 안전성 실마리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        539.0433959960938,
        222.95883178710938,
        579.2032470703125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        539.0433959960938,
        222.95883178710938,
        579.2032470703125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• 일상적인 실마리 정보 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "업무 (위해성 관리 계획 버전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3 2.1.1항 참고)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "• study 10PN-PD-DIT-043의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체계 안에서, 연구에 등록된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험대상자들로부터(신플로릭",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스를 접종 받은 약 100,000명)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "얻어진 핀란드 입원 데이터베",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이스 등록 자료는 시판 후 기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간 동안 발생한 예기치 않은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 실마리 정보를 깊이있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "게 평가할 수 있게 할 것이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        467.48162841796875,
        383.5517883300781,
        650.7650146484375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        553.3078002929688,
        437.76275634765625,
        564.9388427734375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        655.7957763671875,
        155.07595825195312,
        667.4268188476562
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조산아/저체중아에 대한 임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        686.7219848632812,
        222.95883178710938,
        712.617431640625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        686.7219848632812,
        222.95883178710938,
        712.617431640625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study 10PN-PD-DIT-034.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        679.5298461914062,
        383.5517883300781,
        719.8095703125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기적인 최신 안전성 보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        679.5298461914062,
        383.5517883300781,
        719.8095703125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모니터링.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        679.5298461914062,
        383.5517883300781,
        719.8095703125
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU에 제출한 SmPC의 4.4항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        672.4575805664062,
        544.144775390625,
        727.001708984375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음과 같이 기술하고 있다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        672.4575805664062,
        544.144775390625,
        727.001708984375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“면역 억제 치료, 유전적 결",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        672.4575805664062,
        544.144775390625,
        727.001708984375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함, HIV 감염 또는 다른 이유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        672.4575805664062,
        544.144775390625,
        727.001708984375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 37 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 의해 면역 반응 장애가 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 어린이들은 접종에 의한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체 반응이 감소될 수 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EU에 제출한 SmPC의 4.5항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음과 같이 기술하고 있다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“다른 백신과 마찬가지로 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역 억제 치료를 받는 환자에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 저절한 반응이 유도되지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않을 수도 있다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 내용은 의사에게 적절히",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려질 것이고, 이 내용이 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "러한 환자군에서의 위험을 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        100.44273376464844,
        544.144775390625,
        297.9906005859375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "겸형 적혈구증, 비장결손, 신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        371.7062683105469,
        222.95883178710938,
        411.86614990234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장 증후군이 있는 어린이에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        371.7062683105469,
        222.95883178710938,
        411.86614990234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 자료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.04366302490234,
        371.7062683105469,
        222.95883178710938,
        411.86614990234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일상적인 약물감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        357.3219909667969,
        383.5517883300781,
        426.25042724609375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특수 환자군에 대한 내용은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        357.3219909667969,
        383.5517883300781,
        426.25042724609375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "별도의 정기적인 최신 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        357.3219909667969,
        383.5517883300781,
        426.25042724609375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고서 항목에서 논의될 것이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        357.3219909667969,
        383.5517883300781,
        426.25042724609375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        227.63662719726562,
        357.3219909667969,
        383.5517883300781,
        426.25042724609375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU에 제출한 SmPC의 4.4항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다음과 같이 기술하고 있다:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“폐렴구균성 감염 위험이 높",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은 어린이(겸형 적혈구증, 선",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "천성 또는 후천성 비장 기능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애, HIV 감염, 악성 종양,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신장 증후군)의 이용 가능한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성과 면역원성 자료는 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 내용은 의사에게 적절히",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알려질 것이고, 이 내용이 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "러한 환자군에서의 위험을 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "리할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.2295837402344,
        300.1445007324219,
        544.1454467773438,
        483.4279479980469
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 38 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-3",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        61.64658737182617,
        109.06077575683594,
        217.20228576660156,
        125.00334930419922
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수막구균 백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        61.64658737182617,
        109.06077575683594,
        217.20228576660156,
        125.00334930419922
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<Menveo>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        162.16273498535156,
        155.00076293945312,
        178.10531616210938
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        191.6780242919922,
        128.5703125,
        204.32044982910156
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        392.8182067871094,
        260.4988098144531,
        405.46063232421875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        418.5750732421875,
        488.25506591796875,
        430.20611572265625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        418.5750732421875,
        488.25506591796875,
        430.20611572265625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        418.5750732421875,
        488.25506591796875,
        430.20611572265625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        439.9117431640625,
        171.62664794921875,
        451.54278564453125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이알/프리필드시린지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        463.16632080078125,
        189.13824462890625,
        489.0617980957031
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PFS) 내 반투명 입자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        463.16632080078125,
        189.13824462890625,
        489.0617980957031
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이알/PFS에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        463.16632080078125,
        379.11419677734375,
        474.79736328125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이알/바이알로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        463.16632080078125,
        379.11419677734375,
        474.79736328125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포장 변경 및 첨부문서 변경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        477.4307556152344,
        342.29449462890625,
        489.0617980957031
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이알/PFS에서 바이알/바이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        455.97418212890625,
        533.2306518554688,
        496.2539367675781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알로 포장 변경 및 첨부문서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        455.97418212890625,
        533.2306518554688,
        496.2539367675781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        455.97418212890625,
        533.2306518554688,
        496.2539367675781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        500.6853332519531,
        171.62664794921875,
        512.3163452148438
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "길랑바레증후군",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        531.1320190429688,
        138.64419555664062,
        542.7630615234375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질문지 사용과 안전관리부서 판정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        516.8676147460938,
        373.5975341796875,
        557.1473388671875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 통한 추가 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        516.8676147460938,
        373.5975341796875,
        557.1473388671875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Studies V59_54 and 34",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        516.8676147460938,
        373.5975341796875,
        557.1473388671875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        531.1320190429688,
        433.20489501953125,
        542.7630615234375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "급성파종성뇌척수염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        573.565673828125,
        160.71221923828125,
        585.1967163085938
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질문지 사용과 안전관리부서 판정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        559.3012084960938,
        373.5975341796875,
        599.5809936523438
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 통한 추가 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        559.3012084960938,
        373.5975341796875,
        599.5809936523438
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Studies V59_54 and 34",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        559.3012084960938,
        373.5975341796875,
        599.5809936523438
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        573.565673828125,
        433.20489501953125,
        585.1967163085938
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아나필락시스 반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        601.73486328125,
        433.20489501953125,
        627.6303100585938
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        601.73486328125,
        433.20489501953125,
        627.6303100585938
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Studies V59_54 and 34",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        601.73486328125,
        433.20489501953125,
        627.6303100585938
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        601.73486328125,
        433.20489501953125,
        627.6303100585938
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 감소증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        629.7842407226562,
        433.20489501953125,
        655.799560546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        629.7842407226562,
        433.20489501953125,
        655.799560546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Studies V59_54 and 34",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        629.7842407226562,
        433.20489501953125,
        655.799560546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        629.7842407226562,
        433.20489501953125,
        655.799560546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가와사키병과 혈관염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        657.9534301757812,
        433.20489501953125,
        683.848876953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질문지 사용과 안전관리부서 판정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        657.9534301757812,
        433.20489501953125,
        683.848876953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 통한 추가 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        657.9534301757812,
        433.20489501953125,
        683.848876953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        657.9534301757812,
        433.20489501953125,
        683.848876953125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상완 신경염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        686.0027465820312,
        433.20489501953125,
        712.01806640625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        686.0027465820312,
        433.20489501953125,
        712.01806640625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Studies V59_54 and 34",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        686.0027465820312,
        433.20489501953125,
        712.01806640625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        686.0027465820312,
        433.20489501953125,
        712.01806640625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사지부종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        719.3263549804688,
        433.20489501953125,
        731.3170166015625
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        719.3263549804688,
        433.20489501953125,
        731.3170166015625
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        719.3263549804688,
        433.20489501953125,
        731.3170166015625
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.28050231933594,
        465.4390869140625,
        238.17596435546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GSK",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.28050231933594,
        465.4390869140625,
        238.17596435546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.28050231933594,
        465.4390869140625,
        238.17596435546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2010.02.19",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.28050231933594,
        465.4390869140625,
        238.17596435546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(International Birth Date)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.28050231933594,
        465.4390869140625,
        238.17596435546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        245.8438262939453,
        396.5046691894531,
        271.7392883300781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Menveo",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        245.8438262939453,
        396.5046691894531,
        271.7392883300781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 관리 계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        245.8438262939453,
        396.5046691894531,
        271.7392883300781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호 (버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        245.8438262939453,
        396.5046691894531,
        271.7392883300781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Version 7.2",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        245.8438262939453,
        396.5046691894531,
        271.7392883300781
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        282.28399658203125,
        532.8706665039062,
        308.1794738769531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        282.28399658203125,
        532.8706665039062,
        308.1794738769531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(상세내용 생략)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        282.28399658203125,
        532.8706665039062,
        308.1794738769531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능·효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        316.0870666503906,
        532.9913330078125,
        341.9825134277344
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        316.0870666503906,
        532.9913330078125,
        341.9825134277344
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 Y 군에 의한 침습성 수막구균 질환의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        316.0870666503906,
        532.9913330078125,
        341.9825134277344
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        347.0132751464844,
        271.53216552734375,
        372.9087219238281
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1회 0.5mg   근육주사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        347.0132751464844,
        271.53216552734375,
        372.9087219238281
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(상세내용 생략)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        347.0132751464844,
        271.53216552734375,
        372.9087219238281
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 39 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주사부위 반응(중증)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        105.59709930419922,
        433.20489501953125,
        117.58773803710938
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        105.59709930419922,
        433.20489501953125,
        117.58773803710938
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        105.59709930419922,
        433.20489501953125,
        117.58773803710938
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전신 반응(중증)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        129.69076538085938,
        433.20489501953125,
        141.68141174316406
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        129.69076538085938,
        433.20489501953125,
        141.68141174316406
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        129.69076538085938,
        433.20489501953125,
        141.68141174316406
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신기능상실",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        148.63006591796875,
        433.20489501953125,
        174.52552795410156
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질문지 사용과 안전관리부서 판정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        148.63006591796875,
        433.20489501953125,
        174.52552795410156
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 통한 추가 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        148.63006591796875,
        433.20489501953125,
        174.52552795410156
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        148.63006591796875,
        433.20489501953125,
        174.52552795410156
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        181.8337860107422,
        144.16152954101562,
        193.46482849121094
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 수유 중 백신 안전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        207.96522521972656,
        189.13714599609375,
        233.9805450439453
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        207.96522521972656,
        189.13714599609375,
        233.9805450439453
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        200.89295959472656,
        379.1143798828125,
        226.7884063720703
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "US",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        200.89295959472656,
        379.1143798828125,
        226.7884063720703
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        200.89295959472656,
        379.1143798828125,
        226.7884063720703
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "레지스트리와",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        200.89295959472656,
        379.1143798828125,
        226.7884063720703
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "case",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        200.89295959472656,
        379.1143798828125,
        226.7884063720703
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "control study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        229.42178344726562,
        263.7474060058594,
        241.05282592773438
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.6: 임부에 대한 임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        207.96522521972656,
        527.713623046875,
        233.9805450439453
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료는 불충분하다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        207.96522521972656,
        527.713623046875,
        233.9805450439453
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역기능 이상 환자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        264.66326904296875,
        270.8128967285156,
        276.2943115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        264.66326904296875,
        270.8128967285156,
        276.2943115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.4: 면역 저하 환자에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        243.2067108154297,
        533.2310180664062,
        297.7508544921875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서 백신 접종으로 적절한 항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        243.2067108154297,
        533.2310180664062,
        297.7508544921875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체 반응이 나타나지 않을 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        243.2067108154297,
        533.2310180664062,
        297.7508544921875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        243.2067108154297,
        533.2310180664062,
        297.7508544921875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출혈 장애 환자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        357.2021179199219,
        270.8128967285156,
        368.8331604003906
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        357.2021179199219,
        270.8128967285156,
        368.8331604003906
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC   4.4: Menveo는 혈소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "판감소증 환자, 출혈 장애",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자 및 혈종의 위험 때문에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항응고 요법을 받고 있는 환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자에서는 평가되지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보건의료전문가가 혈종의 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험이 있는 사람의 경우 근육",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주사 후의 위험-혜택에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비율을 평가해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        300.0246276855469,
        533.2306518554688,
        426.01068115234375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중대한 급성, 만성 또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        428.1645812988281,
        433.20489501953125,
        454.1799011230469
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진행성 질환 환자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        428.1645812988281,
        433.20489501953125,
        454.1799011230469
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        428.1645812988281,
        433.20489501953125,
        454.1799011230469
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        428.1645812988281,
        433.20489501953125,
        454.1799011230469
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "길랑바레증후군의 병력",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        461.4881591796875,
        433.20489501953125,
        473.11920166015625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        461.4881591796875,
        433.20489501953125,
        473.11920166015625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        461.4881591796875,
        433.20489501953125,
        473.11920166015625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고령자에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        494.6918640136719,
        194.6541748046875,
        506.3229064941406
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        494.6918640136719,
        194.6541748046875,
        506.3229064941406
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성 자료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        501.8840026855469,
        270.8128967285156,
        520.7071533203125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        501.8840026855469,
        270.8128967285156,
        520.7071533203125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.2: 56~65세 사람들에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        480.4274597167969,
        533.2306518554688,
        534.9715576171875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 자료는 충분하지 않다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        480.4274597167969,
        533.2306518554688,
        534.9715576171875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "65세 이상 고령자에 대한 자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        480.4274597167969,
        533.2306518554688,
        534.9715576171875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료는 존재하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        480.4274597167969,
        533.2306518554688,
        534.9715576171875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가 접종을 포함한 반복",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        580.03857421875,
        194.6541748046875,
        606.0538940429688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용량 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        580.03857421875,
        194.6541748046875,
        606.0538940429688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        537.12548828125,
        378.99530029296875,
        563.1408081054688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지속성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        537.12548828125,
        378.99530029296875,
        563.1408081054688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        537.12548828125,
        378.99530029296875,
        563.1408081054688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        537.12548828125,
        378.99530029296875,
        563.1408081054688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        537.12548828125,
        378.99530029296875,
        563.1408081054688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "V59P20E1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        565.774169921875,
        379.1145324707031,
        648.9669799804688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2~10세 소아에게 1회 접종과 2 회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        565.774169921875,
        379.1145324707031,
        648.9669799804688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종을 비교하는 Study V59_57",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        565.774169921875,
        379.1145324707031,
        648.9669799804688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여행자 백신과 멘비오를 동시 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        565.774169921875,
        379.1145324707031,
        648.9669799804688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종하는 성인에 대한 연구:V59-38",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        565.774169921875,
        379.1145324707031,
        648.9669799804688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and V59_53",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        565.774169921875,
        379.1145324707031,
        648.9669799804688
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        587.230712890625,
        433.20489501953125,
        598.8617553710938
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2세 미만이나 off-label",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        679.6497192382812,
        194.65455627441406,
        705.6650390625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(허가외) 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        679.6497192382812,
        194.65455627441406,
        705.6650390625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반 약물감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        651.1209106445312,
        379.11419677734375,
        677.016357421875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "High",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        651.1209106445312,
        379.11419677734375,
        677.016357421875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Level",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        651.1209106445312,
        379.11419677734375,
        677.016357421875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Term",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        651.1209106445312,
        379.11419677734375,
        677.016357421875
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“Maladministrations (잘못 복용/접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        679.6497192382812,
        378.9949645996094,
        719.929443359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종)”과 Preferred Term “Drug",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        679.6497192382812,
        378.9949645996094,
        719.929443359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "administered",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        679.6497192382812,
        378.9949645996094,
        719.929443359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "to",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        679.6497192382812,
        378.9949645996094,
        719.929443359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "patients",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        679.6497192382812,
        378.9949645996094,
        719.929443359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        679.6497192382812,
        378.9949645996094,
        719.929443359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "inappropriate age (부적절한 연령",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        722.5628051757812,
        379.1145324707031,
        734.19384765625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.2: 멘비오는 2세 미",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        651.1209106445312,
        533.2306518554688,
        734.19384765625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만에서의 안전성과 유효성이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        651.1209106445312,
        533.2306518554688,
        734.19384765625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아직 확립되지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        651.1209106445312,
        533.2306518554688,
        734.19384765625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재까지의 자료는 5.1항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        651.1209106445312,
        533.2306518554688,
        734.19384765625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술되어 있으나 추천 용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        651.1209106445312,
        533.2306518554688,
        734.19384765625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "은 확립되지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        383.7919921875,
        651.1209106445312,
        533.2306518554688,
        734.19384765625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 40 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        188.68130493164062,
        390.02862548828125,
        201.32373046875
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 약물 복용/접종)”, “Off",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        100.44273376464844,
        379.1141662597656,
        169.25128173828125
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "label use (허가외 사용)”로 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        100.44273376464844,
        379.1141662597656,
        169.25128173828125
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된 증례 수 모니터링 – 정기안전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        100.44273376464844,
        379.1141662597656,
        169.25128173828125
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성보고서로 보건당국에 보고 될",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        100.44273376464844,
        379.1141662597656,
        169.25128173828125
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        199.33197021484375,
        100.44273376464844,
        379.1141662597656,
        169.25128173828125
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        214.4381561279297,
        410.417236328125,
        226.06919860839844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        214.4381561279297,
        410.417236328125,
        226.06919860839844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제출일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        214.4381561279297,
        410.417236328125,
        226.06919860839844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study V59_57",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        246.56304931640625,
        133.8470001220703,
        258.194091796875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2~10세 소아에게 멘비오 1회 또는 2회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        160.59295654296875,
        232.1787567138672,
        372.6376953125,
        272.45849609375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종시 단기와 장기 항체 역가를 평가하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        160.59295654296875,
        232.1787567138672,
        372.6376953125,
        272.45849609375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        160.59295654296875,
        232.1787567138672,
        372.6376953125,
        272.45849609375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        239.37091064453125,
        530.2316284179688,
        251.001953125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험결과보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        239.37091064453125,
        530.2316284179688,
        251.001953125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2014년 4분기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        253.63531494140625,
        448.9163513183594,
        265.266357421875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study V59_34OB",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        281.8045349121094,
        367.240966796875,
        307.6999816894531
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11~20세 피험자에게 MenACWY의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        281.8045349121094,
        367.240966796875,
        307.6999816894531
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 평가하는 4상 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        281.8045349121094,
        367.240966796875,
        307.6999816894531
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기안전성보고서 매년 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        274.6123962402344,
        531.3117065429688,
        314.8921203613281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 임상시험 결과보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        274.6123962402344,
        531.3117065429688,
        314.8921203613281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2015년 8월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        274.6123962402344,
        531.3117065429688,
        314.8921203613281
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study V59_54OB",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        331.3104248046875,
        372.63739013671875,
        357.32574462890625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2~10세 집단에서 MenACWY의 안전성을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        331.3104248046875,
        372.63739013671875,
        357.32574462890625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하는 4상 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        331.3104248046875,
        372.63739013671875,
        357.32574462890625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간 보고서 배년 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        317.0460205078125,
        531.3117065429688,
        371.59014892578125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정기안전성보고서 매년 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        317.0460205078125,
        531.3117065429688,
        371.59014892578125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 임상시험 결과보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        317.0460205078125,
        531.3117065429688,
        371.59014892578125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2015년 12월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        317.0460205078125,
        531.3117065429688,
        371.59014892578125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study V59P20E1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        388.0084533691406,
        141.52334594726562,
        399.6394958496094
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY 접합 백신의 소아 백신 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        160.59295654296875,
        373.7440490722656,
        372.6376953125,
        414.0237731933594
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5년 후 면역원성 유지 및 추가접종에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        160.59295654296875,
        373.7440490722656,
        372.6376953125,
        414.0237731933594
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 면역 반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        160.59295654296875,
        373.7440490722656,
        372.6376953125,
        414.0237731933594
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 임상시험 결과보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        380.9361877441406,
        530.2322998046875,
        406.8316345214844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2013년 말까지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        377.4354553222656,
        380.9361877441406,
        530.2322998046875,
        406.8316345214844
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study V59_38",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        416.17767333984375,
        530.2322998046875,
        442.0731201171875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여행자 백신과 멘비오를 동시 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        416.17767333984375,
        530.2322998046875,
        442.0731201171875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 임상시험 결과보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        416.17767333984375,
        530.2322998046875,
        442.0731201171875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2013년 2분기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        416.17767333984375,
        530.2322998046875,
        442.0731201171875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 41 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<Nimenrix>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        98.99178314208984,
        159.4384765625,
        114.93435668945312
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        128.62693786621094,
        128.5703125,
        141.2693634033203
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        329.5273742675781,
        260.4988098144531,
        342.1697998046875
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        149.1095428466797,
        474.6716003417969,
        175.12486267089844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GSK (구 허가권자)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        149.1095428466797,
        474.6716003417969,
        175.12486267089844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pfizer (현 허가권자)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        149.1095428466797,
        474.6716003417969,
        175.12486267089844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        149.1095428466797,
        474.6716003417969,
        175.12486267089844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2012.04.20(EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        149.1095428466797,
        474.6716003417969,
        175.12486267089844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        195.4988555908203,
        209.6378936767578,
        207.12989807128906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nimenrix",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        195.4988555908203,
        209.6378936767578,
        207.12989807128906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        318.66729736328125,
        181.23443603515625,
        398.7838439941406,
        192.865478515625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        318.66729736328125,
        181.23443603515625,
        398.7838439941406,
        192.865478515625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호 (버",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        318.66729736328125,
        195.4988555908203,
        393.2668762207031,
        221.51417541503906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        318.66729736328125,
        195.4988555908203,
        393.2668762207031,
        221.51417541503906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        227.62374877929688,
        473.982177734375,
        253.63906860351562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Meningococcal group A, C, W-135 and Y conjugate vaccine",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        227.62374877929688,
        473.982177734375,
        253.63906860351562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(상세 내용 생략)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        227.62374877929688,
        473.982177734375,
        253.63906860351562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능·효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        262.865234375,
        475.1824645996094,
        274.49627685546875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        262.865234375,
        475.1824645996094,
        274.49627685546875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        283.7224426269531,
        260.8581237792969,
        309.6178894042969
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "근육주사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        283.7224426269531,
        260.8581237792969,
        309.6178894042969
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(상세 내용 생략)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        283.7224426269531,
        260.8581237792969,
        309.6178894042969
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        355.28424072265625,
        457.79156494140625,
        366.915283203125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        355.28424072265625,
        457.79156494140625,
        366.915283203125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        355.28424072265625,
        457.79156494140625,
        366.915283203125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        377.9394836425781,
        171.62664794921875,
        389.5705261230469
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.7145690917969,
        375.27630615234375,
        412.7052307128906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.7145690917969,
        375.27630615234375,
        412.7052307128906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.7145690917969,
        375.27630615234375,
        412.7052307128906
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        423.36981201171875,
        171.62664794921875,
        435.0008544921875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "길랑바레 증후군",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        462.4471130371094,
        144.16152954101562,
        474.0781555175781
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        440.9905700683594,
        348.6523742675781,
        466.8860168457031
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Targeted",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        440.9905700683594,
        348.6523742675781,
        466.8860168457031
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Follow-up",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        440.9905700683594,
        348.6523742675781,
        466.8860168457031
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Questionnaire",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        469.5193786621094,
        335.45819091796875,
        495.5346984863281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        469.5193786621094,
        335.45819091796875,
        495.5346984863281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재는 위해성 완화조치가 필요하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        440.9905700683594,
        527.7139892578125,
        495.5346984863281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지 않음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        440.9905700683594,
        527.7139892578125,
        495.5346984863281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety signal이 탐지되는 경우 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        440.9905700683594,
        527.7139892578125,
        495.5346984863281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성 완화조치 필요여부 재평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        440.9905700683594,
        527.7139892578125,
        495.5346984863281
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자색반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        519.1451416015625,
        94.7483139038086,
        530.7761840820312
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        497.6885986328125,
        348.6523742675781,
        523.5840454101562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Targeted",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        497.6885986328125,
        348.6523742675781,
        523.5840454101562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Follow-up",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        497.6885986328125,
        348.6523742675781,
        523.5840454101562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Questionnaire",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        526.2174072265625,
        340.9751892089844,
        552.2327270507812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        526.2174072265625,
        340.9751892089844,
        552.2327270507812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재는 위해성 완화조치가 필요하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        497.6885986328125,
        527.7139892578125,
        552.2327270507812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지 않음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        497.6885986328125,
        527.7139892578125,
        552.2327270507812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety signal이 탐지되는 경우 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        497.6885986328125,
        527.7139892578125,
        552.2327270507812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성 완화조치 필요여부 재평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        497.6885986328125,
        527.7139892578125,
        552.2327270507812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈관염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        568.6510009765625,
        340.9751892089844,
        594.6663208007812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        568.6510009765625,
        340.9751892089844,
        594.6663208007812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        568.6510009765625,
        340.9751892089844,
        594.6663208007812
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재는 위해성 완화조치가 필요하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        554.3865966796875,
        527.7139892578125,
        608.9307250976562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지 않음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        554.3865966796875,
        527.7139892578125,
        608.9307250976562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety signal이 탐지되는 경우 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        554.3865966796875,
        527.7139892578125,
        608.9307250976562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성 완화조치 필요여부 재평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        554.3865966796875,
        527.7139892578125,
        608.9307250976562
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "급 성 파 종 성 뇌 척 수 염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        625.3490600585938,
        200.04930114746094,
        651.3643798828125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ADEM)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        625.3490600585938,
        200.04930114746094,
        651.3643798828125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        625.3490600585938,
        335.45819091796875,
        651.3643798828125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        625.3490600585938,
        335.45819091796875,
        651.3643798828125
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재는 위해성 완화조치가  필요",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        611.0846557617188,
        527.7139892578125,
        665.6287841796875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지 않음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        611.0846557617188,
        527.7139892578125,
        665.6287841796875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety signal이 탐지되는 경우 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        611.0846557617188,
        527.7139892578125,
        665.6287841796875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성 완화조치 필요여부 재평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        611.0846557617188,
        527.7139892578125,
        665.6287841796875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상완 신경염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        682.1669921875,
        335.45819091796875,
        708.0624389648438
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        682.1669921875,
        335.45819091796875,
        708.0624389648438
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        682.1669921875,
        335.45819091796875,
        708.0624389648438
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재는 위해성 완화조치가 필요하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        667.7826538085938,
        527.7139892578125,
        722.3268432617188
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지 않음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        667.7826538085938,
        527.7139892578125,
        722.3268432617188
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety signal이 탐지되는 경우 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        667.7826538085938,
        527.7139892578125,
        722.3268432617188
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성 완화조치 필요여부 재평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        667.7826538085938,
        527.7139892578125,
        722.3268432617188
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 42 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아나필락시스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        136.1636962890625,
        335.45819091796875,
        162.05914306640625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        136.1636962890625,
        335.45819091796875,
        162.05914306640625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        136.1636962890625,
        335.45819091796875,
        162.05914306640625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU SmPC에 다음 내용 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        527.7139892578125,
        197.8999786376953
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.3:“활성 물질 또는 부형제에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        527.7139892578125,
        197.8999786376953
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 과민성\"은 금기 사항으로 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        527.7139892578125,
        197.8999786376953
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.4: \"백신 접종 후 드물게 발생하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        527.7139892578125,
        197.8999786376953
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 아나필락시스를 대비하여 적절",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        527.7139892578125,
        197.8999786376953
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 치료와 감독이 항상 가능해야",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        527.7139892578125,
        197.8999786376953
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합니다.\"라고 명시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        527.7139892578125,
        197.8999786376953
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수막구균 역학/혈청 그룹",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        200.05157470703125,
        240.33360290527344
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "교체의 변화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        200.05157470703125,
        240.33360290527344
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 ECDC 보고서 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        200.0538787841797,
        348.6510314941406,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국가별 MenACWY-TT의 분",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        200.0538787841797,
        348.6510314941406,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배 분포에 대한 정보를 매",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        200.0538787841797,
        348.6510314941406,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년 제공",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        200.0538787841797,
        348.6510314941406,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재는 위해성 완화조치가 필요하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        200.0538787841797,
        527.7139892578125,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지 않음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        200.0538787841797,
        527.7139892578125,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety signal이 탐지되는 경우 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        200.0538787841797,
        527.7139892578125,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성 완화조치 필요여부 재평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        200.0538787841797,
        527.7139892578125,
        254.5980224609375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효과부족",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        306.8571472167969,
        105.78233337402344,
        318.4881896972656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        256.7519226074219,
        348.6523742675781,
        282.6473693847656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Targeted",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        256.7519226074219,
        348.6523742675781,
        282.6473693847656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Follow-up",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        256.7519226074219,
        348.6523742675781,
        282.6473693847656
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Questionnaire",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        285.4006042480469,
        348.6510314941406,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        285.4006042480469,
        348.6510314941406,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 ECDC 보고서 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        285.4006042480469,
        348.6510314941406,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국가 별 MenACWY-TT의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        285.4006042480469,
        348.6510314941406,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분배 분포에 대한 정보를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        285.4006042480469,
        348.6510314941406,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "매년 제공",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        285.4006042480469,
        348.6510314941406,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU SmPC 4.4항에 다음 내용 기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "술:“어떤 백신접종자에게는 면역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응이 나타자지 않을 수도 있습",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지정된 기준 충족시, 회사는 감염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통제 기관이 설립된 개별 국가로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부터 혈청 그룹 분포 데이터를 얻",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        256.7519226074219,
        533.2306518554688,
        368.47357177734375
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈관내, 피내, 피하투여로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        385.0117492675781,
        200.05123901367188,
        410.9071960449219
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        385.0117492675781,
        200.05123901367188,
        410.9071960449219
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        385.0117492675781,
        340.9751892089844,
        410.9071960449219
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        385.0117492675781,
        340.9751892089844,
        410.9071960449219
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU SmPC 4.4항에 다음 내용 기술:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        370.747314453125,
        533.2306518554688,
        425.2914733886719
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "\"Nimenrix는 어떤 경우에도 혈관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        370.747314453125,
        533.2306518554688,
        425.2914733886719
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내, 피내, 피하로 접종하지 않아야",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        370.747314453125,
        533.2306518554688,
        425.2914733886719
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합니다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        370.747314453125,
        533.2306518554688,
        425.2914733886719
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출혈 위험이 있는 혈소판",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        448.90191650390625,
        199.93130493164062,
        489.0617980957031
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감소증 또는 응고 장애가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        448.90191650390625,
        199.93130493164062,
        489.0617980957031
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 사람에게 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        448.90191650390625,
        199.93130493164062,
        489.0617980957031
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        455.97418212890625,
        335.45819091796875,
        481.989501953125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        455.97418212890625,
        335.45819091796875,
        481.989501953125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU SmPC 4.4항에 다음 내용 기술:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        427.44537353515625,
        533.2306518554688,
        510.5183410644531
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nimenrix를 혈소판 감소증 또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        427.44537353515625,
        533.2306518554688,
        510.5183410644531
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응고 장애가 있는 사람에게 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        427.44537353515625,
        533.2306518554688,
        510.5183410644531
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시 주의를 기울여야합니다. 이러한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        427.44537353515625,
        533.2306518554688,
        510.5183410644531
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에게 IM 투여 후 출혈이 발생",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        427.44537353515625,
        533.2306518554688,
        510.5183410644531
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 수 있기 때문입니다",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        427.44537353515625,
        533.2306518554688,
        510.5183410644531
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "광범위한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        527.0564575195312,
        200.05157470703125,
        538.6875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사지부종/중증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        527.0564575195312,
        200.05157470703125,
        538.6875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주사부위 반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        541.3208618164062,
        133.24777221679688,
        552.951904296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        527.0564575195312,
        335.45819091796875,
        552.951904296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        527.0564575195312,
        335.45819091796875,
        552.951904296875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현재는 위해성 완화조치가 필요하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        512.7920532226562,
        527.7139892578125,
        567.336181640625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지 않음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        512.7920532226562,
        527.7139892578125,
        567.336181640625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety signal이 탐지되는 경우 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        512.7920532226562,
        527.7139892578125,
        567.336181640625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성 완화조치 필요여부 재평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        512.7920532226562,
        527.7139892578125,
        567.336181640625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        574.6444702148438,
        144.16152954101562,
        586.2755126953125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역 저하 및 면역 결핍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        643.6890258789062,
        200.05157470703125,
        669.58447265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(무비증 포함) 환자 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        643.6890258789062,
        200.05157470703125,
        669.58447265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study MenACY-TT084",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        636.4968872070312,
        338.43218994140625,
        676.776611328125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        636.4968872070312,
        338.43218994140625,
        676.776611328125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        636.4968872070312,
        338.43218994140625,
        676.776611328125
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU SmPC 4.4항에 다음 내용 기술:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "\"면역 억제 치료를 받는 환자나",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역 결핍 환자에게 적절한 면역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응이 유도되지 않을 수도 있습",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니다.\"및 \"말초의 보체 결핍 및 해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부학적 또는 기능적 무증상과 같",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "은 증상으로 인해 수막구균 감염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 대한 감수성이 증가된 환자에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서 안전성과 면역원성이 평가되지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        593.5838012695312,
        533.2306518554688,
        719.689697265625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 43 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        56.609317779541016,
        579.9620361328125,
        356.4465026855469,
        592.2608032226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PSUR: Periodic Safety Update Report 정기 안전성 보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        579.9620361328125,
        356.4465026855469,
        592.2608032226562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        56.609317779541016,
        598.6615600585938,
        497.0106506347656,
        610.9603271484375
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        598.6615600585938,
        497.0106506347656,
        610.9603271484375
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고 1. 연구목록",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        636.4968872070312,
        139.3641357421875,
        648.1279296875
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않았습니다. 이러한 사람에서는 적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        533.2306518554688,
        140.60260009765625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절한 면역 반응이 유도되지 않을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        533.2306518554688,
        140.60260009765625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있습니다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        100.44273376464844,
        533.2306518554688,
        140.60260009765625
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만성질환자 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        142.87635803222656,
        375.27630615234375,
        168.7718048095703
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        142.87635803222656,
        375.27630615234375,
        168.7718048095703
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        142.87635803222656,
        375.27630615234375,
        168.7718048095703
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        142.87635803222656,
        375.27630615234375,
        168.7718048095703
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신, 수유 중 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        292.4728698730469,
        335.45819091796875,
        318.4881896972656
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        292.4728698730469,
        335.45819091796875,
        318.4881896972656
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에 보고된 사례 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        292.4728698730469,
        335.45819091796875,
        318.4881896972656
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU SmPC 4.6항에 다음 내용 기술:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임산부에게 Nimenrix를 사용한 경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험은 제한적입니다. 동물 연구는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신, 태아/태아발달, 분만 또는 산",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후 발달과 관련하여 직접 또는 간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접적인 유해한 영향이 나타나지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않았습니다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nimenrix는 임신 중에는 꼭 필요",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 때만, 그리고 가능한 이점이 태",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아에 대한 잠재적 위험보다 많을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것으로 여겨질 때만 사용해야 합",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nimenrix가 모유에 포함되는지 여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부는 알려지지 않았습니다. 모유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수유 중에는 가능한 이점이 잠재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적인 위험보다 많은 경우에만",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nimenrix를 사용해야 합니다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        170.9257049560547,
        533.2306518554688,
        440.0353698730469
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 백신 반응 지속성 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        492.29449462890625,
        200.05157470703125,
        518.18994140625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가 접종 필요",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        492.29449462890625,
        200.05157470703125,
        518.18994140625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2상, 3상 연구의 연장 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        442.1892395019531,
        343.134033203125,
        496.7333984375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로 항체 지속성 및 추가 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        442.1892395019531,
        343.134033203125,
        496.7333984375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종 필요성 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        442.1892395019531,
        343.134033203125,
        496.7333984375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(참고1. Study list)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        442.1892395019531,
        343.134033203125,
        496.7333984375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가로 12~23개월에 1~2회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        513.7510375976562,
        348.6510314941406,
        568.295166015625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가 접종시 즉각적인 항체",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        513.7510375976562,
        348.6510314941406,
        568.295166015625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역가와 장기간의 항체역가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        513.7510375976562,
        348.6510314941406,
        568.295166015625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 평가하는 연구 시작",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        204.7290496826172,
        513.7510375976562,
        348.6510314941406,
        568.295166015625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        353.3284912109375,
        499.48663330078125,
        375.27630615234375,
        511.11767578125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        659.391845703125,
        292.7610168457031,
        671.0228881835938
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구제목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        659.391845703125,
        292.7610168457031,
        671.0228881835938
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-016/017/018/019/020",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        676.0536499023438,
        240.82693481445312,
        730.1182861328125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:015Y1/Y2/Y3/Y4/Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        676.0536499023438,
        240.82693481445312,
        730.1182861328125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-099",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        676.0536499023438,
        240.82693481445312,
        730.1182861328125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:015Y6/Y7/Y8/Y9/Y10);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        676.0536499023438,
        240.82693481445312,
        730.1182861328125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강한 청소년 및 성인에게 접종시 MenACWY-TT 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        704.1029663085938,
        532.9907836914062,
        730.1182861328125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        704.1029663085938,
        532.9907836914062,
        730.1182861328125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 44 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        554.521484375,
        390.02862548828125,
        567.1639404296875
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        100.44273376464844,
        527.47412109375,
        126.33818054199219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신 추가 접종 반응 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        100.44273376464844,
        527.47412109375,
        126.33818054199219
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-028/29/030/031/032",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        128.49208068847656,
        235.30992126464844,
        154.3875274658203
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:027 Y1/Y2/Y3/Y4/Y5);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        128.49208068847656,
        235.30992126464844,
        154.3875274658203
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-100",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        170.9257049560547,
        193.54177856445312,
        196.82115173339844
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:027Y6/Y7/Y8/Y9/Y10)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        170.9257049560547,
        193.54177856445312,
        196.82115173339844
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강한 청소년 및 성인에게 접종시 MenACWY-TT",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        156.6613006591797,
        532.9911499023438,
        211.2054443359375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        156.6613006591797,
        532.9911499023438,
        211.2054443359375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        156.6613006591797,
        532.9911499023438,
        211.2054443359375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT 백신 추가 접종 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        156.6613006591797,
        532.9911499023438,
        211.2054443359375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-059",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        227.62374877929688,
        169.22621154785156,
        253.51919555664062
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:052 Y1/Y3/Y5);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        227.62374877929688,
        169.22621154785156,
        253.51919555664062
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10~25세",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        213.3593292236328,
        532.9907836914062,
        224.99037170410156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        213.3593292236328,
        532.9907836914062,
        224.99037170410156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "청소년",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        213.3593292236328,
        532.9907836914062,
        224.99037170410156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        213.3593292236328,
        532.9907836914062,
        224.99037170410156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        213.3593292236328,
        532.9907836914062,
        224.99037170410156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        213.3593292236328,
        532.9907836914062,
        224.99037170410156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        227.62374877929688,
        527.47412109375,
        267.9034729003906
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        227.62374877929688,
        527.47412109375,
        267.9034729003906
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신 추가 접종 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        227.62374877929688,
        527.47412109375,
        267.9034729003906
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-062",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        284.32177734375,
        169.22621154785156,
        310.33709716796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:055 Y1/Y3/Y5);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        284.32177734375,
        169.22621154785156,
        310.33709716796875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9~12",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        270.057373046875,
        532.9911499023438,
        281.68841552734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개월의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        270.057373046875,
        532.9911499023438,
        281.68841552734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        270.057373046875,
        532.9911499023438,
        281.68841552734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아기에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        270.057373046875,
        532.9911499023438,
        281.68841552734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        270.057373046875,
        532.9911499023438,
        281.68841552734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        270.057373046875,
        532.9911499023438,
        281.68841552734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        270.057373046875,
        532.9911499023438,
        281.68841552734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        284.32177734375,
        527.47412109375,
        324.60150146484375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        284.32177734375,
        527.47412109375,
        324.60150146484375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가 접종 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        284.32177734375,
        527.47412109375,
        324.60150146484375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-043",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        326.7554016113281,
        185.53781127929688,
        352.6508483886719
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:036 Y2/Y3/Y4/Y5);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        326.7554016113281,
        185.53781127929688,
        352.6508483886719
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강한 청소년 및 성인에게 수막구균 백신 GSK134612",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        326.7554016113281,
        532.9916381835938,
        352.6508483886719
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종 후 항체반응 지속성을 보기 위한 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        326.7554016113281,
        532.9916381835938,
        352.6508483886719
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-101",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        361.99688720703125,
        201.9662628173828,
        388.01220703125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:036Y6/Y7/Y8/Y9/Y10);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        361.99688720703125,
        201.9662628173828,
        388.01220703125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        354.92462158203125,
        532.99072265625,
        395.08447265625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중 하나를 접종한 건강한 11-17세 대상자에게 10년 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        354.92462158203125,
        532.99072265625,
        395.08447265625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Menacwy-tt 백신 추가 접종을 평가하는 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        354.92462158203125,
        532.99072265625,
        395.08447265625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-048",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        397.2383728027344,
        184.09898376464844,
        423.2536926269531
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:039 Y2,Y3,Y4,Y5);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        397.2383728027344,
        184.09898376464844,
        423.2536926269531
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "핀란드의 14개 센터에서 실시된 두 개의 병행군으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        397.2383728027344,
        532.9907836914062,
        423.2536926269531
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이루어진 무작위, 공개, 대조 3상 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        397.2383728027344,
        532.9907836914062,
        423.2536926269531
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-102",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        432.5997314453125,
        207.4844970703125,
        458.49517822265625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT:039 Y6/Y7/Y8/Y9/Y10);",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        432.5997314453125,
        207.4844970703125,
        458.49517822265625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        425.4075927734375,
        532.9907836914062,
        465.68731689453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        425.4075927734375,
        532.9907836914062,
        465.68731689453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 항체 지속성을 평가하는 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        425.4075927734375,
        532.9907836914062,
        465.68731689453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-088",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        474.9134826660156,
        197.62277221679688,
        500.9288024902344
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(EXT: 081 Y2, Y3, Y4, Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        474.9134826660156,
        197.62277221679688,
        500.9288024902344
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수막구균 백신 GSK134612를 건강한 어린이에게 1차",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        467.8412170410156,
        516.4397583007812,
        508.0010986328125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종 후 항체 지속성과 1차 접종 후 68개월에 추가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        467.8412170410156,
        516.4397583007812,
        508.0010986328125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종시 안전성과 면역원성 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        248.7451934814453,
        467.8412170410156,
        516.4397583007812,
        508.0010986328125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MenACWY-TT-084.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        510.2748718261719,
        532.9907836914062,
        536.1702880859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수막구균 백신 GSK134612을 1 세에서 18세 미만에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        510.2748718261719,
        532.9907836914062,
        536.1702880859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종시 면역원성 및 안전성 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        510.2748718261719,
        532.9907836914062,
        536.1702880859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        578.7200317382812,
        467.0265808105469,
        590.35107421875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제출일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        578.7200317382812,
        467.0265808105469,
        590.35107421875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 항체 지속성 및 추가 접종 필요 연구:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-059  (EXT:052 Y1/Y3/Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-062  (EXT:055 Y1/Y3/Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        596.2208862304688,
        378.12176513671875,
        736.5912475585938
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 45 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        100.44273376464844,
        429.2477111816406,
        154.3875274658203
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MenACWY-TT-084",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        157.14076232910156,
        423.73004150390625,
        196.82115173339844
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        157.14076232910156,
        423.73004150390625,
        196.82115173339844
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인 항체 역가와 장기간의 항체 역가를 평가하는 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        157.14076232910156,
        423.73004150390625,
        196.82115173339844
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 CSR:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        434.0447692871094,
        170.9257049560547,
        489.0949401855469,
        196.82115173339844
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2015년 6월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        434.0447692871094,
        170.9257049560547,
        489.0949401855469,
        196.82115173339844
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        198.9750518798828,
        429.2470397949219,
        239.25479125976562
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        198.9750518798828,
        429.2470397949219,
        239.25479125976562
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성을 평가 하는 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        198.9750518798828,
        429.2470397949219,
        239.25479125976562
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 CSR:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        434.0447692871094,
        206.1671905517578,
        494.6119384765625,
        232.06263732910156
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2014년 12월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        434.0447692871094,
        206.1671905517578,
        494.6119384765625,
        232.06263732910156
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 46 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-4",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        66.32405090332031,
        109.06077575683594,
        254.86187744140625,
        125.00334930419922
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수두바이러스 백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        66.32405090332031,
        109.06077575683594,
        254.86187744140625,
        125.00334930419922
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<Shingrix>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        56.609317779541016,
        169.11514282226562,
        149.36328125,
        185.05772399902344
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        202.7059783935547,
        128.5703125,
        215.34840393066406
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        418.94964599609375,
        260.4988098144531,
        431.5920715332031
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        234.9357452392578,
        480.427734375,
        246.56678771972656
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GSK",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        234.9357452392578,
        480.427734375,
        246.56678771972656
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        234.9357452392578,
        480.427734375,
        246.56678771972656
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018.03.28.(EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        234.9357452392578,
        480.427734375,
        246.56678771972656
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        271.49578857421875,
        203.15975952148438,
        283.1268310546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        271.49578857421875,
        203.15975952148438,
        283.1268310546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        257.23138427734375,
        401.66229248046875,
        268.8624267578125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        257.23138427734375,
        401.66229248046875,
        268.8624267578125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호 (버",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        271.49578857421875,
        396.1452941894531,
        297.3912353515625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        271.49578857421875,
        396.1452941894531,
        297.3912353515625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver 1.0",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        406.33978271484375,
        271.49578857421875,
        443.279296875,
        283.1268310546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        310.9327087402344,
        391.5482482910156,
        322.5637512207031
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Varicella Zoster Virus glycoprotein E antigen",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        310.9327087402344,
        391.5482482910156,
        322.5637512207031
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능·효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        338.8621826171875,
        494.2518005371094,
        350.49322509765625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        338.8621826171875,
        494.2518005371094,
        350.49322509765625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        362.59625244140625,
        537.1885375976562,
        388.49169921875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "0.5mL 2개월 간격으로 2회 근육 내 투여. 불가피한 경우 2번째 접종은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        362.59625244140625,
        537.1885375976562,
        388.49169921875
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "첫 번째 접종 이후 6개월 이내에 투여할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        362.59625244140625,
        537.1885375976562,
        388.49169921875
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        452.25823974609375,
        499.52862548828125,
        463.8892822265625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        452.25823974609375,
        499.52862548828125,
        463.8892822265625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        452.25823974609375,
        499.52862548828125,
        463.8892822265625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        475.3929748535156,
        173.06585693359375,
        487.0240173339844
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        498.5276794433594,
        417.1339416503906,
        510.1587219238281
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        498.5276794433594,
        417.1339416503906,
        510.1587219238281
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        498.5276794433594,
        417.1339416503906,
        510.1587219238281
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        521.662353515625,
        173.06585693359375,
        533.2933959960938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종 후 잠재적 면역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        539.4029541015625,
        218.88189697265625,
        565.2984619140625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "매개질환(potential",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        539.4029541015625,
        218.88189697265625,
        565.2984619140625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Immune",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        539.4029541015625,
        218.88189697265625,
        565.2984619140625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mediated Disorders, pIMD)의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        567.9318237304688,
        218.88104248046875,
        593.9471435546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        567.9318237304688,
        218.88104248046875,
        593.9471435546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        546.4752807617188,
        390.38818359375,
        586.7550048828125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 비교관찰연구 (EPI-Zoster-030",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        546.4752807617188,
        390.38818359375,
        586.7550048828125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VS)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        546.4752807617188,
        390.38818359375,
        586.7550048828125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        560.8595581054688,
        417.1339416503906,
        572.4906005859375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진 병력이 있으며, 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        646.0863647460938,
        213.48428344726562,
        686.3661499023438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역력이 있는 사람에서의 바이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        646.0863647460938,
        213.48428344726562,
        686.3661499023438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "러스 재발현",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        646.0863647460938,
        213.48428344726562,
        686.3661499023438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        653.278564453125,
        361.0043640136719,
        679.1740112304688
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험(Zoster–062, 056)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        653.278564453125,
        361.0043640136719,
        679.1740112304688
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.4, 5.1 항목에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        596.1010131835938,
        539.8270874023438,
        664.9096069335938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        596.1010131835938,
        539.8270874023438,
        664.9096069335938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SmPC 4.4: 대상포진 병력",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        596.1010131835938,
        539.8270874023438,
        664.9096069335938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 다중 공존이환질환을 가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        596.1010131835938,
        539.8270874023438,
        664.9096069335938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        596.1010131835938,
        539.8270874023438,
        664.9096069335938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취약한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        596.1010131835938,
        539.8270874023438,
        664.9096069335938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람들에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        596.1010131835938,
        539.8270874023438,
        664.9096069335938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Shingrix의 투여에 대한 자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        667.54296875,
        539.82763671875,
        736.4713745117188
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "료는 제한적이다(5.1 참고).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        667.54296875,
        539.82763671875,
        736.4713745117188
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서 의료진이 개별적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        667.54296875,
        539.82763671875,
        736.4713745117188
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거에 따라 대상포진 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        667.54296875,
        539.82763671875,
        736.4713745117188
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종에 대한 유익성 및 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        667.54296875,
        539.82763671875,
        736.4713745117188
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 47 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        515.5640258789062,
        390.02862548828125,
        528.2064819335938
      ],
      "page_num": 52,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해성을 판단하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        101.76129150390625,
        518.9343872070312,
        113.39232635498047
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        120.94033813476562,
        145.60073852539062,
        132.57138061523438
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 유효성과 50세 이상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        140.11936950683594,
        218.88104248046875,
        180.39910888671875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인에서의 백신 추가 접종의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        140.11936950683594,
        218.88104248046875,
        180.39910888671875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필요성에 대한 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        140.11936950683594,
        218.88104248046875,
        180.39910888671875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험(Zoster–049)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        154.3837890625,
        417.1339416503906,
        166.01483154296875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        154.3837890625,
        417.1339416503906,
        166.01483154296875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 성인에서의 장기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        182.55299377441406,
        417.1339416503906,
        208.44845581054688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        182.55299377441406,
        417.1339416503906,
        208.44845581054688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험(Zoster–060, 049)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        182.55299377441406,
        417.1339416503906,
        208.44845581054688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        182.55299377441406,
        417.1339416503906,
        208.44845581054688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 취약한 성인에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        274.97198486328125,
        351.3795471191406,
        300.9873352050781
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 Shingrix의 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        274.97198486328125,
        351.3795471191406,
        300.9873352050781
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험(Zoster–063, 064)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        274.97198486328125,
        351.3795471191406,
        300.9873352050781
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC 4.4, 5.1 항목에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        210.6023406982422,
        539.8270874023438,
        279.53076171875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        210.6023406982422,
        539.8270874023438,
        279.53076171875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SmPC 4.4: 대상포진 병력",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        210.6023406982422,
        539.8270874023438,
        279.53076171875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 다중 공존이환질환을 가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        210.6023406982422,
        539.8270874023438,
        279.53076171875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        210.6023406982422,
        539.8270874023438,
        279.53076171875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취약한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        210.6023406982422,
        539.8270874023438,
        279.53076171875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람들에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        210.6023406982422,
        539.8270874023438,
        279.53076171875
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Shingrix의 투여에 대한 자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        282.16412353515625,
        539.82763671875,
        365.3569641113281
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "료는 제한적이다(5.1 참고).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        282.16412353515625,
        539.82763671875,
        365.3569641113281
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서 의료진이 개별적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        282.16412353515625,
        539.82763671875,
        365.3569641113281
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거에 따라 대상포진 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        282.16412353515625,
        539.82763671875,
        365.3569641113281
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종에 대한 유익성 및 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        282.16412353515625,
        539.82763671875,
        365.3569641113281
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해성을 판단하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        395.0658874511719,
        282.16412353515625,
        539.82763671875,
        365.3569641113281
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역력이 저하된 성인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        367.5108642578125,
        218.88070678710938,
        393.40631103515625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        367.5108642578125,
        218.88070678710938,
        393.40631103515625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험(Zoster–002, 028, 039,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        367.5108642578125,
        417.1339416503906,
        393.40631103515625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "041)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        367.5108642578125,
        417.1339416503906,
        393.40631103515625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        367.5108642578125,
        417.1339416503906,
        393.40631103515625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 면역매개질환(pIMD)를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        395.5602111816406,
        218.88104248046875,
        421.5755310058594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "갖고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        395.5602111816406,
        218.88104248046875,
        421.5755310058594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        395.5602111816406,
        218.88104248046875,
        421.5755310058594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        395.5602111816406,
        218.88104248046875,
        421.5755310058594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        424.2088928222656,
        129.16964721679688,
        435.8399353027344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험(Zoster–069)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        409.9444885253906,
        417.1339416503906,
        421.5755310058594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        409.9444885253906,
        417.1339416503906,
        421.5755310058594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진, 대상포진 후 신경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        437.99383544921875,
        213.48428344726562,
        492.5379943847656
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "통, 대상포진과 관련된 합병",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        437.99383544921875,
        213.48428344726562,
        492.5379943847656
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증을 예방하는 Shingrix의 유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        437.99383544921875,
        213.48428344726562,
        492.5379943847656
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        437.99383544921875,
        213.48428344726562,
        492.5379943847656
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교관찰연구(EPI-Zoster-031)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        459.45037841796875,
        417.1339416503906,
        471.0814208984375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        459.45037841796875,
        417.1339416503906,
        471.0814208984375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구제목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.478515625,
        429.0071716308594,
        569.4938354492188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.478515625,
        429.0071716308594,
        569.4938354492188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.478515625,
        429.0071716308594,
        569.4938354492188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.478515625,
        429.0071716308594,
        569.4938354492188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        543.478515625,
        524.5953369140625,
        569.4938354492188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        543.478515625,
        524.5953369140625,
        569.4938354492188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제출날짜",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        543.478515625,
        524.5953369140625,
        569.4938354492188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-049:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.6477661132812,
        221.5199432373047,
        626.19189453125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 예방적 유효성, 안",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.6477661132812,
        221.5199432373047,
        626.19189453125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전성과 면역원성의 지속성을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.6477661132812,
        221.5199432373047,
        626.19189453125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.6477661132812,
        221.5199432373047,
        626.19189453125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.6477661132812,
        221.5199432373047,
        626.19189453125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "110390과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.6477661132812,
        221.5199432373047,
        626.19189453125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "113077",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        628.8252563476562,
        216.00259399414062,
        640.456298828125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        628.8252563476562,
        216.00259399414062,
        640.456298828125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ZOSTER-006/022) 장기 추적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        643.0896606445312,
        216.0029296875,
        726.2825317382812
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구(ZOE-LTFU)와 50세 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        643.0896606445312,
        216.0029296875,
        726.2825317382812
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 성인에서의 0 또는 0, 2 개",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        643.0896606445312,
        216.0029296875,
        726.2825317382812
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "월에 1회 또는 2회 추가접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        643.0896606445312,
        216.0029296875,
        726.2825317382812
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 하는 2개의 군에 대한 평",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        643.0896606445312,
        216.0029296875,
        726.2825317382812
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가를 위한 공개, 다국가, 다기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        643.0896606445312,
        216.0029296875,
        726.2825317382812
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 유효성, 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        607.3687133789062,
        339.2961120605469,
        676.17724609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과 면역원성 평가 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        607.3687133789062,
        339.2961120605469,
        676.17724609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1회 또는 2회 추가접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        607.3687133789062,
        339.2961120605469,
        676.17724609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종에 대한 반응원성,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        607.3687133789062,
        339.2961120605469,
        676.17724609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        607.3687133789062,
        339.2961120605469,
        676.17724609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        607.3687133789062,
        339.2961120605469,
        676.17724609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        678.9304809570312,
        248.14517211914062,
        690.5615234375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 유효성 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        585.9121704101562,
        434.40423583984375,
        654.720703125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        585.9121704101562,
        434.40423583984375,
        654.720703125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인에서의 추가접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        585.9121704101562,
        434.40423583984375,
        654.720703125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종의 필요성 평",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        585.9121704101562,
        434.40423583984375,
        654.720703125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        585.9121704101562,
        434.40423583984375,
        654.720703125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        671.7383422851562,
        434.40423583984375,
        697.6337890625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        671.7383422851562,
        434.40423583984375,
        697.6337890625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        671.7383422851562,
        434.40423583984375,
        697.6337890625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        700.3870239257812,
        387.9894104003906,
        712.01806640625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        636.0173950195312,
        475.90252685546875,
        647.6484375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        636.0173950195312,
        475.90252685546875,
        647.6484375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        650.2817993164062,
        450.1160583496094,
        661.912841796875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간보고서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        607.3687133789062,
        545.5839233398438,
        647.6484375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2021.03.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        607.3687133789062,
        545.5839233398438,
        647.6484375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        607.3687133789062,
        545.5839233398438,
        647.6484375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        607.3687133789062,
        545.5839233398438,
        647.6484375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        650.2817993164062,
        540.06689453125,
        661.912841796875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        650.2817993164062,
        540.06689453125,
        661.912841796875
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        664.5462036132812,
        545.5839233398438,
        690.5615234375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2024.10.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        664.5462036132812,
        545.5839233398438,
        690.5615234375
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 48 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관, 제 3b상 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ZOSTER-060:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 접종 후 108개월과 120",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개월에 Shingrix의 면역 반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 지속성과 안전성을 평가하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고   ZOSTER-003에 참여하였",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "던 60세 이상의 건강한 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상자의 초기접종 10년 후, 2",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회 추가접종에 대하여 평가하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기 위한 공개, 제 3b상, 장기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확장 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        256.03643798828125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원성의 지속성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        144.19491577148438,
        339.2961120605469,
        213.1233367919922
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 평가 및 2회",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        144.19491577148438,
        339.2961120605469,
        213.1233367919922
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가접종에 대한 반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        144.19491577148438,
        339.2961120605469,
        213.1233367919922
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응원성, 안전성 그리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        144.19491577148438,
        339.2961120605469,
        213.1233367919922
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고 면역원성 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        144.19491577148438,
        339.2961120605469,
        213.1233367919922
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        165.65147399902344,
        434.40423583984375,
        191.6667938232422
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        165.65147399902344,
        434.40423583984375,
        191.6667938232422
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        165.65147399902344,
        434.40423583984375,
        191.6667938232422
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        194.30015563964844,
        387.9894104003906,
        205.9311981201172
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        172.84361267089844,
        475.90252685546875,
        184.4746551513672
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        172.84361267089844,
        475.90252685546875,
        184.4746551513672
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        187.10801696777344,
        450.1160583496094,
        198.7390594482422
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간보고서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        144.19491577148438,
        545.5839233398438,
        184.4746551513672
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019.04.30",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        144.19491577148438,
        545.5839233398438,
        184.4746551513672
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        144.19491577148438,
        545.5839233398438,
        184.4746551513672
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        144.19491577148438,
        545.5839233398438,
        184.4746551513672
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        187.10801696777344,
        540.06689453125,
        198.7390594482422
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        187.10801696777344,
        540.06689453125,
        198.7390594482422
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        201.49229431152344,
        545.5839233398438,
        227.38775634765625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2020.03.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        201.49229431152344,
        545.5839233398438,
        227.38775634765625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-064:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.2626037597656,
        216.002685546875,
        291.2779235839844
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-006과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.2626037597656,
        216.002685546875,
        291.2779235839844
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-022",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.2626037597656,
        216.002685546875,
        291.2779235839844
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구를 참여한 50세 이상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험대상자를 대상으로 진행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 삶의 질에 대한 설문조사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 코드화하여, 이를 근거로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 취약한 상태와 인구학적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특성에 따른 Shingrix의 유효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성, 안전성과 면역원성의 기술",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적 분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        293.9112854003906,
        221.5196075439453,
        405.6329650878906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        258.1903381347656,
        339.2957763671875,
        269.8213806152344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "취약한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        258.1903381347656,
        339.2957763671875,
        269.8213806152344
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태와 대상포진 발",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병의 다른 예후인자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 인구학적 특성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Z O S T E R - 0 0 6 과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-022 연구를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참여한 시험대상자를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상으로 진행한 삶",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 질에 대한 설문조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사를 기반으로 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위한 관찰연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        272.4547424316406,
        339.2957763671875,
        412.8251037597656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 취",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        315.36785888671875,
        434.4039001464844,
        355.6475830078125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약한 성인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        315.36785888671875,
        434.4039001464844,
        355.6475830078125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        315.36785888671875,
        434.4039001464844,
        355.6475830078125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        322.55999755859375,
        470.3855285644531,
        334.1910400390625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        322.55999755859375,
        470.3855285644531,
        334.1910400390625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "됨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        336.82440185546875,
        450.1160583496094,
        348.4554443359375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        308.17572021484375,
        540.06689453125,
        319.8067626953125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        308.17572021484375,
        540.06689453125,
        319.8067626953125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        322.55999755859375,
        540.06689453125,
        334.1910400390625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        322.55999755859375,
        540.06689453125,
        334.1910400390625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        336.82440185546875,
        545.5839233398438,
        362.7198486328125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2020.09.30",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        336.82440185546875,
        545.5839233398438,
        362.7198486328125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-063:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5196075439453,
        440.99432373046875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5196075439453,
        440.99432373046875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5196075439453,
        440.99432373046875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5196075439453,
        440.99432373046875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종 후 반응원성이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        443.627685546875,
        221.5196075439453,
        483.90740966796875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "삶의 질에 미치는 여향을 평",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        443.627685546875,
        221.5196075439453,
        483.90740966796875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가하기 위한 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        443.627685546875,
        221.5196075439453,
        483.90740966796875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 반응원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        429.36328125,
        339.2957763671875,
        469.52313232421875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 삶의 질에 미치는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        429.36328125,
        339.2957763671875,
        469.52313232421875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영향을 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        429.36328125,
        339.2957763671875,
        469.52313232421875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 취",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        429.36328125,
        434.4039001464844,
        469.52313232421875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약한 성인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        429.36328125,
        434.4039001464844,
        469.52313232421875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        429.36328125,
        434.4039001464844,
        469.52313232421875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        436.435546875,
        475.90252685546875,
        448.06658935546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        436.435546875,
        475.90252685546875,
        448.06658935546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        450.81982421875,
        450.1160583496094,
        462.45086669921875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        422.171142578125,
        540.06689453125,
        433.80218505859375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        422.171142578125,
        540.06689453125,
        433.80218505859375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        436.435546875,
        540.06689453125,
        448.06658935546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        436.435546875,
        540.06689453125,
        448.06658935546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        450.81982421875,
        545.5839233398438,
        476.71527099609375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019.12.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        450.81982421875,
        545.5839233398438,
        476.71527099609375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EPI-ZOSTER-030 VS:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        507.5178527832031,
        168.72447204589844,
        533.4132690429688
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        507.5178527832031,
        168.72447204589844,
        533.4132690429688
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국에서 50세 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        486.0613098144531,
        339.2957763671875,
        511.9567565917969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        486.0613098144531,
        339.2957763671875,
        511.9567565917969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        486.0613098144531,
        339.2957763671875,
        511.9567565917969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 안전성을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        514.590087890625,
        339.2957763671875,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하기 위한 비중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        514.590087890625,
        339.2957763671875,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "재(관찰적),",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        514.590087890625,
        339.2957763671875,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전향적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        514.590087890625,
        339.2957763671875,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "코호트 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        557.503173828125,
        286.6446533203125,
        569.1342163085938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        500.3257141113281,
        434.40423583984375,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 면역매개",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        500.3257141113281,
        434.40423583984375,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환(pIMD)의 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        500.3257141113281,
        434.40423583984375,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        500.3257141113281,
        434.40423583984375,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        514.590087890625,
        470.3855285644531,
        526.2211303710938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        514.590087890625,
        470.3855285644531,
        526.2211303710938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "됨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        528.974365234375,
        450.1160583496094,
        540.6054077148438
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        500.3257141113281,
        540.06689453125,
        511.9567565917969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        500.3257141113281,
        540.06689453125,
        511.9567565917969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        514.590087890625,
        540.06689453125,
        526.2211303710938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        514.590087890625,
        540.06689453125,
        526.2211303710938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        528.974365234375,
        545.5839233398438,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2025.03.30",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        528.974365234375,
        545.5839233398438,
        554.8698120117188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-002:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자가 조혈 줄기세포 이식 성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인 환자를 대상으로 2회 근육",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내 투여하였을 때 Shingrix의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예방적 유효성, 안전성과 면역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원성을 평가하기 위한 무작위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배정, 관찰자 맹검, 위약 대조,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다기관, 제 3상 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        571.4080200195312,
        221.5199432373047,
        683.129638671875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18세 이상 자가 조혈",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        585.6724243164062,
        339.2957763671875,
        640.216552734375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "줄기세포 이식 환자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        585.6724243164062,
        339.2957763671875,
        640.216552734375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서의 Shingrix의 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        585.6724243164062,
        339.2957763671875,
        640.216552734375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상포진을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        585.6724243164062,
        339.2957763671875,
        640.216552734375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예방하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        585.6724243164062,
        339.2957763671875,
        640.216552734375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신의 유효성, 면역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        642.8499145507812,
        333.77911376953125,
        668.865234375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원성과  안전성 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        642.8499145507812,
        333.77911376953125,
        668.865234375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력이 저하된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        607.1289672851562,
        434.40423583984375,
        647.40869140625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 인 에 서 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        607.1289672851562,
        434.40423583984375,
        647.40869140625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        607.1289672851562,
        434.40423583984375,
        647.40869140625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        614.3211059570312,
        475.90252685546875,
        625.9521484375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        614.3211059570312,
        475.90252685546875,
        625.9521484375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        628.5855102539062,
        450.1160583496094,
        640.216552734375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        599.9368286132812,
        540.06689453125,
        611.56787109375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        599.9368286132812,
        540.06689453125,
        611.56787109375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        614.3211059570312,
        540.06689453125,
        625.9521484375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        614.3211059570312,
        540.06689453125,
        625.9521484375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        628.5855102539062,
        545.5839233398438,
        654.48095703125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019.03.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        628.5855102539062,
        545.5839233398438,
        654.48095703125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-039:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        685.2835693359375,
        221.5199432373047,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18세 이상의 혈액악성종양 성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        685.2835693359375,
        221.5199432373047,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인 환자를 대상으로 2회 근육",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        685.2835693359375,
        221.5199432373047,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18세 이상의 혈액악",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        685.2835693359375,
        339.2957763671875,
        711.1790161132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성종양",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        685.2835693359375,
        339.2957763671875,
        711.1790161132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        685.2835693359375,
        339.2957763671875,
        711.1790161132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 안전성, 반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        713.9322509765625,
        333.77911376953125,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력이 저하된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        685.2835693359375,
        434.40423583984375,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 인 에 서 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        685.2835693359375,
        434.40423583984375,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        685.2835693359375,
        434.40423583984375,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        692.4757080078125,
        475.90252685546875,
        704.1067504882812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        692.4757080078125,
        475.90252685546875,
        704.1067504882812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        706.7401123046875,
        450.1160583496094,
        718.3711547851562
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        685.2835693359375,
        540.06689453125,
        696.9146118164062
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        685.2835693359375,
        540.06689453125,
        696.9146118164062
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        699.5479736328125,
        540.06689453125,
        711.1790161132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        699.5479736328125,
        540.06689453125,
        711.1790161132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        713.9322509765625,
        545.5839233398438,
        725.5632934570312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 49 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내 투여하였을 때 Shingrix의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        170.68971252441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성과 면역원성을 평가하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        170.68971252441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기 위한 무작위배정, 관찰자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        170.68971252441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "맹검, 위약 대조, 다기관, 제 3",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        170.68971252441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        101.76129150390625,
        221.5199432373047,
        170.68971252441406
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "응원성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        123.21783447265625,
        339.2957763671875,
        134.848876953125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        123.21783447265625,
        339.2957763671875,
        134.848876953125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        130.4099884033203,
        530.59130859375,
        149.23316955566406
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019.03.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        130.4099884033203,
        530.59130859375,
        149.23316955566406
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-041:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18세 이상의 신장 이식 성인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자를 대상으로 0개월과 1~2",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개월에 근육 내 투여하였을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "때 Shingrix의 면역원성과 안",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전성을 평가하기 위한 무작위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배정, 관찰자 맹검, 위약 대조,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다기관, 제 3상 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        172.84361267089844,
        221.5199432373047,
        284.5652770996094
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18세 이상의 신장이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        194.30015563964844,
        339.2957763671875,
        220.19561767578125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        194.30015563964844,
        339.2957763671875,
        220.19561767578125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        194.30015563964844,
        339.2957763671875,
        220.19561767578125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 안전성, 반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        222.9488525390625,
        339.2957763671875,
        248.84429931640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응원성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        222.9488525390625,
        339.2957763671875,
        248.84429931640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        222.9488525390625,
        339.2957763671875,
        248.84429931640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        251.4776611328125,
        248.14517211914062,
        263.10870361328125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력이 저하된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        208.5645751953125,
        434.40423583984375,
        248.84429931640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 인 에 서 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        208.5645751953125,
        434.40423583984375,
        248.84429931640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        208.5645751953125,
        434.40423583984375,
        248.84429931640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        215.7567138671875,
        475.90252685546875,
        227.38775634765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        215.7567138671875,
        475.90252685546875,
        227.38775634765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        230.0211181640625,
        450.1160583496094,
        241.65216064453125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        201.49229431152344,
        540.06689453125,
        213.1233367919922
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        201.49229431152344,
        540.06689453125,
        213.1233367919922
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        215.7567138671875,
        540.06689453125,
        227.38775634765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        215.7567138671875,
        540.06689453125,
        227.38775634765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 사 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        230.0211181640625,
        545.5839233398438,
        256.03643798828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019.03.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        230.0211181640625,
        545.5839233398438,
        256.03643798828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-028:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18세 이상의 함암치료를 받고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 고형암 성인 환자를 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상으로 0개월과 1~2개월에 근",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "육 내 투여하였을 때 Shingrix",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 면역원성과 안전성을 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위한 무작위배정, 관찰자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "맹검, 위약대조, 다기관, 제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2/3상 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        286.7191467285156,
        221.5199432373047,
        412.8251037597656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18세 이상의 항암치",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        308.17572021484375,
        339.2957763671875,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료를 받고 있는 고형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        308.17572021484375,
        339.2957763671875,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암 환 자 에 서 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        308.17572021484375,
        339.2957763671875,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 안전성, 반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        308.17572021484375,
        339.2957763671875,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응원성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        308.17572021484375,
        339.2957763671875,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        308.17572021484375,
        339.2957763671875,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        379.7375183105469,
        248.14517211914062,
        391.3685607910156
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력이 저하된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        329.63226318359375,
        434.40423583984375,
        369.9119873046875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 인 에 서 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        329.63226318359375,
        434.40423583984375,
        369.9119873046875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        329.63226318359375,
        434.40423583984375,
        369.9119873046875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        336.82440185546875,
        475.90252685546875,
        348.4554443359375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        336.82440185546875,
        475.90252685546875,
        348.4554443359375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        351.08880615234375,
        450.1160583496094,
        362.7198486328125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        322.55999755859375,
        540.06689453125,
        334.1910400390625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        322.55999755859375,
        540.06689453125,
        334.1910400390625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        336.82440185546875,
        540.06689453125,
        348.4554443359375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        336.82440185546875,
        540.06689453125,
        348.4554443359375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        351.08880615234375,
        545.5839233398438,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019.03.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        351.08880615234375,
        545.5839233398438,
        377.1041259765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-069:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 면역매개질환(pIMD)을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "갖고 있는 성인을 대상으로 0",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개월과 1~2개월에 근육 내 투",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여하였을 때 Shingrix의 면역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원성과 안전성을 평가하기 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 무작위배정, 관찰자 맹검,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위약대조, 다기관, 제 3상 임",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        414.97900390625,
        221.5199432373047,
        541.0848999023438
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 면역매개질환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        443.627685546875,
        339.2961120605469,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(pIMD)을 갖고 있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        443.627685546875,
        339.2961120605469,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인에서의 Shingrix",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        443.627685546875,
        339.2961120605469,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 안전성, 반응원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        443.627685546875,
        339.2961120605469,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과 면역원성 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        443.627685546875,
        339.2961120605469,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 면역매개",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        443.627685546875,
        429.00750732421875,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환(pIMD)를 갖",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        443.627685546875,
        429.00750732421875,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고 있는 성인에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        443.627685546875,
        429.00750732421875,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서의 Shingrix 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        443.627685546875,
        429.00750732421875,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        443.627685546875,
        429.00750732421875,
        512.4362182617188
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        465.084228515625,
        470.3855285644531,
        476.71527099609375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        465.084228515625,
        470.3855285644531,
        476.71527099609375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "됨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        479.3486328125,
        450.1160583496094,
        490.97967529296875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        450.81982421875,
        540.06689453125,
        462.45086669921875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        450.81982421875,
        540.06689453125,
        462.45086669921875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        465.084228515625,
        540.06689453125,
        476.71527099609375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        465.084228515625,
        540.06689453125,
        476.71527099609375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        479.3486328125,
        545.5839233398438,
        505.36395263671875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2025.06.30",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        479.3486328125,
        545.5839233398438,
        505.36395263671875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-062:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 대상포진 병력이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 성인을 대상으로 0개월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과 1~2개월에 근육 내 투여하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "였을 때 Shingrix의 면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과 안전성을 평가하기 위한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무작위배정, 관찰자 맹검, 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약대조, 다기관, 제 3상 임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        543.23876953125,
        221.5199432373047,
        669.3447265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진 병력이 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        571.8875122070312,
        339.2957763671875,
        626.431640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 시험대상자에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        571.8875122070312,
        339.2957763671875,
        626.431640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix의 안전성, 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        571.8875122070312,
        339.2957763671875,
        626.431640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역원성과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        571.8875122070312,
        339.2957763671875,
        626.431640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        571.8875122070312,
        339.2957763671875,
        626.431640625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        629.0650024414062,
        248.14517211914062,
        640.696044921875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진 병력이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        571.8875122070312,
        434.40423583984375,
        597.782958984375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으며,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        571.8875122070312,
        434.40423583984375,
        597.782958984375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        571.8875122070312,
        434.40423583984375,
        597.782958984375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 있는 시험대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        600.4163208007812,
        429.00750732421875,
        640.696044921875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상자에서의 바이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        600.4163208007812,
        429.00750732421875,
        640.696044921875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "러스의 재발현",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        600.4163208007812,
        429.00750732421875,
        640.696044921875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        593.3440551757812,
        470.3855285644531,
        604.97509765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        593.3440551757812,
        470.3855285644531,
        604.97509765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "됨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        607.6084594726562,
        450.1160583496094,
        619.239501953125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        578.9597778320312,
        540.06689453125,
        590.5908203125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        578.9597778320312,
        540.06689453125,
        590.5908203125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        593.3440551757812,
        540.06689453125,
        604.97509765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        593.3440551757812,
        540.06689453125,
        604.97509765625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        607.6084594726562,
        545.5839233398438,
        633.50390625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2022.06.30",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        607.6084594726562,
        545.5839233398438,
        633.50390625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-056:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        671.4985961914062,
        216.002685546875,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-006과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        671.4985961914062,
        216.002685546875,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTER-022",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        671.4985961914062,
        216.002685546875,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구에서 위약군이었던 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        700.1473388671875,
        221.5188446044922,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상자를 대상으로 Shingrix",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        700.1473388671875,
        221.5188446044922,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종 후 모",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        671.4985961914062,
        339.2961120605469,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "든",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        671.4985961914062,
        339.2961120605469,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험대상자(백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        671.4985961914062,
        339.2961120605469,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종 이전에 대상포",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        700.1473388671875,
        333.77911376953125,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진의 병력이 있는 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        700.1473388671875,
        333.77911376953125,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진 병력이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        671.4985961914062,
        434.40423583984375,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으며,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        671.4985961914062,
        434.40423583984375,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        671.4985961914062,
        434.40423583984375,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 있는 시험대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        700.1473388671875,
        429.00750732421875,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상자에서의 바이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        700.1473388671875,
        429.00750732421875,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        685.7630615234375,
        475.90252685546875,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        685.7630615234375,
        475.90252685546875,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        700.1473388671875,
        450.1160583496094,
        711.7783813476562
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        671.4985961914062,
        540.06689453125,
        683.129638671875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        671.4985961914062,
        540.06689453125,
        683.129638671875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        685.7630615234375,
        540.06689453125,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        685.7630615234375,
        540.06689453125,
        697.3941040039062
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        700.1473388671875,
        545.5839233398438,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2020.07.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        700.1473388671875,
        545.5839233398438,
        726.0427856445312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 50 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교차 접종 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        159.0586700439453,
        140.08407592773438,
        170.68971252441406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험대상자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        101.76129150390625,
        333.77911376953125,
        113.39232635498047
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함)에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        101.76129150390625,
        333.77911376953125,
        113.39232635498047
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 안전성 평가.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        116.14556884765625,
        339.2961120605469,
        156.30543518066406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 전체 기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        116.14556884765625,
        339.2961120605469,
        156.30543518066406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동안",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        116.14556884765625,
        339.2961120605469,
        156.30543518066406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        116.14556884765625,
        339.2961120605469,
        156.30543518066406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의심되는 사례 발생",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        159.0586700439453,
        339.2961120605469,
        199.21853637695312
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "률 평가(백신 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        159.0586700439453,
        339.2961120605469,
        199.21853637695312
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이전에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        159.0586700439453,
        339.2961120605469,
        199.21853637695312
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        159.0586700439453,
        339.2961120605469,
        199.21853637695312
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병력이 있는 시험대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        201.97177124023438,
        333.7787780761719,
        227.8672332763672
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상자 포함)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        201.97177124023438,
        333.7787780761719,
        227.8672332763672
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "러스의 재발현",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        159.0586700439453,
        415.45452880859375,
        170.68971252441406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EPI-ZOSTER-031:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.8619384765625,
        221.5196075439453,
        334.6705017089844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국에서 50세 이상의 시험대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.8619384765625,
        221.5196075439453,
        334.6705017089844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상자에게서 백신 유효성을 평",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.8619384765625,
        221.5196075439453,
        334.6705017089844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가하기 위한 후향적 코호트",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.8619384765625,
        221.5196075439453,
        334.6705017089844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관찰(비중재) 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        265.8619384765625,
        221.5196075439453,
        334.6705017089844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미국에서 50세 이상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험대상자에서 전체",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 연령별 대상포진,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진 후 신경통",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 안부대상포진을예",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방하는 Shingrix의 유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효성 평가.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Shingrix 접종 후 10",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년까지의 백신의 유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효성 평가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        226.19740295410156,
        230.0211181640625,
        339.2962646484375,
        370.3914794921875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진, 대상포",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        258.6697998046875,
        434.40423583984375,
        341.8626403808594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진 후 신경통 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        258.6697998046875,
        434.40423583984375,
        341.8626403808594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진,  관련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        258.6697998046875,
        434.40423583984375,
        341.8626403808594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합병증을 예방하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        258.6697998046875,
        434.40423583984375,
        341.8626403808594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 Shingrix의 유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        258.6697998046875,
        434.40423583984375,
        341.8626403808594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        343.97357177734375,
        258.6697998046875,
        434.40423583984375,
        341.8626403808594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        287.3185119628906,
        470.3855285644531,
        298.9495544433594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        287.3185119628906,
        470.3855285644531,
        298.9495544433594
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "됨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        439.08203125,
        301.5829162597656,
        450.1160583496094,
        313.2139587402344
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실행가능성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        237.2132568359375,
        545.58544921875,
        291.7574157714844
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Feasibility)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        237.2132568359375,
        545.58544921875,
        291.7574157714844
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가보고서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        237.2132568359375,
        545.58544921875,
        291.7574157714844
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018.07.31",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        237.2132568359375,
        545.58544921875,
        291.7574157714844
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        308.7750549316406,
        540.06689453125,
        320.4060974121094
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        308.7750549316406,
        540.06689453125,
        320.4060974121094
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        323.0394592285156,
        540.06689453125,
        334.6705017089844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        323.0394592285156,
        540.06689453125,
        334.6705017089844
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보 고 서 :",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        337.3038635253906,
        545.5839233398438,
        363.3192138671875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2033.08.01",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        480.57952880859375,
        337.3038635253906,
        545.5839233398438,
        363.3192138671875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 51 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<Zostavax>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        98.99178314208984,
        161.83755493164062,
        114.93435668945312
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        128.62693786621094,
        128.5703125,
        141.2693634033203
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        366.447021484375,
        260.4988098144531,
        379.0894470214844
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        165.0521240234375,
        485.9466857910156,
        176.68316650390625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MSD",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        165.0521240234375,
        485.9466857910156,
        176.68316650390625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        165.0521240234375,
        485.9466857910156,
        176.68316650390625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2006.05.19. (EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        165.0521240234375,
        485.9466857910156,
        176.68316650390625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        207.0062713623047,
        207.4795684814453,
        218.63731384277344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zostavax",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        207.0062713623047,
        207.4795684814453,
        218.63731384277344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        192.7418670654297,
        401.66229248046875,
        204.37290954589844
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        192.7418670654297,
        401.66229248046875,
        204.37290954589844
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호 (버",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        207.0062713623047,
        396.1452941894531,
        233.02159118652344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        320.946044921875,
        207.0062713623047,
        396.1452941894531,
        233.02159118652344
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        249.08029174804688,
        359.8966369628906,
        260.7113342285156
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Varicella-zoster virus (live, attenuated)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        249.08029174804688,
        359.8966369628906,
        260.7113342285156
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능·효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        279.7667541503906,
        378.87432861328125,
        291.3977966308594
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "50세 이상의 성인에서의 대상포진의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        279.7667541503906,
        378.87432861328125,
        291.3977966308594
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        307.45648193359375,
        531.791748046875,
        333.3519592285156
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        307.45648193359375,
        531.791748046875,
        333.3519592285156
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 선호된다. 혈관내 또는 근육 주사를 하여서는 안된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        307.45648193359375,
        531.791748046875,
        333.3519592285156
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        389.9263610839844,
        488.4945983886719,
        401.5574035644531
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        389.9263610839844,
        488.4945983886719,
        401.5574035644531
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        389.9263610839844,
        488.4945983886719,
        401.5574035644531
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        413.06109619140625,
        173.06585693359375,
        424.692138671875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.075927734375,
        406.09991455078125,
        447.70697021484375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.075927734375,
        406.09991455078125,
        447.70697021484375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.075927734375,
        406.09991455078125,
        447.70697021484375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성 및 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        459.2106628417969,
        239.03012084960938,
        470.8417053222656
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진 백신에 의한 일시적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        584.2340087890625,
        213.48428344726562,
        624.5137329101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인 대상포진-유사 또는 수두-",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        584.2340087890625,
        213.48428344726562,
        624.5137329101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유사 발진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        584.2340087890625,
        213.48428344726562,
        624.5137329101562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "판매가 되면 대상포진-유사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 수두-유사 발진을 포함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 이상사례 보고서가 수집",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "될 수 있음. 이들이 시간적으",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로 조스타박스 투여와 관련성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 있을 수는 있지만, 이들이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "야생형 수두 대상포진 바이러",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스와 관련되어 있거나 또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수두 대상포진 바이러스와 전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혀 관련되어 있지 않을 수도",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다.  이 발진이 오카/머크",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Oka/Merck) 바이러스 또는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "야생형 수두 대상포진 바이러",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스의 발현과 관련성이 있을지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여부는 임상적으로나 혈청학",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적으로나 구별하는 것이 가능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지 않다. 이런 문제의 해결",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        476.9512634277344,
        379.35406494140625,
        731.7965087890625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.8, 5.1에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        512.7920532226562,
        483.2178039550781,
        524.423095703125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.8, c. 바람직하지 못한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        541.3208618164062,
        539.8270874023438,
        595.8650512695312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효과, 기재된 이상약물반응의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        541.3208618164062,
        539.8270874023438,
        595.8650512695312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개요에 대상포진-유사 및 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        541.3208618164062,
        539.8270874023438,
        595.8650512695312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두-유사 발진 포함됨.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        541.3208618164062,
        539.8270874023438,
        595.8650512695312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수두 대상포진 바이러스 확인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        612.8826904296875,
        539.8270263671875,
        638.7781372070312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로그램(Varicella",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        612.8826904296875,
        539.8270263671875,
        638.7781372070312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zoster",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        612.8826904296875,
        539.8270263671875,
        638.7781372070312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Virus",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        641.5313720703125,
        539.8286743164062,
        653.1624145507812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Identification",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        641.5313720703125,
        539.8286743164062,
        653.1624145507812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Programme)을 통하여 종합효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        655.7957763671875,
        539.8278198242188,
        681.6912231445312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        655.7957763671875,
        539.8278198242188,
        681.6912231445312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연쇄반응(Poly",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        655.7957763671875,
        539.8278198242188,
        681.6912231445312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "merase",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        655.7957763671875,
        539.8278198242188,
        681.6912231445312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "chain reaction, PCR) 분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        684.4444580078125,
        514.5211181640625,
        696.0755004882812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 52 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "을 돕기 위하여 이상사례를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.35467529296875,
        156.30543518066406
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보고하는 의료진에게 수두 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.35467529296875,
        156.30543518066406
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상포진 바이러스 확인프로그",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.35467529296875,
        156.30543518066406
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "램(Varicella",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.35467529296875,
        156.30543518066406
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Zoster",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.35467529296875,
        156.30543518066406
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Virus",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.35467529296875,
        156.30543518066406
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Identification",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        159.0586700439453,
        379.35406494140625,
        170.68971252441406
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Programme)에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        159.0586700439453,
        379.35406494140625,
        170.68971252441406
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시료 샘플을 제출할 수 있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        173.32308959960938,
        379.35406494140625,
        199.21853637695312
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기회를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        173.32308959960938,
        379.35406494140625,
        199.21853637695312
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오카/머크(Oka/Merck_",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        430.3222351074219,
        218.88104248046875,
        441.9532775878906
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        430.3222351074219,
        218.88104248046875,
        441.9532775878906
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이러스의 잠재적 전염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        444.5866394042969,
        184.1002197265625,
        456.2176818847656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        387.40911865234375,
        379.3532409667969,
        456.2176818847656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이런 문제의 해결을 돕기 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        387.40911865234375,
        379.3532409667969,
        456.2176818847656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여 이상사례를 보고하는 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        387.40911865234375,
        379.3532409667969,
        456.2176818847656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료진에게 수두 대상포진 바이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        387.40911865234375,
        379.3532409667969,
        456.2176818847656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "러스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        387.40911865234375,
        379.3532409667969,
        456.2176818847656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인프로그램(Varicella",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        387.40911865234375,
        379.3532409667969,
        456.2176818847656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zoster",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        458.9709167480469,
        379.355712890625,
        470.6019592285156
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Virus",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        458.9709167480469,
        379.355712890625,
        470.6019592285156
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Identification",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        458.9709167480469,
        379.355712890625,
        470.6019592285156
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Programme)에 시료 샘플을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        473.2353210449219,
        379.35406494140625,
        499.1307678222656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제출할 기회를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        473.2353210449219,
        379.35406494140625,
        499.1307678222656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.4 에 경고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        201.49229431152344,
        466.3072814941406,
        213.1233367919922
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.4:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조스타박스에 대한 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 백신 바이러스의 전염은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고되지 않았다. 그러나, 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두백신의 시판 후 경험은 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두-유사 발진 증상을 보인 사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "람들과 접촉에 민감한 사람들",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예를 들면, 수두대상포진 바",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이러스에 민감한 유아) 사이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 백신 바이러스의 전염이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "드물지만 발생할 수 있다는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것을 말해준다. 또한 수두-유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사 증상이 발생하지 않은 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두백신 접종자로부터도 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이러스의 전염이 보고된 바",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다. 이는 조스터박스 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 대한 이론적인 위험이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신 접종자로부터 접촉에 민",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감한 사람들에게로 약독화 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신 바이러스가 전염될 위험은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자연적인 대상포진의 발생 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접촉에 민감한 사람들로의 야",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생형 대상포진 바이러스의 잠",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "재적 전염의 위험과 비교하여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가되어야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        230.0211181640625,
        539.8270874023438,
        584.9569702148438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수두 대상포진 바이러스 확인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        601.974609375,
        539.8270263671875,
        627.8700561523438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로그램(Varicella",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        601.974609375,
        539.8270263671875,
        627.8700561523438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zoster",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        601.974609375,
        539.8270263671875,
        627.8700561523438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Virus",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        630.623291015625,
        539.8286743164062,
        642.2543334960938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Identification",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        630.623291015625,
        539.8286743164062,
        642.2543334960938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Programme)을 통하여 종합효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        644.8876953125,
        539.8278198242188,
        670.7831420898438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        644.8876953125,
        539.8278198242188,
        670.7831420898438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연쇄반응(Poly",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        644.8876953125,
        539.8278198242188,
        670.7831420898438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "merase",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        644.8876953125,
        539.8278198242188,
        670.7831420898438
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "chain reaction, PCR) 분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        673.536376953125,
        514.5211181640625,
        685.1674194335938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력이 약화된 사람의 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        701.5857543945312,
        211.56533813476562,
        713.216796875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        687.3213500976562,
        373.95733642578125,
        727.481201171875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획된 안전성과 면역원성 임",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        687.3213500976562,
        373.95733642578125,
        727.481201171875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        687.3213500976562,
        373.95733642578125,
        727.481201171875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.3, 4.4, 5.1에 기재",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        687.3213500976562,
        505.6455993652344,
        698.952392578125
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- SPC 4.3:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        715.8501586914062,
        441.8396301269531,
        727.481201171875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 53 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원발성 및 다음의 조건으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인한 후천성 면역결핍 상태에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 환자: 급성 및 만성 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈병, 림프종 또는 골수/림프",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계에 영향을 미치는 기타 상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "황, HIV/AIDS에 의한 면역억",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제, 세포성 면역결핍.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- SPC 4.4:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조스타박스는 약독화된 대상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포진생바이러스 백신으로 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역억제환자 또는 면역결핍환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자에게 투여시 치명적인 결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "를 포함하여 수두-대상포진",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스 관련 산재성 질환이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타날 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- SPC 5.1:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 백신은 면역기능이 손상된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험대상자를 대상으로 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된 바가 없다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        539.8270874023438,
        370.8709411621094
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "잠재적인 중추신경 사례",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        444.5866394042969,
        184.1002197265625,
        456.2176818847656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        373.14471435546875,
        379.3532409667969,
        441.9532775878906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이런 문제의 해결을 돕기 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        373.14471435546875,
        379.3532409667969,
        441.9532775878906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여 이상반응을 보고하는 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        373.14471435546875,
        379.3532409667969,
        441.9532775878906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료진에게 수두 대상포진 바이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        373.14471435546875,
        379.3532409667969,
        441.9532775878906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "러스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        373.14471435546875,
        379.3532409667969,
        441.9532775878906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인프로그램(Varicella",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        373.14471435546875,
        379.3532409667969,
        441.9532775878906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zoster",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        444.5866394042969,
        379.355712890625,
        456.2176818847656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Virus",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        444.5866394042969,
        379.355712890625,
        456.2176818847656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Identification",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        444.5866394042969,
        379.355712890625,
        456.2176818847656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Programme)에 종합효소 연쇄",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        458.9709167480469,
        379.3537902832031,
        484.8663635253906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응(Poly",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        458.9709167480469,
        379.3537902832031,
        484.8663635253906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "merase",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        458.9709167480469,
        379.3537902832031,
        484.8663635253906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "chain",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        458.9709167480469,
        379.3537902832031,
        484.8663635253906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "reaction, PCR) 분석을 한 뇌",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        487.4997253417969,
        373.95733642578125,
        527.7794189453125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "척수액을 포함하여 시료 샘플",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        487.4997253417969,
        373.95733642578125,
        527.7794189453125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 제출할 기회를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        487.4997253417969,
        373.95733642578125,
        527.7794189453125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수두 대상포진 바이러스 확인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        408.86566162109375,
        539.8270263671875,
        434.7611389160156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로그램(Varicella",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        408.86566162109375,
        539.8270263671875,
        434.7611389160156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zoster",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        408.86566162109375,
        539.8270263671875,
        434.7611389160156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Virus",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        437.5143737792969,
        539.8286743164062,
        449.1454162597656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Identification",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        437.5143737792969,
        539.8286743164062,
        449.1454162597656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Programme)을 통하여 종합효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        451.7787780761719,
        539.8278198242188,
        477.6742248535156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        451.7787780761719,
        539.8278198242188,
        477.6742248535156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연쇄반응(Poly",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        451.7787780761719,
        539.8278198242188,
        477.6742248535156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "merase",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        451.7787780761719,
        539.8278198242188,
        477.6742248535156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "chain reaction, PCR) 분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        480.4274597167969,
        514.5211181640625,
        492.0585021972656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 알레르기 반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        594.302978515625,
        173.06619262695312,
        605.9340209960938
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        572.846435546875,
        373.95733642578125,
        627.3905639648438
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품의 라벨을 통하여 이상사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        572.846435546875,
        373.95733642578125,
        627.3905639648438
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "례 및 특성 집단에서의 금기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        572.846435546875,
        373.95733642578125,
        627.3905639648438
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항에 대한 경고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        572.846435546875,
        373.95733642578125,
        627.3905639648438
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.4 에 경고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        529.933349609375,
        466.3072814941406,
        541.5643920898438
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- SPC 4.4:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        558.58203125,
        534.4303588867188,
        613.1261596679688
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 뿐만 아니라 첨가제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        558.58203125,
        534.4303588867188,
        613.1261596679688
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예, 네오마이신)에 대한 아니",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        558.58203125,
        534.4303588867188,
        613.1261596679688
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "필락시스/아니필락시스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        558.58203125,
        534.4303588867188,
        613.1261596679688
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        558.58203125,
        534.4303588867188,
        613.1261596679688
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응의 가능성에 대해 적절한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        615.759521484375,
        539.8270874023438,
        670.3037109375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료처치 및 감독이 언제든",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        615.759521484375,
        539.8270874023438,
        670.3037109375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이뤄질 수 있도록 준비되어야",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        615.759521484375,
        539.8270874023438,
        670.3037109375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        615.759521484375,
        539.8270874023438,
        670.3037109375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        686.8418579101562,
        213.48394775390625,
        698.472900390625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        686.8418579101562,
        213.48394775390625,
        698.472900390625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        686.8418579101562,
        213.48394775390625,
        698.472900390625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        686.8418579101562,
        213.48394775390625,
        698.472900390625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(booster dose)의 필요성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        701.1062622070312,
        182.1812744140625,
        712.7373046875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성 임상시험 Protocol 004",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        672.4575805664062,
        373.95733642578125,
        727.001708984375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 백신 접종을 받았던 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        672.4575805664062,
        373.95733642578125,
        727.001708984375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험대상자를 대상으로 장기 유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        672.4575805664062,
        373.95733642578125,
        727.001708984375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효성 연구 완료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        672.4575805664062,
        373.95733642578125,
        727.001708984375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 54 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 백신과의 병용 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        209.04405212402344,
        189.4969482421875,
        220.6750946044922
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 성인 백신과의 병용투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        194.77963256835938,
        373.95733642578125,
        235.0593719482422
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 평가하기 위한 연구가 계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        194.77963256835938,
        373.95733642578125,
        235.0593719482422
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획되어 있음.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        194.77963256835938,
        373.95733642578125,
        235.0593719482422
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.5 다른 의약품과의 상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        534.4303588867188,
        142.04103088378906
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "호작용 및 기타 상호작용 항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        534.4303588867188,
        142.04103088378906
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 기술:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        101.76129150390625,
        534.4303588867188,
        142.04103088378906
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- SPC 4.5: 조스타박스는 불",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활화 인플루엔자 백신과 다른",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여부위에 병용투여가 가능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조스타박스와 23가 폐렴구균",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신과의 병용투여는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조스타박스의 면역원성을 감",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소시키므로 병용투여 하지 않",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는다. 따라서 두 백신의 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 필요할 경우, 최소 4주 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상의 간격을 두고 접종할 것",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 고려하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        159.0586700439453,
        539.8270874023438,
        327.9578552246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 중 ZOSTAVAXⓇ 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        466.0431823730469,
        201.97021484375,
        477.6742248535156
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        430.3222351074219,
        379.35406494140625,
        470.6019592285156
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바리박스주(VARIVAX)의 임부",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        430.3222351074219,
        379.35406494140625,
        470.6019592285156
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "레지스트리(registry)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        430.3222351074219,
        379.35406494140625,
        470.6019592285156
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        430.3222351074219,
        379.35406494140625,
        470.6019592285156
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ZOSTAVAX를 포함한 모든",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        473.2353210449219,
        379.35406494140625,
        513.5150146484375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VZV 백신을 포함하도록 확장",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        473.2353210449219,
        379.35406494140625,
        513.5150146484375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 예정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        473.2353210449219,
        379.35406494140625,
        513.5150146484375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.3 금기 항에 기술:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        330.2315979003906,
        539.8270874023438,
        384.7757568359375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- SPC 4.3: 임신. 백신 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        330.2315979003906,
        539.8270874023438,
        384.7757568359375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후 1개월은 임신을 피해야 한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        330.2315979003906,
        539.8270874023438,
        384.7757568359375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        330.2315979003906,
        539.8270874023438,
        384.7757568359375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC 4.6 수태능, 임신 및 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유 항에 기술:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- SPC 4.6: 임산부의 조스타",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박스 투여에 대한 자료는 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 비임상 연구는 생식독성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 확인하기에는 불충분하다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지만 자연적으로 발생하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상포진 바이러스의 감염은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "때로는 태아에 해를 가하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것으로 알려져 있다. 조스타",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박스는 임산부의 투여를 권장",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지 않는다. 백신 투여 후 1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개월은 임신을 피해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        401.67352294921875,
        539.8278198242188,
        584.9569702148438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임부 레지스트리(registry)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        384.0318603515625,
        601.974609375,
        510.2952880859375,
        613.6056518554688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예측하지 못한 안전성 시그날",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        658.6726684570312,
        213.48428344726562,
        684.568115234375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 검출",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        658.6726684570312,
        213.48428344726562,
        684.568115234375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시 활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허 가 조 건 ( r e g u l a t o r y",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "commitment)으로써 3개의 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후, 위약대조 일반 안전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가 후, 대규모 (백신 접종한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20,000명의 시험대상자) 안전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 관찰 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        615.759521484375,
        379.35528564453125,
        727.481201171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 55 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        202.22650146484375,
        390.02862548828125,
        214.86892700195312
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        56.609317779541016,
        226.94784545898438,
        543.6653442382812,
        239.18734741210938
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Protocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        226.94784545898438,
        543.6653442382812,
        239.18734741210938
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다. 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.16034698486328,
        245.00474548339844,
        538.1483154296875,
        256.6357727050781
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.16034698486328,
        262.505615234375,
        411.23272705078125,
        274.13665771484375
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        56.609317779541016,
        292.5162048339844,
        538.1483764648438,
        304.7557067871094
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Protocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        292.5162048339844,
        538.1483764648438,
        304.7557067871094
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(예상되는 시험 대상자수: 7,000명)을 진행하고 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        73.16034698486328,
        310.4532165527344,
        341.6951599121094,
        322.0842590332031
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.3555908203125,
        113.39232635498047
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.3555908203125,
        113.39232635498047
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Protocol",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        101.76129150390625,
        379.3555908203125,
        113.39232635498047
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "004에서 백신 접종을 받았던",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        116.14556884765625,
        379.35406494140625,
        170.68971252441406
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험대상자를 대상으로 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        116.14556884765625,
        379.35406494140625,
        170.68971252441406
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간의 장기 지속성을 평가하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        116.14556884765625,
        379.35406494140625,
        170.68971252441406
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기 위한 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        223.558837890625,
        116.14556884765625,
        379.35406494140625,
        170.68971252441406
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 56 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-5",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        220.08042907714844,
        125.00334930419922
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일본뇌염 백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        220.08042907714844,
        125.00334930419922
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<Ixiaro>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        162.7620849609375,
        133.6514892578125,
        178.7046661376953
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        192.27737426757812,
        128.5703125,
        204.9197998046875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        451.0745544433594,
        260.4988098144531,
        463.71697998046875
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        227.38400268554688,
        489.4236755371094,
        239.01504516601562
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Valneva Austria GmbH",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        227.38400268554688,
        489.4236755371094,
        239.01504516601562
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        227.38400268554688,
        489.4236755371094,
        239.01504516601562
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2009.03.31. (EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        227.38400268554688,
        489.4236755371094,
        239.01504516601562
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        266.4613037109375,
        189.98779296875,
        278.09234619140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ixiaro",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        266.4613037109375,
        189.98779296875,
        278.09234619140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        328.38201904296875,
        252.1968994140625,
        405.0201416015625,
        263.82794189453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        328.38201904296875,
        252.1968994140625,
        405.0201416015625,
        263.82794189453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호 (버",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        328.38201904296875,
        266.4613037109375,
        399.50347900390625,
        292.47662353515625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        328.38201904296875,
        266.4613037109375,
        399.50347900390625,
        292.47662353515625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        305.658447265625,
        497.46038818359375,
        317.28948974609375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        305.658447265625,
        497.46038818359375,
        317.28948974609375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능·효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        333.58795166015625,
        463.0686950683594,
        345.218994140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        333.58795166015625,
        463.0686950683594,
        345.218994140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        383.0938415527344,
        118.13597106933594,
        394.7248840332031
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        163.35147094726562,
        354.4451599121094,
        531.671875,
        423.3735656738281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        163.35147094726562,
        354.4451599121094,
        531.671875,
        423.3735656738281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        163.35147094726562,
        354.4451599121094,
        531.671875,
        423.3735656738281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 기초접종: 28일 간격으로 2회 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        163.35147094726562,
        354.4451599121094,
        531.671875,
        423.3735656738281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        163.35147094726562,
        354.4451599121094,
        531.671875,
        423.3735656738281
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        485.5818176269531,
        474.822021484375,
        497.2128601074219
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        485.5818176269531,
        474.822021484375,
        497.2128601074219
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        485.5818176269531,
        474.822021484375,
        497.2128601074219
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        508.3569641113281,
        173.06585693359375,
        519.9879760742188
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과민/알레르기 반응:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        575.9630126953125,
        188.7772674560547,
        644.7716064453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피부염, 호흡곤란, 홍반,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        575.9630126953125,
        188.7772674560547,
        644.7716064453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "눈부위 가려움, 홍조,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        575.9630126953125,
        188.7772674560547,
        644.7716064453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과민성, 가려움증, 발진,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        575.9630126953125,
        188.7772674560547,
        644.7716064453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두드러기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        575.9630126953125,
        188.7772674560547,
        644.7716064453125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시(개별이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례보고(ICSR), 정기안전성보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PSUR), 안전성 프로파일 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "링, 안전성 실마리정보 개발 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탐지)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ongoing",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "follow-up",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "studies",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        525.8577880859375,
        365.6818542480469,
        623.3150634765625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-324, 325, Ongoing study",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        626.0682983398438,
        365.6820373535156,
        666.2281494140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-322",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        626.0682983398438,
        365.6820373535156,
        666.2281494140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-401",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        626.0682983398438,
        365.6820373535156,
        666.2281494140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sentinel",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        626.0682983398438,
        365.6820373535156,
        666.2281494140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sites에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        626.0682983398438,
        365.6820373535156,
        666.2281494140625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20,000 Ixiaro 접종자에 대한 강",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        668.9813842773438,
        360.28472900390625,
        694.8768310546875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화된 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        668.9813842773438,
        360.28472900390625,
        694.8768310546875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC Section 4.3 금기사항:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        561.6986083984375,
        542.7055053710938,
        659.1558837890625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 또는 부형제나 불순물(예.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        561.6986083984375,
        542.7055053710938,
        659.1558837890625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로타민황산염)에 대한 과민반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        561.6986083984375,
        542.7055053710938,
        659.1558837890625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        561.6986083984375,
        542.7055053710938,
        659.1558837890625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 백신을 1회 접종 후 과민반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        561.6986083984375,
        542.7055053710938,
        659.1558837890625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 보인 자는 2차 접종을 하지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        561.6986083984375,
        542.7055053710938,
        659.1558837890625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않아야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        561.6986083984375,
        542.7055053710938,
        659.1558837890625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신경계 이상반응:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        704.2228393554688,
        148.57510375976562,
        730.1182861328125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        704.2228393554688,
        148.57510375976562,
        730.1182861328125
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시(개별이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        697.0307006835938,
        360.28472900390625,
        737.3104248046875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사례보고(ICSR), 정기안전성보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        697.0307006835938,
        360.28472900390625,
        737.3104248046875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(PSUR), 안전성 프로파일 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        697.0307006835938,
        360.28472900390625,
        737.3104248046875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인 위해성 완화 조치는 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        704.2228393554688,
        537.1888427734375,
        730.1182861328125
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        704.2228393554688,
        537.1888427734375,
        730.1182861328125
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 57 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "링, 안전성 실마리정보 개발 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6822814941406,
        142.04103088378906
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탐지)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6822814941406,
        142.04103088378906
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6822814941406,
        142.04103088378906
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ongoing",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6822814941406,
        142.04103088378906
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "follow-up",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6822814941406,
        142.04103088378906
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "studies IC51-324, 325, Ongoing",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        144.6743927001953,
        365.6815490722656,
        184.95413208007812
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "study IC51-322",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        144.6743927001953,
        365.6815490722656,
        184.95413208007812
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-401",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        144.6743927001953,
        365.6815490722656,
        184.95413208007812
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sentinel",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        144.6743927001953,
        365.6815490722656,
        184.95413208007812
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sites에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        144.6743927001953,
        365.6815490722656,
        184.95413208007812
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20,000 Ixiaro 접종자에 대한 강",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        187.58749389648438,
        360.28472900390625,
        213.60281372070312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화된 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        187.58749389648438,
        360.28472900390625,
        213.60281372070312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        219.47265625,
        173.06585693359375,
        231.10369873046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과민/알레르기 반응:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        301.4630432128906,
        162.96730041503906,
        327.3584899902344
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결막염, 저혈압",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        301.4630432128906,
        162.96730041503906,
        327.3584899902344
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시(개별이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례보고(ICSR), 정기안전성보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PSUR), 안전성 프로파일 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "링, 안전성 실마리정보 개발 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탐지)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ongoing",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "follow-up",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        237.09339904785156,
        365.6822814941406,
        320.1663513183594
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "studies IC51-324, 325, Ongoing",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        322.9195861816406,
        365.6815490722656,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "study IC51-322",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        322.9195861816406,
        365.6815490722656,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-401",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        322.9195861816406,
        365.6815490722656,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sentinel",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        322.9195861816406,
        365.6815490722656,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sites에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        322.9195861816406,
        365.6815490722656,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20,000 Ixiaro 접종자에 대한 강",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        365.83270263671875,
        360.28472900390625,
        391.7281494140625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화된 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        365.83270263671875,
        360.28472900390625,
        391.7281494140625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC Section 4.3 금기사항:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        265.6222229003906,
        542.7055053710938,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 또는 부형제나 불순물(예.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        265.6222229003906,
        542.7055053710938,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Protamin Sulphate)에 대한 과민",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        265.6222229003906,
        542.7055053710938,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        265.6222229003906,
        542.7055053710938,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 백신을 1회 접종 후 과민반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        265.6222229003906,
        542.7055053710938,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 보인 자는 2차 접종을 하지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        265.6222229003906,
        542.7055053710938,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않아야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        265.6222229003906,
        542.7055053710938,
        363.0794677734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신경계 이상반응:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.7951354980469,
        183.26068115234375,
        505.60369873046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "급성파종성뇌척수염, 급",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.7951354980469,
        183.26068115234375,
        505.60369873046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성뇌염, 급성척수염, 중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.7951354980469,
        183.26068115234375,
        505.60369873046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추신경계 염증, 길랑-바",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.7951354980469,
        183.26068115234375,
        505.60369873046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "레 증후군",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        436.7951354980469,
        183.26068115234375,
        505.60369873046875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시(개별이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례보고(ICSR), 정기안전성보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PSUR), 안전성 프로파일 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "링, 안전성 실마리정보 개발 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탐지)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ongoing",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "follow-up",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        393.8820495605469,
        365.6822814941406,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "studies IC51-324, 325, Ongoing",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        479.708251953125,
        365.6815490722656,
        519.9879760742188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "study IC51-322",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        479.708251953125,
        365.6815490722656,
        519.9879760742188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-401",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        479.708251953125,
        365.6815490722656,
        519.9879760742188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sentinel",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        479.708251953125,
        365.6815490722656,
        519.9879760742188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sites에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        479.708251953125,
        365.6815490722656,
        519.9879760742188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20,000 Ixiaro 접종자에 대한 강",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        522.621337890625,
        360.28472900390625,
        548.5167846679688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화된 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        522.621337890625,
        360.28472900390625,
        548.5167846679688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가적인 위해성 완화 조치는 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        465.44384765625,
        536.109619140625,
        477.07489013671875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        555.9448852539062,
        145.60073852539062,
        567.575927734375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임부에서의 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        632.0617065429688,
        145.60107421875,
        643.6927490234375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시(개별이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례보고(ICSR), 정기안전성보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PSUR), 안전성 프로파일 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "링, 안전성 실마리정보 개발 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탐지)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 증례의 분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-401",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sentinel",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sites에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        574.8842163085938,
        365.6814880371094,
        672.3414306640625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20,000 Ixiaro 접종자에 대한 강",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        674.974853515625,
        360.28472900390625,
        700.8703002929688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화된 감시활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        674.974853515625,
        360.28472900390625,
        700.8703002929688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC Section 4.6 임부 및 수유부:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        610.6051635742188,
        542.7055053710938,
        665.1492919921875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예방책으로써, 임신 또는 수유기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        610.6051635742188,
        542.7055053710938,
        665.1492919921875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동안에는 Ixiaro의 사용을 피해야",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        610.6051635742188,
        542.7055053710938,
        665.1492919921875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        610.6051635742188,
        542.7055053710938,
        665.1492919921875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역저하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        703.14404296875,
        188.77735900878906,
        714.7750854492188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        703.14404296875,
        188.77735900878906,
        714.7750854492188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        717.408447265625,
        85.15384674072266,
        729.0394897460938
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시(개별이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        703.14404296875,
        360.284423828125,
        729.0394897460938
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례보고(ICSR), 정기안전성보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        703.14404296875,
        360.284423828125,
        729.0394897460938
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC Section 4.5 다른 의약품과의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        703.14404296875,
        542.7052001953125,
        729.0394897460938
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호작용 및 기타 상호작용: 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        703.14404296875,
        542.7052001953125,
        729.0394897460938
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 58 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        312.2662353515625,
        390.02862548828125,
        324.9086608886719
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(PSUR), 안전성 프로파일 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6814880371094,
        170.68971252441406
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "링, 안전성 실마리정보 개발 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6814880371094,
        170.68971252441406
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탐지)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6814880371094,
        170.68971252441406
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개별 증례 분석, PSUR에 보고된",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6814880371094,
        170.68971252441406
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        101.76129150390625,
        365.6814880371094,
        170.68971252441406
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역억제요법으로 치료 중이거나",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        108.95343017578125,
        542.7055053710938,
        163.49757385253906
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역결핍 환자에서는 적절한 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        108.95343017578125,
        542.7055053710938,
        163.49757385253906
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역반응이 나타나지 않을 수 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        108.95343017578125,
        542.7055053710938,
        163.49757385253906
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        108.95343017578125,
        542.7055053710938,
        163.49757385253906
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백신 동시접종 자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        63.08580780029297,
        222.9488525390625,
        151.11810302734375,
        234.57989501953125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인 의약품 감시(개별이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사례보고(ICSR), 정기안전성보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PSUR), 안전성 프로파일 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "링, 안전성 실마리정보 개발 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "탐지)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 여행자 백신으로 Ixiaro와",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동시접종 시 영향에 대한 새로운",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 IC51-316",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        193.4551544189453,
        172.84361267089844,
        365.6814880371094,
        284.5652770996094
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가적인 위해성 완화 조치는 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        215.7567138671875,
        537.1888427734375,
        241.65216064453125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        370.3592834472656,
        215.7567138671875,
        537.1888427734375,
        241.65216064453125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        345.5748291015625,
        193.33486938476562,
        357.20587158203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구제목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        345.5748291015625,
        193.33486938476562,
        357.20587158203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-324",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        369.06915283203125,
        536.8290405273438,
        395.8037109375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        369.06915283203125,
        536.8290405273438,
        395.8037109375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        369.06915283203125,
        536.8290405273438,
        395.8037109375
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-325",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        418.0955810546875,
        104.70355224609375,
        429.72662353515625
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        149.31907653808594,
        403.8311767578125,
        542.3453979492188,
        443.99102783203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        149.31907653808594,
        403.8311767578125,
        542.3453979492188,
        443.99102783203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        149.31907653808594,
        403.8311767578125,
        542.3453979492188,
        443.99102783203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "IC51-322",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        451.8986511230469,
        536.948974609375,
        478.6331787109375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        451.8986511230469,
        536.948974609375,
        478.6331787109375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        451.8986511230469,
        536.948974609375,
        478.6331787109375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IC51-401",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        486.66064453125,
        542.3455200195312,
        512.5560913085938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        486.66064453125,
        542.3455200195312,
        512.5560913085938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "surveillance)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        486.66064453125,
        542.3455200195312,
        512.5560913085938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 59 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-6",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        61.64658737182617,
        109.06077575683594,
        249.22463989257812,
        125.00334930419922
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타바이러스 백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        61.64658737182617,
        109.06077575683594,
        249.22463989257812,
        125.00334930419922
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<Rotarix>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        165.51907348632812,
        144.32614135742188,
        181.46165466308594
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        195.03436279296875,
        128.5703125,
        207.67678833007812
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        400.6097106933594,
        260.4988098144531,
        413.25213623046875
      ],
      "page_num": 64,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 최초 제출(2006) (lyophilized formulation)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        419.4237365722656,
        273.7826232910156,
        431.6363220214844
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        218.39382934570312,
        457.16119384765625,
        244.28927612304688
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GlaxoSmithKline Biologicals",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        218.39382934570312,
        457.16119384765625,
        244.28927612304688
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "S.A.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        218.39382934570312,
        457.16119384765625,
        244.28927612304688
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        218.39382934570312,
        457.16119384765625,
        244.28927612304688
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2006.2.21. (EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        218.39382934570312,
        457.16119384765625,
        244.28927612304688
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        252.1968994140625,
        372.8791809082031,
        278.09234619140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타릭스 (Rotarix)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        252.1968994140625,
        372.8791809082031,
        278.09234619140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성관리계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        252.1968994140625,
        372.8791809082031,
        278.09234619140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획번호(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        252.1968994140625,
        372.8791809082031,
        278.09234619140625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        285.88006591796875,
        454.16668701171875,
        297.5111083984375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약독 사람 로타 바이러스 (human rotavirus, live attenuated)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        285.88006591796875,
        454.16668701171875,
        297.5111083984375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능.효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        305.4187316894531,
        481.8988342285156,
        317.0497741699219
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        305.4187316894531,
        481.8988342285156,
        317.0497741699219
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법.용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        346.2940673828125,
        108.6611099243164,
        357.92510986328125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        324.8374938964844,
        534.9100952148438,
        379.38165283203125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        324.8374938964844,
        534.9100952148438,
        379.38165283203125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        324.8374938964844,
        534.9100952148438,
        379.38165283203125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        324.8374938964844,
        534.9100952148438,
        379.38165283203125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        446.3846740722656,
        518.5985717773438,
        458.0157165527344
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        446.3846740722656,
        518.5985717773438,
        458.0157165527344
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        446.3846740722656,
        518.5985717773438,
        458.0157165527344
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기관지염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        465.8034362792969,
        273.57171630859375,
        477.4344787597656
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study 036",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        465.8034362792969,
        273.57171630859375,
        477.4344787597656
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장중첩증 (Intussusception)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        518.1861572265625,
        196.78350830078125,
        529.8171997070312
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EU내에서 능동적 감시 (PSUR)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.23793029785156,
        482.4652404785156,
        408.8580627441406,
        537.0093383789062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Active surveillance in EU (PSUR))",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.23793029785156,
        482.4652404785156,
        408.8580627441406,
        537.0093383789062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실제 보고된 내용과 예상된 내용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.23793029785156,
        482.4652404785156,
        408.8580627441406,
        537.0093383789062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.23793029785156,
        482.4652404785156,
        408.8580627441406,
        537.0093383789062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PASS study (Mexico) 1)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.23793029785156,
        552.5117797851562,
        337.54974365234375,
        565.6580200195312
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴 사망",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        570.5689086914062,
        326.3114318847656,
        582.199951171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PASS study (Mexico)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        570.5689086914062,
        326.3114318847656,
        582.199951171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        588.7890014648438,
        395.5453186035156,
        600.4200439453125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유럽 로타바이러스 조사 네트워크",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        588.7890014648438,
        395.5453186035156,
        600.4200439453125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신바이러스의 유전학적 안",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        606.8892211914062,
        214.44378662109375,
        632.78466796875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        606.8892211914062,
        214.44378662109375,
        632.78466796875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "벨기에에서 백신 유전학적 안정성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.23793029785156,
        606.8892211914062,
        414.3750915527344,
        632.78466796875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        225.23793029785156,
        606.8892211914062,
        414.3750915527344,
        632.78466796875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신바이러스 전파",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        636.5399780273438,
        489.09490966796875,
        649.5663452148438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study 052 2)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        636.5399780273438,
        489.09490966796875,
        649.5663452148438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rota study 052",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        636.5399780273438,
        489.09490966796875,
        649.5663452148438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미숙아에서의 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        653.3215942382812,
        489.09490966796875,
        666.4678955078125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study 054 3)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        653.3215942382812,
        489.09490966796875,
        666.4678955078125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rota study 054",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        653.3215942382812,
        489.09490966796875,
        666.4678955078125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역력이 약화된 영아에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        671.4985961914062,
        489.09490966796875,
        697.3941040039062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        671.4985961914062,
        489.09490966796875,
        697.3941040039062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study 022 4)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        671.4985961914062,
        489.09490966796875,
        697.3941040039062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rota study 022",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        671.4985961914062,
        489.09490966796875,
        697.3941040039062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경구 폴리오백신과의 병용접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        702.4248046875,
        284.7783508300781,
        728.3202514648438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종   후 추가적인 효능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        702.4248046875,
        284.7783508300781,
        728.3202514648438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study 024 5)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        67.40347290039062,
        702.4248046875,
        284.7783508300781,
        728.3202514648438
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 60 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        99.00430297851562,
        479.9498596191406,
        110.63533782958984
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        118.78268432617188,
        537.6690063476562,
        130.41372680664062
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) RMP 변경 제출(2008) (liquid formulation 추가)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        144.5545196533203,
        303.5254821777344,
        156.18556213378906
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        165.0521240234375,
        171.62664794921875,
        208.44845581054688
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당사항 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        165.0521240234375,
        171.62664794921875,
        208.44845581054688
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        165.0521240234375,
        171.62664794921875,
        208.44845581054688
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기관지염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.08384704589844,
        396.6247253417969,
        225.11024475097656
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study Rota 036 6)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.08384704589844,
        396.6247253417969,
        225.11024475097656
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        212.08384704589844,
        396.6247253417969,
        225.11024475097656
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장중첩증(Intussusception)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        334.5469055175781,
        185.6295623779297,
        346.1779479980469
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "l EU내에서 능동적 감시:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        278.0885925292969,
        344.3089904785156,
        289.7196350097656
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a) Germany (ESPED)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        306.6174011230469,
        327.06243896484375,
        332.63275146484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b) UK (BPSU): 보류됨",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        306.6174011230469,
        327.06243896484375,
        332.63275146484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "l 실제 보고된 내용과 예상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        349.530517578125,
        364.4824523925781,
        375.54583740234375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "된 내용 비교분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        349.530517578125,
        364.4824523925781,
        375.54583740234375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "l PASS study (Mexico) 1)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        389.7297058105469,
        340.548095703125,
        402.756103515625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        227.26412963867188,
        534.9097290039062,
        310.45697021484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.3. 금기:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        227.26412963867188,
        534.9097290039062,
        310.45697021484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장중첩증의 병력이 있는 자.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        227.26412963867188,
        534.9097290039062,
        310.45697021484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장중첩증이 일어나기 쉬운 교",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        227.26412963867188,
        534.9097290039062,
        310.45697021484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정되지 않은 선천성 위장관 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        227.26412963867188,
        534.9097290039062,
        310.45697021484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상이 있는 자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        227.26412963867188,
        534.9097290039062,
        310.45697021484375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.8. 이상반응:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "63,225명의 피험자가 참여한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라틴아메리카와 핀란드에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대규모 안전성 임상시험에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장중첩증의 위험을 평가하였",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 해당 시험에서 이 백신 투",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여군에서의 장중첩증 위험도는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위약군과 비교하였을때 증가하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        327.474609375,
        534.9097900390625,
        453.460693359375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐렴 사망",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        455.7344665527344,
        396.6247253417969,
        467.3655090332031
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PASS study (Mexico)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        455.7344665527344,
        396.6247253417969,
        467.3655090332031
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        455.7344665527344,
        396.6247253417969,
        467.3655090332031
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        470.83795166015625,
        144.16152954101562,
        482.468994140625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        507.5178527832031,
        295.0096740722656,
        519.1488647460938
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study (Belgium)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        507.5178527832031,
        295.0096740722656,
        519.1488647460938
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        486.0613098144531,
        534.9097900390625,
        540.6054077148438
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.4. 경고 및 주의사항: 모든",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        486.0613098144531,
        534.9097900390625,
        540.6054077148438
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신접종자에서 방어면역반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        486.0613098144531,
        534.9097900390625,
        540.6054077148438
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 나타나지 않을 수도 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        486.0613098144531,
        534.9097900390625,
        540.6054077148438
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후 환경에서, 순환 RV",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        545.7560424804688,
        213.48411560058594,
        571.6514892578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "균주의 다양성 모니터링",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        545.7560424804688,
        213.48411560058594,
        571.6514892578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유럽 로타바이러스 조사 네",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        545.7560424804688,
        396.6247253417969,
        571.6514892578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "트워크",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        545.7560424804688,
        396.6247253417969,
        571.6514892578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        545.7560424804688,
        396.6247253417969,
        571.6514892578125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신바이러스의 유전학적 안",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        576.8021240234375,
        207.96728515625,
        602.6975708007812
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        576.8021240234375,
        207.96728515625,
        602.6975708007812
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "벨기에에서 백신 유전학적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        576.8021240234375,
        396.6247253417969,
        602.6975708007812
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안정성   시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        576.8021240234375,
        396.6247253417969,
        602.6975708007812
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        576.8021240234375,
        396.6247253417969,
        602.6975708007812
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신바이러스 전파",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        640.6922607421875,
        160.59263610839844,
        652.3233032226562
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study Rota 052 2)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        653.5613403320312,
        305.2872314453125,
        666.5877685546875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        604.8514404296875,
        396.3601989746094,
        616.4824829101562
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.4 경고 및 주의사항:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        633.5001220703125,
        529.5130004882812,
        716.6929931640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신접종자와 접촉한 항체음성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        633.5001220703125,
        529.5130004882812,
        716.6929931640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인 자에게, 배출된 백신 바이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        633.5001220703125,
        529.5130004882812,
        716.6929931640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "러스가 전이된 경우 임상적 증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        633.5001220703125,
        529.5130004882812,
        716.6929931640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상을 야기하지 않는 것으로 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        633.5001220703125,
        529.5130004882812,
        716.6929931640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "찰되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        633.5001220703125,
        529.5130004882812,
        716.6929931640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "미숙아에서의 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        717.3316650390625,
        396.3601989746094,
        730.4779052734375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study Rota 054 3)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        717.3316650390625,
        396.3601989746094,
        730.4779052734375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        717.3316650390625,
        396.3601989746094,
        730.4779052734375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 61 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        620.0748291015625,
        536.8287353515625,
        631.7058715820312
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[Study Title]",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) PASS:",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Post-Authorization",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Safety",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Study",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(PASS)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Post-Marketing",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Surveillance",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        643.81640625,
        538.2109375,
        671.6333618164062
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Intussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        672.465087890625,
        538.2606201171875,
        699.9630126953125
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(IMSS) in Mexico",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        672.465087890625,
        538.2606201171875,
        699.9630126953125
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(https://clinicaltrials.gov/ct2/show/NCT00595205)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        672.465087890625,
        538.2606201171875,
        699.9630126953125
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        715.378173828125,
        538.2623901367188,
        728.8108520507812
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4.4. 경고 및 주의사항:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        100.44273376464844,
        534.9097900390625,
        197.8999786376953
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조산아 140명에서의 제한된 자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        100.44273376464844,
        534.9097900390625,
        197.8999786376953
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "료에 따르면, 이 백신은 조산",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        100.44273376464844,
        534.9097900390625,
        197.8999786376953
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아에게 투여될 수 있으나, 더",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        100.44273376464844,
        534.9097900390625,
        197.8999786376953
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "낮은 면역반응이 관찰될 수 있",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        100.44273376464844,
        534.9097900390625,
        197.8999786376953
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으며 임상적 방어 수준이 알려",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        100.44273376464844,
        534.9097900390625,
        197.8999786376953
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "져 있지 않다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        100.44273376464844,
        534.9097900390625,
        197.8999786376953
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역력이 약화된 영아에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        321.6010437011719,
        305.2872314453125,
        347.4964904785156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        321.6010437011719,
        305.2872314453125,
        347.4964904785156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Study Rota 022 4)",
      "font_size": 7.074217319488525,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        321.6010437011719,
        305.2872314453125,
        347.4964904785156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.3. 금기:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알려진 또는 의심되는 면역결",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "핍증이 있는 자.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무증상의 인간면역결핍바이러",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(HIV,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Human",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        200.0538787841797,
        534.91064453125,
        283.1268310546875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Immunodeficiency Virus) 감염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        285.88006591796875,
        534.9097900390625,
        383.3373107910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "은 로타릭스의 안전성과 유효",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        285.88006591796875,
        534.9097900390625,
        383.3373107910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성에 영향을 주지 않을 것으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        285.88006591796875,
        534.9097900390625,
        383.3373107910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예상되나, 충분한 자료가 없으",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        285.88006591796875,
        534.9097900390625,
        383.3373107910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "므로 무증상의 HIV 감염자에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        285.88006591796875,
        534.9097900390625,
        383.3373107910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 이 백신의 투여를 권장하지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        285.88006591796875,
        534.9097900390625,
        383.3373107910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        285.88006591796875,
        534.9097900390625,
        383.3373107910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.4. 경고 및 주의사항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        400.235107421875,
        534.9097900390625,
        483.4279479980469
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역이 결핍된 자(예. 악성 종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        400.235107421875,
        534.9097900390625,
        483.4279479980469
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양환자나 다른 면역 저해 환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        400.235107421875,
        534.9097900390625,
        483.4279479980469
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자, 면역억제요법을 받고 있는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        400.235107421875,
        534.9097900390625,
        483.4279479980469
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자 등)와 접촉하는 경우에는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        400.235107421875,
        534.9097900390625,
        483.4279479980469
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 백신을 주의하여 투여한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        400.235107421875,
        534.9097900390625,
        483.4279479980469
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투약/접종 오류 가능성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        528.4949340820312,
        180.50184631347656,
        540.1259765625
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR을 통한 검토:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        492.77398681640625,
        375.3959045410156,
        547.318115234375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "label and packaging 변경에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        492.77398681640625,
        375.3959045410156,
        547.318115234375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따른 영향을 평가하기 위해,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        492.77398681640625,
        375.3959045410156,
        547.318115234375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투약오류사례의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        492.77398681640625,
        375.3959045410156,
        547.318115234375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고빈도를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        492.77398681640625,
        375.3959045410156,
        547.318115234375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국가별로 면밀히 모니터링",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        549.9514770507812,
        369.87921142578125,
        590.231201171875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 것이며, 관련결과를 추후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        549.9514770507812,
        369.87921142578125,
        590.231201171875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PSUR에   요약할 것이다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        218.16175842285156,
        549.9514770507812,
        369.87921142578125,
        590.231201171875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SPC:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        492.77398681640625,
        531.4320068359375,
        561.58251953125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.4. 경고 및 주의사항:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        492.77398681640625,
        531.4320068359375,
        561.58251953125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 백신은 절대로 주사하여서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        492.77398681640625,
        531.4320068359375,
        561.58251953125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 안 된다. 새롭게 개정된 라",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        492.77398681640625,
        531.4320068359375,
        561.58251953125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "벨과 패키지가 이용 가능하다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        374.67694091796875,
        492.77398681640625,
        531.4320068359375,
        561.58251953125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 62 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of horizontal transmission of the RIX4414 vaccine strain between within a family",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        97.45349884033203,
        456.8174743652344,
        110.6870346069336
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        111.71791076660156,
        520.74658203125,
        139.3357391357422
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        111.71791076660156,
        520.74658203125,
        139.3357391357422
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        154.63101196289062,
        538.2188720703125,
        168.06365966796875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        169.01528930664062,
        538.1424560546875,
        196.51324462890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        169.01528930664062,
        538.1424560546875,
        196.51324462890625
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(https://clinicaltrials.gov/ct2/show/study/NCT00420745)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        197.5441131591797,
        306.66448974609375,
        210.7776641845703
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        226.1927947998047,
        538.2244873046875,
        239.6254425048828
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "reactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        240.45721435546875,
        538.203369140625,
        282.3394470214844
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "human rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        240.45721435546875,
        538.203369140625,
        282.3394470214844
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6, 10 and 14 weeks of age",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        240.45721435546875,
        538.203369140625,
        282.3394470214844
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        283.37030029296875,
        537.7664184570312,
        310.9881591796875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "man/000639/WC500143025.pdf)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        283.37030029296875,
        537.7664184570312,
        310.9881591796875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        326.2834167480469,
        538.203369140625,
        339.716064453125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        340.6676940917969,
        538.2296142578125,
        368.1656494140625
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Routine EPI Vaccinations Including OPV in Healthy Infants",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        340.6676940917969,
        538.2296142578125,
        368.1656494140625
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(https://clinicaltrials.gov/ct2/show/NCT00139347)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        369.1965026855469,
        278.9591979980469,
        382.4300537109375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        397.84521484375,
        538.2112426757812,
        411.2778625488281
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "study to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        412.109619140625,
        538.2023315429688,
        453.9918518066406
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "attenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        412.109619140625,
        538.2023315429688,
        453.9918518066406
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "childhood vaccinations",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        62.12632751464844,
        412.109619140625,
        538.2023315429688,
        453.9918518066406
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        455.0227355957031,
        478.4046630859375,
        468.25628662109375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 63 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<RotaTeq>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        98.99178314208984,
        156.3199462890625,
        114.93435668945312
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        128.62693786621094,
        128.5703125,
        141.2693634033203
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        378.7935485839844,
        260.4988098144531,
        391.43597412109375
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        710.575927734375,
        479.9498596191406,
        722.2069702148438
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        730.3543090820312,
        536.8287353515625,
        741.9853515625
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        151.9864044189453,
        462.6781921386719,
        163.61744689941406
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MSD VACCINS",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        151.9864044189453,
        462.6781921386719,
        163.61744689941406
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        151.9864044189453,
        462.6781921386719,
        163.61744689941406
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2006.06.27. (EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        151.9864044189453,
        462.6781921386719,
        163.61744689941406
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        169.9667510986328,
        372.8791809082031,
        195.98207092285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "RotaTeq",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        169.9667510986328,
        372.8791809082031,
        195.98207092285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성관리계",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        169.9667510986328,
        372.8791809082031,
        195.98207092285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "획번호(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        169.9667510986328,
        372.8791809082031,
        195.98207092285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분   및 함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        230.98007202148438,
        141.88311767578125,
        256.8755187988281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        230.98007202148438,
        141.88311767578125,
        256.8755187988281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "One dose (2 ml) contains:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        202.33139038085938,
        330.7807312011719,
        285.52423095703125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타바이러스 G1 2.2 x 106IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        202.33139038085938,
        330.7807312011719,
        285.52423095703125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타바이러스 G2 2.8 x 106 IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        202.33139038085938,
        330.7807312011719,
        285.52423095703125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타바이러스 G3 2.2 x 106IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        202.33139038085938,
        330.7807312011719,
        285.52423095703125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타바이러스 G4 2.0 x 106IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        202.33139038085938,
        330.7807312011719,
        285.52423095703125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타바이러스 P1A 2.3 x 106IU 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        202.33139038085938,
        330.7807312011719,
        285.52423095703125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능.효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        296.1888122558594,
        526.2752685546875,
        307.8198547363281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        296.1888122558594,
        526.2752685546875,
        307.8198547363281
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법.용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        332.7488708496094,
        108.6611099243164,
        344.3799133300781
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        318.48443603515625,
        534.7898559570312,
        358.6443176269531
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        318.48443603515625,
        534.7898559570312,
        358.6443176269531
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추가 투여한다. 3차 투여는 생후 32주를 넘어서는 안 된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        318.48443603515625,
        534.7898559570312,
        358.6443176269531
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        407.067626953125,
        336.8970947265625,
        418.69866943359375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        407.067626953125,
        336.8970947265625,
        418.69866943359375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장중첩증 (Intussusception)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        447.2237548828125,
        191.26760864257812,
        458.85479736328125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 9.951866149902344,
      "font_name": "Wingdings-Regular",
      "bbox": [
        254.3821258544922,
        428.2844543457031,
        496.5305480957031,
        439.9154968261719
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수동적 보고와 US 시판 후 안전성조사 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        428.2844543457031,
        496.5305480957031,
        439.9154968261719
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 9.951866149902344,
      "font_name": "Wingdings-Regular",
      "bbox": [
        254.3821258544922,
        451.7787780761719,
        521.8367919921875,
        477.6742248535156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ESPED와 collaboration을 통한 독일에서의 장중첩",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        451.7787780761719,
        521.8367919921875,
        477.6742248535156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증 역학 조사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        451.7787780761719,
        521.8367919921875,
        477.6742248535156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신효과와 혈청형 변경",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        496.9693908691406,
        188.29795837402344,
        508.6004333496094
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유럽에서의 로타바이러스 감시: 연속적인 로타바이러",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        482.7049865722656,
        521.8367919921875,
        522.8648071289062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스 seasons에 유행하는 다양한 로타바이러스 혈청형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        482.7049865722656,
        521.8367919921875,
        522.8648071289062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 확인하는 것",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        482.7049865722656,
        521.8367919921875,
        522.8648071289062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종자로부터 밀접 접촉자로의 전파의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        527.8955688476562,
        325.8630676269531,
        553.791015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험과   새로운 재조합체 출현 가능성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        527.8955688476562,
        325.8630676269531,
        553.791015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수동적 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        527.8955688476562,
        325.8630676269531,
        553.791015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로타바이러스 감염의 장외발현 가능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        558.82177734375,
        244.18731689453125,
        584.7172241210938
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성(향신경작용과 간독성을 포함)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        558.82177734375,
        244.18731689453125,
        584.7172241210938
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수동적 보고와 US 시판 후 안전성조사 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        558.82177734375,
        481.5386962890625,
        570.4528198242188
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HIV감염된 영아에 대한 접종: 해당",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        589.7479858398438,
        255.22132873535156,
        658.6763916015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아이들이 백신을 접종받은 다른 영",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        589.7479858398438,
        255.22132873535156,
        658.6763916015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아로부터 백신 바이러스를 우연히",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        589.7479858398438,
        255.22132873535156,
        658.6763916015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전파 받게 될 위험성을 평가할 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        589.7479858398438,
        255.22132873535156,
        658.6763916015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있을 것임",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        589.7479858398438,
        255.22132873535156,
        658.6763916015625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "태국과 남아프리카에서 임상시험 (protocol 011)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        254.3821258544922,
        618.3966674804688,
        492.66265869140625,
        630.0277099609375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위식도역류질환의 가능성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        663.5872802734375,
        481.5386962890625,
        675.2183227539062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수동적 보고와 US 시판 후 안전성조사 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        663.5872802734375,
        481.5386962890625,
        675.2183227539062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과민반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        680.2490844726562,
        481.5386962890625,
        691.880126953125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수동적 보고와 US 시판 후 안전성조사 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.88645935058594,
        680.2490844726562,
        481.5386962890625,
        691.880126953125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 64 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-7",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        462.70892333984375,
        125.00334930419922
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "홍역·유해성이하선염 및 풍진(MMR) 혼합백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        462.70892333984375,
        125.00334930419922
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<M-M-RVaxPro>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        161.3236541748047,
        211.61056518554688,
        177.2662353515625
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        190.9588165283203,
        128.5703125,
        203.6012420654297
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        215.6368408203125,
        465.5566101074219,
        227.26788330078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sanofi Pasteur MSD",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        215.6368408203125,
        465.5566101074219,
        227.26788330078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        215.6368408203125,
        465.5566101074219,
        227.26788330078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2006.05.05. (EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        215.6368408203125,
        465.5566101074219,
        227.26788330078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        255.193603515625,
        222.12948608398438,
        266.82464599609375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "M-M-RVaxPro",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        255.193603515625,
        222.12948608398438,
        266.82464599609375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        315.0692443847656,
        233.737060546875,
        381.153076171875,
        274.01678466796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        315.0692443847656,
        233.737060546875,
        381.153076171875,
        274.01678466796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        315.0692443847656,
        233.737060546875,
        381.153076171875,
        274.01678466796875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        362.9558410644531,
        138.64486694335938,
        374.5868835449219
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0.5ml 안에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        283.3628234863281,
        205.08883666992188,
        294.9938659667969
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "홍역 바이러스. Enders' Edmonston strain (생약독화 백신)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        310.1366882324219,
        511.76263427734375,
        323.7090759277344
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1x103 CCID50* 이하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        310.1366882324219,
        511.76263427734375,
        323.7090759277344
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "볼거리 바이러스, Jeryl Lynn™ [Level B] strain",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        334.4270324707031,
        520.15771484375,
        360.3224792480469
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(생약독화 백신)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        334.4270324707031,
        520.15771484375,
        360.3224792480469
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12.5x103 CCID50 이하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        334.4270324707031,
        520.15771484375,
        360.3224792480469
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        369.7115783691406,
        506.2456359863281,
        383.2839660644531
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1x103 CCID50 이하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        369.7115783691406,
        506.2456359863281,
        383.2839660644531
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        481.50628662109375,
        105.66239929199219,
        493.1373291015625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        392.0840148925781,
        529.39306640625,
        417.9794616699219
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시 예방 접종으로 받을 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        392.0840148925781,
        529.39306640625,
        417.9794616699219
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        427.8049621582031,
        534.9100952148438,
        453.8202819824219
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        427.8049621582031,
        534.9100952148438,
        453.8202819824219
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        463.64581298828125,
        534.9097900390625,
        503.8056640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        463.64581298828125,
        534.9097900390625,
        503.8056640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여 받지 않은9개월 이상의 사람에게 사용될 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        463.64581298828125,
        534.9097900390625,
        503.8056640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        513.6311645507812,
        443.0155029296875,
        525.26220703125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        699.4281005859375,
        105.66239929199219,
        711.0591430664062
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        531.3717651367188,
        174.1456298828125,
        543.0028076171875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12개월 또는 이상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        552.8283081054688,
        240.10986328125,
        564.4593505859375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        574.2848510742188,
        534.9100952148438,
        628.8289794921875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        574.2848510742188,
        534.9100952148438,
        628.8289794921875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(second dose)을 투여 받을 수 있다. 두 번째 용량은 이유와 상관 없이 첫",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        574.2848510742188,
        534.9100952148438,
        628.8289794921875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        574.2848510742188,
        534.9100952148438,
        628.8289794921875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9개월에서 12개월 사이의 유아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        660.111083984375,
        306.0741271972656,
        671.7421264648438
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        681.567626953125,
        534.9097900390625,
        736.1117553710938
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "M-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        681.567626953125,
        534.9097900390625,
        736.1117553710938
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        681.567626953125,
        534.9097900390625,
        736.1117553710938
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "병 또는 홍역 유병율이 높은 지역으로의 여행). 이러한 유아들은 12~15개",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        681.567626953125,
        534.9097900390625,
        736.1117553710938
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 65 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        432.3749694824219,
        260.4988098144531,
        445.01739501953125
      ],
      "page_num": 70,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "월 때 다시 백신 투여를 받아야 한다. 홍역 바이러스가 포함된 백신의 추",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        100.44273376464844,
        529.39306640625,
        126.33818054199219
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가 투여량은 권고 사항에 따라 고려 되어져야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        100.44273376464844,
        529.39306640625,
        126.33818054199219
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9개월미만의 유아",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        157.6202392578125,
        240.10986328125,
        169.25128173828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        179.07679748535156,
        529.39306640625,
        204.9722442626953
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 자료는 현재 존재하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        179.07679748535156,
        529.39306640625,
        204.9722442626953
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여 방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        236.25430297851562,
        201.6107177734375,
        247.88534545898438
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 백신은 근육내 또는 피하로 투여되어야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        257.71087646484375,
        402.2623291015625,
        269.3419189453125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        279.16741943359375,
        534.9097900390625,
        319.4471435546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        279.16741943359375,
        534.9097900390625,
        319.4471435546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "당된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        279.16741943359375,
        534.9097900390625,
        319.4471435546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        329.27264404296875,
        534.9097900390625,
        355.1681213378906
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주사되어야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        329.27264404296875,
        534.9097900390625,
        355.1681213378906
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        364.9936218261719,
        534.9100952148438,
        390.8890686035156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        364.9936218261719,
        534.9100952148438,
        390.8890686035156
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈관 내로 투여하지 않는다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        152.07757568359375,
        400.7145690917969,
        292.37713623046875,
        412.3456115722656
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 문제 요약",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        454.2960205078125,
        149.67886352539062,
        465.92706298828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        470.95782470703125,
        365.8017272949219,
        482.5888671875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        470.95782470703125,
        365.8017272949219,
        482.5888671875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        501.8840026855469,
        171.62664794921875,
        513.5150146484375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HSA(human serum albumin) 및 rHA(recombinant human albumin)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        196.69338989257812,
        487.6195983886719,
        529.5130004882812,
        527.7794189453125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        196.69338989257812,
        487.6195983886719,
        529.5130004882812,
        527.7794189453125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        196.69338989257812,
        487.6195983886719,
        529.5130004882812,
        527.7794189453125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        532.8101806640625,
        218.76144409179688,
        544.4412231445312
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임부",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        532.8101806640625,
        218.76144409179688,
        544.4412231445312
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성   중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        564.2158813476562,
        416.533935546875,
        575.846923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품   감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        564.2158813476562,
        416.533935546875,
        575.846923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성   완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        564.2158813476562,
        416.533935546875,
        575.846923828125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한   잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        579.439208984375,
        182.54074096679688,
        591.0702514648438
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HSA(human",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        597.4195556640625,
        190.8161163330078,
        609.0505981445312
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "serum",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        597.4195556640625,
        190.8161163330078,
        609.0505981445312
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "albumin)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        611.6840209960938,
        190.81658935546875,
        623.3150634765625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        611.6840209960938,
        190.81658935546875,
        623.3150634765625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "rHA(recombinant human",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        626.0682983398438,
        190.81678771972656,
        694.8768310546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "albumin)의 교체와 관련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        626.0682983398438,
        190.81678771972656,
        694.8768310546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "된 M-M-RTMII의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        626.0682983398438,
        190.81678771972656,
        694.8768310546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로파일에서의 잠재적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        626.0682983398438,
        190.81678771972656,
        694.8768310546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        626.0682983398438,
        190.81678771972656,
        694.8768310546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.49404907226562,
        633.1405639648438,
        296.3590393066406,
        644.7716064453125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.49404907226562,
        633.1405639648438,
        296.3590393066406,
        644.7716064453125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.49404907226562,
        647.5248413085938,
        239.50985717773438,
        659.1558837890625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자 및 전문가용 사용설명서를 통한 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        633.1405639648438,
        534.9097900390625,
        659.1558837890625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        633.1405639648438,
        534.9097900390625,
        659.1558837890625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        701.2261352539062,
        149.67886352539062,
        712.857177734375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.49404907226562,
        716.4495239257812,
        534.9097900390625,
        728.08056640625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품 환자 및 전문가용 사용설명서를 통한 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        195.49404907226562,
        716.4495239257812,
        534.9097900390625,
        728.08056640625
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 66 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임부",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        400.8344421386719,
        239.50985717773438,
        419.5377502441406
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.64658737182617,
        400.8344421386719,
        239.50985717773438,
        419.5377502441406
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완화",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        100.44273376464844,
        323.1048889160156,
        112.07376861572266
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-SmPC-",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        128.9715576171875,
        529.39306640625,
        183.5157012939453
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.3 금기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        128.9715576171875,
        529.39306640625,
        183.5157012939453
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임부. 추가로, 예방 접종 1달 가량 임신을 피",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        128.9715576171875,
        529.39306640625,
        183.5157012939453
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해야 합니다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        128.9715576171875,
        529.39306640625,
        183.5157012939453
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(중략)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        200.53334045410156,
        329.91119384765625,
        212.1643829345703
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.6 수태능, 임신 및 수유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신한 여성은 M-M-RVAXPRO로 예방접종을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "받아서는 안 된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신한 여성에 대한 M-M-RVAXPRO의 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "은 수행되지 않았다. 이것이 임부에게 투여되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "었을 때 태아에게 위해가 발생되거나 추후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신에 영향을 미치는지 알 수 없다. 하지만,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "홍역 또는 볼거리 바이러스가 임산부에게 전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "달되었을 때 태아 위해성이 보고되었다. 비록",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이론적인 위험성이 배제될 수 는 없지만, 볼",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "거리가 포함된 백신을 투여 받았을 때 임신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초기 알지 못한 3500명 이상의 취약한 여성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 선천성 풍진 증후군은 보고되지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그러므로 임신 여부를 모르는 여성에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의도치 않은 홍역, 볼거리 또는 풍진을 포함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 백신의 접종은 임신 중단의 원인이 되어",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서는 안 된다. 백신 접종 후 1달 간 임신은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피해야 하며, 임신을 계획하고 있는 여성은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "게획을 미루어야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        229.18203735351562,
        534.9100952148438,
        512.5560913085938
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-Package leaflet for users-",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        529.57373046875,
        534.9097900390625,
        612.6466674804688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 및 모유 수유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        529.57373046875,
        534.9097900390625,
        612.6466674804688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "M-M-RVAXPRO는 임산부에게 투여되어 서는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        529.57373046875,
        534.9097900390625,
        612.6466674804688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안 된다. 가임기 여성은 1달 동안 또는 의사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        529.57373046875,
        534.9097900390625,
        612.6466674804688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 조언에 따라 백신을 투여 받은 후, 임신을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        529.57373046875,
        534.9097900390625,
        612.6466674804688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피하기 위해 조치를 취해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        529.57373046875,
        534.9097900390625,
        612.6466674804688
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수유부나 또는 모유 수유를 계획하는 자는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        629.6643676757812,
        534.9100952148438,
        655.559814453125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주치의에게",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        629.6643676757812,
        534.9100952148438,
        655.559814453125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "말해야",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        629.6643676757812,
        534.9100952148438,
        655.559814453125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        629.6643676757812,
        534.9100952148438,
        655.559814453125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주치의는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        629.6643676757812,
        534.9100952148438,
        655.559814453125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "M-M-RVAXPRO가 주어져야 하는지 결정해야",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        658.3130493164062,
        534.9097900390625,
        712.857177734375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다. 만약 당신이 임신부나 수유부 또는 임",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        658.3130493164062,
        534.9097900390625,
        712.857177734375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신 가능성이 있다면, 의사 또는 약사에게 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        658.3130493164062,
        534.9097900390625,
        712.857177734375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신 투여를 받기 전 조언을 구해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        301.0368347167969,
        658.3130493164062,
        534.9097900390625,
        712.857177734375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 67 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1-8",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        284.0054931640625,
        125.00334930419922
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종 바이러스백신",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        63.08580780029297,
        109.06077575683594,
        284.0054931640625,
        125.00334930419922
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<Cervarix>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        160.72430419921875,
        157.15899658203125,
        176.66688537597656
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        190.35946655273438,
        128.5703125,
        203.00189208984375
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        440.52606201171875,
        260.4988098144531,
        453.1684875488281
      ],
      "page_num": 72,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver. 17)되어, 해당 version의 assessment",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        459.69012451171875,
        543.78466796875,
        485.5855712890625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "report인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        459.69012451171875,
        543.78466796875,
        485.5855712890625
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        217.9143524169922,
        485.1071472167969,
        229.54539489746094
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GSK",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        217.9143524169922,
        485.1071472167969,
        229.54539489746094
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        217.9143524169922,
        485.1071472167969,
        229.54539489746094
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2007.09.20. (EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        217.9143524169922,
        485.1071472167969,
        229.54539489746094
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        260.2281188964844,
        94.7483139038086,
        271.8591613769531
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cervarix",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        238.7715606689453,
        314.22967529296875,
        293.3157043457031
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 백신[16, 18",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        238.7715606689453,
        314.22967529296875,
        293.3157043457031
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "형] (재조합, 항원보조제, 흡",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        238.7715606689453,
        314.22967529296875,
        293.3157043457031
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "착)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        238.7715606689453,
        314.22967529296875,
        293.3157043457031
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        326.94281005859375,
        245.9636993408203,
        392.9067077636719,
        286.1235656738281
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획 번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        326.94281005859375,
        245.9636993408203,
        392.9067077636719,
        286.1235656738281
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        326.94281005859375,
        245.9636993408203,
        392.9067077636719,
        286.1235656738281
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver. 17",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        405.500244140625,
        260.2281188964844,
        442.440185546875,
        271.8591613769531
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        295.4696044921875,
        369.0400085449219,
        321.48492431640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 16형 L1 단백질- 20㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        295.4696044921875,
        369.0400085449219,
        321.48492431640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 18형 L1 단백질- 20㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        295.4696044921875,
        369.0400085449219,
        321.48492431640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능·효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        337.9032287597656,
        116.69641876220703,
        349.5342712402344
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        323.6388244628906,
        532.9910888671875,
        363.7986755371094
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        323.6388244628906,
        532.9910888671875,
        363.7986755371094
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문암의 예방",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        323.6388244628906,
        532.9910888671875,
        363.7986755371094
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        387.52899169921875,
        116.69641876220703,
        399.1600341796875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        164.7906951904297,
        365.63629150390625,
        531.5519409179688,
        391.9678955078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만 9~14세: 0.5ml씩 2회 접종한다. 2차 접종은 1차 접종 후 5~13개월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        365.63629150390625,
        531.5519409179688,
        391.9678955078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이에 투여한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        365.63629150390625,
        531.5519409179688,
        391.9678955078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        164.7906951904297,
        394.16510009765625,
        493.2929992675781,
        406.40460205078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        394.16510009765625,
        493.2929992675781,
        406.40460205078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        164.7906951904297,
        408.54937744140625,
        393.02655029296875,
        420.78887939453125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 백신은 삼각근 부위에 근육주사 한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        408.54937744140625,
        393.02655029296875,
        420.78887939453125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        494.8117370605469,
        403.5809631347656,
        506.4427795410156
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        494.8117370605469,
        403.5809631347656,
        506.4427795410156
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        494.8117370605469,
        403.5809631347656,
        506.4427795410156
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        517.5868530273438,
        171.62664794921875,
        529.2178955078125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(없음)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        540.2420654296875,
        90.640869140625,
        551.8731079101562
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        563.0171508789062,
        171.62664794921875,
        574.648193359375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신접종 후 백신유발",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        580.51806640625,
        177.14366149902344,
        620.7977905273438
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자가면역 질환 획득에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        580.51806640625,
        177.14366149902344,
        620.7977905273438
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 이론적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        580.51806640625,
        177.14366149902344,
        620.7977905273438
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래 ‘의약품 감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        587.710205078125,
        321.065673828125,
        613.6056518554688
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획’ 표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        587.710205078125,
        321.065673828125,
        613.6056518554688
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        587.710205078125,
        321.065673828125,
        613.6056518554688
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        626.6676025390625,
        144.16152954101562,
        638.2986450195312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HIV감염 시험대상자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        658.5527954101562,
        171.62698364257812,
        713.096923828125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 면역결핍이 알려",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        658.5527954101562,
        171.62698364257812,
        713.096923828125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진 시험대상자에서 서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        658.5527954101562,
        171.62698364257812,
        713.096923828125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바릭스의 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        658.5527954101562,
        171.62698364257812,
        713.096923828125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래 ‘의약품 감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        672.8171997070312,
        288.8031311035156,
        698.712646484375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획’ 표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        672.8171997070312,
        288.8031311035156,
        698.712646484375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[일반적 조치] SmPC 문구(경고 및 사용상 주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        644.1685180664062,
        529.872802734375,
        727.361328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의사항)추가:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        644.1685180664062,
        529.872802734375,
        727.361328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“데이터가 부족한 무증상 HIV 감염 환자는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        644.1685180664062,
        529.872802734375,
        727.361328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제외(“약력학적 영향” 참조). 면역억제치료",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        644.1685180664062,
        529.872802734375,
        727.361328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 받는 환자와 같이 면역반응성이 저하된 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        644.1685180664062,
        529.872802734375,
        727.361328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험대상자에서 서바릭스 사용에 대한 자료는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        644.1685180664062,
        529.872802734375,
        727.361328125
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 68 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        573.4607543945312,
        390.02862548828125,
        586.1032104492188
      ],
      "page_num": 73,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        592.6248168945312,
        543.6653442382812,
        619.359375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        592.6248168945312,
        543.6653442382812,
        619.359375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없다. 다른 백신과 마찬가지로 이러한 개인에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        100.44273376464844,
        535.3898315429688,
        154.98687744140625
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서는 적절한 면역 반응이 도출되지 않을 수도",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        100.44273376464844,
        535.3898315429688,
        154.98687744140625
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        100.44273376464844,
        535.3898315429688,
        154.98687744140625
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[추가적 조치] 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        100.44273376464844,
        535.3898315429688,
        154.98687744140625
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의도치 않게 백신에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        300.1445007324219,
        171.62698364257812,
        340.4242248535156
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노출된 임신부에서 서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        300.1445007324219,
        171.62698364257812,
        340.4242248535156
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바릭스의 영향",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        300.1445007324219,
        171.62698364257812,
        340.4242248535156
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래 ‘의약품 감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        307.3366394042969,
        288.8031311035156,
        333.2320861816406
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획’ 표 참조.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        307.3366394042969,
        288.8031311035156,
        333.2320861816406
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[일반적 조치] SmPC 문구(임신 항) 추가:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“임신부를 대상으로 백신에 대한 특별한 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "험은 수행되지 않았다. 임신 등록대장",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(registry), 역학 연구 및 임상시험 중 의도치",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않은 노출의 일환으로 수집된 임신부에서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료는 서바릭스 백신접종이 자연유산을 포함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 유해한 임신 결과 위해성에 영향을 주는지",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여부에 대한 결론을 내리기에는 충분하지 않",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 그러나 임상 개발 프로그램 중, 서바릭스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "를 투여받은 여성에서의 5,387건을 포함하여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "총 10,476건의 임신이 보고되었다. 전체적으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특정 결과(예: 정상 영아, 선천성 기형을 포함",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 비정상 영아, 조산 및 자연유산)를 경험한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신한 시험대상자 비율은 투여군간 유사했",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동물시험에서 수태능, 임신, 배/태자 발생, 출",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "산 또는 생후 발달과 관련하여 직접 또는 간",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접적인 유해 영향은 나타나지 않았다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예방 조치로, 임신 중에는 서바릭스 사용을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피하는 것이 바람직하다. 임신부 또는 임신을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고자 하는 여성은 임신 종결 시까지 백신접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종을 연기 또는 중지하도록 권고한다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[추가적 조치] 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        299.1178894042969,
        157.14076232910156,
        535.868896484375,
        483.4279479980469
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HPV 유형 대체",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        485.5818176269531,
        137.80531311035156,
        511.59716796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(substitution)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        485.5818176269531,
        137.80531311035156,
        511.59716796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래 ‘의약품 감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        485.5818176269531,
        321.065673828125,
        511.59716796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획’ 표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        485.5818176269531,
        321.065673828125,
        511.59716796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        485.5818176269531,
        321.065673828125,
        511.59716796875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항문 병소 및 암에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        513.7510375976562,
        171.62698364257812,
        539.646484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 영향 및 유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        513.7510375976562,
        171.62698364257812,
        539.646484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래 ‘의약품 감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        513.7510375976562,
        321.065673828125,
        539.646484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획’ 표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        513.7510375976562,
        321.065673828125,
        539.646484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        184.46002197265625,
        513.7510375976562,
        321.065673828125,
        539.646484375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구/활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        655.4361572265625,
        239.630126953125,
        667.0671997070312
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        655.4361572265625,
        239.630126953125,
        667.0671997070312
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        641.1717529296875,
        356.0870056152344,
        681.4514770507812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "점 검 토 항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        641.1717529296875,
        356.0870056152344,
        681.4514770507812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        641.1717529296875,
        356.0870056152344,
        681.4514770507812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        648.3638916015625,
        527.47412109375,
        674.2593383789062
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간/최종 보고서 제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        648.3638916015625,
        527.47412109375,
        674.2593383789062
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출일(목표 날짜)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        648.3638916015625,
        527.47412109375,
        674.2593383789062
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 HPV-019",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        693.1948852539062,
        207.36761474609375,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18-25세의 사람 면역결핍 바",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        693.1948852539062,
        207.36761474609375,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이러스(HIV) 감염 여성 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        693.1948852539062,
        207.36761474609375,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HIV 양성 여성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        693.1948852539062,
        297.918212890625,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        693.1948852539062,
        297.918212890625,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        693.1948852539062,
        297.918212890625,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        693.1948852539062,
        361.60369873046875,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HIV 양성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        693.1948852539062,
        361.60369873046875,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시 험 대 상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        693.1948852539062,
        361.60369873046875,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        700.3870239257812,
        412.8162841796875,
        726.2825317382812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        700.3870239257812,
        412.8162841796875,
        726.2825317382812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2014년 6월까지 24",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        693.1948852539062,
        532.9907836914062,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개월 연구 결과를 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        693.1948852539062,
        532.9907836914062,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용할 수 있을 것으로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        693.1948852539062,
        532.9907836914062,
        733.4746704101562
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 69 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상자에서 3회 투여 일정(0,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        212.88511657714844,
        140.60260009765625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1, 6개월)에 따라 근육 내로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        212.88511657714844,
        140.60260009765625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        212.88511657714844,
        140.60260009765625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "GlaxoSmithKline",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        212.88511657714844,
        140.60260009765625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Biologicals의 HPV-16/18 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        143.3558349609375,
        207.36761474609375,
        212.1643829345703
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신의 안전성 및 면역원성 평",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        143.3558349609375,
        207.36761474609375,
        212.1643829345703
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가를 위한 제1/2상, 부분 눈",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        143.3558349609375,
        207.36761474609375,
        212.1643829345703
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가림, 무작위 배정, 대조 임",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        143.3558349609375,
        207.36761474609375,
        212.1643829345703
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상시험. (범주 3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        143.3558349609375,
        207.36761474609375,
        212.1643829345703
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자 에 서 의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        143.3558349609375,
        361.603759765625,
        169.25128173828125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        143.3558349609375,
        361.603759765625,
        169.25128173828125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예상되었으나, 등록",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        121.89927673339844,
        532.9907836914062,
        190.7078399658203
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 예상보다 길어져",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        121.89927673339844,
        532.9907836914062,
        190.7078399658203
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과를 나중에 이용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        121.89927673339844,
        532.9907836914062,
        190.7078399658203
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "할 수 있게 될 것이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        121.89927673339844,
        532.9907836914062,
        190.7078399658203
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다(2018년 3월 추정).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        121.89927673339844,
        532.9907836914062,
        190.7078399658203
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 HPV-039",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        212.88511657714844,
        283.2467041015625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18-25세의 건강한 중국인 여",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        212.88511657714844,
        283.2467041015625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 시험대상자에서 0, 1, 6개",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        212.88511657714844,
        283.2467041015625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "월 일정에 따라 근육 내로",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        212.88511657714844,
        283.2467041015625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        212.88511657714844,
        283.2467041015625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GlaxoSmithKline",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        214.3182830810547,
        212.88511657714844,
        283.2467041015625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Biologicals의 HPV-16/18 L1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        212.884765625,
        369.0729064941406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VLP AS04 백신의 유효성, 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        212.884765625,
        369.0729064941406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역원성 및 안전성 평가를 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        212.884765625,
        369.0729064941406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 제2/3상, 이중 눈가림, 무",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        212.884765625,
        369.0729064941406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작위 배정, 대조 임상시험.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        212.884765625,
        369.0729064941406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(범주 3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        212.884765625,
        369.0729064941406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중국인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        257.23138427734375,
        297.91851806640625,
        268.8624267578125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        257.23138427734375,
        297.91851806640625,
        268.8624267578125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시 험 대 상 자 에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        271.61566162109375,
        297.9180908203125,
        297.5111083984375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        271.61566162109375,
        297.9180908203125,
        297.5111083984375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        271.61566162109375,
        297.9180908203125,
        297.5111083984375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        300.1445007324219,
        297.91851806640625,
        311.7755432128906
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        300.1445007324219,
        297.91851806640625,
        311.7755432128906
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        314.5287780761719,
        250.54388427734375,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        242.96697998046875,
        361.60400390625,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        242.96697998046875,
        361.60400390625,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자 가 면 역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        242.96697998046875,
        361.60400390625,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        242.96697998046875,
        361.60400390625,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        242.96697998046875,
        361.60400390625,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        242.96697998046875,
        361.60400390625,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        242.96697998046875,
        361.60400390625,
        326.1598205566406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        328.7931823730469,
        352.0089111328125,
        340.4242248535156
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        278.68792724609375,
        412.8162841796875,
        304.7032470703125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        278.68792724609375,
        412.8162841796875,
        304.7032470703125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2016년 12월 연구 종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        278.68792724609375,
        527.47412109375,
        304.7032470703125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "료 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        278.68792724609375,
        527.47412109375,
        304.7032470703125
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 HPV-040",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GlaxoSmithKline Biologicals의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HPV-16/18 L1 VLP AS04 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신두 가지 백신접종 전략으",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로 12-15세의 건강한 여성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 남성 시험대상자에서 0,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1, 6개월 일정에 따라 근육",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투여했을 때 감염 유병률 감",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소에 대한 유효성 평가를 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 제3/4상 지역사회 무작위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배정, 대조 임상시험. (범주",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        371.226806640625,
        212.88462829589844,
        540.1259765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건강한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        392.683349609375,
        297.91851806640625,
        404.31439208984375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        392.683349609375,
        297.91851806640625,
        404.31439208984375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 남성 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        406.94775390625,
        297.9206237792969,
        461.4919128417969
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대 상 자 에 서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        406.94775390625,
        297.9206237792969,
        461.4919128417969
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HPV-16/18 감",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        406.94775390625,
        297.9206237792969,
        461.4919128417969
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "염의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        406.94775390625,
        297.9206237792969,
        461.4919128417969
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유병률",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        406.94775390625,
        297.9206237792969,
        461.4919128417969
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감소 측면에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        464.1252746582031,
        297.918212890625,
        504.405029296875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "두 가지 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        464.1252746582031,
        297.918212890625,
        504.405029296875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        464.1252746582031,
        297.918212890625,
        504.405029296875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전략의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        464.1252746582031,
        297.918212890625,
        504.405029296875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        507.0383605957031,
        250.54388427734375,
        518.6693725585938
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        406.94775390625,
        361.60400390625,
        490.1405944824219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        406.94775390625,
        361.60400390625,
        490.1405944824219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자 가 면 역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        406.94775390625,
        361.60400390625,
        490.1405944824219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        406.94775390625,
        361.60400390625,
        490.1405944824219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        406.94775390625,
        361.60400390625,
        490.1405944824219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        406.94775390625,
        361.60400390625,
        490.1405944824219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        406.94775390625,
        361.60400390625,
        490.1405944824219
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        492.77398681640625,
        352.0089111328125,
        504.405029296875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        442.6687316894531,
        412.8162841796875,
        468.6840515136719
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        442.6687316894531,
        412.8162841796875,
        468.6840515136719
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 임상시험 결과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        442.6687316894531,
        527.4737548828125,
        468.6840515136719
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고 (2016년 6월)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        442.6687316894531,
        527.4737548828125,
        468.6840515136719
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EPI-HPV-048 (범주 3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        570.9285278320312,
        212.88429260253906,
        668.3858032226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2016년까지 영국 여성 중 유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        570.9285278320312,
        212.88429260253906,
        668.3858032226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "형별 HPV 감염에 대한 조사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        570.9285278320312,
        212.88429260253906,
        668.3858032226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구(EPI-HPV-033의 추적관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        570.9285278320312,
        212.88429260253906,
        668.3858032226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "찰). 또한, 30세 미만 여성의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        570.9285278320312,
        212.88429260253906,
        668.3858032226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자궁경부암에서 유형별 HPV",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        570.9285278320312,
        212.88429260253906,
        668.3858032226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조사.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        570.9285278320312,
        212.88429260253906,
        668.3858032226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신 및 비 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        542.3997192382812,
        297.918212890625,
        596.94384765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신 유형에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        542.3997192382812,
        297.918212890625,
        596.94384765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 백신의 유",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        542.3997192382812,
        297.918212890625,
        596.94384765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        542.3997192382812,
        297.918212890625,
        596.94384765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입증을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        542.3997192382812,
        297.918212890625,
        596.94384765625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해(즉, 유형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        599.5772094726562,
        297.91851806640625,
        654.121337890625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대체) HPV 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        599.5772094726562,
        297.91851806640625,
        654.121337890625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신을 접종 받",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        599.5772094726562,
        297.91851806640625,
        654.121337890625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        599.5772094726562,
        297.91851806640625,
        654.121337890625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성생활을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        599.5772094726562,
        297.91851806640625,
        654.121337890625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 여성에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        656.7547607421875,
        292.4015197753906,
        697.0344848632812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 유형별 조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        656.7547607421875,
        292.4015197753906,
        697.0344848632812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        656.7547607421875,
        292.4015197753906,
        697.0344848632812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        599.5772094726562,
        361.60369873046875,
        639.85693359375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HPV 유형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        599.5772094726562,
        361.60369873046875,
        639.85693359375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대체",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        599.5772094726562,
        361.60369873046875,
        639.85693359375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        613.8416137695312,
        474.6127624511719,
        625.47265625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019년 2Q",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        613.8416137695312,
        474.6127624511719,
        625.47265625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EPI-HPV-069 (범주 3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        699.4281005859375,
        207.36761474609375,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회사의 연구 및 외부에서 수",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        699.4281005859375,
        207.36761474609375,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행된 출판된 연구로부터 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        699.4281005859375,
        207.36761474609375,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서바릭스 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        699.4281005859375,
        297.91851806640625,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "접종 후 자가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        699.4281005859375,
        297.91851806640625,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "면역 갑상선염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        699.4281005859375,
        297.91851806640625,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잠재적 위",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        699.4281005859375,
        361.603759765625,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        699.4281005859375,
        361.603759765625,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자 가 면 역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        699.4281005859375,
        361.603759765625,
        739.7078247070312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        706.6202392578125,
        478.0609130859375,
        732.5156860351562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        706.6202392578125,
        478.0609130859375,
        732.5156860351562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2016년 9월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        706.6202392578125,
        478.0609130859375,
        732.5156860351562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 70 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용 가능한 모든 데이터를 이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        150.4281005859375,
        207.36761474609375,
        176.44342041015625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용한 메타분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        150.4281005859375,
        207.36761474609375,
        176.44342041015625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 상대 위험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도에 대한 전",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반적인 평가를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제 공 함 으 로 써",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서바릭스 백신",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종과 자가면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "갑상선염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        100.44273376464844,
        297.918212890625,
        197.8999786376953
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생의 잠재적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        200.53334045410156,
        297.918212890625,
        226.42880249023438
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련성 평가.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        200.53334045410156,
        297.918212890625,
        226.42880249023438
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "갑상선염",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        157.6202392578125,
        346.61181640625,
        169.25128173828125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후 조사 활동(범주 3):",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        228.7025604248047,
        212.88462829589844,
        311.7755432128906
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5개 국가(핀란드, 네덜란드,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        228.7025604248047,
        212.88462829589844,
        311.7755432128906
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "영국, 노르웨이 및 덴마크)의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        228.7025604248047,
        212.88462829589844,
        311.7755432128906
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암 등록부로부터 항문암 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        228.7025604248047,
        212.88462829589844,
        311.7755432128906
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 HPV 관련 암의 연차",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        228.7025604248047,
        212.88462829589844,
        311.7755432128906
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보고 모니터링",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        228.7025604248047,
        212.88462829589844,
        311.7755432128906
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항문암 및 기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        235.77484130859375,
        297.91851806640625,
        304.7032470703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "타 HPV 관련",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        235.77484130859375,
        297.91851806640625,
        304.7032470703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암의 5년 경향",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        235.77484130859375,
        297.91851806640625,
        304.7032470703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 대한 데이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        235.77484130859375,
        297.91851806640625,
        304.7032470703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "터 수집",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        235.77484130859375,
        297.91851806640625,
        304.7032470703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        235.77484130859375,
        361.60369873046875,
        276.0545654296875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항문 병소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        235.77484130859375,
        361.60369873046875,
        276.0545654296875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        235.77484130859375,
        361.60369873046875,
        276.0545654296875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        235.77484130859375,
        361.60369873046875,
        276.0545654296875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 영향",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        278.68792724609375,
        361.60369873046875,
        304.7032470703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        278.68792724609375,
        361.60369873046875,
        304.7032470703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        264.42352294921875,
        483.5779113769531,
        276.0545654296875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2016년 12월",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        264.42352294921875,
        483.5779113769531,
        276.0545654296875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시판 후 조사 활동(범주 3):",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        335.385986328125,
        212.88462829589844,
        389.93011474609375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5년마다 항문암 및 기타",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        335.385986328125,
        212.88462829589844,
        389.93011474609375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HPV 관련 암에 대한 경향",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        335.385986328125,
        212.88462829589844,
        389.93011474609375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        335.385986328125,
        212.88462829589844,
        389.93011474609375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서바릭스 사용",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        313.9294128417969,
        297.91851806640625,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국가에서 항문",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        313.9294128417969,
        297.91851806640625,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        313.9294128417969,
        297.91851806640625,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        313.9294128417969,
        297.91851806640625,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        313.9294128417969,
        297.91851806640625,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HPV 관련 암",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        356.842529296875,
        292.4015197753906,
        411.38665771484375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 발생 시기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        356.842529296875,
        292.4015197753906,
        411.38665771484375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 잠재적 변",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        356.842529296875,
        292.4015197753906,
        411.38665771484375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화 기술.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        217.5620880126953,
        356.842529296875,
        292.4015197753906,
        411.38665771484375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부족 정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        328.3136901855469,
        361.60369873046875,
        368.47357177734375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항문 병소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        328.3136901855469,
        361.60369873046875,
        368.47357177734375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        328.3136901855469,
        361.60369873046875,
        368.47357177734375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "암에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        328.3136901855469,
        361.60369873046875,
        368.47357177734375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 영향",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        371.226806640625,
        361.60369873046875,
        397.12225341796875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        302.59600830078125,
        371.226806640625,
        361.60369873046875,
        397.12225341796875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        366.281494140625,
        356.842529296875,
        388.3495178222656,
        368.47357177734375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2021년 12월(다음 정",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        328.3136901855469,
        532.9925537109375,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        328.3136901855469,
        532.9925537109375,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PBRER(Periodic",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        328.3136901855469,
        532.9925537109375,
        354.20916748046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "B e n e f i t - R i s k",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        356.842529296875,
        532.9911499023438,
        397.12225341796875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation Report)과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        356.842529296875,
        532.9911499023438,
        397.12225341796875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함께 제출).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        423.0107421875,
        356.842529296875,
        532.9911499023438,
        397.12225341796875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 71 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<Gardasil 9>",
      "font_size": 15.946965217590332,
      "font_name": "HYwulB",
      "bbox": [
        58.64821243286133,
        102.46797943115234,
        176.7099609375,
        118.41055297851562
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 품목 개요",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        134.97999572753906,
        128.5703125,
        147.62242126464844
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 안전성 중점검토항목 및 조치계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        550.3260498046875,
        260.4988098144531,
        562.968505859375
      ],
      "page_num": 76,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. 1)되어, 해당 assessment report인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        580.51806640625,
        543.7852783203125,
        606.4135131835938
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        580.51806640625,
        543.7852783203125,
        606.4135131835938
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "회사명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        163.97329711914062,
        490.6539611816406,
        175.60433959960938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MSD",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        163.97329711914062,
        490.6539611816406,
        175.60433959960938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        163.97329711914062,
        490.6539611816406,
        175.60433959960938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2015.06.10. (EU)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        163.97329711914062,
        490.6539611816406,
        175.60433959960938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        206.0473175048828,
        214.68365478515625,
        217.67835998535156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Gardasil 9",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        206.0473175048828,
        214.68365478515625,
        217.67835998535156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 관리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        326.94281005859375,
        191.6630401611328,
        400.7024841308594,
        217.67835998535156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        326.94281005859375,
        191.6630401611328,
        400.7024841308594,
        217.67835998535156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        326.94281005859375,
        191.6630401611328,
        400.7024841308594,
        217.67835998535156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(버전)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        326.94281005859375,
        220.31173706054688,
        355.817138671875,
        231.94277954101562
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver. 1",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        405.500244140625,
        206.0473175048828,
        436.9231872558594,
        217.67835998535156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분 및 함량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        298.1067199707031,
        138.64453125,
        309.7377624511719
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 6형 L1 단백질- 30㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 11형 L1 단백질- 40㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 16형 L1 단백질- 60㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 18형 L1 단백질- 40㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 31형 L1 단백질- 20㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 33형 L1 단백질- 20㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 45형 L1 단백질- 20㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 52형 L1 단백질- 20㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인유두종바이러스 58형 L1 단백질- 20㎍",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        240.92919921875,
        369.0400085449219,
        367.0351257324219
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효능·효과",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        393.4025573730469,
        116.69641876220703,
        405.0335998535156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만 9세 이상에서 인유두종바이러스에 의한 질병의 예방:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        371.9460144042969,
        535.749267578125,
        397.9613342285156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        371.9460144042969,
        535.749267578125,
        397.9613342285156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "항문의 전암성 병변 또는 암",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        175.70477294921875,
        400.5946960449219,
        318.66729736328125,
        412.2257385253906
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        414.859130859375,
        506.8153076171875,
        426.49017333984375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용법·용량",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        474.43402099609375,
        116.69641876220703,
        486.0650634765625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        164.7906951904297,
        431.0847473144531,
        340.61505126953125,
        443.3242492675781
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최초 접종 시 만 9세~14세에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        431.0847473144531,
        340.61505126953125,
        443.3242492675781
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 가다실9는 2회 접종할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        445.78533935546875,
        400.3186340332031,
        486.23736572265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        445.78533935546875,
        400.3186340332031,
        486.23736572265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        164.7906951904297,
        445.78533935546875,
        400.3186340332031,
        486.23736572265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최초 접종 시 만 15세 이상 연령에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        445.78533935546875,
        400.3186340332031,
        486.23736572265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        488.69842529296875,
        535.7493286132812,
        528.9781494140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ÿ",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        164.7906951904297,
        488.69842529296875,
        535.7493286132812,
        528.9781494140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 백신은 근육주사되어야 한다. 상완의 삼각근이나 대퇴부 전외측",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        488.69842529296875,
        535.7493286132812,
        528.9781494140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상부 부분에 주사하는 것이 선호된다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        164.7906951904297,
        488.69842529296875,
        535.7493286132812,
        528.9781494140625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        610.4852905273438,
        162.9913330078125,
        636.5006103515625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        610.4852905273438,
        162.9913330078125,
        636.5006103515625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품 감시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        610.4852905273438,
        355.4870300292969,
        636.5006103515625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        610.4852905273438,
        355.4870300292969,
        636.5006103515625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해성 완화조치방법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        610.4852905273438,
        355.4870300292969,
        636.5006103515625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 규명된 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        642.3704833984375,
        171.62664794921875,
        654.0015258789062
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과민반응(1형)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        681.44775390625,
        240.8294677734375,
        707.3432006835938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당사항 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        681.44775390625,
        240.8294677734375,
        707.3432006835938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        681.44775390625,
        240.8294677734375,
        707.3432006835938
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[일반적 조치] 가다실 또는 가다실9 백신 성분에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        659.9912109375,
        535.2698974609375,
        728.7997436523438
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과민반응이 SmPC 4.3항에 금기로 포함되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        659.9912109375,
        535.2698974609375,
        728.7997436523438
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“본제 주성분 또는 6.1항에 기술된 부형제들에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        659.9912109375,
        535.2698974609375,
        728.7997436523438
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과민반응이 있을 경우. 이전에 가다실9 또는 가다실을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        659.9912109375,
        535.2698974609375,
        728.7997436523438
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종받은 후에 과민반응을 경험한 환자는 가다실9을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        659.9912109375,
        535.2698974609375,
        728.7997436523438
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 72 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접종받지 말아야 한다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        100.44273376464844,
        529.7528686523438,
        197.8999786376953
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        100.44273376464844,
        529.7528686523438,
        197.8999786376953
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에 4가백신의 시판 후 사용 중 보고된 약물 이상반응",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        100.44273376464844,
        529.7528686523438,
        197.8999786376953
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로서 포함되었다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        100.44273376464844,
        529.7528686523438,
        197.8999786376953
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“면역계장애: 아나필락시스/아나필락시스양 반응을 포",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        100.44273376464844,
        529.7528686523438,
        197.8999786376953
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함한 과민반응, 기관지경련 및 두드러기”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        100.44273376464844,
        529.7528686523438,
        197.8999786376953
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[추가적 조치] 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        100.44273376464844,
        529.7528686523438,
        197.8999786376953
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요한 잠재적 위해성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        205.20823669433594,
        171.62664794921875,
        216.8392791748047
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가다실 및 가다실9",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        259.8684997558594,
        168.3887481689453,
        285.8838195800781
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간의 제품 혼동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        259.8684997558594,
        168.3887481689453,
        285.8838195800781
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당사항 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        259.8684997558594,
        240.8294677734375,
        285.8838195800781
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        259.8684997558594,
        240.8294677734375,
        285.8838195800781
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[일반적 조치] 구분되는 제품명 및 포장을 사용한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        224.1475372314453,
        535.2698974609375,
        321.60479736328125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가권자는 각 회원국의 국가 관계당국과 협의 하에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        224.1475372314453,
        535.2698974609375,
        321.60479736328125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국가별/의료시스템 별 특이적인 추가적 조치가 요구되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        224.1475372314453,
        535.2698974609375,
        321.60479736328125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는지 여부를 고려할 것이다. (예: 처방의 및 백신접종자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        224.1475372314453,
        535.2698974609375,
        321.60479736328125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에게 9가백신과 4가백신 사이의 구분되는 특성에 관하",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        224.1475372314453,
        535.2698974609375,
        321.60479736328125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여 안내)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        224.1475372314453,
        535.2698974609375,
        321.60479736328125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[추가적조치] 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        224.1475372314453,
        535.2698974609375,
        321.60479736328125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가다실 및 가다실9",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        416.77703857421875,
        168.3887481689453,
        442.6724853515625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사이의 혼합 요법",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        416.77703857421875,
        168.3887481689453,
        442.6724853515625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당사항 없",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        416.77703857421875,
        240.8294677734375,
        442.6724853515625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        416.77703857421875,
        240.8294677734375,
        442.6724853515625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가다실9에 대해 시행되지 않았음을 나타내는 문구를",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SmPC에 포함하였다(4.2 및 4.4항).",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 연구들은 가다실9에 대해 수행되지 않았다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“가다실9을 2가 또는 4가 HPV백신과 교차접종하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것이 가능한지에 대한 안전성, 면역원성 또는 유효성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료는 없다.”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가권자는 각 회원국의 국가 관계당국과 협의 하에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "국가별/의료시스템 별 특이적인 추가적 조치가 요구되",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는지 여부를 고려할 것이다. (예:처방의 및 백신접종자",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에게  9가백신과 4가백신 사이의 구분되는 특성에 관",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여 안내)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[추가적조치] 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        323.7586669921875,
        535.2698974609375,
        535.6907958984375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요한 부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        541.5606079101562,
        144.16152954101562,
        553.191650390625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 중 노출",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        630.623291015625,
        127.73077392578125,
        642.2543334960938
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래‘의약품",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        616.35888671875,
        246.34649658203125,
        656.6386108398438
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감 시 계 획 ’",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        616.35888671875,
        246.34649658203125,
        656.6386108398438
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        616.35888671875,
        246.34649658203125,
        656.6386108398438
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가다실 9는 임신 중 사용이 권장되지 않음을 명시하는",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“임신한 여성에 대한 많은 양의 자료(1000 건 이상의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성을 나타내지 않았다(5.1항 참조). 동물연구에서도 생",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식독성을 나타내지 않았다(5.3항 참조). 하지만, 이러한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료들은 가다실9을 임신 중에 사용할 수 있다고 권장",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기에는 부족하다고 여겨진다. 따라서 백신 접종은 임",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신이 종료될 때까지 연기되어야 한다(5.1항 참조).”",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[추가적조치] 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        559.181396484375,
        535.2695922851562,
        713.8161010742188
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 유효성 및 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        721.1243896484375,
        272.97174072265625,
        732.7554321289062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래‘의약품 없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        721.1243896484375,
        272.97174072265625,
        732.7554321289062
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 73 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획",
      "font_size": 11.99020004272461,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        233.99179077148438,
        390.02862548828125,
        246.63421630859375
      ],
      "page_num": 78,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. 1)되어, 해당 assessment report인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        253.03598022460938,
        543.7852783203125,
        279.0513000488281
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        56.609317779541016,
        253.03598022460938,
        543.7852783203125,
        279.0513000488281
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        246.34649658203125,
        126.33818054199219
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감 시 계 획 ’",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        246.34649658203125,
        126.33818054199219
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        246.34649658203125,
        126.33818054199219
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이러스형",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        135.68421936035156,
        162.99166870117188,
        147.3152618408203
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대체",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        135.68421936035156,
        162.99166870117188,
        147.3152618408203
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(replacement)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        149.94862365722656,
        128.41973876953125,
        161.5796661376953
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래‘의약품",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        128.49208068847656,
        246.34649658203125,
        168.7718048095703
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감 시 계 획 ’",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        128.49208068847656,
        246.34649658203125,
        168.7718048095703
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        128.49208068847656,
        246.34649658203125,
        168.7718048095703
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        142.87635803222656,
        272.97174072265625,
        154.5074005126953
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26세 초과 여성에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        170.9257049560547,
        162.99166870117188,
        211.2054443359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 면역원성 및 안",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        170.9257049560547,
        162.99166870117188,
        211.2054443359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        170.9257049560547,
        162.99166870117188,
        211.2054443359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래‘의약품",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        170.9257049560547,
        246.34649658203125,
        211.2054443359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "감 시 계 획 ’",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        170.9257049560547,
        246.34649658203125,
        211.2054443359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 참조",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        173.0662078857422,
        170.9257049560547,
        246.34649658203125,
        211.2054443359375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        251.02395629882812,
        185.1901092529297,
        272.97174072265625,
        196.82115173339844
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구/활동",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        283.1230773925781,
        522.5564575195312,
        309.0185546875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목적",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        283.1230773925781,
        522.5564575195312,
        309.0185546875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 중점검토항",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        283.1230773925781,
        522.5564575195312,
        309.0185546875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        283.1230773925781,
        522.5564575195312,
        309.0185546875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상태",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        283.1230773925781,
        522.5564575195312,
        309.0185546875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간/최종 보고서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        283.1230773925781,
        522.5564575195312,
        309.0185546875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제출일(목표 날짜)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        283.1230773925781,
        522.5564575195312,
        309.0185546875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신한 사람에 대",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        354.0855407714844,
        157.35438537597656,
        394.3652648925781
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 등록대장 작성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        354.0855407714844,
        157.35438537597656,
        394.3652648925781
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(범주 3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        354.0855407714844,
        157.35438537597656,
        394.3652648925781
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 중 9가 HPV 백",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        347.0132751464844,
        272.25244140625,
        401.5574035644531
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신에 노출된 여성에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        347.0132751464844,
        272.25244140625,
        401.5574035644531
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 임신 결과 모니터",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        347.0132751464844,
        272.25244140625,
        401.5574035644531
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "링",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        347.0132751464844,
        272.25244140625,
        401.5574035644531
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        361.2776794433594,
        410.7773742675781,
        387.1731262207031
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임신 중 노출",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        361.2776794433594,
        410.7773742675781,
        387.1731262207031
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        361.2776794433594,
        410.7773742675781,
        387.1731262207031
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간 보고서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2016년 8월 31일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2017년 8월 31일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018년 8월 31일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2019년 8월 31일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2020년 8월 31일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 보고서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마지막 환자 등록",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후 약 18개월 후",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        311.17242431640625,
        532.7512817382812,
        437.27838134765625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "V503-021 북유럽",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기 추적관찰 연",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구(V503-001 시험",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상자에서의 10",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년 연장 연구) (범",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주 3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 자궁경부암 스",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "크리닝에 대한 집",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중화된 인프라가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "갖춰진 나라들에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서 가다실9을 접",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종받은",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16-26세",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        439.4322814941406,
        157.35472106933594,
        608.4512939453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여성들에서의 장",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        611.0846557617188,
        157.35438537597656,
        680.0130615234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간 유효성, 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        611.0846557617188,
        157.35438537597656,
        680.0130615234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역원성, 안전성을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        611.0846557617188,
        157.35438537597656,
        680.0130615234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하기 위한 레",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        611.0846557617188,
        157.35438537597656,
        680.0130615234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지스트리",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        611.0846557617188,
        157.35438537597656,
        680.0130615234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기반",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        611.0846557617188,
        157.35438537597656,
        680.0130615234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "V503-001 확장연",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        682.6464233398438,
        151.83737182617188,
        708.5418701171875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        682.6464233398438,
        151.83737182617188,
        708.5418701171875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9가 HPV 백신의 장기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        525.2584228515625,
        277.7694396972656,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 모니터링.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        525.2584228515625,
        277.7694396972656,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9가 HPV 백신의 장기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        525.2584228515625,
        277.7694396972656,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효과 및 면역원성 모",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        525.2584228515625,
        277.7694396972656,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "니터링.",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        525.2584228515625,
        277.7694396972656,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효과 지속기간에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        525.2584228515625,
        277.7694396972656,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정보 획득",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        525.2584228515625,
        277.7694396972656,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        546.7149658203125,
        378.5148620605469,
        601.2591552734375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바이러스형 대체,",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        546.7149658203125,
        378.5148620605469,
        601.2591552734375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기적 효과 및 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        546.7149658203125,
        378.5148620605469,
        601.2591552734375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        546.7149658203125,
        378.5148620605469,
        601.2591552734375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.7093200683594,
        568.1715698242188,
        410.7773742675781,
        579.8026123046875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간 보고서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        525.2584228515625,
        524.8355102539062,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~4Q2017",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        525.2584228515625,
        524.8355102539062,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~4Q2019",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        525.2584228515625,
        524.8355102539062,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~4Q2021",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        525.2584228515625,
        524.8355102539062,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~4Q2023",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        525.2584228515625,
        524.8355102539062,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종보고서 제출:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        525.2584228515625,
        524.8355102539062,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~2026년 12월 31일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        525.2584228515625,
        524.8355102539062,
        622.7156982421875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "V503-002-20 대상",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        710.69580078125,
        157.35438537597656,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "청소년에 대한 장",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        710.69580078125,
        157.35438537597656,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9가 HPV 백신의 장기",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        710.69580078125,
        277.7694396972656,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성 및 면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        710.69580078125,
        277.7694396972656,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        710.69580078125,
        527.2342529296875,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장기적 효과 및 면",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        710.69580078125,
        527.2342529296875,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        710.69580078125,
        527.2342529296875,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간 72개월 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        710.69580078125,
        527.2342529296875,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        710.69580078125,
        527.2342529296875,
        736.7111206054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 74 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기추적관찰 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3차 접종 후 10",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "년 연장 연구) (범",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주 3)",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ": 젊은 여성(16-26",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세)와 비교하였을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때 소아 및 청소",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "년(9-15세)에서 가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다실9의",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역원",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        100.44273376464844,
        157.3540496826172,
        226.42880249023438
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성, 내약성 및 제",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        229.18203735351562,
        151.83770751953125,
        283.7261962890625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조일관성을 확인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        229.18203735351562,
        151.83770751953125,
        283.7261962890625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위한 3상 연",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        229.18203735351562,
        151.83770751953125,
        283.7261962890625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        229.18203735351562,
        151.83770751953125,
        283.7261962890625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모니터링",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        171.88465881347656,
        277.7694396972656,
        212.1643829345703
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "효과 지속기간에 대한",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        171.88465881347656,
        277.7694396972656,
        212.1643829345703
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정보 확보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        171.88465881347656,
        277.7694396972656,
        212.1643829345703
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        186.26893615722656,
        315.4287414550781,
        197.8999786376953
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~4Q2017",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        150.4281005859375,
        527.2342529296875,
        233.62094116210938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간 96개월 보고",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        150.4281005859375,
        527.2342529296875,
        233.62094116210938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        150.4281005859375,
        527.2342529296875,
        233.62094116210938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~4Q2019",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        150.4281005859375,
        527.2342529296875,
        233.62094116210938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 보고서 제출:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        150.4281005859375,
        527.2342529296875,
        233.62094116210938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~2023년 3월 31일",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        431.16632080078125,
        150.4281005859375,
        527.2342529296875,
        233.62094116210938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "V503-004-02",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "27-45세 여성에서",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9vHPV 백신의 시",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "판 후 면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 안전성 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ": 젊은 여성(16-26",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세)와 비교하였을",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "때",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        285.88006591796875,
        157.35438537597656,
        397.60174560546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(27-45세)에서 가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.35498046875,
        157.35438537597656,
        469.1635437011719
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다실9의 면역원성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.35498046875,
        157.35438537597656,
        469.1635437011719
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 내약성을 확인",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.35498046875,
        157.35438537597656,
        469.1635437011719
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위한 오픈라",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.35498046875,
        157.35438537597656,
        469.1635437011719
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "벨 3상 연구",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        61.76652526855469,
        400.35498046875,
        157.35438537597656,
        469.1635437011719
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "27~45세 여성에서 9가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백신 HPV 유형 각각",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 대한 면역원성 입",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "27~45세 여성에서 9가",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "HPV 백신의 안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "프로파일에 대한 데이",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "터 수집",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        162.0321807861328,
        321.6010437011719,
        277.7694396972656,
        433.44256591796875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중요부족정보",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        350.2497253417969,
        384.0318603515625,
        404.79388427734375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26세 초과 여성에",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        350.2497253417969,
        384.0318603515625,
        404.79388427734375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서의 면역원성 및",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        350.2497253417969,
        384.0318603515625,
        404.79388427734375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        282.4469299316406,
        350.2497253417969,
        384.0318603515625,
        404.79388427734375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.7093200683594,
        364.5141296386719,
        494.5875549316406,
        390.5294494628906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종 보고서:",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.7093200683594,
        364.5141296386719,
        494.5875549316406,
        390.5294494628906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "~1Q 2019",
      "font_size": 11.030982971191406,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        388.7093200683594,
        364.5141296386719,
        494.5875549316406,
        390.5294494628906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 75 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        774.4439697265625,
        314.4545593261719,
        784.3931274414062
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“위해성관리계획 -백신- 사례집(민원인 안내서)”",
      "font_size": 14.987749099731445,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        124.13272094726562,
        322.75665283203125,
        470.86480712890625,
        338.5596923828125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        375.5720520019531,
        169.948486328125,
        389.2258605957031
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        375.5720520019531,
        169.948486328125,
        389.2258605957031
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        375.5720520019531,
        169.948486328125,
        389.2258605957031
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        401.5836486816406,
        169.948486328125,
        415.2374572753906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        401.5836486816406,
        169.948486328125,
        415.2374572753906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        401.5836486816406,
        169.948486328125,
        415.2374572753906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원 장",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        427.475341796875,
        169.948486328125,
        441.129150390625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        453.4869079589844,
        169.94790649414062,
        467.1407165527344
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "집",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        453.4869079589844,
        169.94790649414062,
        467.1407165527344
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        453.4869079589844,
        169.94790649414062,
        467.1407165527344
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        453.4869079589844,
        169.94790649414062,
        467.1407165527344
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도 움 주 신  분",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        557.413330078125,
        169.94790649414062,
        571.0671997070312
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        661.2198486328125,
        169.94976806640625,
        674.8737182617188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        661.2198486328125,
        169.94976806640625,
        674.8737182617188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        661.2198486328125,
        169.94976806640625,
        674.8737182617188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        85.0339126586914,
        661.2198486328125,
        169.94976806640625,
        674.8737182617188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018년 11월",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        375.5720520019531,
        270.5733642578125,
        389.2258605957031
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 선 희",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        401.5836486816406,
        244.42752075195312,
        415.2374572753906
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "김 대 철",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        427.475341796875,
        244.42752075195312,
        441.129150390625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(바이오생약심사부 생물제제과)",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        453.4869079589844,
        376.086181640625,
        467.1407165527344
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백선영, 임재현, 진미령, 김도근, 지승완, 임종미,",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        479.49847412109375,
        523.3963623046875,
        493.15228271484375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        505.3901672363281,
        515.4800415039062,
        519.0440063476562
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마,",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        557.413330078125,
        523.3960571289062,
        571.0671997070312
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학,",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        583.3049926757812,
        523.3963623046875,
        596.9588623046875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일양약품㈜, ㈜한국백신, 한국엠에스디(유)",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        609.3165893554688,
        441.5707092285156,
        622.970458984375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원 바이오생약심사부 생물제제과",
      "font_size": 12.94941520690918,
      "font_name": "ÈÞ¸Õ¸íÁ¶",
      "bbox": [
        192.6156005859375,
        661.2198486328125,
        501.5671081542969,
        674.8737182617188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    }
  ],
  "markdown_content": "백신 위해성 관리 계획 사례집\n\n- -일본, 유럽연합-\n<!-- PAGE_1 -->\n# [민원인 안내서]\n\n<!-- PAGE_1 -->\n## 2018. 11.\n\n<!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n**[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2. 소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다. | • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다. 단, 3차 접종 | 부터 60일 이상의 간격을   둔다. | Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다. | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사. | - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음. | 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까? | One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가. | 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음. | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3. 금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자. | 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver. 1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문. | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다. | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다. |\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11. | 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver. 3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다. | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. (예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3. 금기: | 장중첩증의 병력이 있는 자. | 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다. 또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가. | Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다. | 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다. 이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다. 하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다. 비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다. | 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다. 백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다. | 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다). | 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다. | 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다. | Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다. |\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다. | 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다. | 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver. 17 | Ver. 3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다. | 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다. | 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다. 극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다. 이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다. | 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문. | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다. | 1. 고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다. | l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다. | 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)). 또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다. | 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다. | 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다. | 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다. | 내용을 단순 편집 또는 나열한 것입니까? | 아래 ‘의약품 감시 | 계획’ 표 참조. | a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다. |\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다. | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해. | 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다. | 홍역 바이러스. Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다. | 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다. 3차 투여는 생후 32주를 넘어서는 안 된다. | 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다. 정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다. | 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다. | 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항). | “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. (예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8. 이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다. 해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다. | 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다. | 0.5mL을 1회 접종한다. | 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다. | 2. 소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다. | 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술. | 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다. | Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출). |\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해. | 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다. | 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해. | 내용입니까? | 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요). 열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다. | 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다. | Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다. 2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다. | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다. 모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다. (자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다. |\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다. |\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해. | Table. | 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련. | 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다. | l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다. | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다. | 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4. 경고 및 주의사항 | 면역이 결핍된 자(예. 악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다. |\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다. | 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다. | 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다. | 용법 | 근육주사(IM) 한다. 권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다. | Ÿ | 이 백신은 삼각근 부위에 근육주사 한다. | 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다. | 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다. |\n**정리한 자료입니까?**\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다. 이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다. | Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득. | 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다. | 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다. | Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험. | 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1. Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음. | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다. | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. | Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항). | 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다. | 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다. | 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다. | 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다. 그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다. | ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다. | 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다. | chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다. | 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4. 경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다. |\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4. 경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다. 새롭게 개정된 라 | 벨과 패키지가 이용 가능하다. |\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음. | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다. | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음. | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까? (민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다. |\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다. | 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까? | 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다. 그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n상기 사항에 대하여 확인하였음.\n\n2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n<!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ. 서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ. 백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1. 일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1. 폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2. 유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1. 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2. 폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3. 수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4. 수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5. 일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6. 로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7. 홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8. 인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ. 서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n<!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n<!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다. 일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n<!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n- - 2 -\n<!-- PAGE_7 -->\n### Ⅱ. 국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1. 일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n<!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n<!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n<!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n용법 및 용량\n\n- 1. 고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1. 추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n- 2. 1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n변경이유:\n\n- 1. 사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n- 2. 설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n- - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다. 피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n- - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다. 본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다. 13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다. 현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다. 또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다. 소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다. 또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n- - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다. 일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다. 또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n- - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지. 도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n- 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다. 또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다. 0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n이상으로 등록예정 증례수를 1000례로 설정했다.\n\n【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n- • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n- - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다. 또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다. 일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n- • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n- • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n- • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006). ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링. | 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링. | 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기). 위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다. | -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다. 가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다. |\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1. 일반적인 의약품 감시 활동 | 2. 비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다. |\n| 현재는 위해성 완화조치가 필요하 | 지 않음. | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다. | 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다. 두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다. | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다. | 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다. SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다. | 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음. | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다. | 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다. | 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술. | 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n- • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가. | 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다. 열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다. | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다. | 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정). |\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부. 추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다. |\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다. 백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다. |\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험. (범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다. 계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다. 제안된 OvE 실시 방 | 법이 승인되었다. |\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27. (EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A. | 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V. | 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다. 임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다. 그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다. 전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다. | 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다. | 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다. 임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10. (EU) | 회사명 | MSD | 허가일 | 2006.05.19. (EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자. | 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자. |\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다. 동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다. | Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다. | 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다. 모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다. | 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다. | 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다. | 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05. (EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A. | 허가일 | 2006.2.21. (EU) | 회사명 | GSK | 허가일 | 2007.09.20. (EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31. (EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28.(EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험. | (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다. 혈관내 또는 근육 주사를 하여서는 안된다. | 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험. (범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다. | 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다. |\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다. | 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. | Ÿ | 이 백신은 근육주사되어야 한다. 상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다. |\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다. |\n| MenACWY-TT-084. | 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2. 유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다. 제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n<!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다. 백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n<!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다. 예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n<!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다. 자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n- - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n용법\n\n근육주사(IM) 한다. 권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기. 주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다. 이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다. 이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n- - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n- - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다. 이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n- - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n- 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\nCategory 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n**[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다. |\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰). 또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사. | Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군). |\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034. | 정기적인 최신 안전성 보고서 | 모니터링. |\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n- - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다. 기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다. 첫번째 접종은 생후 6주에\n\n진행할 수도 있다. 4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다. 첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다. 세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다. 기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다. 첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver. 3.2\n\n하는 것도 가능하다.\n\n네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n(4.4항 및 5.1항 참고).\n\n생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다. 세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n(SmPC 5.1항 참고).\n\n만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다. 아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n- - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n- - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno.(체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다. 기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다. 첫번째\n\n접종은 생후 6주에도 할 수 있다. 추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. (생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다. 첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다. 추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. (생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다. 추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다. (4.4항과 5.1항 참고).\n\n- - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다. 추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n- - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다. 의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다. 열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\nEU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다. 연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다. 회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n- - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다. 연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다. 회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다. (5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n- - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음. 이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.  이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다. 이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다.\"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다. |\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조). 면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다. | 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다. |\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음. | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n- - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다.\"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1. 연구목록\n\n않았습니다. 이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여. 불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\nSmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\nSmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n**[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다. 비임상 연구는 생식독성 | 을 확인하기에는 불충분하다. | 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다. 조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다. 백신 투여 후 1 | 개월은 임신을 피해야 한다. |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c. 바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨. |\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. | 프로타민황산염)에 대한 과민반 | 응. | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다. | 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다. | 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다. | 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다. 따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다. |\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다. 그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다. 또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다. 이는 조스터박스 투여 | 에 대한 이론적인 위험이다. | 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다. | 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다. 이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. | Protamin Sulphate)에 대한 과민 | 반응. | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. |\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신. 백신 접종 | 후 1개월은 임신을 피해야 한 | 다. |\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다. | “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조). 동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조). 하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다. 따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다. 만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다. |\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n- - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n- - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n- - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4. 경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n- - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행). 이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다. 홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver. 17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n- - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n없다. 다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. 1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n[일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n“본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우. 이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n“면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. 1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n역원성\n\n감 시 계 획 ’\n\n표 참조\n\n- - 74 -\n기추적관찰 연구\n\n(3차 접종 후 10\n\n년 연장 연구) (범\n\n주 3)\n\n: 젊은 여성(16-26\n\n세)와 비교하였을\n\n때 소아 및 청소\n\n년(9-15세)에서 가\n\n다실9의\n\n면역원\n\n- - 75 -",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "백신 위해성 관리 계획 사례집\n\n- -일본, 유럽연합-\n<!-- PAGE_1 -->\n# [민원인 안내서]\n\n<!-- PAGE_1 -->\n## 2018. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 85,
        "word_count": 19,
        "page_number": 1,
        "window_text": "백신 위해성 관리 계획 사례집\n\n- -일본, 유럽연합-\n<!-- PAGE_1 -->\n# [민원인 안내서]\n\n<!-- PAGE_1 -->\n## 2018.  11.\n\n <!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2. ",
        "original_sentence": "백신 위해성 관리 계획 사례집\n\n- -일본, 유럽연합-\n<!-- PAGE_1 -->\n# [민원인 안내서]\n\n<!-- PAGE_1 -->\n## 2018. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "11.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 5,
        "word_count": 1,
        "page_number": 1,
        "window_text": "백신 위해성 관리 계획 사례집\n\n- -일본, 유럽연합-\n<!-- PAGE_1 -->\n# [민원인 안내서]\n\n<!-- PAGE_1 -->\n## 2018.  11.\n\n <!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2.  소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다. ",
        "original_sentence": "11.\n\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "<!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 130,
        "word_count": 24,
        "page_number": 1,
        "window_text": "백신 위해성 관리 계획 사례집\n\n- -일본, 유럽연합-\n<!-- PAGE_1 -->\n# [민원인 안내서]\n\n<!-- PAGE_1 -->\n## 2018.  11.\n\n <!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2.  소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다.  | • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다. ",
        "original_sentence": "<!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "**[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 48,
        "word_count": 12,
        "page_number": 2,
        "window_text": "백신 위해성 관리 계획 사례집\n\n- -일본, 유럽연합-\n<!-- PAGE_1 -->\n# [민원인 안내서]\n\n<!-- PAGE_1 -->\n## 2018.  11.\n\n <!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2.  소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다.  | • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다.  단, 3차 접종 | 부터 60일 이상의 간격을   둔다. ",
        "original_sentence": "**[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2. "
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 64,
        "word_count": 17,
        "page_number": 5,
        "window_text": "11.\n\n <!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2.  소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다.  | • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다.  단, 3차 접종 | 부터 60일 이상의 간격을   둔다.  | Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다. ",
        "original_sentence": "소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "| • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 5,
        "window_text": "<!-- PAGE_1 -->\n## 바이오생약심사부 생물제제과\n\n<!-- PAGE_2 -->\n### 지침·안내서 제‧개정 점검표\n\n명칭\n\n백신 위해성관리계획 사례집(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n **[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2.  소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다.  | • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다.  단, 3차 접종 | 부터 60일 이상의 간격을   둔다.  | Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사. ",
        "original_sentence": "| • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "단, 3차 접종 | 부터 60일 이상의 간격을   둔다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 32,
        "word_count": 9,
        "page_number": 8,
        "window_text": "**[표 시작]**\n\n| □ 이미 등록된 지침·안내서 중 동일·유사한 내용의 | 2.  소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다.  | • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다.  단, 3차 접종 | 부터 60일 이상의 간격을   둔다.  | Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사.  | - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음. ",
        "original_sentence": "단, 3차 접종 | 부터 60일 이상의 간격을   둔다. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "| Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 196,
        "word_count": 64,
        "page_number": 2,
        "window_text": "소아 | • 1차 면역: 보통, 1회 0.5 mL씩을 3회, 모두 27일 이상의 간격으로 | 피하에   주사한다.  | • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다.  단, 3차 접종 | 부터 60일 이상의 간격을   둔다.  | Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사.  | - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음.  | 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까? ",
        "original_sentence": "| Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 176,
        "word_count": 52,
        "page_number": 44,
        "window_text": "| • 추가면역: 보통, 1회 0.5mL를   1회, 피하에 주사한다.  단, 3차 접종 | 부터 60일 이상의 간격을   둔다.  | Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사.  | - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음.  | 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까?  | One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가. ",
        "original_sentence": "| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사. "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "| - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 85,
        "word_count": 28,
        "page_number": 24,
        "window_text": "단, 3차 접종 | 부터 60일 이상의 간격을   둔다.  | Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사.  | - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음.  | 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까?  | One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가.  | 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
        "original_sentence": "| - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음. "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "| 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 78,
        "word_count": 24,
        "page_number": 5,
        "window_text": "| Ÿ | 뇌병증, 뇌염 | 없음 | 역원성 | Ver 2.1 | 중 | □ 예 | ■ 아니오 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 첫번째 접종을 신플로릭스로 한 대상자들은 신플로릭스로 접종 코스를 마치 | 는 것이 권장된다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사.  | - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음.  | 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까?  | One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가.  | 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3. ",
        "original_sentence": "| 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 284,
        "word_count": 77,
        "page_number": 5,
        "window_text": "| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 프랑스, 독일, 네덜란드, 노르 | 웨이 및 영국의 국가 감시 체 | 계를 사용하여 5년 동안 5개 | 유럽 국가의 침습성 질환 발 | 생률, 영국과 네덜란드의 폐렴 | 발생률 및 5년간 영국의 급성 | 중이염 발생률에 대한 인구 | 기반 조사.  | - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음.  | 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까?  | One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가.  | 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3.  금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자. ",
        "original_sentence": "| One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가. "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "| 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 57,
        "word_count": 17,
        "page_number": 24,
        "window_text": "| - 해당 국가의 접종 권역이 | 위해성 관리 | 계획 | 번호 |\n| 다른 성인 백신과의 병용투여 | 를 평가하기 위한 연구가 계 | 획되어 있음.  | 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까?  | One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가.  | 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3.  금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자.  | 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver. ",
        "original_sentence": "| 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 2,
        "window_text": "| 18세 이상의 신장이 | 식 | 환자에서의 | 계획 번호 (버 | 전) | 위해성 | 관리 | 면역원성 |\n| 지침·안내서가 있습니까?  | One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가.  | 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3.  금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자.  | 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver.  1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문. ",
        "original_sentence": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 27,
        "window_text": "| One dose (2 ml) contains: | 로타바이러스 G1 2.2 x 106IU 이상 | 로타바이러스 G2 2.8 x 106 IU 이상 | 로타바이러스 G3 2.2 x 106IU 이상 | 로타바이러스 G4 2.0 x 106IU 이상 | 로타바이러스 P1A 2.3 x 106IU 이상 | 일반 약물감시 | US | 임신 | 레지스트리와 | case | PSUR에 ECDC 보고서 및 | 국가별 MenACWY-TT의 분 | 배 분포에 대한 정보를 매 | 년 제공 | 발생의 잠재적 | 관련성 평가.  | 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3.  금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자.  | 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver.  1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다. ",
        "original_sentence": "금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자. "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "| 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 191,
        "word_count": 54,
        "page_number": 53,
        "window_text": "| 병력이 있는 시험대 | 상자 포함) | (중략) | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3.  금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자.  | 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver.  1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다.  | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다. ",
        "original_sentence": "| 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 143,
        "word_count": 38,
        "page_number": 5,
        "window_text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC: | 4.3.  금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자.  | 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver.  1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다.  | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다.  |\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11. ",
        "original_sentence": "1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문. "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 93,
        "word_count": 25,
        "page_number": 10,
        "window_text": "금기: | 알려진 또는 의심되는 면역결 | 핍증이 있는 자.  | 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver.  1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다.  | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다.  |\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11.  | 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver. ",
        "original_sentence": "| 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "| 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 72,
        "word_count": 21,
        "page_number": 30,
        "window_text": "| 무증상의 인간면역결핍바이러 | 스 | (HIV, | Human | SPC 4.4 에 경고 | 없음 |\n| 기술방식(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | 계획 번호 (버 | 전) | 위해성 관리 | 계획   번호 | (버전) | Ver.  1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다.  | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다.  |\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11.  | 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver.  3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다. ",
        "original_sentence": "| 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "|\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 614,
        "word_count": 148,
        "page_number": 5,
        "window_text": "1 | 최종 CSR: | 2014년 12월 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 천식의 이상약물반응 보고는 없었으나 일본 외 국 | 가에서 시판 후 자발보고가 있었기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다.  | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다.  |\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11.  | 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver.  3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다.  | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. ",
        "original_sentence": "|\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 2,
        "window_text": "| 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 천식의 보고가 없기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는다.  | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다.  |\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11.  | 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver.  3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다.  | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3. ",
        "original_sentence": "| 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver. "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 69,
        "word_count": 18,
        "page_number": 2,
        "window_text": "| 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SmPC 4.6: 임부에 대한 임상 | 자료는 불충분하다.  |\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11.  | 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver.  3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다.  | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3.  금기: | 장중첩증의 병력이 있는 자. ",
        "original_sentence": "3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 79,
        "word_count": 20,
        "page_number": 52,
        "window_text": "|\n| 회사명 | Sanofi Pasteur | 허가일 | 2013.04.17(EU) | 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드(PT) | 필라멘트 헤마글루티닌(FHA) | Pertactin(PRN) | Fimbriae Types 2+3 (FIM) | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 수막구균 단백과 접합된 헤모필루스 인플루엔자비형균 다당류 | 백신접종과의 인과관계에 대한 증거가 없는 면밀한 감독의 대 | 상인 이상사례: | Ÿ | 영아 돌연사 증후군(Sudden Infant Death Syndrome, SIDS), | 돌연사(Sudden Unexpected Death, SUD), 생명 위협 사건 | (Apparent Life-Threatening Event, ALTE) | 10~25세 | 건강한 | 청소년 | 및 | 성인에게 | 접종시 | 진 | 행 | 20 IU 이상 | 40 IU 이상 | 20 μg | 20 μg | 3 μg | 5 μg | 40 DU | 8 DU | 32 DU | 10 μg | 50 μg |\n| 1 | 안내서-0909-01 | 2018.11.  | 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver.  3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다.  | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3.  금기: | 장중첩증의 병력이 있는 자.  | 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다. ",
        "original_sentence": "| 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "(예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 83,
        "word_count": 22,
        "page_number": 2,
        "window_text": "| 제정 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침·안내서의 개정을 우선적으로 | (버전) | Ver.  3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다.  | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3.  금기: | 장중첩증의 병력이 있는 자.  | 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가. ",
        "original_sentence": "(예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "금기: | 장중첩증의 병력이 있는 자. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 27,
        "window_text": "3 |\n| Shingrix의 안전성, 반 | 응원성과 | 면역원성 | [일반적 조치] 구분되는 제품명 및 포장을 사용한다.  | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3.  금기: | 장중첩증의 병력이 있는 자.  | 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가.  | Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다. ",
        "original_sentence": "금기: | 장중첩증의 병력이 있는 자. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 76,
        "word_count": 22,
        "page_number": 30,
        "window_text": "| 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3.  금기: | 장중첩증의 병력이 있는 자.  | 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가.  | Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다.  | 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다. ",
        "original_sentence": "| 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 179,
        "word_count": 48,
        "page_number": 5,
        "window_text": "(예: 처방의 및 백신접종자 | 에게 9가백신과 4가백신 사이의 구분되는 특성에 관하 | 여 안내) | [추가적조치] 없음 | SPC: | 4.3.  금기: | 장중첩증의 병력이 있는 자.  | 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가.  | Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다.  | 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다.  이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다. ",
        "original_sentence": "또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "| Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 200,
        "word_count": 53,
        "page_number": 5,
        "window_text": "금기: | 장중첩증의 병력이 있는 자.  | 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가.  | Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다.  | 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다.  이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다.  하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다. ",
        "original_sentence": "| Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "| 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 13,
        "window_text": "| 장중첩증이 일어나기 쉬운 교 | 정되지 않은 선천성 위장관 이 | 상이 있는 자 |\n| 준수하셔야 하는 사항이 아님을 알려드립니다.  또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가.  | Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다.  | 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다.  이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다.  하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다.  비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다. ",
        "original_sentence": "| 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 61,
        "word_count": 17,
        "page_number": 30,
        "window_text": "또한, 본 안내서는 | 2~10세 소아에게 멘비오 1회 또는 2회 | 접종시 단기와 장기 항체 역가를 평가하 | 는 연구 | control study | 미국에서 50세 이상의 | 시험대상자에서 전체 | 및 연령별 대상포진, | 대상포진 후 신경통 | 및 안부대상포진을예 | 방하는 Shingrix의 유 | 효성 평가.  | Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다.  | 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다.  이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다.  하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다.  비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다.  | 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다. ",
        "original_sentence": "이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 55,
        "word_count": 14,
        "page_number": 24,
        "window_text": "| Shingrix 접종 후 10 | 년까지의 백신의 유 | 효성 평가 | MenACWY-TT 백신 (GSK134612) 대 Menactra 장기 항 | 체 지속성 및 1차 백신 접종 5년 후 MenACWY-TT 백 | 신 추가 접종 연구 | 4.6 수태능, 임신 및 수유 | 임신 | 임신한 여성은 M-M-RVAXPRO로 예방접종을 | 받아서는 안 된다.  | 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다.  이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다.  하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다.  비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다.  | 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다.  백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다. ",
        "original_sentence": "하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 111,
        "word_count": 32,
        "page_number": 30,
        "window_text": "| 임신한 여성에 대한 M-M-RVAXPRO의 시험 | 은 수행되지 않았다.  이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다.  하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다.  비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다.  | 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다.  백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다.  | 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다). ",
        "original_sentence": "비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 89,
        "word_count": 27,
        "page_number": 2,
        "window_text": "이것이 임부에게 투여되 | 었을 때 태아에게 위해가 발생되거나 추후 | 임신에 영향을 미치는지 알 수 없다.  하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다.  비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다.  | 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다.  백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다.  | 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다).  | 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다. ",
        "original_sentence": "| 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 58,
        "word_count": 17,
        "page_number": 5,
        "window_text": "하지만, | 홍역 또는 볼거리 바이러스가 임산부에게 전 | 달되었을 때 태아 위해성이 보고되었다.  비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다.  | 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다.  백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다.  | 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다).  | 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다.  | 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다. ",
        "original_sentence": "백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "| 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 365,
        "word_count": 93,
        "page_number": 30,
        "window_text": "비록 | 이론적인 위험성이 배제될 수 는 없지만, 볼 | 거리가 포함된 백신을 투여 받았을 때 임신 | 초기 알지 못한 3500명 이상의 취약한 여성 | 에서 선천성 풍진 증후군은 보고되지 않았다.  | 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다.  백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다.  | 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다).  | 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다.  | 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다.  | Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다. ",
        "original_sentence": "| 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다). "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "| 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 138,
        "word_count": 45,
        "page_number": 32,
        "window_text": "| 그러므로 임신 여부를 모르는 여성에 대한 | 의도치 않은 홍역, 볼거리 또는 풍진을 포함 | 한 백신의 접종은 임신 중단의 원인이 되어 | 서는 안 된다.  백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다.  | 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다).  | 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다.  | 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다.  | Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다.  |\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다. ",
        "original_sentence": "| 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "| 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 211,
        "word_count": 61,
        "page_number": 24,
        "window_text": "백신 접종 후 1달 간 임신은 | 피해야 하며, 임신을 계획하고 있는 여성은 | 게획을 미루어야 한다.  | 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다).  | 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다.  | 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다.  | Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다.  |\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다.  | 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다. ",
        "original_sentence": "| 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "| Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 470,
        "word_count": 125,
        "page_number": 5,
        "window_text": "| 중 |\n| 투여 방법 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 백셀리스(Vaxelis) 투여와 관련된 아나필락시스 반 | 응을 포함한 과민반응의 잠재적 가능성은 SmPC | 에 기술되어 있다 | (4.3항 금기: 이 백신의 성분 또는 구성성분에 대 | 해 과민반응을 보이는 환자에게 백신을 투여해서 | 는 안 된다; | 4.4항 특수 경고 및 사용상의 주의사항: 위해성 | 완화를 위해 적절한 의학적 치료 및 관리가 항상 | 신속히 이루어질 수 있도록 준비되어야 한다).  | 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다.  | 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다.  | Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다.  |\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다.  | 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다.  | 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver. ",
        "original_sentence": "| Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "|\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 302,
        "word_count": 87,
        "page_number": 5,
        "window_text": "| 항문암 및 기 | 타 HPV 관련 | 암의 5년 경향 | 에 대한 데이 | 터 수집 | 2-3개월의 전환 기간에 일어 | 나는 백신 실패는 영국, 프란 | 스, 독일, 네덜란드 및 노르웨 | 이의 국가 감시 프로그램에 | 의해 평가될 것이다.  | 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다.  | Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다.  |\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다.  | 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다.  | 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver.  17 | Ver. ",
        "original_sentence": "|\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다. "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "| 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 60,
        "word_count": 16,
        "page_number": 5,
        "window_text": "| 부족 정보 | 항문 병소 | 및 | 암에 | 위해성 관리 | 계획 번호 | (버전) | 없음 |\n| 의약품 안전성 감시활동의 내용 및 선택 이유: | 【내용】 | • 일반   의약품 안전성 감시활동 | 【선택이유】 | 제조판매 후에 대하여 쇼크, 아나필락시스의 발현이 확인된 경우는, 사용 성적 조 | 사의 증례를 포함한 충분한 정보수집에 노력하는 것으로 감시를 강화한다.  | Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다.  |\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다.  | 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다.  | 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver.  17 | Ver.  3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다. ",
        "original_sentence": "| 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "| 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 127,
        "word_count": 39,
        "page_number": 2,
        "window_text": "| Cervarix | 인유두종바이러스 백신[16, 18 | 형] (재조합, 항원보조제, 흡 | 착) | 인유두종바이러스 6형 L1 단백질- 30㎍ | 인유두종바이러스 11형 L1 단백질- 40㎍ | 인유두종바이러스 16형 L1 단백질- 60㎍ | 인유두종바이러스 18형 L1 단백질- 40㎍ | 인유두종바이러스 31형 L1 단백질- 20㎍ | 인유두종바이러스 33형 L1 단백질- 20㎍ | 인유두종바이러스 45형 L1 단백질- 20㎍ | 인유두종바이러스 52형 L1 단백질- 20㎍ | 인유두종바이러스 58형 L1 단백질- 20㎍ | 최종 | 임상시험결과보고서 |\n| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 위해성 관리 | 위해성 관리 | 계획 번호 | (버전) | 위해성 | 관리 | SmPC 4.4: 면역 저하 환자에 | 서 백신 접종으로 적절한 항 | 체 반응이 나타나지 않을 수 | 있다.  |\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다.  | 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다.  | 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver.  17 | Ver.  3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다.  | 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다. ",
        "original_sentence": "| 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver. "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "17 | Ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 5,
        "window_text": "|\n| 평가 | - 해당 국가가 전국적인 폐 | 위해성 | 관리 |\n| 2018년 11월 현재의 과학적ㆍ기술적 사실 및 유효한 법규를 토대로 | 자발보고 | Targeted | Follow-up | 중국인 | 여성 | 위해성 | 관리 | EU SmPC 4.4항에 다음 내용 기 | 술:“어떤 백신접종자에게는 면역 | 반응이 나타자지 않을 수도 있습 | 니다.” | 지정된 기준 충족시, 회사는 감염 | 통제 기관이 설립된 개별 국가로 | 부터 혈청 그룹 분포 데이터를 얻 | 어 평가 | 뇌병증, 뇌염은 SmPC 다음 항에 | 기술되었다.  | 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다.  | 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver.  17 | Ver.  3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다.  | 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다.  | 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다. ",
        "original_sentence": "17 | Ver. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 57,
        "word_count": 17,
        "page_number": 25,
        "window_text": "| 2014년 4분기 |\n| 제품명 | Hexacima | 본 백신은 근육내 또는 피하로 투여되어야 한다.  | 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver.  17 | Ver.  3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다.  | 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다.  | 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다.  극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다. ",
        "original_sentence": "3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "| 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 231,
        "word_count": 45,
        "page_number": 5,
        "window_text": "| 해당사항 없 | 음 | 노인에서의 | 취약한 | 계획 번호 | 대상포진, 대상포 | 진 후 신경통 및 | 대상포진,  관련 | 합병증을 예방하 | 는 Shingrix의 유 | 효성 | 계획   번호 | (버전) | Ver.  17 | Ver.  3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다.  | 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다.  | 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다.  극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다.  이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다. ",
        "original_sentence": "| 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "| 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 56,
        "word_count": 16,
        "page_number": 30,
        "window_text": "17 | Ver.  3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다.  | 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다.  | 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다.  극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다.  이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다.  | 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문. ",
        "original_sentence": "| 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 185,
        "word_count": 43,
        "page_number": 33,
        "window_text": "3.2 | Ver 8.0 |\n| 를 통하여 접종 후 4~6년간의 유효성 평가 결과를 수집할 수 있다.  | 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다.  | 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다.  극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다.  이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다.  | 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다. ",
        "original_sentence": "극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 55,
        "word_count": 13,
        "page_number": 28,
        "window_text": "| 계획 번호 (버 | 전) | 계획 | 2016년 12월 |\n| (사유 :                                                                 ) | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 임상시험을 통해 조산아에서의 투여에 대해 | 얻은 제한적인 자료에 근거하여 백셀리스(Vaxelis) | 를 미숙아에게 투여할 수 있다고 기술되어 있다.  | 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다.  극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다.  이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다.  | 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.  | 1. ",
        "original_sentence": "이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "| 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 405,
        "word_count": 126,
        "page_number": 30,
        "window_text": "| 그러나, 보다 낮은 수준의 면역반응이 관찰될 수 | 있고 임상적 방어 수준도 알려져 있지 않다.  극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다.  이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다.  | 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.  | 1.  고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다. ",
        "original_sentence": "| 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "| 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 93,
        "word_count": 25,
        "page_number": 10,
        "window_text": "극미 | 숙아(very premature infants) (출생시 재태기간이 | 28주 미만)와 특히 호흡계 미성숙 기왕력이 있는 | 영유아에 대한 기초접종을 실시할 경우 SmPC | (4.4항 특수 경고 및 사용상의 주의사항)에 기술 | 된 무호흡의 잠재적 위험과 48-72시간 동안 호흡 | 모니터링의 필요성을 고려해야 한다.  이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다.  | 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.  | 1.  고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다.  | l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다. ",
        "original_sentence": "| 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "| 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 5,
        "window_text": "이러한 영아 | 에서 예방접종의 유익성이 높으므로, 예방접종을 | 보류하거나 지연해서는 안 된다.  | 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.  | 1.  고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다.  | l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다.  | 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)). ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 284,
        "word_count": 69,
        "page_number": 5,
        "window_text": "| 시 험 대 상 자 에 | 서의 | 안전성, | 상태와 대상포진 발 | 병의 다른 예후인자 | 를 인구학적 특성과 | Z O S T E R - 0 0 6 과 | ZOSTER-022 연구를 | 참여한 시험대상자를 | 대상으로 진행한 삶 | 의 질에 대한 설문조 | 사를 기반으로 평가 | 하기 위한 관찰연구 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 9~12 | 개월의 | 건강한 | 아기에게 | 1회 | 또는 | 2회 | 계획 번호 (버 | 전) | Ver 1.0 |\n| 중요한 특정 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아> | 소아의 일본 국내 임상시험에서 무호흡의 보고는 없었으나, 일본 외 국가에서 호흡 | 곤란, 호흡 이상, 호흡장애, 호흡부전이 시판 후 자발보고에 있기 때문.  | 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.  | 1.  고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다.  | l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다.  | 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)).  또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다. ",
        "original_sentence": "고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "| l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 594,
        "word_count": 150,
        "page_number": 5,
        "window_text": "| 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고 | 에서 무호흡의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.  | 1.  고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다.  | l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다.  | 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)).  또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다.  | 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다. ",
        "original_sentence": "| l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "| 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 146,
        "word_count": 35,
        "page_number": 11,
        "window_text": "| 1.  고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다.  | l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다.  | 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)).  또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다.  | 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다.  | 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다. ",
        "original_sentence": "| 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)). "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 71,
        "word_count": 19,
        "page_number": 22,
        "window_text": "고연령층 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 감염증의   예방 | (버전) | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 8월 |\n| 작성되었으므로 이후 최신 개정 법규 내용 및 구체적인 사실관계 | 선호되는 접종 부위는 어린 소아 (younger children)일 경우 허벅지 전외측 | 부위이며, 소아 (older children), 청소년 그리고 성인일 경우 삼각근이 해 | 당된다.  | l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다.  | 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)).  또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다.  | 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다.  | 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다.  | 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
        "original_sentence": "또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 512,
        "word_count": 143,
        "page_number": 2,
        "window_text": "| l EU내에서 능동적 감시: | 대한 영향 | 및 유효성 | 연구 시 | 작 | 2016년 12월 연구 종 | 료 보고 |\n| □ 법령(법‧시행령‧시행규칙) 또는 행정규칙(고시‧훈령‧예규)의 | CRM197 단백질 접합, 알루미늄 포스페이트 흡착 | 1회 용량 (0.5mL)은 CRM197 단백질 약 32μg과 0.125mg 알루미늄을 포함 | 0.5ml 안에 | Questionnaire | PSUR에 보고된 사례 기술 | PSUR에 ECDC 보고서 및 | 국가 별 MenACWY-TT의 | 분배 분포에 대한 정보를 | 매년 제공 | DTaP-IPV-Hep B-PRP-T는 다음과 같은 대상자에서 연구되지 | 않았다: | Ÿ | 미숙아 | - 해당 국가의 접종 권역이 | MenACWY-TT 백신 (GSK134612) 접종시 장기 항체 지 | 속성 및 1차 백신 접종 5년 후 MenACWY-TT 백신 추 | 가 접종 연구 | Immunodeficiency Virus) 감염 | 은 로타릭스의 안전성과 유효 | 성에 영향을 주지 않을 것으로 | 예상되나, 충분한 자료가 없으 | 므로 무증상의 HIV 감염자에 | 는 이 백신의 투여를 권장하지 | 않는다.  | 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)).  또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다.  | 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다.  | 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다.  | 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 내용을 단순 편집 또는 나열한 것입니까? ",
        "original_sentence": "| 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "| 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 68,
        "word_count": 19,
        "page_number": 30,
        "window_text": "| 계 | 획 |\n| 중요한 잠재적 위해성으로 지정한 이유: | <위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)> | 대상마다 접종경로가 다르기 때문에 잘못된 경로로 접종 받을 우려가 있다(접종경 | 로: 근육 내(고연령층), 피하(소아)).  또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다.  | 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다.  | 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다.  | 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 아래 ‘의약품 감시 | 계획’ 표 참조. ",
        "original_sentence": "| 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "| 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 112,
        "word_count": 40,
        "page_number": 25,
        "window_text": "또, 고연령층(65세 이상의 성인) 및 소아를 대상 | 으로 한 제제이기 때문에 승인 받지 않은 대상에 대한 접종이 우려된다.  | 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다.  | 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다.  | 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 아래 ‘의약품 감시 | 계획’ 표 참조.  | a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다. ",
        "original_sentence": "| 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "| 내용을 단순 편집 또는 나열한 것입니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 2,
        "window_text": "| 없음 | □ 예 | ■ 아니오 |\n| 목적 | 검토된 | 안전성 |\n| 디프테리아 톡소이드 | 파상풍 톡소시드 | 백일해 톡소이드 | 필라멘트 헤마글루티닌 | 불활화 폴리오 바이러스 제1형 | 불활화 폴리오 바이러스 제2형 | 불활화 폴리오 바이러스 제3형 | 정제B형 간염 표면단백항원 | 파상풍톡소이드와 접합된 헤모필루스 인플루엔자비형균 다당류 | 면역원성 | 및 | 실시기간: 판매시작 후 6개월간 | 평가 예정 시기: 판매시작부터 | 2, 4, 6개월 후 | 보고 예정시기: 판매시작부터 8 | 개월 이내 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 시기절적하게 시판후 연구 | 의 주 목적을 만족시키기 | 에 충분할 때 | SmPC   4.4: Menveo는 혈소 | 판감소증 환자, 출혈 장애 | 환자 및 혈종의 위험 때문에 | 항응고 요법을 받고 있는 환 | 자에서는 평가되지 않았다.  | 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다.  | 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 아래 ‘의약품 감시 | 계획’ 표 참조.  | a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다.  |\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다. ",
        "original_sentence": "| 내용을 단순 편집 또는 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "| 아래 ‘의약품 감시 | 계획’ 표 참조. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 25,
        "word_count": 8,
        "page_number": 53,
        "window_text": "| 보건의료전문가가 혈종의 위 | 험이 있는 사람의 경우 근육 | 주사 후의 위험-혜택에 대한 | 비율을 평가해야 한다.  | 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 아래 ‘의약품 감시 | 계획’ 표 참조.  | a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다.  |\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다.  | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해. ",
        "original_sentence": "| 아래 ‘의약품 감시 | 계획’ 표 참조. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "| a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 121,
        "word_count": 34,
        "page_number": 30,
        "window_text": "| 됨 | 20 IU 이상 | 40 IU 이상 | 25 μg | 25 μg | 40 DU | 8 DU | 32 DU | 10 μg | 12 μg |\n| 등에 따라 달리 적용될 수 있음을 알려드립니다.  | 내용을 단순 편집 또는 나열한 것입니까?  | 아래 ‘의약품 감시 | 계획’ 표 참조.  | a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다.  |\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다.  | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해.  | 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다. ",
        "original_sentence": "| a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "|\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 44,
        "word_count": 10,
        "page_number": 2,
        "window_text": "| 내용을 단순 편집 또는 나열한 것입니까?  | 아래 ‘의약품 감시 | 계획’ 표 참조.  | a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다.  |\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다.  | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해.  | 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다.  | 홍역 바이러스. ",
        "original_sentence": "|\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 121,
        "word_count": 32,
        "page_number": 9,
        "window_text": "| 아래 ‘의약품 감시 | 계획’ 표 참조.  | a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다.  |\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다.  | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해.  | 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다.  | 홍역 바이러스.  Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "| 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 80,
        "word_count": 21,
        "page_number": 7,
        "window_text": "| a) Germany (ESPED) | b) UK (BPSU): 보류됨 | 5년 동안 프리베나 13 혈청형 | 에서의 잠재적 변화를 모니터 | 하기 위해 5개의 유럽 인구 | 기반 감시 체계가 사용될 것 | 이다.  |\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다.  | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해.  | 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다.  | 홍역 바이러스.  Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다. ",
        "original_sentence": "| 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다. "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "| 홍역 바이러스. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 57,
        "window_text": "|\n| 등록대상 | (예상되는 시험 대상자수: 7,000명)을 진행하고 있다.  | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해.  | 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다.  | 홍역 바이러스.  Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다.  | 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다. ",
        "original_sentence": "| 홍역 바이러스. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 609,
        "word_count": 173,
        "page_number": 5,
        "window_text": "| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 천식의 발현상황, 기초질환 등의 환자배경에 관한 정보를 폭넓게 수집 | 하기 위해.  | 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다.  | 홍역 바이러스.  Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다.  | 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다.  3차 투여는 생후 32주를 넘어서는 안 된다. ",
        "original_sentence": "Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "| □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 62,
        "word_count": 17,
        "page_number": 2,
        "window_text": "| 또한, 제조판매 후에 대하여 천식의 발현이 확인된 경우는 사용 성적 조사의 증례 | 를 포함한 충분한 정보수집에 노력하여 감시를 강화한다.  | 홍역 바이러스.  Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다.  | 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다.  3차 투여는 생후 32주를 넘어서는 안 된다.  | 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "| 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 57,
        "word_count": 17,
        "page_number": 5,
        "window_text": "| 홍역 바이러스.  Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다.  | 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다.  3차 투여는 생후 32주를 넘어서는 안 된다.  | 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다.  정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다. ",
        "original_sentence": "| 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "3차 투여는 생후 32주를 넘어서는 안 된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 13,
        "window_text": "Enders' Edmonston strain (생약독화 백신) | 1x103 CCID50* 이하 | 18세 이상의 항암치 | 료를 받고 있는 고형 | 암 환 자 에 서 의 | Shingrix의 안전성, 반 | 응원성과 | 면역원성 | 중간 보고서: | 2016년 8월 31일 | 2017년 8월 31일 | 2018년 8월 31일 | 2019년 8월 31일 | 2020년 8월 31일 | 최종 보고서: | 마지막 환자 등록 | 후 약 18개월 후 |\n| Ÿ 18 이상의 성인 및 고령자 | 생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로 인 | 한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방 (예방에 대한 능동 면 | 역) | 만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및 폐 | 렴에 대한 예방 (예방에 대한 능동 면역) | 유효성 | 서바릭스 사용 | 국가에서 항문 | 암 | 및 | 기타 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 | 중간 보고서 배년 보고 | 정기안전성보고서 매년 보고 | 최종 임상시험 결과보고서 | 2015년 12월 |\n| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다.  | 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다.  3차 투여는 생후 32주를 넘어서는 안 된다.  | 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다.  정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다.  | 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다. ",
        "original_sentence": "3차 투여는 생후 32주를 넘어서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 151,
        "word_count": 46,
        "page_number": 37,
        "window_text": "| □ 예 | ■ 아니오 | 이 백신은 매 회차에 1튜브(2ml) 전량을 경구투여하고, 3차에 걸쳐 투여한다.  | 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다.  3차 투여는 생후 32주를 넘어서는 안 된다.  | 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다.  정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다.  | 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다.  | 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항). ",
        "original_sentence": "| 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 143,
        "word_count": 38,
        "page_number": 5,
        "window_text": "| 1차 투여는 생후 6～12주에 하고, 이 후 각 투여간 최소 4주 간격을 두고 | 추가 투여한다.  3차 투여는 생후 32주를 넘어서는 안 된다.  | 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다.  정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다.  | 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다.  | 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항).  | “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. ",
        "original_sentence": "정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "| 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 84,
        "word_count": 24,
        "page_number": 5,
        "window_text": "3차 투여는 생후 32주를 넘어서는 안 된다.  | 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다.  정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다.  | 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다.  | 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항).  | “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8. ",
        "original_sentence": "| 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "| 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 362,
        "word_count": 84,
        "page_number": 32,
        "window_text": "| 27~45세 여성에서 9가 | 백신 HPV 유형 각각 | 에 대한 면역원성 입 | 증 | 27~45세 여성에서 9가 | HPV 백신의 안전성 | 프로파일에 대한 데이 | 터 수집 | 일상적인 약물감시 활동을 통 | 해 회사로 보고된 백신 실패 | 를 검토할 것이다.  정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다.  | 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다.  | 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항).  | “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8.  이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다. ",
        "original_sentence": "| 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항). "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "| “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 215,
        "word_count": 52,
        "page_number": 39,
        "window_text": "정기적인 | 최신 안전성 보고서 분석을 | 통해 프리베나에서 프리베나 | 13으로 | 전환하는 | 환자에서 |\n| “위해성관리계획 -백신- 사례집(민원인 안내서)” | 생후 6주 이후에 1차 경구 투여하며 최소 4주 간격을 두고 2차 경구 투여 | 한다.  | 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다.  | 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항).  | “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8.  이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다.  해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다. ",
        "original_sentence": "| “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "(예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 76,
        "word_count": 19,
        "page_number": 2,
        "window_text": "| 생후 16주 이전에 2차 경구 투여를 완료하되, 동 기간 내에 투여를 하지 | 못한 경우에는 최대 생후 24주 내에 2차 투여를 완료하여야 한다.  | 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항).  | “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8.  이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다.  해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다.  | 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다. ",
        "original_sentence": "(예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8. "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 82,
        "word_count": 18,
        "page_number": 20,
        "window_text": "| 9세 이상에서 발암을 유발하는 인유두종바이러스 유형에 관련된 항문-성 | 기(자궁경부, 외음부, 질, 항문) 부위의 전암성 병변 또는 자궁경부 및 항 | 문암의 예방 | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 건강한 청소년 및 성인에게 수막구균 백신 GSK134612 | 접종 후 항체반응 지속성을 보기 위한 연구 | [일반적 조치]  가다실9는 다른 HPV 백신과 호환 가능 | 하지 않으며 HPV 백신의 혼합 요법을 이용한 연구는 | 가다실9에 대해 시행되지 않았음을 나타내는 문구를 | SmPC에 포함하였다(4.2 및 4.4항).  | “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8.  이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다.  해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다.  | 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다.  | 0.5mL을 1회 접종한다. ",
        "original_sentence": "이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다. "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 60,
        "word_count": 16,
        "page_number": 30,
        "window_text": "| “HPV백신들에 대한 혼합 요법(교차접종 가능성)에 대 | 한 연구들은 가다실9에 대해 수행되지 않았다.” | “가다실9을 2가 또는 4가 HPV백신과 교차접종하는 | 것이 가능한지에 대한 안전성, 면역원성 또는 유효성 | 자료는 없다.” | 허가권자는 각 회원국의 국가 관계당국과 협의 하에 | 국가별/의료시스템 별 특이적인 추가적 조치가 요구되 | 는지 여부를 고려할 것이다.  (예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8.  이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다.  해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다.  | 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다.  | 0.5mL을 1회 접종한다.  | 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다. ",
        "original_sentence": "해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 73,
        "word_count": 24,
        "page_number": 2,
        "window_text": "(예:처방의 및 백신접종자 | 에게  9가백신과 4가백신 사이의 구분되는 특성에 관 | 하여 안내) | [추가적조치] 없음 | 4.8.  이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다.  해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다.  | 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다.  | 0.5mL을 1회 접종한다.  | 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다.  | 2. ",
        "original_sentence": "| 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "| 0.5mL을 1회 접종한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 5,
        "window_text": "이상반응: | 63,225명의 피험자가 참여한 | 라틴아메리카와 핀란드에서의 | 대규모 안전성 임상시험에서 | 장중첩증의 위험을 평가하였 | 다.  해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다.  | 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다.  | 0.5mL을 1회 접종한다.  | 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다.  | 2.  소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다. ",
        "original_sentence": "| 0.5mL을 1회 접종한다. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 5,
        "window_text": "해당 시험에서 이 백신 투 | 여군에서의 장중첩증 위험도는 | 위약군과 비교하였을때 증가하 | 지 않았다.  | 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다.  | 0.5mL을 1회 접종한다.  | 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다.  | 2.  소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다.  | 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술. ",
        "original_sentence": "| 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| 2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| 없음 | 계 | 획 |\n| 여부 | 혈소판 감소증 또는 다른 혈액응고 장애가 있는 경우 본 백신은 피하로 | 주사되어야 한다.  | 0.5mL을 1회 접종한다.  | 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다.  | 2.  소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다.  | 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술.  | 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 840,
        "word_count": 245,
        "page_number": 5,
        "window_text": "| 0.5mL을 1회 접종한다.  | 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다.  | 2.  소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다.  | 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술.  | 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다.  | Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출). ",
        "original_sentence": "소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "| 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 109,
        "word_count": 33,
        "page_number": 5,
        "window_text": "| 프리베나13의 후속 투여를 통한 재접종에 대한 필요성은 확립되지 않았다.  | 2.  소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다.  | 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술.  | 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다.  | Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출).  |\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해. ",
        "original_sentence": "| 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "| 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 73,
        "word_count": 21,
        "page_number": 30,
        "window_text": "| 2.  소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다.  | 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술.  | 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다.  | Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출).  |\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해.  | 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다. ",
        "original_sentence": "| 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "| Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 196,
        "word_count": 50,
        "page_number": 46,
        "window_text": "소아 | 폐렴구균(혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 및 | 23F)에 의한 침습성   감염증의 예방 | Ÿ | (질병 또는 치료로 인해) 면역기능이 저하된 대상자 | 임신 결과 | 부족 정보 | 항문 병소 | 및 | 암에 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | 종료 | 2021년 12월(다음 정 | 기 | PBRER(Periodic |\n| 볼거리 바이러스, Jeryl Lynn™ [Level B] strain | (생약독화 백신) | 12.5x103 CCID50 이하 | 됨 | 진 | 행 |\n| 면역기능이 저하 | 된 유아에서  유 | 효성과 안전성 | 면역기능이 | 저하 |\n| □ 1년 이내 한시적 적용 또는 일회성 지시·명령에 해당하는 | 임신 중 9가 HPV 백 | 신에 노출된 여성에서 | 의 임신 결과 모니터 | 링 | Ÿ | 심부전 또는 신부전을 포함하는 급성 또는 만성 질환을 가 | 진 대상자 | - 해당 국가가 전국적인 폐 | 보 | 류 | 중 | 2013년 제4분기 | (요약 및 개요) | □ 예 | ■ 아니오 |\n| 1회 용량(0.5mL)당 CRM197 단백질 약 32μg과 알루미늄 0.125mg 포함 | l 실제 보고된 내용과 예상 | 된 내용 비교분석 | 중요부족정보 | 26세 초과 여성에 | 서의 면역원성 및 | 안전성 | 중 |\n| ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 | 다음의 접종 일정에 따라, 3세 이상의 소아, 청소년, 성인 및 고령자는 1 | 회 0.5 mL을, 2개월 이상 3세 미만의 소아는 1회 0.25 mL을 근육주사한 | 다.  | 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술.  | 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다.  | Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출).  |\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해.  | 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다.  | 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해. ",
        "original_sentence": "| Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출). "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "|\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 149,
        "word_count": 40,
        "page_number": 9,
        "window_text": "| 1) 기초접종: 28일 간격으로 2회 접종 | 2) 추가접종: 2차 접종 후 2년 이내(즉, 12-24개월)에 3차 접종 | HPV 관련 암 | 의 발생 시기 | 의 잠재적 변 | 화 기술.  | 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다.  | Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출).  |\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해.  | 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다.  | 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해.  | 내용입니까? ",
        "original_sentence": "|\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해. "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "| 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 97,
        "word_count": 23,
        "page_number": 9,
        "window_text": "| 일상적인 약물감시 활동 | 특수 환자군에 대한 내용은 | 별도의 정기적인 최신 안전성 | 보고서 항목에서 논의될 것이 | 다.  | Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출).  |\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해.  | 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다.  | 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해.  | 내용입니까?  | 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요). ",
        "original_sentence": "| 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다. "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 9,
        "window_text": "| Menacwy-tt Vaccine (Nimenrix) 또는 Mencevax Acwy | 중 하나를 접종한 건강한 11-17세 대상자에게 10년 후 | Menacwy-tt 백신 추가 접종을 평가하는 연구 | 된 유아에   대한 | 투여 | 계획 | B e n e f i t - R i s k | Evaluation Report)과 | 함께 제출).  |\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해.  | 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다.  | 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해.  | 내용입니까?  | 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요).  열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다. ",
        "original_sentence": "| 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해. "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "| 내용입니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 2,
        "window_text": "|\n| 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종에 의한 과민증 관련 사례의 발현상황, 기초질환 등의 환자배경에 관련된 정보 | 를 사용 성적 조사의 증례도 포함해 폭넓게 수집하기 위해.  | 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다.  | 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해.  | 내용입니까?  | 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요).  열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다.  | 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다. ",
        "original_sentence": "| 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 139,
        "word_count": 34,
        "page_number": 10,
        "window_text": "| 위해성 최소화(완화) 활동의 내용 및 선택이유: | 【내용】 | • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재 | 하고 주의를 환기한다.  | 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해.  | 내용입니까?  | 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요).  열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다.  | 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다.  | Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다. ",
        "original_sentence": "| 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요). "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 10,
        "window_text": "| 【선택이유】 | 의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해.  | 내용입니까?  | 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요).  열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다.  | 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다.  | Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다.  2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다. ",
        "original_sentence": "열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 122,
        "word_count": 34,
        "page_number": 30,
        "window_text": "| 내용입니까?  | 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요).  열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다.  | 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다.  | Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다.  2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다. ",
        "original_sentence": "| 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다. "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 5,
        "window_text": "| 백셀리스(Vaxelis) 투여와 관련된 열성 경련을 포 | 함한 경련에 대한 잠재적인 가능성은 SmPC에 기 | 술되어 있다 (4.4항 특수 경고 및 사용상의 주의 | 사항과 4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요).  열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다.  | 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다.  | Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다.  2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다.  모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다. ",
        "original_sentence": "| Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 5,
        "window_text": "열성 경련을 포함한 경련의 | 병력이 있는 환자는 면밀하게 추적조사를 실시해 | 야 한다.  | 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다.  | Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다.  2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다.  모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다.  (자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다. ",
        "original_sentence": "2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다. "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 186,
        "word_count": 54,
        "page_number": 44,
        "window_text": "| 중요부족정보 | 임신 중 노출 | 계획 | (Pending) |\n| 본 제제를 투여하거나 다루기 이전에 취해야 할 주의 사항과 투여 전 본 | 제품의 구성 성분에 대한 지침에 대해서 sectin 6.6을 참고한다.  | Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다.  2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다.  모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다.  (자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다.  |\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 453,
        "word_count": 120,
        "page_number": 26,
        "window_text": "| Ÿ | 만 9~14세: 0.5ml씩 2회 접종한다.  2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다.  모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다.  (자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다.  |\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다. ",
        "original_sentence": "모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "(자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 120,
        "word_count": 32,
        "page_number": 5,
        "window_text": "2차 접종은 1차 접종 후 5~13개월 | 사이에 투여한다.  | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다.  모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다.  (자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다.  |\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다.  |\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해. ",
        "original_sentence": "(자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "|\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 53,
        "word_count": 17,
        "page_number": 7,
        "window_text": "| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | 렴구균성 질환 감시 체계 | 를 갖추고 있을 때 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 생물학적제제를 주사하기 전에, 투 | 여를 담당하는 사람은 알레르기 | 반응 또는 기타 반응의 예방을 위 | 해 알려진 모든 주의조치를 실시 | 해야 한다.  모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다.  (자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다.  |\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다.  |\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해.  | Table. ",
        "original_sentence": "|\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "| □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 310,
        "word_count": 91,
        "page_number": 2,
        "window_text": "모든 주사형 백신의 경 | 우와 마찬가지로, 백신을 투여한 | 후 아나필락시스 반응이 발생하는 | 경우 적절한 의학적 치료 및 관리 | 가 항상 신속히 이루어질 수 있도 | 록 준비되어야 한다 | 4.8항 [부작용]: | 피부 및 피하조직 이상 | 드물게: 발진 | 계획 | 최종 보고서: | ~1Q 2019 | 없음 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | 풍진 바이러스, Wistar RA 27/3 strain (생약독화 백신) | 1x103 CCID50 이하 | Ÿ | 발작 병력이 있는 대상자 | 임상시험(Zoster–002, 028, 039, | 041) | 없음 | 임상 자료를 추가적으로 통합 | 한 결과가 위해성 관리계획 | 버전 3에 기재되어 있다.  (자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다.  |\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다.  |\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해.  | Table.  | 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련. ",
        "original_sentence": "| □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "|\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 144,
        "word_count": 38,
        "page_number": 3,
        "window_text": "(자 | 료 마감 시점 2018-06-15) | 대한 영향 | 및 유효성 | EU SmPC 4.4항에 다음 내용 기술: | \"Nimenrix는 어떤 경우에도 혈관 | 내, 피내, 피하로 접종하지 않아야 | 합니다.  |\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다.  |\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해.  | Table.  | 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련.  | 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다. ",
        "original_sentence": "|\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "| Table. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 20,
        "window_text": "|\n| 발 | 행 | 일 | 폐렴구균 백신 | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다.  |\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해.  | Table.  | 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련.  | 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다.  | l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다. ",
        "original_sentence": "| Table. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 396,
        "word_count": 109,
        "page_number": 2,
        "window_text": "| □ 예 | ■ 아니오 | MenACWY 접합 백신의 소아 백신 접종 | 5년 후 면역원성 유지 및 추가접종에 대 | 한 면역 반응 | 2018년 11월 | 실시기간: 승인 후 6개월간 | 평가 예정시기: 승인부터 2, 4, | 6개월 후 | 보고 예정시기: 승인부터 8개월 | 이내 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상반응을 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 장기 유효성을 모니터하기 위 | 해 유럽, 캐나다 및 미국의 감 | 시 체계가 사용될 것이다.  |\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해.  | Table.  | 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련.  | 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다.  | l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다.  | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다. ",
        "original_sentence": "| 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련. "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "| 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 74,
        "word_count": 20,
        "page_number": 5,
        "window_text": "|\n| 알기 쉽게 풀어서 설명하거나 특정한 사안에 대하여 식품의약품 | 의약품 안전성 감시활동의 내용 및 선택이유: | 【내용】 | • 일반적인 의약품 안전성 감시활동 | 【선택이유】 | 접종대상 및 접종경로 선택에 관한 과오 상황을 폭넓게 파악하기 위해.  | Table.  | 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련.  | 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다.  | l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다.  | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다.  | 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4. ",
        "original_sentence": "| 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "| l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 120,
        "word_count": 33,
        "page_number": 2,
        "window_text": "| Table.  | 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련.  | 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다.  | l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다.  | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다.  | 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4.  경고 및 주의사항 | 면역이 결핍된 자(예. ",
        "original_sentence": "| l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 342,
        "word_count": 88,
        "page_number": 30,
        "window_text": "| 65 세 이상의 성인을 대상으로 하는 사용 성적 조사의 주요 조사항목 | 평가 | 최종 임상시험 결과보고서 | 2013년 말까지 |\n| 자발보고 | PSUR에 보고된 사례 기술 | Ÿ | 유전적 다형성을 지닌 인구는 연구되거나 제외되지 않았다 | 일반적인 의약품 감시 활동 | 이런 문제의 해결을 돕기 위 | 하여 이상사례를 보고하는 의 | 료진에게 수두 대상포진 바이 | 러스 | 확인프로그램(Varicella | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 신경계 이상 | 발열을 동반하거나 동반하지 않는 | 경련.  | 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다.  | l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다.  | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다.  | 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4.  경고 및 주의사항 | 면역이 결핍된 자(예.  악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다. ",
        "original_sentence": "| 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "| 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 33,
        "word_count": 12,
        "page_number": 44,
        "window_text": "| 없음 |\n| M-M-RVAXPRO는 12개월 이상에서 홍역, 볼거리 그리고 풍진에 대한 동 | 시 예방 접종으로 받을 수 있다.  | l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다.  | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다.  | 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4.  경고 및 주의사항 | 면역이 결핍된 자(예.  악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다.  |\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다. ",
        "original_sentence": "| 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "경고 및 주의사항 | 면역이 결핍된 자(예. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 2,
        "window_text": "| l PASS study (Mexico) 1) |\n| 조사목적 | 주요 조사항목 | Ÿ 생후 6주에서 생후 6개월까지의 영아 | Ÿ | 만 15세 이상:  0, 1, 6 개월 일정으로 0.5ml씩 3회 접종한다.  | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다.  | 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4.  경고 및 주의사항 | 면역이 결핍된 자(예.  악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다.  |\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다.  | 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다. ",
        "original_sentence": "경고 및 주의사항 | 면역이 결핍된 자(예. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 79,
        "word_count": 23,
        "page_number": 44,
        "window_text": "| 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | 건강한 | 여성 | 해당 국가가 시기절적하게 돌 | 발 감염/백신 실패/혈청형 치 | 환 가능성의 조사가 가능할 | 만큼의 최소한의 폐렴구균성 | 질환 발생이 발생할 때 | 핀란드의 14개 센터에서 실시된 두 개의 병행군으로 | 이루어진 무작위, 공개, 대조 3상 연구 |\n| 발 | 행 | 인 | 안전처의 입장을 기술하는 것(식품의약품안전처 지침서등의 관리에 | 혈관 내로 투여하지 않는다.  | 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4.  경고 및 주의사항 | 면역이 결핍된 자(예.  악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다.  |\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다.  | 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다.  | 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다. ",
        "original_sentence": "악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "|\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 169,
        "word_count": 50,
        "page_number": 2,
        "window_text": "| 항문의 전암성 병변 또는 암 | 이 선 희 | 4.4.  경고 및 주의사항 | 면역이 결핍된 자(예.  악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다.  |\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다.  | 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다.  | 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다.  | 용법 | 근육주사(IM) 한다. ",
        "original_sentence": "|\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 136,
        "word_count": 49,
        "page_number": 22,
        "window_text": "경고 및 주의사항 | 면역이 결핍된 자(예.  악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다.  |\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다.  | 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다.  | 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다.  | 용법 | 근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다. ",
        "original_sentence": "| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 13,
        "window_text": "악성 종 | 양환자나 다른 면역 저해 환 | 자, 면역억제요법을 받고 있는 | 자 등)와 접촉하는 경우에는 | 이 백신을 주의하여 투여한다.  |\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다.  | 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다.  | 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다.  | 용법 | 근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다.  | Ÿ | 이 백신은 삼각근 부위에 근육주사 한다. ",
        "original_sentence": "| 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "| 용법 | 근육주사(IM) 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 13,
        "window_text": "|\n| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 및 남성 시험 | 대 상 자 에 서 | HPV-16/18 감 | 염의 | 유병률 | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 발생하는 백신 실패의 모든 | 보고서를 확인할 것이다.  | 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다.  | 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다.  | 용법 | 근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다.  | Ÿ | 이 백신은 삼각근 부위에 근육주사 한다.  | 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다. ",
        "original_sentence": "| 용법 | 근육주사(IM) 한다. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 5,
        "window_text": "| 잠재적 위 | 해성 | 자 가 면 역 | 질환 | 부족정보 | 임신 | 및 | 종료 | 없음 | □ 예 | ■ 아니오 |\n| 용량 | 기초접종: 공식 권장 사항에 따라 2회 접종 또는 3회 접종 (최소 1달 간 | 격) 스케줄로 투여한다.  | 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다.  | 용법 | 근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다.  | Ÿ | 이 백신은 삼각근 부위에 근육주사 한다.  | 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다.  | 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다. ",
        "original_sentence": "권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "| Ÿ | 이 백신은 삼각근 부위에 근육주사 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 29,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후 | 추가접종한다.  | 용법 | 근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다.  | Ÿ | 이 백신은 삼각근 부위에 근육주사 한다.  | 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다.  | 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다.  |\n**정리한 자료입니까?",
        "original_sentence": "| Ÿ | 이 백신은 삼각근 부위에 근육주사 한다. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "| 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 106,
        "word_count": 24,
        "page_number": 5,
        "window_text": "| 용법 | 근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다.  | Ÿ | 이 백신은 삼각근 부위에 근육주사 한다.  | 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다.  | 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다.  |\n**정리한 자료입니까? **\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다. ",
        "original_sentence": "| 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 282,
        "word_count": 75,
        "page_number": 20,
        "window_text": "권장되는 주사부위는 대퇴부 전외측 또는 보다 높은 | 연령의 소아(15개월 이상부터)의 경우 삼각근이다.  | Ÿ | 이 백신은 삼각근 부위에 근육주사 한다.  | 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다.  | 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다.  |\n**정리한 자료입니까? **\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다.  이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다. ",
        "original_sentence": "| 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "|\n**정리한 자료입니까?",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 2,
        "window_text": "| Ÿ | 이 백신은 삼각근 부위에 근육주사 한다.  | 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다.  | 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다.  |\n**정리한 자료입니까? **\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다.  이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다.  | Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득. ",
        "original_sentence": "|\n**정리한 자료입니까?"
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "**\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 222,
        "word_count": 64,
        "page_number": 3,
        "window_text": "| 임상시험(Zoster–069) | 없음 | study 10PN-PD-DIT- 015의 | 최종 결과가 위해성 관리 계 | 획 버전 3 1.2.2.2.1항과 별첨 | 7에 기재되어 있다.  | 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다.  |\n**정리한 자료입니까? **\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다.  이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다.  | Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득.  | 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다. ",
        "original_sentence": "**\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 93,
        "word_count": 25,
        "page_number": 30,
        "window_text": "| 접종대상자 배경(성별, 연령, 병력 등) | 본 제제 접종 이전의 폐렴구균백신 접종이력, 기타 | 다른 백신 접종이력 | 본 제제의 접종기록(접종량, 접종부위, 접종경로, 로 | 트 번호) | 동시 접종백신(동시 접종백신명, 접종부위), 본 제제 | 접종 후의 다른     백신 접종상황 |\n| - 특정 인유두종바이러스 유형에 의한 생식기 사마귀(첨형콘딜로마) | 해당사항 없 | 음 | plunger 및 바늘 덮개의 색 | 상 및 carton 포장과 라벨에 | 서 차이를 가지도록 할 것이 | 다.  |\n**정리한 자료입니까? **\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다.  이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다.  | Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득.  | 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다.  | 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "| Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 157,
        "word_count": 40,
        "page_number": 5,
        "window_text": "|\n**정리한 자료입니까? **\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다.  이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다.  | Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득.  | 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다.  | 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다.  | Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험. ",
        "original_sentence": "| Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "| 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 226,
        "word_count": 58,
        "page_number": 36,
        "window_text": "**\n| 편 집 위 원 장 | 관한 규정 제2조) | 김 대 철 | MenACWY-TT 또는 Meningitec을 접종했던 아이에게 4 | 년 후 같은 백신으로 추가 접종 후 2, 3, 4, 5, 6 년에 | 장기 항체 지속성을 평가하는 연구 | EU SmPC 4.4항에 다음 내용 기술: | Nimenrix를 혈소판 감소증 또는 | 응고 장애가 있는 사람에게 투여 | 시 주의를 기울여야합니다.  이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다.  | Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득.  | 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다.  | 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다.  | Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험.  | 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1. ",
        "original_sentence": "| 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "| 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 33,
        "word_count": 7,
        "page_number": 2,
        "window_text": "이러한 | 환자에게 IM 투여 후 출혈이 발생 | 할 수 있기 때문입니다 |\n| M-M-RVAXPRO는 특정한 상황에서는 9개월 이하의 유아에게 투여될 수 | 있다.  | Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득.  | 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다.  | 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다.  | Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험.  | 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1.  Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
        "original_sentence": "| 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "| Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 120,
        "word_count": 34,
        "page_number": 25,
        "window_text": "| Ÿ | 최초 접종 시 만 9세~14세에서 | 2014년 6월 20일에 고연령층에 대한 ‘폐렴구균(혈청형 1, 3, 4, 5, 6A, | 6B, 7F, 9V, 14, 18C, 19A, 19F 및 23F)에 의한 감염증의 예방’의 효 | 능·효과로 승인사항 일부변경 승인을 취득.  | 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다.  | 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다.  | Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험.  | 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1.  Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다. ",
        "original_sentence": "| Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험. "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "| 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 96,
        "word_count": 30,
        "page_number": 30,
        "window_text": "| 일반적인 의약품 감시 활동 | 바리박스주(VARIVAX)의 임부 | 레지스트리(registry) | 연구에 | Shingrix의 반응원성 | 이 삶의 질에 미치는 | 영향을 평가 | Ÿ | 수동적 보고와 US 시판 후 안전성조사 연구 | 50세 이상의 취 | 약한 성인에서의 | Shingrix 접종 |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침·안내서 등록 대상이 아닙니다.  | 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다.  | Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험.  | 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1.  Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다.  | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. ",
        "original_sentence": "| 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 153,
        "word_count": 41,
        "page_number": 5,
        "window_text": "| 지침·안내서 제·개정 절차를 적용하실 필요는 없습니다.  | Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험.  | 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1.  Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다.  | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항). ",
        "original_sentence": "Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 170,
        "word_count": 42,
        "page_number": 2,
        "window_text": "| Ÿ 생후 6주에서 만5세까지의 영아 및 어린이 | HIV 양성 어린이, 조숙아 및 | 이전에 12가 폐렴구균 백신을 | 접종한 겸형 적혈구증을 가진 | 어린이에서의 안전성 및 면역 | 원성에 대한  임상 시험.  | 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1.  Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다.  | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항).  | 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다. ",
        "original_sentence": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "| - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 13,
        "window_text": "| 진 | 행 |\n| 자발보고 | Targeted | Follow-up | 2상, 3상 연구의 연장 연구 | 로 항체 지속성 및 추가 접 | 종 필요성 평가 | (참고1.  Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다.  | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항).  | 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다.  | 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다. ",
        "original_sentence": "| - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "| Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 664,
        "word_count": 176,
        "page_number": 5,
        "window_text": "Study list) | 프리베나13의 안전성 프로파 | 일을 모니터하기 위한 시판후 | 안전성 관찰 연구와 일상적인 | 약물감시 활동 | COMPAS 임상시험의 추가 접 | 종 기간 동안 경련(열성 및 | 비열성)을 수집 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다.  | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항).  | 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다.  | 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다.  | 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다. ",
        "original_sentence": "| Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항). "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "| 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 232,
        "word_count": 55,
        "page_number": 5,
        "window_text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 생후 6주 이상의 영유아에서 디프테리아, 파상풍, 백일해, B형 간염, 폴리 | 오(소아마비) 및 b형 헤모필루스 인플루엔자(Hib)에 의해 발생되는 침습성 | 질환의 예방 | - 가다실9는 2회 접종할 수 있다.  | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항).  | 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다.  | 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다.  | 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다.  | 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다. ",
        "original_sentence": "| 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "| 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 186,
        "word_count": 49,
        "page_number": 43,
        "window_text": "| - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항).  | 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다.  | 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다.  | 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다.  | 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다.  그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다. ",
        "original_sentence": "| 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다. "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "| 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 276,
        "word_count": 64,
        "page_number": 5,
        "window_text": "| Ÿ | 최초 접종 시 만 15세 이상 연령에서 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 | Zoster | Virus | Identification | 잠재적 면역매개질환 | (pIMD)을 갖고 있는 | 성인에서의 Shingrix | 의 안전성, 반응원성 | 과 면역원성 평가 | 잠재적 면역매개 | 질환(pIMD)를 갖 | 고 있는 성인에 | 서의 Shingrix 접 | 종 | 연구 시 | 작 | 최종 임상시험 결과 | 보고 (2016년 6월) |\n| Ÿ | ESPED와 collaboration을 통한 독일에서의 장중첩 | 증 역학 조사 | 중 |\n| 편 | 집 | 위 | 원 | 사용실태의 파악 | (바이오생약심사부 생물제제과) | 자발보고 | PSUR에 보고된 사례 기술 | SmPC 4.8항 [부작용]: | 신경계 이상 | 매우 드물게: 저긴장성 반응 또는 | 저긴장성-저반응성 에피소드 | 바이알/PFS에서 바이알/바이 | 알로 포장 변경 및 첨부문서 | 변경 |\n| 백셀리스(Vaxelis) 투여와 관련된 저긴장성-저반응 | 성 에피소드의 잠재적 가능성은 SmPC에 기술되 | 어 있다 (4.8항/c 바람직하지 못한 효과/기재된 이 | 상약물반응의 개요) (4.4항 특수 경고 및 사용상 | 의 주의사항).  | 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다.  | 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다.  | 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다.  | 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다.  그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다.  | ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다. ",
        "original_sentence": "| 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "| 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 13,
        "window_text": "| 비교관찰연구(EPI-Zoster-031) | 없음 | Zoster | Virus | Identification | Programme)에 종합효소 연쇄 | 반응(Poly | merase | chain |\n| 홍역 발병 또는 사후 노출 후 백신 접종 또는 취약한 임신부 그리고 볼거 | 리와 풍진에 대해 취약할 것으로 예상되는 사람과 접촉한 이전에 백신을 | 투여 받지 않은9개월 이상의 사람에게 사용될 수 있다.  | 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다.  | 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다.  | 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다.  그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다.  | ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다.  | 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다. ",
        "original_sentence": "| 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 310,
        "word_count": 78,
        "page_number": 33,
        "window_text": "| 바이알/PFS에서 | 바이알/바이알로 | 감소 측면에서 | 두 가지 백신 | 접종 | 전략의 | (Adverse | Event | of | 없음 | 계 | 획 |\n| *일본 국내에서 실시된 2개의 임상시험에서 13vPnC와의 인과관계를 배제할 수 없 | 는 이상반응(이상약물반응) 중 빈도가 낮은 사례와 발현빈도는 다음과 같다.  | 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다.  | 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다.  그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다.  | ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다.  | 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다.  | chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "| ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 324,
        "word_count": 69,
        "page_number": 51,
        "window_text": "| 6096A1-3003 시험: 주사부위 자극감, 주사부위 열감, 간장애, 기관지염, 감염성 크 | 루프, 돌발성 발진, 천식, 알레르기성 피부염, 과다각화 및 지루성 피부염 각 1건 | (0.52%) | 6096A1-3024 시험: 주사부위 경결 1건(0.55%) | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | SmPC (4.4항 특수 경고 및 사용상의 주의사항)에 | 는 백신의 면역원성이 면역억제치료 또는 면역결 | 핍상태에 의해 감소될 수 있다고 기술되어 있다.  | 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다.  그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다.  | ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다.  | 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다.  | chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다. ",
        "original_sentence": "| ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "| 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 34,
        "word_count": 10,
        "page_number": 13,
        "window_text": "| 그러한 치료가 종료되거나 질병이 치유될 때까지 | 예방접종을 연기하도록 권장된다.  그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다.  | ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다.  | 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다.  | chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다.  | 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4. ",
        "original_sentence": "| 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "| chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 36,
        "window_text": "그럼에도 불구 | 하고, HIV 감염 등 만성 면역결핍이 있는 환자에 | 대한 예방접종은 항체반응이 제한적일 수 있기는 | 하지만 권장된다 | Questionnaire | PSUR에 보고된 사례 기술 | 수막구균 백신 GSK134612를 건강한 어린이에게 1차 | 접종 후 항체 지속성과 1차 접종 후 68개월에 추가 | 접종시 안전성과 면역원성 연구 | □ 예(☞지침서) | ■ 아니오 |\n| 포장 변경 및 첨부문서 변경 | Special Interest, AESI)로 | 규명된 사례 | Programme)에 시료 샘플을 | 제출할 기회를 제공한다.  | ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다.  | 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다.  | chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다.  | 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4.  경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다. ",
        "original_sentence": "| chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "(공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 97,
        "word_count": 27,
        "page_number": 8,
        "window_text": "| ZOSTAVAX를 포함한 모든 | VZV 백신을 포함하도록 확장 | 할 예정 |\n| 백선영, 임재현, 진미령, 김도근, 지승완, 임종미, | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | EU내에서 능동적 감시 (PSUR) | (Active surveillance in EU (PSUR)) | 실제 보고된 내용과 예상된 내용 | 비교분석 | Study 10PN-PD-DIT-016 BST: | 015 | SmPC 4.2: 56~65세 사람들에 | 대한 자료는 충분하지 않다.  | 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다.  | chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다.  | 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4.  경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다.  |\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4. ",
        "original_sentence": "(공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "| 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 114,
        "word_count": 29,
        "page_number": 24,
        "window_text": "| 65세 이상 고령자에 대한 자 | 료는 존재하지 않는다.  | chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다.  | 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4.  경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다.  |\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4.  경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다. ",
        "original_sentence": "| 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 50,
        "word_count": 13,
        "page_number": 2,
        "window_text": "| chain reaction, PCR) 분석 | 됨 |\n| 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다.  | 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4.  경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다.  |\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4.  경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다.  새롭게 개정된 라 | 벨과 패키지가 이용 가능하다. ",
        "original_sentence": "경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "|\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 239,
        "word_count": 56,
        "page_number": 49,
        "window_text": "(공무원용) | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | reaction, PCR) 분석을 한 뇌 | 척수액을 포함하여 시료 샘플 | 을 제출할 기회를 제공한다.  | 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4.  경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다.  |\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4.  경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다.  새롭게 개정된 라 | 벨과 패키지가 이용 가능하다.  |\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
        "original_sentence": "|\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4. "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 39,
        "word_count": 12,
        "page_number": 2,
        "window_text": "| 미국에서 50세 이상 | 의 | 성인에서의 | 유럽에서의 로타바이러스 감시: 연속적인 로타바이러 | 스 seasons에 유행하는 다양한 로타바이러스 혈청형 | 을 확인하는 것 | SPC: | 4.4.  경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다.  |\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4.  경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다.  새롭게 개정된 라 | 벨과 패키지가 이용 가능하다.  |\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다. ",
        "original_sentence": "경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "새롭게 개정된 라 | 벨과 패키지가 이용 가능하다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 13,
        "window_text": "경고 및 주의사항: 모든 | 백신접종자에서 방어면역반응 | 이 나타나지 않을 수도 있다.  |\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4.  경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다.  새롭게 개정된 라 | 벨과 패키지가 이용 가능하다.  |\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다.  | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
        "original_sentence": "새롭게 개정된 라 | 벨과 패키지가 이용 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "|\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 151,
        "word_count": 42,
        "page_number": 30,
        "window_text": "|\n| HSA(human serum albumin) 및 rHA(recombinant human albumin) | 의 교체와 관련된 M-M-RTMII의 안전성 프로파일에서의 잠재적 변 | 화 | 없음 |\n| Ÿ 생후 6주에서 생후 6개월 사이의 영아 | PSUR을 통한 검토: | label and packaging 변경에 | 따른 영향을 평가하기 위해, | 투약오류사례의 | 보고빈도를 | 임신 결과 | SPC: | 4.4.  경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다.  새롭게 개정된 라 | 벨과 패키지가 이용 가능하다.  |\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다.  | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까? ",
        "original_sentence": "|\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음. "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 374,
        "word_count": 100,
        "page_number": 2,
        "window_text": "경고 및 주의사항: | 이 백신은 절대로 주사하여서 | 는 안 된다.  새롭게 개정된 라 | 벨과 패키지가 이용 가능하다.  |\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다.  | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까?  (민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다. ",
        "original_sentence": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다. "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 230,
        "word_count": 62,
        "page_number": 8,
        "window_text": "새롭게 개정된 라 | 벨과 패키지가 이용 가능하다.  |\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다.  | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까?  (민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다.  |\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다. ",
        "original_sentence": "| 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 134,
        "word_count": 37,
        "page_number": 2,
        "window_text": "|\n| 자발보고 | Targeted | Follow-up | 정기적인 최신 안전성 보고서 | 을 통한 열성 경련 발생 사례 | 의 모니터링 | Shingrix 접종 후 | 잠재적 면역매개 | 질환(pIMD)의 위 | 험 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다.  | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까?  (민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다.  |\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다.  | 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "(민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 218,
        "word_count": 59,
        "page_number": 5,
        "window_text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 없음 |\n| □ 법령, 고시‧훈령‧예규와 같은 규정 또는 식약처장이 정한 특정한 | 오상연, 이연희, 배창준, 김병철, 김현국, 이유림, 이가영 | 유효성 | 소아 및 고연령층의 시판 직후 | 조사기간 | 고연령층의 추가 승인 시 | 안전성 정기보고의 시기 |\n| 구분 | 전환점이 되는 증례 | 수/목표증례수 | 국소반응 및 전신반응 | 그 밖의 이상반응 | 중점조사항목: 없음 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 | ■ 예(☞안내서) | □ 아니오 |\n| 이상반응 | 발현상황의 | M-M-RVAXPRO는 공식적인 권고사항에 기반해 사용된다.  | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까?  (민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다.  |\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다.  | 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까?  | 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다. ",
        "original_sentence": "(민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "|\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 40,
        "word_count": 13,
        "page_number": 11,
        "window_text": "| 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | 추가로 12~23개월에 1~2회 | 추가 접종시 즉각적인 항체 | 역가와 장기간의 항체역가 | 를 평가하는 연구 시작 | Shingrix의 안전성을 | 평가하기 위한 비중 | 재(관찰적), | 전향적 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까?  (민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다.  |\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다.  | 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까?  | 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다.  그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
        "original_sentence": "|\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다. "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "| 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 357,
        "word_count": 105,
        "page_number": 8,
        "window_text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | SPC 4.8, 5.1에 기재 | 계 | 획 |\n| 사안에 대하여 그 절차 등의 내용을 알기 쉽게 풀어 설명하거나 | 식약처의 입장을 기술하는 것입니까?  (민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다.  |\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다.  | 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까?  | 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다.  그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n",
        "original_sentence": "| 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 13,
        "window_text": "(민원인용) | 소아: 8년 | 고연령층: 1차 승인 | 에 관계된 재심사기 | 간의 잔여기간 | 없음 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Questionnaire | PSUR에 보고된 사례 기술 | 자발보고 | PSUR에 보고된 사례 기술 | 조산아/저체중아 및 만삭 아 | 기의 시판후 사례는 정기적인 | 최신 안전성 보고서에서 논의 | 될 것이다.  |\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다.  | 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까?  | 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다.  그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n",
        "original_sentence": "| 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 2,
        "window_text": "|\n| 파악 | 용량 | 무호흡은 SmPC 다음 항에 기술되 | 었다.  | 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까?  | 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다.  그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n",
        "original_sentence": "그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 83,
        "word_count": 18,
        "page_number": 2,
        "window_text": "| 해당 없음 | SPC 4.4 에 경고 | 됨 |\n| 일반 약물감시 | 지속성 | 자료에 | 대한 | Study |\n| 승인번호 | 22500AMX00917000 |\n| 유럽 로타바이러스 조사 네 | 트워크 | 없음 | 진행 | 상태 | 제출날짜 |\n| 도 움 주 신  분 | □ 상위 법령을 일탈하여 새로운 규제를 신설·강화하거나 | 12개월 또는 이상 | ㈜글락소스미스클라인, ㈜녹십자, ㈜보령바이오파마, | PASS study (Mexico) 1) | 해당 없음 | □ 예 | ■ 아니오 |\n| 코호트 연구 | 수동적 보고와 US 시판 후 안전성조사 연구 | 없음 | 없음 |\n| 기타 확인 | 민원인을 구속하는 내용이 있습니까?  | 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다.  그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n",
        "original_sentence": "지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "상기 사항에 대하여 확인하였음.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 2,
        "window_text": "| 계획 |\n\n**[표 끝]**\n\n고려하시기 바랍니다.  그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ. ",
        "original_sentence": "상기 사항에 대하여 확인하였음.\n\n"
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 142,
        "word_count": 30,
        "page_number": 3,
        "window_text": "그럼에도 불구하고 동 지침·안내서의 제정이 필요한\n\n경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ.  서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ. ",
        "original_sentence": "2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 176,
        "word_count": 34,
        "page_number": 3,
        "window_text": "지침·안내서\n\n사항\n\n☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침·\n\n안내서 제·개정 절차를 진행하시기 바랍니다.\n\n 상기 사항에 대하여 확인하였음.\n\n 2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ.  서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ.  백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "<!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 137,
        "word_count": 25,
        "page_number": 3,
        "window_text": "상기 사항에 대하여 확인하였음.\n\n 2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ.  서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ.  백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1.  일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 131,
        "word_count": 9,
        "page_number": 4,
        "window_text": "2018  년  11  월     일\n\n담당자\n\n확  인(부서장)\n\n백 선 영\n\n<!-- PAGE_3 -->\n###### 이 안내서는 해외규제기관의 백신 위해성 관리 계획의 사례를 공유\n\n<!-- PAGE_3 -->\n###### 하고자 작성하였습니다.\n\n <!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ.  서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ.  백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1.  일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1.  폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2. ",
        "original_sentence": "서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 92,
        "word_count": 12,
        "page_number": 4,
        "window_text": "<!-- PAGE_3 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의\n\n<!-- PAGE_3 -->\n###### ※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원 바이오생약심사부\n\n<!-- PAGE_3 -->\n###### 생물제제과로 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ.  서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ.  백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1.  일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1.  폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2.  유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1. ",
        "original_sentence": "백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 135,
        "word_count": 8,
        "page_number": 4,
        "window_text": "<!-- PAGE_3 -->\n###### 전화번호 : 043-719-3452\n\n<!-- PAGE_3 -->\n###### 팩스번호 : 043-719-3450\n\n<!-- PAGE_4 -->\n# 목  차\n\n<!-- PAGE_4 -->\n##### Ⅰ.  서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ.  백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1.  일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1.  폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2.  유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1.  디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2. ",
        "original_sentence": "일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 100,
        "word_count": 9,
        "page_number": 4,
        "window_text": "서 론 ································································································   1\n\n<!-- PAGE_4 -->\n##### Ⅱ.  백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1.  일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1.  폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2.  유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1.  디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2.  폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3. ",
        "original_sentence": "폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 128,
        "word_count": 8,
        "page_number": 4,
        "window_text": "백신별 위해성 관리계획 공개 현황 ··········································   2\n\n<!-- PAGE_4 -->\n##### 1.  일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1.  폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2.  유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1.  디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2.  폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3.  수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4. ",
        "original_sentence": "유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1. "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 75,
        "word_count": 10,
        "page_number": 4,
        "window_text": "일본 ····································································································· 3\n\n<!-- PAGE_4 -->\n##### 1.1.  폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2.  유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1.  디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2.  폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3.  수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4.  수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5. ",
        "original_sentence": "디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 115,
        "word_count": 9,
        "page_number": 4,
        "window_text": "폐렴구균 백신(프리베나13주) ·····················································  3\n\n<!-- PAGE_4 -->\n##### 2.  유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1.  디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2.  폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3.  수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4.  수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5.  일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6. ",
        "original_sentence": "폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 115,
        "word_count": 9,
        "page_number": 4,
        "window_text": "유럽연합 ··························································································· 19\n\n<!-- PAGE_4 -->\n##### 1.1.  디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2.  폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3.  수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4.  수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5.  일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6.  로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7. ",
        "original_sentence": "수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4. "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 109,
        "word_count": 9,
        "page_number": 4,
        "window_text": "디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 ·············   20\n\n<!-- PAGE_4 -->\n##### 1.2.  폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3.  수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4.  수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5.  일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6.  로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7.  홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8. ",
        "original_sentence": "수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 115,
        "word_count": 9,
        "page_number": 4,
        "window_text": "폐렴구균 백신 ··········································································  29\n\n<!-- PAGE_4 -->\n##### 1.3.  수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4.  수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5.  일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6.  로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7.  홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8.  인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ. ",
        "original_sentence": "일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 109,
        "word_count": 9,
        "page_number": 4,
        "window_text": "수막구균 백신 ··········································································  38\n\n<!-- PAGE_4 -->\n##### 1.4.  수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5.  일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6.  로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7.  홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8.  인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ.  서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n",
        "original_sentence": "로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 76,
        "word_count": 11,
        "page_number": 4,
        "window_text": "수두바이러스 백신 ··································································  46\n\n<!-- PAGE_4 -->\n##### 1.5.  일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6.  로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7.  홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8.  인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ.  서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n <!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n",
        "original_sentence": "홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 251,
        "word_count": 39,
        "page_number": 5,
        "window_text": "일본뇌염 백신 ··········································································  56\n\n<!-- PAGE_4 -->\n##### 1.6.  로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7.  홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8.  인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ.  서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n <!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n <!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다. ",
        "original_sentence": "인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 311,
        "word_count": 65,
        "page_number": 6,
        "window_text": "로타바이러스 백신 ··································································  59\n\n<!-- PAGE_4 -->\n##### 1.7.  홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8.  인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ.  서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n <!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n <!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다.  일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n",
        "original_sentence": "서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "<!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 319,
        "word_count": 69,
        "page_number": 6,
        "window_text": "홍역·유행성이하선염 및 풍진(MMR) 혼합백신 ·················  64\n\n<!-- PAGE_4 -->\n##### 1.8.  인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ.  서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n <!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n <!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다.  일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n <!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n",
        "original_sentence": "<!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "<!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 187,
        "word_count": 40,
        "page_number": 6,
        "window_text": "인유두종바이러스 백신 ··························································  67\n\n<!-- PAGE_5 -->\n## 제․개정 이력\n\n<!-- PAGE_5 -->\n###### 연번\n\n<!-- PAGE_5 -->\n###### 제·개정번호\n\n<!-- PAGE_5 -->\n###### 승인일자\n\n<!-- PAGE_5 -->\n###### 주요내용\n\n- - 1 -\n<!-- PAGE_6 -->\n### Ⅰ.  서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n <!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n <!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다.  일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n <!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n - - 2 -\n<!-- PAGE_7 -->\n### Ⅱ. ",
        "original_sentence": "<!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 227,
        "word_count": 41,
        "page_number": 6,
        "window_text": "서론\n\n<!-- PAGE_6 -->\n###### 신약, 희귀의약품 등의 경우 2015년 7월 이후부터 품목허가 신청 시 시판 후\n\n<!-- PAGE_6 -->\n###### 해당 의약품의 부작용 및 위해 요인을 최소화하기 위하여 위해성 관리 계획을\n\n<!-- PAGE_6 -->\n###### 제출·이행하도록 하였으며, 2017년 7월 이후부터는 「의약품 등의 안전에 관한\n\n<!-- PAGE_6 -->\n###### 규칙」제22조에 따른 재심사대상 의약품도 적용됨에 따라 위해성 관리 계획\n\n<!-- PAGE_6 -->\n###### 제출 대상이 확대되었다.\n\n <!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n <!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다.  일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n <!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n - - 2 -\n<!-- PAGE_7 -->\n### Ⅱ.  국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1. ",
        "original_sentence": "일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "<!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 293,
        "word_count": 64,
        "page_number": 6,
        "window_text": "<!-- PAGE_6 -->\n###### 위해성 관리 계획의 목적은 의약품 품목허가시 또는 시판 후 안전성\n\n<!-- PAGE_6 -->\n###### 중점검토를 위해 해당 품목의 ‘중요한 규명된 위해성, 중요한 잠재적 위해성 및\n\n<!-- PAGE_6 -->\n###### 중요한 부족 정보’를 확인하고 시판 후 부작용 조사를 위한 의약품 감시방법 및\n\n<!-- PAGE_6 -->\n###### 위해성 완화를 위해 첨부문서, 환자용 사용설명서 및 전문가용 설명자료 등을\n\n<!-- PAGE_6 -->\n###### 마련함으로써 의약품의 안전사용을 강화하고자 하는 것이다.\n\n <!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다.  일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n <!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n - - 2 -\n<!-- PAGE_7 -->\n### Ⅱ.  국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1.  일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n",
        "original_sentence": "<!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "- - 2 -\n<!-- PAGE_7 -->\n### Ⅱ. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 7,
        "window_text": "<!-- PAGE_6 -->\n###### 특히, 백신의 경우 허가 후 장기 안전성 및 유효성 검증 체계를 마련하고자\n\n<!-- PAGE_6 -->\n###### 추가적 검토가 필요한 중요 안전성·유효성 검토항목에 대한 조치계획으로서\n\n<!-- PAGE_6 -->\n###### 유용성 평가 또는 장기면역원성 계획을 제출하도록 하고 있다.  일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n <!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n - - 2 -\n<!-- PAGE_7 -->\n### Ⅱ.  국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1.  일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n <!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n",
        "original_sentence": "- - 2 -\n<!-- PAGE_7 -->\n### Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 7,
        "window_text": "일부 백신에\n\n<!-- PAGE_6 -->\n###### 있어서 유효성(efficacy)\n\n<!-- PAGE_6 -->\n###### 임상시험을 수행할 수 없거나 장기적인 면역원성이\n\n<!-- PAGE_6 -->\n###### 필요한 백신에 대해서는 유용성(effectiveness) 평가나 장기 면역원성 시험계획을\n\n<!-- PAGE_6 -->\n###### 제출하고 그 수행한 결과를 보고하도록 하고 있다.\n\n <!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n - - 2 -\n<!-- PAGE_7 -->\n### Ⅱ.  국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1.  일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n <!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n <!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n",
        "original_sentence": "국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 172,
        "word_count": 30,
        "page_number": 7,
        "window_text": "<!-- PAGE_6 -->\n###### 본 사례집은 국내보다 먼저 위해성 관리 계획을 도입한 일본, 유럽연합의\n\n<!-- PAGE_6 -->\n###### 해외 규제기관에서 공개한 백신의 제품별 위해성 관리 계획 사례를 기반으로\n\n<!-- PAGE_6 -->\n###### 국내 백신 개발자가 추가적 검토가 필요한 중요 안전성 검토항목, 유용성 평가\n\n<!-- PAGE_6 -->\n###### 및 장기 면역원성시험 등 위해성 관리 계획서 작성시 참고할 수 있도록\n\n<!-- PAGE_6 -->\n###### 마련하게 되었다.\n\n - - 2 -\n<!-- PAGE_7 -->\n### Ⅱ.  국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1.  일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n <!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n <!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n <!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n",
        "original_sentence": "일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n"
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "<!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 135,
        "word_count": 29,
        "page_number": 7,
        "window_text": "- - 2 -\n<!-- PAGE_7 -->\n### Ⅱ.  국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1.  일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n <!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n <!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n <!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n 용법 및 용량\n\n- 1. ",
        "original_sentence": "<!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "<!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 244,
        "word_count": 49,
        "page_number": 7,
        "window_text": "국가별 위해성 관리 계획 공개 현황\n\n<!-- PAGE_7 -->\n#### 1.  일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n <!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n <!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n <!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n 용법 및 용량\n\n- 1.  고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n",
        "original_sentence": "<!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "<!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 329,
        "word_count": 57,
        "page_number": 7,
        "window_text": "일본\n\n<!-- PAGE_7 -->\n###### 일본의 경우,\n\n<!-- PAGE_7 -->\n###### 2013년 위해성 관리 계획이 도입된 이래로 백신 중 유일하게\n\n<!-- PAGE_7 -->\n###### 프리베나13주(폐렴구균백신)의 위해성 관리 계획이 공개되어 있다(www.pmda.go.jp).\n\n <!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n <!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n <!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n 용법 및 용량\n\n- 1.  고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n 효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1. ",
        "original_sentence": "<!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n"
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "용법 및 용량\n\n- 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 14,
        "word_count": 5,
        "page_number": 5,
        "window_text": "<!-- PAGE_7 -->\n###### 안전성 감시활동에 따라 실시하는 소아 및 고령자 대상 사용성적조사는 목적,\n\n<!-- PAGE_7 -->\n###### 증례수, 실시방법, 관찰기간, 실시계획의 근거 등 상세 내용을 확인할 수 있다.\n\n <!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n <!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n 용법 및 용량\n\n- 1.  고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n 효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1.  추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n",
        "original_sentence": "용법 및 용량\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 5,
        "window_text": "<!-- PAGE_7 -->\n###### 또한,\n\n<!-- PAGE_7 -->\n###### 아나필락시스 등을 중요 안전성 검토항목으로 지정한 사유,\n\n<!-- PAGE_7 -->\n###### 위해성을\n\n<!-- PAGE_7 -->\n###### 완화하기 위해 실시하고자 하는 조치 계획, 선택사유 등이 구체적으로 공개되어\n\n<!-- PAGE_7 -->\n###### 있어 위해성 관리 계획서 작성시 유용한 참고자료가 될 것으로 기대한다.\n\n <!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n 용법 및 용량\n\n- 1.  고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n 효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1.  추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n - 2. ",
        "original_sentence": "고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 70,
        "word_count": 17,
        "page_number": 5,
        "window_text": "<!-- PAGE_7 -->\n#### <프리베나13주>\n\n<!-- PAGE_7 -->\n###### □ 품목개요\n\n승인연월일\n\n2013년 6월 18일\n\n약효분류\n\n876311\n\n재심사기간\n\n국제발매일\n\n2009년 7월 10일\n\n판매명\n\n프리베나13®수성현탁주\n\n유효성분\n\n폐렴구균협막 폴리사카라이드-CRM197결합체\n\n함량 및 제형\n\n1 시린지   중에\n\n폴리사카라이드혈청형1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F:\n\n각 2.2µg\n\n폴리사카라이드혈청형6B: 4.4µg\n\n- - 3 -\nCRM197:약 34µg(단백질량으로)을 함유하는 주사제.\n\n 용법 및 용량\n\n- 1.  고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n 효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1.  추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n - 2.  1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n",
        "original_sentence": "효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 67,
        "word_count": 13,
        "page_number": 8,
        "window_text": "용법 및 용량\n\n- 1.  고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n 효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1.  추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n - 2.  1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n 변경이유:\n\n- 1. ",
        "original_sentence": "추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "- 2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 70,
        "window_text": "고연령층\n1회 0.5mL를 근육 내에 주사한다.\n\n 효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1.  추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n - 2.  1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n 변경이유:\n\n- 1.  사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 86,
        "word_count": 19,
        "page_number": 2,
        "window_text": "효능 또는 효과\n\n승인조건\n\n없음\n\n비고\n\n변경 내역\n\n전회 제출일:\n\n2015년 9월 20일\n\n변경내용의 개요:\n\n- 1.  추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n - 2.  1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n 변경이유:\n\n- 1.  사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n - 2. ",
        "original_sentence": "1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n"
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "변경이유:\n\n- 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 5,
        "window_text": "추가 의약품 안전성 감시활동으로 계획된 사용 성적 조사(고연령층(65세 이상의 성인))에\n관해서 실시상황을 갱신했다.\n\n - 2.  1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n 변경이유:\n\n- 1.  사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n - 2.  설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n",
        "original_sentence": "변경이유:\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 44,
        "word_count": 8,
        "page_number": 8,
        "window_text": "- 2.  1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n 변경이유:\n\n- 1.  사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n - 2.  설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n - - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n",
        "original_sentence": "사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n"
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "- 2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 70,
        "window_text": "1.1 안전성 검토사항의 중요한 부족 정보로 설정한 ‘13vPnC를 복수회 접종한 고연령층\n(65세 이상의 성인)에 대한 안전성’의 설정 이유의 변경.\n\n 변경이유:\n\n- 1.  사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n - 2.  설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n - - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
        "original_sentence": "- 2. "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 8,
        "window_text": "변경이유:\n\n- 1.  사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n - 2.  설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n - - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n",
        "original_sentence": "설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n"
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "- - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 267,
        "word_count": 58,
        "page_number": 9,
        "window_text": "사용 성적 조사(고연령층(65세 이상의 성인))의 실시상황이 변경되었기 때문.\n - 2.  설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n - - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n 주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n",
        "original_sentence": "- - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n"
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 111,
        "word_count": 25,
        "page_number": 9,
        "window_text": "- 2.  설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n - - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n 주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n 한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 9,
        "window_text": "설정 이유에 기재한 일본 외 국가 임상시험의 실시상황이 변경되었기 때문.\n - - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n 주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n 한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n 일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다. ",
        "original_sentence": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 180,
        "word_count": 34,
        "page_number": 9,
        "window_text": "- - 4 -\n<!-- PAGE_9 -->\n###### □ 의약품 위해성 관리계획의 개요\n\n<!-- PAGE_9 -->\n###### - 안전성 검토사항\n\n중요한 특정 위해성\n\n쇼크, 아나필락시스\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두, 일본 국내 임상시험에서 쇼크, 아나필락시스의 보고는 없으\n\n나, 일본 국내외에서 본 제제(이하, 13vPnC)의 시판 후 자발보고가 있었기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n 주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n 한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n 일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다.  피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n",
        "original_sentence": "주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n"
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 172,
        "word_count": 30,
        "page_number": 5,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n 주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n 한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n 일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다.  피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n 또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n",
        "original_sentence": "한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n"
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 88,
        "word_count": 20,
        "page_number": 5,
        "window_text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉구하기 위해.\n\n 주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n 한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n 일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다.  피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n 또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 59,
        "word_count": 12,
        "page_number": 9,
        "window_text": "주사부위   국소반응\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n외국인 영유아 15시험의 병합 데이터(근육 내 접종)에서 각회 접종 후의 13vPnC 접\n\n종부위에 대한 국소반응의 발현비율은 발적 25.1%~40.2%, 종창 21.8%~30.6%, 압통\n\n- 39.0%~46.5%였다.\n 한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n 일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다.  피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n 또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n - - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n",
        "original_sentence": "피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 71,
        "word_count": 17,
        "page_number": 9,
        "window_text": "한편, 일본인 영유아 대상의 일본 국내 임상시험 6096A1-3024 및 3003(피하접종)에\n\n서 각회 접종 후의 발현비율은 각각 발적 53.6%~62.7% 및 67.8%~74.4%, 종창\n\n- 41.1%~49.0% 및 47.2%~57.1%, 압통 7.8%~14.5% 및 13.3%~19.9%의 범위였다.\n 일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다.  피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n 또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n - - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n 위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n",
        "original_sentence": "또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 9,
        "window_text": "일본 국내 임상시험에서 국소반응의 발현비율을 외국인 영유아 15시험 병합 데이\n\n터와 비교하자, 발적 및 종창의 발현비율이 높았고 압통의 발현비율은 낮았다.  피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n 또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n - - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n 위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n 【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "- - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 90,
        "word_count": 18,
        "page_number": 9,
        "window_text": "피\n\n하접종은 일본에서만 승인을 받은 접종경로로, 피하접종 시 국소반응의 발현비율이\n\n높은 경향이었다.\n\n 또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n - - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n 위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n 【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n 경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n",
        "original_sentence": "- - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 94,
        "word_count": 20,
        "page_number": 9,
        "window_text": "또, 고연령층은 일본 외 국가와 동일하게 일본에서도 근육 내 접종이기 때문에, 중\n\n요한 특정 위해성으로는 설정하지 않았다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n - - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n 위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n 【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n 경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n",
        "original_sentence": "위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 191,
        "word_count": 42,
        "page_number": 9,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n - - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n 위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n 【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n 경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n"
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 117,
        "word_count": 26,
        "page_number": 9,
        "window_text": "- - 5 -\n사용성적조사(소아)\n\n【선택이유】\n\n사용성적조사(소아)에서 주사부위 국소반응을 중점 조사 사항으로 설정하고 발현상\n\n황을 집계, 검토하기 위해.\n\n 위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n 【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n 경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n",
        "original_sentence": "경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n"
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 90,
        "word_count": 23,
        "page_number": 10,
        "window_text": "위해성 최소화(완화) 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘기타 이상약물반응’의 항에 기재\n하고 주의를 환기한다.\n\n 【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n 경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
        "original_sentence": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 9,
        "window_text": "【선택이유】\n\n의료기관에 확실한 정보를 제공하고 적정 사용에 관한 이해를 촉진하기 위해\n\n과민증\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n소아, 고연령층 모두에서 일본 국내 임상시험에 대하여 과민증의 보고는 없으나,\n\n일본 외 국가에서 시판 후의 자발보고가 있기 때문.\n\n 경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 104,
        "word_count": 25,
        "page_number": 9,
        "window_text": "경련\n\n중요한 특정 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 경련의 이상약물반응의 보고는 없었으나, 일본 국\n\n내외에서 시판 후 자발보고가 있었기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n 무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n",
        "original_sentence": "사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 111,
        "word_count": 25,
        "page_number": 9,
        "window_text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 경련의 보고가 없었기 때문에 중요한 특정 위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n 무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 9,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n 무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
        "original_sentence": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 139,
        "word_count": 32,
        "page_number": 9,
        "window_text": "사용 성적 조사(소아)\n\n【선택이유】\n\n- - 6 -\n사용 성적 조사(소아)에서 접종에 의한 경련, 열성경련 및 발열을 중점 조사사항으\n\n로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n 무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n",
        "original_sentence": "무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n"
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 9,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n 무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 2,
        "window_text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진한다.\n\n 무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n",
        "original_sentence": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 136,
        "word_count": 27,
        "page_number": 11,
        "window_text": "무호흡\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 무호흡의 발현상황, 기초질환 등의 환자배경에 관한 정보를 사용 성적\n\n조사의 증례도 포함해 폭넓게 수집하기 때문.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n",
        "original_sentence": "중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n"
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 105,
        "word_count": 25,
        "page_number": 9,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n 접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 9,
        "window_text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n 접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n - • 추가 위해성 최소화 활동으로 다음을 실시한다.\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 120,
        "word_count": 24,
        "page_number": 9,
        "window_text": "중요한 잠재적 위해성\n\n다른  폐렴구균백신과의 접종과오\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n13vPnC와 다른 폐렴구균백신을 착오로 잘못 접종할 우려가 있기 때문.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n 접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n - • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n",
        "original_sentence": "뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 130,
        "word_count": 30,
        "page_number": 9,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- - 7 -\n【선택이유】\n\n다른 폐렴구균백신과 접종과오의 상황을 폭넓게 파악하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n 접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n - • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n 혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n",
        "original_sentence": "접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 12,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n 접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n - • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n 혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n",
        "original_sentence": "- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 203,
        "word_count": 45,
        "page_number": 9,
        "window_text": "뉴모박스®NP와의 접종과오 방지의 활동\n\n【선택이유】\n\n뉴모박스®NP와의 접종과오가 우려되므로 과오방지를 위해 의료기관에 대해 확실\n\n한 정보제공, 주의환기 등을 실시하여 적정 사용에 관한 이해를 촉진하기 위해.\n\n 접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n - • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n 혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n",
        "original_sentence": "접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 122,
        "word_count": 26,
        "page_number": 11,
        "window_text": "접종대상 및 접종경로 선택에 관한 과오\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘용법·용량’의 항 및 백신접종을\n받는 사람을 위한 가이드에 기재하고 주의를 환기한다.\n\n - • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n 혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n",
        "original_sentence": "혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n"
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 106,
        "word_count": 28,
        "page_number": 10,
        "window_text": "- • 추가 위해성 최소화 활동으로 다음을 실시한다.\n 접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n 혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
        "original_sentence": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 124,
        "word_count": 28,
        "page_number": 9,
        "window_text": "접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【선택이유】\n\n접종대상자가 2개월령 이상 6세 미만의 소아 및 65세 이상의 고연령층으로 한정되\n\n어 있고 소아(피하)와 고연령층(근육 내)은 대상별로 접종경로가 다르기 때문에 접\n\n종과오를 방지할 목적으로 의료기관, 접종대상자 및 보호자 등에게 확실한 정보를\n\n제공하고, 적정 사용에 관한 이해를 촉진한다.\n\n 혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 90,
        "word_count": 21,
        "page_number": 7,
        "window_text": "혈소판감소성  자반병\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 혈소판감소성 자반병의 보고는 없으나, 일본 국내\n\n시판 후의 자발보고가 있기 때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다. ",
        "original_sentence": "또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 111,
        "word_count": 25,
        "page_number": 9,
        "window_text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 혈소판감소성 자반병의 보고가 없으므로 중요한 잠재적 위해성으로는 설정하\n\n- - 8 -\n지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다.  본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다. ",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 9,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 혈소판감소성 자반병의 발현상황, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다.  본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다.  13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n",
        "original_sentence": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 204,
        "word_count": 40,
        "page_number": 9,
        "window_text": "또한, 제조판매 후에 대하여 혈소판감소성 자반병의 발현이 확인된 경우는 사용 성\n\n적 조사의 증례를 포함해 충분한 정보수집에 노력하는 것으로 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다.  본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다.  13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n",
        "original_sentence": "돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 206,
        "word_count": 46,
        "page_number": 47,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중대한 이상약물반응’의 항 및\n백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다.  본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다.  13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n",
        "original_sentence": "본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다. "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 63,
        "word_count": 14,
        "page_number": 5,
        "window_text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다.  본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다.  13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n",
        "original_sentence": "13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n"
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 96,
        "word_count": 25,
        "page_number": 10,
        "window_text": "돌연사\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n흡착 7가 폐렴구균결합형 백신(무독성 변이 디프테리아 독소결합체)(이하, 7vPnC)에\n\n대하여 발매 이후, 사망증례가 보고되었기 때문에 2011년 3월 24일에 ‘의약품 등\n\n안전대책부회 안전대책조사회 및 자궁경부암 등 백신 예방접종 후 이상약물반응\n\n검토회’가 개최되었다.  본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다.  13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
        "original_sentence": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n"
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 125,
        "word_count": 28,
        "page_number": 9,
        "window_text": "본 검토회에서 백신접종과 사망증례의 사이에 직접적인 명\n\n확한 인과관계는 확인되지 않았으나, 사망증례에 관해서는 자세한 정보를 수집하고\n\n백신접종과의 관련성에 관해서 전문가에 의해 신속히 평가하도록 할 것과 10만 대\n\n비 접종당 사망보고수가 인과관계의 유무에 관계 없는 0.5를 초과한 경우에 조사회\n\n등에서 평가를 실시하고 대응을 신속하게 검토할 것이 결정되었다.  13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 79,
        "word_count": 19,
        "page_number": 7,
        "window_text": "13vPnC의 일본\n\n국내 임상시험에서 사망 보고는 없으나, 일본 국내에서 시판 후의 자발보고가 있기\n\n때문.\n\n 고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
        "original_sentence": "또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 70,
        "word_count": 18,
        "page_number": 9,
        "window_text": "고연령층은 신청 시까지 일본 국내 임상시험 및 일본 외 국가의 시판 후 자발보고\n\n에서 돌연사의 보고가 없었기 때문에, 중요한 잠재적 위해성으로는 설정하지 않는\n\n- 다.\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 2,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n【선택이유】\n\n접종에 의한 돌연사의 발현상황, 동시접종백신, 기초질환 등의 환자배경에 관한 정\n\n보를 폭넓게 수집하기 위해.\n\n 또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다. ",
        "original_sentence": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 9,
        "window_text": "또한, 제조판매 후에 대하여 돌연사의 발현이 확인된 경우는 사용 성적 조사의 증\n\n례를 포함해 충분한 정보수집에 노력하여 감시를 강화한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다.  현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n",
        "original_sentence": "천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 2,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n- - 9 -\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다.  현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n 고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n",
        "original_sentence": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 130,
        "word_count": 25,
        "page_number": 11,
        "window_text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다.  현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n 고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 36,
        "window_text": "천식\n\n위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다.  현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n 고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n",
        "original_sentence": "현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 63,
        "word_count": 12,
        "page_number": 14,
        "window_text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다.  현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n 고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n",
        "original_sentence": "고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 9,
        "window_text": "부적절한   접종 스케줄의 사용(접종간격간 차이)\n\n중요한 잠재적 위해성으로 지정한 이유:\n\n<위해성으로   지정된 대상군: 소아>\n\n소아의 일본 국내 임상시험에서 부적절한 접종 스케줄의 사용(접종간격간 차이)이\n\n1명 보고되었다.  현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n 고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 111,
        "word_count": 28,
        "page_number": 5,
        "window_text": "현재 시판되고 있는 7vPnC에서도 발매 이후, 부적절한 접종 스케\n\n줄의 사용(접종간격간 차이)이 보고되었다.\n\n 고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다. ",
        "original_sentence": "사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 136,
        "word_count": 30,
        "page_number": 9,
        "window_text": "고연령층에 대해서는 정기적인 접종 스케줄이 설정되지 않았으므로, 중요한 잠재적\n\n위해성으로는 설정하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다.  또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 9,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다.  또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 153,
        "word_count": 30,
        "page_number": 15,
        "window_text": "사용 성적 조사(소아)\n\n- - 10 -\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 각 접종회의 접종간격 및 접종 시 월령을 산출해\n\n부적절한 스케줄에 접종된 증례수 및 비율을 집계하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다.  또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n",
        "original_sentence": "중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다. "
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 162,
        "word_count": 27,
        "page_number": 5,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의 ‘용법·용량에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 접종대상자별 접종시기를\n\n기재해   주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다.  또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
        "original_sentence": "또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 9,
        "window_text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고 적정 사용에 관한\n\n이해를 촉진한다.\n\n 중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다.  또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 161,
        "word_count": 31,
        "page_number": 9,
        "window_text": "중요한 부족정보\n\n면역억제상태인 사람에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n일본 국내 임상시험에 대한 면역억제상태인 사람에게 13vPnC를 접종한 데이터는\n\n없기 때문에 부족정보로 설정했다.  또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다. ",
        "original_sentence": "사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 119,
        "word_count": 27,
        "page_number": 9,
        "window_text": "또한, 일본 외 국가에서 18세 이상의 HIV 감염\n\n자를 대상으로 한 임상시험(6115A1-3017),   6~17세의 겸상적혈구증 환자를 대상으\n\n로 한 임상시험(6096A1-3014),   2세 이상의 조혈간세포이식자를 대상으로 한 임상\n\n시험(6115A1-3003)이 완료되었다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다.  소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 70,
        "word_count": 16,
        "page_number": 9,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다.  소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 166,
        "word_count": 38,
        "page_number": 15,
        "window_text": "사용 성적 조사(소아 및 고연령층(65세이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(소아) 및 사용 성적 조사(고연령층(65세 이상의 성인))에서 접종대상\n\n자 배경에 관련된 정보를 수집하고 면역억제상태인 접종대상자에게 접종된 경우는\n\n이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다.  소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n",
        "original_sentence": "다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 73,
        "word_count": 17,
        "page_number": 24,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘효능·효과에 관련된 접종상의\n주의’의 항 및 백신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다.  소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n",
        "original_sentence": "소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 9,
        "window_text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다.  소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 123,
        "word_count": 23,
        "page_number": 9,
        "window_text": "다른 백신과의 동시접종 시의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아, 고연령층(65세 이상의 성인)>\n\n- - 11 -\n일본 국내 임상시험에서는 소아를 대상으로 한 디프테리아, 파상풍 및 백일해 무균\n\n체백신(DPT) 동시접종 시 데이터만을 얻을 수 있었다.  소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n",
        "original_sentence": "사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 89,
        "word_count": 17,
        "page_number": 16,
        "window_text": "소아에 대해서는 DPT 이외\n\n의 백신, 성인에 대해서는 다른 백신과의 동시접종 데이터가 없기 때문에, 부족정\n\n보로 설정했다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다. ",
        "original_sentence": "사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 112,
        "word_count": 27,
        "page_number": 9,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다.  또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 70,
        "word_count": 16,
        "page_number": 9,
        "window_text": "사용성적조사(소아 및 고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용성적 조사(소아)에서 다른 백신과 동시접종했을 때의 국소 및 전신의 이상약물\n\n반응을 중점조사사항으로 설정하고 발현상황을 집계, 검토하기 위해.\n\n 사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다.  또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n 조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n",
        "original_sentence": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 169,
        "word_count": 38,
        "page_number": 15,
        "window_text": "사용 성적 조사(고연령층(65세 이상의 성인))에서 동시접종에 관한 정보를 수집하고\n\n동시접종이 실시된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다.  또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n 조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다. "
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 46,
        "word_count": 8,
        "page_number": 5,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 위해성 최소화 활동으로 첨부문서의‘중요한 기본적 주의’의 항 및 백\n신접종을 받는 사람을 위한 가이드에 기재해 주의를 환기한다.\n\n 【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다.  또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n 조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n",
        "original_sentence": "또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 16,
        "window_text": "【선택이유】\n\n의료기관, 접종대상자 및 보호자 등에게 확실한 정보를 제공하고, 적정 사용에 관\n\n한 이해를 촉진하기 위해.\n\n 임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다.  또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n 조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
        "original_sentence": "조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 9,
        "window_text": "임신 37주 미만에 출생한 조산아의 접종에 대한 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 소아>\n\n일본 국내 임상시험에 대한 임신 37주 미만에 출생한 조산아에게 접종한 증례는\n\n없고, 13vPnC의 안전성은 확립되지 않았기 때문에 소아의 중요한 부족정보로 설정\n\n했다.  또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n 조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n - - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 122,
        "word_count": 26,
        "page_number": 9,
        "window_text": "또한, 일본 외 국가에 대해서는 임상시험(6096A1-4001)이 진행 중이다.\n\n 조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n - - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다. ",
        "original_sentence": "사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 62,
        "word_count": 14,
        "page_number": 9,
        "window_text": "조산아의 접종이므로 고연령층은 대상이 되지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n - - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다.  일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "- - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 69,
        "word_count": 18,
        "page_number": 5,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n - - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다.  일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n 소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n",
        "original_sentence": "- - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 261,
        "word_count": 54,
        "page_number": 5,
        "window_text": "사용 성적 조사(소아)\n\n【선택이유】\n\n사용 성적 조사(소아)에 대하여 재태주수 등의 접종대상자 배경정보를 수집하고 임\n\n신 37주 미만에 출생한 조산아에게 접종한 경우는 이상약물반응 발현상황에 관해\n\n서 기술한다.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n - - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다.  일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n 소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다. "
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 93,
        "word_count": 18,
        "page_number": 5,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에 새로운 위해성 최소화 활동은 실시하지 않는다.\n\n - - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다.  일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n 소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n",
        "original_sentence": "일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 54,
        "word_count": 12,
        "page_number": 15,
        "window_text": "- - 12 -\n【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다.  일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n 소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n",
        "original_sentence": "소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 9,
        "window_text": "13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성\n\n중요한 부족 정보로 지정한 이유:\n\n<위해성으로 지정된 대상군: 고연령층(65세 이상의 성인)>\n\n일본 외 국가 임상시험에서 특기해야 할 이상약물반응은 보고되지 않았으나, 일본\n\n국내 임상시험에서 고연령층(65세 이상의 성인)에 대해 13vPnC를 복수회 접종한 데\n\n이터가 없고, 또 앞으로 일본 국내에서 고연령층(65세 이상의 성인)의 복수회 접종\n\n이 예상되므로, 부족정보로 설정했다.  일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n 소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
        "original_sentence": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 168,
        "word_count": 33,
        "page_number": 9,
        "window_text": "일본 외 국가는 13vPnC의 1차 접종(접종 시\n\n50~59세) 후 5년 시점에 13vPnC의 2차 접종을 받은 임상시험(6115A1-3001)이 완료\n\n되었다.\n\n 소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다. ",
        "original_sentence": "사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 9,
        "window_text": "소아는 복수회 접종을 접종 스케줄로 설정했기 때문에, 중요한 부족정보로는 설정\n\n하지 않는다.\n\n 의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다.  또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 2,
        "window_text": "의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다.  또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n 폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n",
        "original_sentence": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 185,
        "word_count": 37,
        "page_number": 17,
        "window_text": "사용 성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 13vPnC 기존 접종자에 대해 13vPnC가\n\n접종된 경우는 이상약물반응 발현상황에 관해서 기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다.  또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n 폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n - - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
        "original_sentence": "다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 169,
        "word_count": 36,
        "page_number": 20,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다.  또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n 폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n - - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n",
        "original_sentence": "또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 138,
        "word_count": 33,
        "page_number": 17,
        "window_text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다.  또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n 폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n - - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n",
        "original_sentence": "폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n"
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "- - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 190,
        "word_count": 45,
        "page_number": 18,
        "window_text": "다가 폐렴구균 협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n중요한 부족정보로 지정한 이유:\n\n<위해성으로 지정된 대상군:고연령층(65세 이상의 성인)>\n\n고연령층(65세 이상의 성인)에 대한 일본 외 국가 임상시험은 특기해야 할 이상약\n\n물반응의 보고는 없다.  또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n 폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n - - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
        "original_sentence": "- - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 186,
        "word_count": 37,
        "page_number": 9,
        "window_text": "또, 일본 국내 임상시험에서는 다가 폐렴구균 협막 폴리사\n\n카라이드 백신의 접종이력이 있는 사람에게 13vPnC를 접종한 데이터가 없고, 앞으\n\n로 일본 국내에서 다가 폐렴구균 협막 폴리사카라이드 백신의 접종이력이 있는\n\n고연령층(65세 이상의 성인)의 접종이 예상되기 때문에, 부족정보로 설정했다.\n\n 폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n - - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n",
        "original_sentence": "사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n"
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 9,
        "window_text": "폐렴구균에 의한 중대 질환으로 이환될 위험이 높고 겸상적혈구질환 등의 기초질\n\n환이 있는 2세 이상의 소아를 제외하고 소아에게는 다가 폐렴구균 협막 폴리사카\n\n라이드 백신의 접종이 투여되지 않기 때문에 중요한 부족정보로는 설정하지 않는\n\n- 다.\n - - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n",
        "original_sentence": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 2,
        "window_text": "- - 13 -\n<!-- PAGE_18 -->\n###### □ 유효성에 관련된 검토사항: 해당 사항 없음\n\n<!-- PAGE_18 -->\n###### □ 의약품 안전성 감시계획의 개요\n\n의약품 안전성 감시활동의 내용 및 선택이유:\n\n【내용】\n\n- • 일반적인 의약품 안전성 감시활동\n- • 추가 의약품 안전성 감시활동으로 다음을 실시한다.\n 사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n 단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지. ",
        "original_sentence": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 387,
        "word_count": 87,
        "page_number": 18,
        "window_text": "사용성적 조사(고연령층(65세 이상의 성인))\n\n【선택이유】\n\n사용 성적 조사(고연령층(65세 이상의 성인))에 대하여 조사 시작 이전의 폐렴구균\n\n백신 접종이력에 관련된 정보를 수집하고 다가 폐렴구균 협막 폴리사카라이드   백\n\n신 기존 접종자에 대해 13vPnC가 접종된 경우는 이상약물반응 발현상황에 관해서\n\n기술하기 위해.\n\n 위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n 단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지.  도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n",
        "original_sentence": "일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 308,
        "word_count": 63,
        "page_number": 5,
        "window_text": "위해성 최소화 활동의 내용 및 선택이유:\n\n【내용】\n\n현시점에서 위해성 최소화 활동은 실시하지 않는다.\n\n 【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n 단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지.  도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n 중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n",
        "original_sentence": "1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 54,
        "word_count": 11,
        "page_number": 5,
        "window_text": "【선택이유】\n\n통상 및 추가 안전성 감시활동의 결과에 따라 위해성 최소화 활동의 필요 여부를\n\n검토한다.\n\n 일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n 단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지.  도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n 중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n - 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다. ",
        "original_sentence": "단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 5,
        "window_text": "일반적인 의약품 안전성  감시활동\n\n일반적인 의약품 안전성 감시활동의 개요:\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치 보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n사용  성적 조사(소아)\n\n【안전성 검토사항】\n\n주사부위 국소반응, 경련, 부적절한 접종 스케줄의 사용(접종간격간 차이), 면역억\n\n제상태인 사람에 대한 안전성, 다른 백신과 동시접종 시 안전성, 임신 37주 미만에\n\n출생된 조산아에게 접종 했을 때의 안전성\n\n【목적】\n\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종한 영유아에 대하여 조사기간\n\n내에 접종한 전체접종회의 안전성에 관련해 제조판매 후 사용 실태하에 대한 다음\n\n의 사항을 파악하는 것을 목적으로 한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n 단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지.  도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n 중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n - 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다.  또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다. ",
        "original_sentence": "도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n"
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 259,
        "word_count": 49,
        "page_number": 2,
        "window_text": "1) 사용실태의 파악\n\n2) 이상반응의 발현상황의 파악\n\n【실시계획】\n\n조사기간: 2014년 3월~2016년 6월(2년 4개월)\n\n등록기간: 2014년 3월~2015년 2월(1년)\n\n조사대상:\n\n- - 14 -\n2개월령 이상 7개월령 미만에 본 제제를 처음 접종 받는 영유아로 본 제제 1차 접\n\n종 이전에 폐렴구균백신의 접종이력이 없으며 4차 접종이 예상되는 영유아\n\n예정증례수: 1000명\n\n실시방법: 연속조사방식\n\n관찰기간:\n\n각 접종회(1~4차 접종)에 대하여 접종 후 28일차(각 접종일을 1일차로 한다)까지를\n\n안전성 평가기간으로 한다.\n\n 단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지.  도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n 중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n - 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다.  또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다.  0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n",
        "original_sentence": "중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "- 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 5,
        "window_text": "단, 중대한 이상반응은 전기간을 수집기간으로 한다(1차 접종일부터 4차 접종 후\n\n28일차까지.  도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n 중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n - 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다.  또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다.  0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n 이상으로 등록예정 증례수를 1000례로 설정했다.\n\n",
        "original_sentence": "- 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 119,
        "word_count": 25,
        "page_number": 5,
        "window_text": "도중에 접종을 중지한 경우는 1차 접종일부터 마지막 접종 후 28일차\n\n까지).\n\n 중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n - 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다.  또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다.  0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n 이상으로 등록예정 증례수를 1000례로 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n",
        "original_sentence": "또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 73,
        "word_count": 15,
        "page_number": 5,
        "window_text": "중점조사항목:\n\n주사부위 국소반응, 발열, 경련 및 열성경련\n\n다른 백신과의 동시 접종 시 본 제제의 안전성(국소반응 및 전신반응)\n\n【실시계획의 근거】\n\n예정(목표) 증례수의 설정근거:\n\n일본 국내에서 실시된 6096A1-3003 시험 및 6096A1-3024 시험(비열성 시험)에서\n\n보였던 임상시험용의약품(13vPnC)과의 인과관계를 배제할 수 없는 이상반응(이상\n\n약물반응) 중, 빈도가 가장 낮은 사례의 발현빈도는 각각 0.52% 및 0.55%*이다.\n\n - 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다.  또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다.  0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n 이상으로 등록예정 증례수를 1000례로 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n",
        "original_sentence": "0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "이상으로 등록예정 증례수를 1000례로 설정했다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 29,
        "word_count": 5,
        "page_number": 19,
        "window_text": "- 0.5% 발현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증\n례 수를 산출하면, 600례가 필요하다.  또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다.  0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n 이상으로 등록예정 증례수를 1000례로 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n",
        "original_sentence": "이상으로 등록예정 증례수를 1000례로 설정했다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 66,
        "word_count": 18,
        "page_number": 19,
        "window_text": "또, 미국에서 실시된 주요 시험인\n\n6096A1-004 시험에서 1차 면역의 각 회 접종 후 28~42일차까지의 기간에 중대 및\n\n비중대의 경련 각 1례(0.3%)와 중대한 열성경련 1례(0.3%)가 확인되었다.  0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n 이상으로 등록예정 증례수를 1000례로 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n",
        "original_sentence": "【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 105,
        "word_count": 25,
        "page_number": 19,
        "window_text": "0.3% 발\n\n현빈도의 이상반응을 95% 이상의 검출력으로 적어도 1례 검출 가능한 증례수를\n\n산출하면, 1000례가 필요하다.\n\n 이상으로 등록예정 증례수를 1000례로 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n",
        "original_sentence": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 2,
        "window_text": "이상으로 등록예정 증례수를 1000례로 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n - - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n",
        "original_sentence": "- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "- • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 79,
        "word_count": 19,
        "page_number": 2,
        "window_text": "【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n - - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n",
        "original_sentence": "- • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 2,
        "window_text": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시되는 가능성이 있는 추가 조\n\n치 및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n - - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n 조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다. ",
        "original_sentence": "- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "- - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 312,
        "word_count": 64,
        "page_number": 2,
        "window_text": "- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n - - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n 조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다.  또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다. ",
        "original_sentence": "- - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 178,
        "word_count": 32,
        "page_number": 5,
        "window_text": "- • 새로운 안전성 검토사항의 유무도 포함해, 본 조사의 계획내용의 변경 필요 여\n부(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n - - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n 조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다.  또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다.  일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n",
        "original_sentence": "1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 278,
        "word_count": 55,
        "page_number": 2,
        "window_text": "- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해\n검토한다.\n\n - - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n 조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다.  또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다.  일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n",
        "original_sentence": "조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다. "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 277,
        "word_count": 66,
        "page_number": 5,
        "window_text": "- - 15 -\n사용성적조사(고연령층(65세 이상의 성인))\n\n【안전성 검토사항】\n\n면역억제상태인 사람에 대한 안전성, 다른 백신과의 동시 접종 시의 안전성,\n\n13vPnC를 복수회 접종한 고연령층(65세 이상의 성인)에 대한 안전성, 다가 폐렴구균\n\n협막 폴리사카라이드 백신 접종이력이 있는 고연령층(65세 이상의 성인)에게\n\n13vPnC를 접종했을 때의 안전성\n\n【목적】\n\n고연령층(65세 이상의 성인)에 대한 13vPnC(이하, 본 제제) 단회접종 시의 안전성에\n\n관해서 제조판매 후의 사용실태 하에 대한 다음 사항을 파악하는 것을 목적으로\n\n한다.\n\n 1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n 조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다.  또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다.  일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n",
        "original_sentence": "또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 289,
        "word_count": 63,
        "page_number": 5,
        "window_text": "1) 사용실태의 파악\n\n2) 이상반응의 발현상황 파악\n\n조사기간: 2015년 4월~2016년 10월(1년 7개월)\n\n등록기간: 2015년 4월~2016년 9월(1년 6개월)\n\n조사대상: 고연령층(65세 이상의 성인)\n\n예정증례수: 600례\n\n실시방법: 연속조사방식\n\n관찰기간: 본 제제 접종 후 28일차까지로 한다.\n\n 조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다.  또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다.  일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n",
        "original_sentence": "일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 67,
        "word_count": 18,
        "page_number": 19,
        "window_text": "조사항목:\n\n【실시계획의 근거】\n\n예정증례수의 설정근거:\n\n일본 국내에서 실시된 폐렴구균백신의 접종이력이 없는 고연령층(65세 이상의 성인)\n\n을 대상으로 한 임상시험 B1851088(비열성시험) 및 50세 이상의 성인을 대상으로 한\n\n임상시험\n\n6115A1-3004(공개시험)의 65세 이상의 연령군에 대하여 본 제제 접종 후 14일간 전\n\n자일지를 사용해 피험자로부터 보고 받은 국소반응의 발현율은 각각 55.8% 및\n\n- 63.6%이며 전신반응의 발현율은 각각 37.9% 및 52.6%였다.  또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다.  일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n",
        "original_sentence": "【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 103,
        "word_count": 24,
        "page_number": 21,
        "window_text": "또, 두 시험에서 본 제제\n접종 후 약 1개월 동안에 임상시험책임자로부터 보고 받은 본 제제와의 인과관계를\n\n배제할 수 없는 이상반응(이상약물반응)의 발현율은 각각 3.9%(13례/333례) 및\n\n- 6.6%(9례/136례)이며, 일본 국내 임상시험의 결과를 일본 외 국가 임상시험과 비교한\n결과, 65세 이상의 일본인에서 새롭게 주의가 필요한 위해성 요인은 발견되지 않았\n\n- - 16 -\n□ 유효성에 관련된 조사·시험 계획의 개요: 해당 사항 없음\n\n□ 위해성 최소화 계획의 개요\n\n- 다.  일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n",
        "original_sentence": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 2,
        "window_text": "일본 국내 임상시험에 대하여 65세 이상의 고연령층 518례(시험 B1851088: 382\n례 및 시험 6115A1-3004: 136례)에 대해서 본 제제를 접종 받고 안전성 집단에 포함\n\n된 469례(시험 B1851088: 333례 및 시험 6115A1-3004: 136례)으로 안전성이 평가되\n\n었기 때문에 제조판매 후의 사용 실태하에 대한 본 제제의 안전성에 관해서도 일본\n\n국내 임상시험과 동등한 증례 규모로 안전성 정보의 수집 및 검토를 실시하는 것을\n\n목적으로 본 조사의 예정증례수 600례를 설정했다.\n\n 【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n 일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n",
        "original_sentence": "- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "- • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 78,
        "word_count": 19,
        "page_number": 2,
        "window_text": "【전환점이 되는 예정 시기   및 근거】\n\n안전성 정기보고 시 및 조사 종료 시에 안전성의 검토 및 보고를 실시한다.\n\n 【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n 일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n",
        "original_sentence": "- • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 54,
        "word_count": 15,
        "page_number": 2,
        "window_text": "【해당 의약품 안전성 감시활동의 결과에 근거해 실시될 가능성이 있는 추가 조치\n\n및 시작의 결정기준】\n\n전환점이 되는 시기에 다음 내용을 포함한 의약품 위해성 관리계획을 재검토한다.\n\n - • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n 일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n",
        "original_sentence": "- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 193,
        "word_count": 40,
        "page_number": 21,
        "window_text": "- • 현재의 안전성 검토사항에 대한 위해성 최소화 활동의 내용변경의 필요 여부에\n관해 검토한다.\n\n - • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n 일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n - • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n",
        "original_sentence": "일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 73,
        "word_count": 17,
        "page_number": 21,
        "window_text": "- • 새로운 안전성 검토사항의 유무를 포함해 본 조사의 계획내용의 변경 필요 여부\n(조사의 계속·추가조사의 실시 등)에 관해 검토한다.\n\n - • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n 일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n - • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n 【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006). ",
        "original_sentence": "【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "- • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 74,
        "word_count": 19,
        "page_number": 2,
        "window_text": "- • 새로운 안전성 검토사항에 대한 위해성 최소화 대책의 책정 필요 여부에 관해 검\n토한다.\n\n 일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n - • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n 【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006).  ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링. ",
        "original_sentence": "- • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "- • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 99,
        "word_count": 23,
        "page_number": 2,
        "window_text": "일반적인 위해성 최소화 활동\n\n일반적인 위해성 최소화 활동의 개요:\n\n첨부문서 및 백신접종을 받는 사람을 위한 가이드에 의한 정보제공\n\n추가의 위해성 최소화 활동\n\n뉴모박스®NP와의 접종과오 방지의 활동\n\n【안전성 검토사항】\n\n다른 폐렴구균백신과의 접종과오\n\n【목적】\n\n의료기관에 대한 뉴모박스®NP와의 식별 오류에 의한 접종과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n - • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n 【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006).  ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링.  | 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링. ",
        "original_sentence": "- • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 585,
        "word_count": 137,
        "page_number": 22,
        "window_text": "【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n - • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n 【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006).  ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링.  | 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링.  | 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기). ",
        "original_sentence": "【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006). "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 96,
        "word_count": 26,
        "page_number": 36,
        "window_text": "- • 의료기관에 대해 의약정보담당자 등을 통해 제품정보 개요 등을 사용해 두 제제의\n포장 차이 등이 명확하도록 정보를 제공한다.\n\n - • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n 【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006).  ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링.  | 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링.  | 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기).  위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다. ",
        "original_sentence": "ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "| 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 37,
        "word_count": 12,
        "page_number": 37,
        "window_text": "- • 특약점에 대해 의약정보담당자 등을 통해 13vPnC와 뉴모박스®NP의 착오로 인한 접\n종과오를 방지하기 위해, 주사를 투여 받을 때 ‘제품명’을 확인할 것을 의뢰한다.\n\n 【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006).  ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링.  | 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링.  | 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기).  위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다.  | -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다. ",
        "original_sentence": "| 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링. "
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "| 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 303,
        "word_count": 68,
        "page_number": 30,
        "window_text": "【전환점이 되는 예정 시기, 실시한 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판 직후 조사종료 시 및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고 위\n\n해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자재\n\n- - 17 -\n<!-- PAGE_22 -->\n###### □ 의약품 안전성 감시계획, 유효성에 관련된 조사·시험의 계획 및 위해성 최소화 계획의 일람\n\n<!-- PAGE_22 -->\n###### - 의약품 안전성 감시계획의 목록\n\n<!-- PAGE_22 -->\n###### ☐ 유효성에 관련된 조사・시험 계획의 일람\n\n일반적인 의약품 안전성 감시활동\n\n이상약물반응, 문헌·학회정보 및 일본 외 국가 조치보고 등의 수집·확인·분석에 근거한\n\n안전대책의 검토\n\n추가 의약품 안전성 감시활동\n\n**[표 시작]**\n\n| 추가 의약품 안전성 | 감시활동의 명칭 |\n| --- | --- |\n| 장중첩증 (Intussusception) | ACTIV 프로그램을 통한 프랑 | 스에서의 폐렴구균의 비인두 | 집락에 대한 진행 중인 조사 | 와 이스라엘에서의 임상시험 | (Study 3006).  ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링.  | 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링.  | 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기).  위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다.  | -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다.  가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다. ",
        "original_sentence": "| 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기). "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 117,
        "word_count": 33,
        "page_number": 23,
        "window_text": "ACTIV 프로그램 | 을   통한 프랑스에서의 어린 | 이 비인두 세균총의 비-폐렴 | 구균성 세균 치환을 모니터링 |\n| 9가 HPV 백신의 장기 | 안전성 모니터링.  | 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링.  | 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기).  위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다.  | -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다.  가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다.  |\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1. ",
        "original_sentence": "위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "| -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 80,
        "word_count": 18,
        "page_number": 44,
        "window_text": "| 9가 HPV 백신의 장기 | 효과 및 면역원성 모 | 니터링.  | 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기).  위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다.  | -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다.  가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다.  |\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1.  일반적인 의약품 감시 활동 | 2. ",
        "original_sentence": "| -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 69,
        "word_count": 21,
        "page_number": 5,
        "window_text": "| 효과 지속기간에 대한 | 정보 획득 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험: | Ongoing | follow-up | studies | 중간 보고서: | ~4Q2017 | ~4Q2019 | ~4Q2021 | ~4Q2023 | 최종보고서 제출: | ~2026년 12월 31일 |\n| 백셀리스(Vaxelis) 투여와 관련된 뇌병증/뇌염의 | 잠재적 가능성은 SmPC에 기술되어 있다 (4.3항 | 금기).  위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다.  | -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다.  가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다.  |\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1.  일반적인 의약품 감시 활동 | 2.  비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다. ",
        "original_sentence": "가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "|\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 222,
        "word_count": 70,
        "page_number": 30,
        "window_text": "위해성 완화를 위해 백일해 항원 포함 백 | 신으로 이전에 예방접종을 실시한 후 7일 이내에 | 병인을 알 수 없는 뇌병증이 발생된 환자에게 백 | 신을 투여해서는 안 된다는 정보를 처방의사에게 | 제공한다.  | -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다.  가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다.  |\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1.  일반적인 의약품 감시 활동 | 2.  비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다.  |\n| 현재는 위해성 완화조치가 필요하 | 지 않음. ",
        "original_sentence": "|\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1. "
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "일반적인 의약품 감시 활동 | 2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 51,
        "window_text": "| -Package leaflet for users- | 임신 및 모유 수유 | M-M-RVAXPRO는 임산부에게 투여되어 서는 | 안 된다.  가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다.  |\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1.  일반적인 의약품 감시 활동 | 2.  비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다.  |\n| 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다. ",
        "original_sentence": "일반적인 의약품 감시 활동 | 2. "
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 124,
        "word_count": 30,
        "page_number": 30,
        "window_text": "가임기 여성은 1달 동안 또는 의사 | 의 조언에 따라 백신을 투여 받은 후, 임신을 | 피하기 위해 조치를 취해야 한다.  |\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1.  일반적인 의약품 감시 활동 | 2.  비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다.  |\n| 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다.  | 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다. ",
        "original_sentence": "비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다. "
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "|\n| 현재는 위해성 완화조치가 필요하 | 지 않음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 30,
        "word_count": 9,
        "page_number": 24,
        "window_text": "|\n| 시판후 기간 동안 발생하는 | 예기치 않은 안전성 실마리 | 정보 | 백신 및 비 백 | 신 유형에 대 | 한 백신의 유 | 효성 | 입증을 |\n| 시판 직후 조사(소 | 아) | 해당 사항 없음 | 판매시작부터 2, 4, | 6개월 후 | 종료 | 작성완료(2014 | 년 6월 제출) | 자발적보고 | 정기안전성보고(PSUR) | 실마리정보 확인 체계 | 특별관심 | 이상사례 | 1.  일반적인 의약품 감시 활동 | 2.  비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다.  |\n| 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다.  | 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다.  두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다. ",
        "original_sentence": "|\n| 현재는 위해성 완화조치가 필요하 | 지 않음. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 466,
        "word_count": 119,
        "page_number": 2,
        "window_text": "일반적인 의약품 감시 활동 | 2.  비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다.  |\n| 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다.  | 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다.  두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다.  | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다. ",
        "original_sentence": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다. "
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "| 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 72,
        "word_count": 20,
        "page_number": 2,
        "window_text": "비교관찰연구 (EPI-Zoster-030 | VS) | 중요부족정보 | 바이러스형 대체, | 장기적 효과 및 면 | 역원성 |\n| 국가별로 면밀히 모니터링 | 할 것이며, 관련결과를 추후 | PSUR에   요약할 것이다.  |\n| 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다.  | 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다.  두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다.  | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다.  | 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다. ",
        "original_sentence": "| 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 64,
        "word_count": 17,
        "page_number": 25,
        "window_text": "|\n| 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다.  | 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다.  두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다.  | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다.  | 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다.  SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다. ",
        "original_sentence": "두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다. "
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "| 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 296,
        "word_count": 75,
        "page_number": 5,
        "window_text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| 용법 용량 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | Studies V59_54 and 34 | - SPC 4.4: | 주성분 뿐만 아니라 첨가제 | (예, 네오마이신)에 대한 아니 | 필락시스/아니필락시스 | 유사 |\n| V59P20E1 | 2~10세 소아에게 1회 접종과 2 회 | 접종을 비교하는 Study V59_57 | 여행자 백신과 멘비오를 동시 접 | 종하는 성인에 대한 연구:V59-38 | and V59_53 |\n| 폐렴 사망 | PASS study (Mexico) | 대상포진 병력이 있 | 는 시험대상자에서의 | Shingrix의 안전성, 면 | 역원성과 | 반응원성 | 대상포진 병력이 | 있으며, | 면역력 |\n| 12개월 또는 이상인 사람은 정해진 날에 첫 용량(one dose)을 투여받는다.  | 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다.  두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다.  | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다.  | 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다.  SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다.  | 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음. ",
        "original_sentence": "| 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다. "
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "| 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 224,
        "word_count": 57,
        "page_number": 8,
        "window_text": "| 공식적인 권고사항에 따라 적어도 첫 투여 이후 4주 차에서 두 번째 용량 | (second dose)을 투여 받을 수 있다.  두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다.  | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다.  | 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다.  SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다.  | 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다. ",
        "original_sentence": "| 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 97,
        "word_count": 22,
        "page_number": 5,
        "window_text": "두 번째 용량은 이유와 상관 없이 첫 | 번째 용량 (first dose)에 반응을 보이지 않을 경우에 투여된다.  | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다.  | 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다.  SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다.  | 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다.  | 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다. ",
        "original_sentence": "SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "| 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 624,
        "word_count": 186,
        "page_number": 5,
        "window_text": "| 정기보고에 수집된 | 증례수/최종목표증 | 례수: 1000례 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 임상시험 증례의 분석 | IC51-401 | Sentinel | Sites에서 | 벨기에에서 백신 유전학적 | 안정성   시험 | 없음 | 일반적인 의약품 감시 활동 | 제품의 라벨을 통하여 이상사 | 례 및 특성 집단에서의 금기 | 사항에 대한 경고 | 경련은 SmPC 다음 항에 기술되었 | 다.  | 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다.  SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다.  | 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다.  | 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다.  | 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술. ",
        "original_sentence": "| 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 212,
        "word_count": 61,
        "page_number": 2,
        "window_text": "| 해당 없음 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n| 사용 성적 조사(소 | 아) | 안전성 정기보고의 | 시기 | 실시 중 |\n| 사노피파스퇴르㈜, 에스케이바이오사이언스㈜, ㈜엘지화학, | SmPC (4.2항 용법용량)에는 생후 6주 미만의 영 | 아에서 백셀리스(Vaxelis)의 안전성과 유효성은 사 | 용 가능한 데이터가 없으므로 확립되지 않았다고 | 기술되어 있다.  SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다.  | 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다.  | 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다.  | 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술.  | 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n",
        "original_sentence": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "| 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 374,
        "word_count": 101,
        "page_number": 5,
        "window_text": "SmPC 4.8항과 5.1항에 임상시험 | 을 통한 생후 15개월 이후의 유아에서 백셀리스 | (Vaxelis)의 안전성과 면역원성은 연구되지 않았다 | 고 기술되어 있다.  | 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다.  | 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다.  | 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술.  | 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n",
        "original_sentence": "| 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "| 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 172,
        "word_count": 36,
        "page_number": 30,
        "window_text": "| 18세 이상 자가 조혈 | 줄기세포 이식 환자 | 에서의 Shingrix의 대 | 상포진을 | 예방하는 | 장기 유효성 및 | 50세 이상의 성 | 인에서의 추가접 | 종의 필요성 평 | 가 | 해당 없음 |\n| 백신효과 | 유럽 로타바이러스 조사 네트워크 | 아래 ‘의약품 감시 | 계획’ 표 참조 | 없음 |\n| 계 | 획 |\n| 위해(즉, 유형 | 대체) HPV 백 | 신을 접종 받 | 은 | 성생활을 | 부족정보 | HPV 유형 | 대체 | 이 있는 시험대 | 상자에서의 바이 | 러스의 재발현 | 임부 레지스트리(registry) |\n| 백신바이러스의 유전학적 안 | 정성 | Ÿ | 아나필락시스 반응을 포함한 과민반응 | (Adverse | Event | of | 벨기에에서 백신 유전학적 안정성 | 시험 | 장기 유효성, 안전성 | 과 면역원성 평가 및 | 1회 또는 2회 추가접 | 종에 대한 반응원성, | 안전성과 | 면역원성 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 | SPC: |\n| 의약품 감시 | 계획 | 위해성 완화조치방법 | 일양약품㈜, ㈜한국백신, 한국엠에스디(유) | Ÿ GSK는 침습성 질환/돌발 감 | 현재는 위해성 완화조치가  필요 | 하지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다.  | 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다.  | 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술.  | 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n",
        "original_sentence": "| 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "| 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 1028,
        "word_count": 290,
        "page_number": 24,
        "window_text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 | 됨 |\n| 시판 직후 조사(고 | 연령층(65세 이상의 | 성인)) | Ÿ 조산아 (임신 27-36주 사이 출생) | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 일상적인 약물감시 | 효능 부족을 의심하게 하는 | 사례들은 별도로 정기적인 최 | 신 안전성 보고서에서 논의될 | 것이다.  | 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다.  | 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술.  | 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n",
        "original_sentence": "| 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 197,
        "word_count": 45,
        "page_number": 12,
        "window_text": "| 계획된 | study | 계획 | 2019년 2Q | 진 | 행 |\n| 광범위한 팔다리 부기 | 무호흡 | Ÿ | 열성 경련을 포함한 경련 | Special Interest, AESI)로 | 규명된 사례 | 태국과 남아프리카에서 임상시험 (protocol 011) | 없음 |\n| 해당 사항 없음 | 승인부터 2, 4, 6개 | 월 후 | 종료 | 작성완료(2015 | 년 2월 제출) | IC51-324, 325, Ongoing study | IC51-322 | IC51-401 | Sentinel | Sites에서 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 |\n| 평가 | 수유부나 또는 모유 수유를 계획하는 자는 | 주치의에게 | 말해야 | 한다.  | 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술.  | 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n 【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n",
        "original_sentence": "평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 73,
        "word_count": 17,
        "page_number": 21,
        "window_text": "| 주치의는 | 중 |\n| 백신바이러스 전파 | Study 052 2) | Rota study 052 | Ÿ | 저긴장성-저반응성 에피소드(Hypotonic-hyporesponsive episode) | 일반적인 | 의약품 | Study MenACY-TT084 | 자발보고 | PSUR에 보고된 사례 기술.  | 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n 【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가. ",
        "original_sentence": "【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "- • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 70,
        "word_count": 18,
        "page_number": 22,
        "window_text": "| 환자 및 전문가용 사용설명서를 통한 위해성 | 완화 | 진 | 행 |\n| 안전성 중 | 점 검 토 항 | 목 |\n| Ÿ | 뇌병증/뇌염 | 백신의 유효성, 면역 | 원성과  안전성 평가 |\n| 경련 | 감시계획 | 일반 약물감시 | High | Level | Term | 상태 | 중간/최종 보고서 제 | 출일(목표 날짜) | 중 |\n| 격리 질환의 혈청형 치환 가 | 능성 | 중요한 부족 정보 | 영아 돌연사 증후군(SIDS)/돌 | 연사(SUD)/생명 위협 사건 | (ALTE) | 미숙아에서의 사용 | Study 054 3) | Rota study 054 | 하는 여성에서 | 의 유형별 조 | 사 | Study Rota 052 2) | 일반적인 의약품 감시 활동 | 임상시험(Zoster–062, 056) |\n| 사용 성적 조사(고 | 연령층(65세 이상의 | 성인)) | 발 | 행 | 부 | 서 | 9개월에서 12개월 사이의 유아 | 정기보고에 수집된 | 증례수/최종목표증 | 례수: 600례 | Ÿ | 무호흡 (재태기간이 28주 이하인 미숙아에서) | 식품의약품안전평가원 바이오생약심사부 생물제제과 | 없음 | 안전성 정기보 | 고로 보고서를 | 작성한다 |\n**돌발 감염/백신 실패 가능성**\n| 면역력이 약화된 영아에서의 | 사용 | Study 022 4) | Rota study 022 | 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 | Shingrix 접종 후 모 | 든 | 시험대상자(백신 | 안전성 정기보고의 | 시기 | 실시 중 | 50세 이상의 성 | 인에서의 | 장기 | 대상포진 병력이 | 있으며, | 면역력 | 해당 없음 |\n| 아래 ‘의약품 감시 | 계획’ 표 참조 | Ÿ | 백신 접종을 실시한 팔다리의 광범위한 부종 | chain reaction, PCR) 분석 | 없음 |\n| Ÿ 조산아 (임신 37주 미만) | 평가 |\n| chain reaction, PCR) 분석 | SPC 4.3, 4.4, 5.1에 기재 | 진 | 행 |\n\n**[표 끝]**\n\n작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n 【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가.  | 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다. ",
        "original_sentence": "- • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 161,
        "word_count": 39,
        "page_number": 21,
        "window_text": "평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n접종대상 및 접종경로 선택에 관한 과오방지의 활동\n\n【안전성 검토사항】\n\n접종대상 및 접종경로 선택에 관한 과오\n\n【목적】\n\n의료기관에 대한, 접종대상자(소아: 2개월령 이상 6세 미만 및 고연령층: 65세 이상\n\n의 성인) 및 접종경로(소아: 피하, 고연령층: 근육 내)의 투여 과오를 방지한다.\n\n 【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n 【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가.  | 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다.  열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다. ",
        "original_sentence": "【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 577,
        "word_count": 159,
        "page_number": 23,
        "window_text": "【구체적인 방법】\n\n- • 제품의 포장(겉상자, 안상자 필름, 시린지 라벨)에 접종대상자 및 접종경로의 정보\n를 직접 기재한다.\n\n - • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n 【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가.  | 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다.  열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다.  | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다. ",
        "original_sentence": "평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가. "
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "| 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 284,
        "word_count": 81,
        "page_number": 20,
        "window_text": "- • 의료기관에 대해 앞의 내용의 접종과오 방지의 주의환기를 도모하기 위한 문서 혹\n은 자재를 작성하고 정보를 제공한다.\n\n 【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가.  | 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다.  열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다.  | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다.  | 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정). ",
        "original_sentence": "| 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다. "
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 10,
        "window_text": "【전환점이 되는 예정 시기, 실시된 결과에 근거해 채택될 가능성이 있는 더 나은\n\n조치】\n\n시판  직후 조사종료 시  및 안전성 정기보고 시에 대한 접종과오 상황을 확인하고\n\n위해성 최소화 활동의 내용변경의 필요 여부(자재의 개정, 실시방법의 변경, 추가 자\n\n재작성 등)를 검토한다.\n\n 평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가.  | 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다.  열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다.  | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다.  | 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정).  |\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부. ",
        "original_sentence": "열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "| 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 295,
        "word_count": 80,
        "page_number": 25,
        "window_text": "평가, 보고의 예정시기: 안전성 정기보고 제출 시\n\n- - 18 -\n<!-- PAGE_23 -->\n###### ☐ 위해성 최소화 계획의 일람\n\n**[표 시작]**\n\n| 유효성에 관련된 조 | 사·시험의 명칭 | 전환점이 되는 증례 | 수/목표증례수 | 전환점이 되는 | 예정 시기 | 실시상황 | 보고서의 | 작성예정일 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1-3 | 수막구균 백신 | 1-6 | 로타바이러스 백신 | 1-1 | 디프테리아·파상풍·백일해(DTaP) 기반 혼합백신 | 1-2 | 폐렴구균 백신 | 1-5 | 일본뇌염 백신 | 1-7 | 홍역·유해성이하선염 및 풍진(MMR) 혼합백신 | 1-8 | 인유두종 바이러스백신 | 1-4 | 수두바이러스 백신 |\n| 각국의 권고사항에 따라 예방 | 접종을 모두 받은 어린이에 | 서 발생한 백신 실패 | Ÿ | 백일해 항원에 의한 방어면역기간 | Ÿ | 아나필락시스 | 004에서 백신 접종을 받았던 | 시험대상자를 대상으로 예방 | 기간의 장기 지속성을 평가하 | 기 위한 임상시험 | 의 안전성 평가.  | 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다.  열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다.  | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다.  | 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정).  |\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부.  추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다. ",
        "original_sentence": "| 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다. "
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "| 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 71,
        "word_count": 21,
        "page_number": 30,
        "window_text": "| 임상시험 전체 기간 | 동안 | 대상포진으로 | 4.4항 [특수 경고 및 사용상의 주 | 의사항]: | 백일해 포함 백신을 투여 받은 후 | 다음의 사례가 발생된 것으로 알 | 려진 경우, 백일해 포함 백신의 추 | 가 접종 여부에 대한 결정은 신중 | 하게 결정해야 한다: | 백신접종 후 3일 이내에 발생된 | 발열을 동반하거나 동반하지 않는 | 경련 | 열성 경련 병력, 가족력에 경련 또 | 는 영아 돌연사 증후군이 있더라 | 도 DTaP-IPV-HepB-PRP-T 투여의 | 금기사항은 아니다.  열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다.  | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다.  | 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정).  |\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부.  추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다.  |\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다. ",
        "original_sentence": "| 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정). "
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "|\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 185,
        "word_count": 44,
        "page_number": 8,
        "window_text": "열성 경련의 | 병력이 있는 자는 접종 후 2~3일 | 이내에 그러한 이상사례가 발생될 | 수도 있으므로 면밀하게 추적관찰 | 되어야 한다.  | 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다.  | 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정).  |\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부.  추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다.  |\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다.  백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다. ",
        "original_sentence": "|\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 5,
        "window_text": "| 4.8항 [부작용] | 잠재적 이상사례 (즉, 헥사심주 | (Hexacima)의 구성요소 또는 성분 | 이 1개 이상 포함된 다른 백신 접 | 종 시 보고되었으나 헥사심주 투 | 여와는 직접적인 관련이 없는 이 | 상사례): | 호흡, 흉부 및 종격동 이상 | 극미숙아 (출생시 재태기간 28주 | 이하)에서의 무호흡 (4.4항 참조) |\n| 프리베나로 기초 접종 후 프 | 리베나13으로 추가 접종했을 | 때 6개의 추가 혈청형에 대한 | 면역원성 | 중요한 부족정보 | 아나필락시스는 SmPC 다음 항에 | 기술되었다.  | 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정).  |\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부.  추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다.  |\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다.  백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다.  |\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험. ",
        "original_sentence": "추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "|\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 288,
        "word_count": 74,
        "page_number": 26,
        "window_text": "| 예상되었으나, 등록 | 이 예상보다 길어져 | 결과를 나중에 이용 | 할 수 있게 될 것이 | 다(2018년 3월 추정).  |\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부.  추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다.  |\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다.  백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다.  |\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험.  (범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다. ",
        "original_sentence": "|\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 86,
        "word_count": 23,
        "page_number": 30,
        "window_text": "|\n| 응원성과 | 면역원성 |\n| 전신 반응(중증) | 일반 약물감시 | 해당 없음 | MenACWY-TT-028/29/030/031/032 | (EXT:027 Y1/Y2/Y3/Y4/Y5); | 부족정보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 평가 | 2019.03.31 | -SmPC- | 4.3 금기 | 임부.  추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다.  |\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다.  백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다.  |\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험.  (범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다.  계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다. ",
        "original_sentence": "백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다. "
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "|\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 134,
        "word_count": 37,
        "page_number": 8,
        "window_text": "추가로, 예방 접종 1달 가량 임신을 피 | 해야 합니다.  |\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다.  백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다.  |\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험.  (범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다.  계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다.  제안된 OvE 실시 방 | 법이 승인되었다. ",
        "original_sentence": "|\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험. "
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "(범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 275,
        "word_count": 74,
        "page_number": 5,
        "window_text": "|\n| 아나필락시스 | 자발보고 | PSUR에 보고된 사례 기술 | 바이러스형 | 대체 |\n| 해당 사항 없음 | 장기 유효성과 50세 이상의 | 성인에서의 백신 추가 접종의 | 필요성에 대한 평가 | SmPC (4.1항 효능효과)에는 백셀리스(Vaxelis)가 | 생후 6주 이상 경과된 영유아에게 디프테리아, 파 | 상풍, 백일해, B형 간염, 소아마비, Hib(b형 헤모 | 필루스 인플루엔자균)에 의해 발생되는 침습성 | 질병에 대한 기초접종 및 추가접종을 위해 사용 | 하도록 되어 있다고 기술되어 있다.  백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다.  |\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험.  (범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다.  계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다.  제안된 OvE 실시 방 | 법이 승인되었다.  |\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27. ",
        "original_sentence": "(범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다. "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 67,
        "word_count": 18,
        "page_number": 30,
        "window_text": "백셀리스 | (Vaxelis)의 생후 6주령 미만의 영아에 대한 투여 | 는 연구되지 않았으며 그에 따라 이 연령군의 영 | 아에게 투여해서는 안 된다.  |\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험.  (범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다.  계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다.  제안된 OvE 실시 방 | 법이 승인되었다.  |\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27.  (EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A. ",
        "original_sentence": "계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "제안된 OvE 실시 방 | 법이 승인되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 13,
        "window_text": "|\n| 만성질환자 사용 | 자발보고 | PSUR에 보고된 사례 기술 | 없음 | Biologicals의 HPV-16/18 백 | 신의 안전성 및 면역원성 평 | 가를 위한 제1/2상, 부분 눈 | 가림, 무작위 배정, 대조 임 | 상시험.  (범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다.  계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다.  제안된 OvE 실시 방 | 법이 승인되었다.  |\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27.  (EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A.  | 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V. ",
        "original_sentence": "제안된 OvE 실시 방 | 법이 승인되었다. "
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "|\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 156,
        "word_count": 39,
        "page_number": 24,
        "window_text": "(범주 3) | studies IC51-324, 325, Ongoing | study IC51-322 | IC51-401 | Sentinel | Sites에서 | 약효군 효과 또는 사용 경험을 근거로 면밀한 감독의 대상인 | 이상사례: | Ÿ | 무호흡 | 면역원성의 지속성과 | 안전성 평가 및 2회 | 추가접종에 대한 반 | 응원성, 안전성 그리 | 고 면역원성 평가 | 없음 | 자 에 서 의 | 사용 | 엄밀히 말하면, 이는 위해성 완화 | 조치방법이 아니라 약물감시 활동 | 이다.  계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다.  제안된 OvE 실시 방 | 법이 승인되었다.  |\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27.  (EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A.  | 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V.  | 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다. ",
        "original_sentence": "|\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27. "
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "(EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 90,
        "word_count": 18,
        "page_number": 52,
        "window_text": "계획된 정기적인 관찰값 대 | 비 예상값(OvE) 분석을 실시하면 | 신뢰할 수 있는 실마리정보 확인 | 이 가능하다.  제안된 OvE 실시 방 | 법이 승인되었다.  |\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27.  (EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A.  | 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V.  | 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다.  임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다. ",
        "original_sentence": "(EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A. "
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "| 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 117,
        "word_count": 29,
        "page_number": 5,
        "window_text": "제안된 OvE 실시 방 | 법이 승인되었다.  |\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27.  (EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A.  | 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V.  | 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다.  임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다.  그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다. ",
        "original_sentence": "| 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "| 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 411,
        "word_count": 93,
        "page_number": 5,
        "window_text": "|\n| 백신기능상실 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 회사명 | GSK (구 허가권자) | Pfizer (현 허가권자) | 허가일 | 2012.04.20(EU) | 회사명 | MSD VACCINS | 허가일 | 2006.06.27.  (EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A.  | 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V.  | 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다.  임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다.  그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다.  전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다. ",
        "original_sentence": "| 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 150,
        "word_count": 39,
        "page_number": 20,
        "window_text": "(EU) | 용 가능한 모든 데이터를 이 | 용한 메타분석 | (replacement) | 회사명 | GlaxoSmithKline Biologicals S.A.  | 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V.  | 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다.  임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다.  그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다.  전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다.  | 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다. ",
        "original_sentence": "임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 75,
        "word_count": 17,
        "page_number": 30,
        "window_text": "| 허가일 | 2009.03.30(EU) | ~4Q2017 | 중간 96개월 보고 | 서: | ~4Q2019 | 최종 보고서 제출: | ~2023년 3월 31일 |\n| 회사명 | MCM Vaccine B.V.  | 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다.  임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다.  그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다.  전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다.  | 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다.  | 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다. ",
        "original_sentence": "그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다. "
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 93,
        "word_count": 25,
        "page_number": 44,
        "window_text": "| 허가일 | 2016.02.15(EU) | MenACWY-TT-084 | CHMP와 합의된 계획서에 따라 12~23개월에 1~2회 추가 접종시 즉각적 | 인 항체 역가와 장기간의 항체 역가를 평가하는 연구 | 안전성   중점검토항목 | 일반적인   위해성 완화 조치방법 | 추가적인   위해 | 성 완화 조치방법 | 임상시험(Zoster–049) | 없음 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT | Vaccine (PF-06866681) 대 Meningitec 또는 Mencevax | ACWY의 장기 항체 지속성 및 1차 백신 접종 10년 후 | MenACWY-TT 백신 추가 접종 연구 | [일반적 조치] SmPC 문구(임신 항) 추가: | “임신부를 대상으로 백신에 대한 특별한 시 | 험은 수행되지 않았다.  임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다.  그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다.  전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다.  | 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다.  | 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다.  임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10. ",
        "original_sentence": "전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다. "
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "| 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 32,
        "window_text": "임신 등록대장 | (registry), 역학 연구 및 임상시험 중 의도치 | 않은 노출의 일환으로 수집된 임신부에서의 | 자료는 서바릭스 백신접종이 자연유산을 포함 | 한 유해한 임신 결과 위해성에 영향을 주는지 | 여부에 대한 결론을 내리기에는 충분하지 않 | 다.  그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다.  전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다.  | 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다.  | 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다.  임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10.  (EU) | 회사명 | MSD | 허가일 | 2006.05.19. ",
        "original_sentence": "| 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "| 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 42,
        "word_count": 11,
        "page_number": 13,
        "window_text": "그러나 임상 개발 프로그램 중, 서바릭스 | 를 투여받은 여성에서의 5,387건을 포함하여 | 총 10,476건의 임신이 보고되었다.  전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다.  | 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다.  | 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다.  임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10.  (EU) | 회사명 | MSD | 허가일 | 2006.05.19.  (EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자. ",
        "original_sentence": "| 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 261,
        "word_count": 70,
        "page_number": 30,
        "window_text": "전체적으로 | 특정 결과(예: 정상 영아, 선천성 기형을 포함 | 한 비정상 영아, 조산 및 자연유산)를 경험한 | 임신한 시험대상자 비율은 투여군간 유사했 | 다.  | 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다.  | 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다.  임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10.  (EU) | 회사명 | MSD | 허가일 | 2006.05.19.  (EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자.  | 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자. ",
        "original_sentence": "임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10. "
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "(EU) | 회사명 | MSD | 허가일 | 2006.05.19. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 5,
        "window_text": "| 동물시험에서 수태능, 임신, 배/태자 발생, 출 | 산 또는 생후 발달과 관련하여 직접 또는 간 | 접적인 유해 영향은 나타나지 않았다.  | 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다.  임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10.  (EU) | 회사명 | MSD | 허가일 | 2006.05.19.  (EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자.  | 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자.  |\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다. ",
        "original_sentence": "(EU) | 회사명 | MSD | 허가일 | 2006.05.19. "
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "(EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 97,
        "word_count": 26,
        "page_number": 27,
        "window_text": "| 예방 조치로, 임신 중에는 서바릭스 사용을 | 피하는 것이 바람직하다.  임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10.  (EU) | 회사명 | MSD | 허가일 | 2006.05.19.  (EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자.  | 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자.  |\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다.  동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다. ",
        "original_sentence": "(EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "| 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 184,
        "word_count": 46,
        "page_number": 5,
        "window_text": "임신부 또는 임신을 | 하고자 하는 여성은 임신 종결 시까지 백신접 | 종을 연기 또는 중지하도록 권고한다.” | [추가적 조치] 없음 |\n| 교차 접종 연구 | 9개월미만의 유아 | Identification | Programme)에 | 의심되는 사례 발생 | 률 평가(백신 접종 | 이전에 | 대상포진의 | 갑상선염 | 러스의 재발현 |\n| 중요한 규명된 위해성 | 해당사항 없음 | 중요한 잠재적 위해성 | 회사명 | MSD | 허가일 | 2015.06.10.  (EU) | 회사명 | MSD | 허가일 | 2006.05.19.  (EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자.  | 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자.  |\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다.  동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다.  | Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다. ",
        "original_sentence": "| 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "|\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 564,
        "word_count": 123,
        "page_number": 5,
        "window_text": "(EU) | 회사명 | MSD | 허가일 | 2006.05.19.  (EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자.  | 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자.  |\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다.  동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다.  | Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다.  | 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다. ",
        "original_sentence": "|\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 32,
        "window_text": "(EU) | 50세 이상의 성 | 인에서의 | 장기 | 4.3항 [금기]: | 헥사심주(Hexacima)를 이전에 투여 | 한 후 아나필락시스 반응의 이력 | 이 있는 자.  | 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자.  |\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다.  동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다.  | Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다.  | 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다.  모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다. ",
        "original_sentence": "동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다. "
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "| Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 92,
        "word_count": 27,
        "page_number": 30,
        "window_text": "| 주성분, Section 6.1에 열거된 첨가 | 제, 미량의 잔류물질 (글루타르알 | 데히드, 포름알데히드, 네오마이신, | 스트렙토마이신, 폴리믹신 B), 백 | 일해 백신에 대해, 또는 이전에 헥 | 사심주(Hexacima) 또는 동일한 성 | 분 또는 구성성분이 포함된 백신 | 을 투여한 후 과민반응이 있었던 | 자.  |\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다.  동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다.  | Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다.  | 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다.  모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다.  | 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다. ",
        "original_sentence": "| Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "| 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 13,
        "window_text": "|\n| MenACWY-TT-100 | (EXT:027Y6/Y7/Y8/Y9/Y10) | 제품명 | RotaTeq | 위해성관리계 | 획번호(버전) | 26세 초과 여성에서 | 의 면역원성 및 안 | 전성 | Ÿ 예방 접종은 받지   않은 생후 7개월 이상 영아 및 어린이 | Synflorix suspension for injection in | pre-filled syringe | Synflorix suspension for injection | Synflorix suspension for injection in | multidose container (2 doses) | Synflorix suspension for injection in | multidose container (4 doses) | 폐렴구균 다당류 접합 백신 (흡착) | 모니터링 | 효과 지속기간에 대한 | 정보 확보 | 아래‘의약품 | 감 시 계 획 ’ | 표 참조 | 위해성 관리 | 계획 번호 | (버전) | EU SmPC 4.6항에 다음 내용 기술: | 임신 | 임산부에게 Nimenrix를 사용한 경 | 험은 제한적입니다.  동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다.  | Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다.  | 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다.  모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다.  | 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다.  | 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다. ",
        "original_sentence": "| 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다. "
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 30,
        "window_text": "동물 연구는 | 임신, 태아/태아발달, 분만 또는 산 | 후 발달과 관련하여 직접 또는 간 | 접적인 유해한 영향이 나타나지 | 않았습니다.  | Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다.  | 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다.  모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다.  | 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다.  | 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다.  | 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05. ",
        "original_sentence": "모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "| 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 361,
        "word_count": 93,
        "page_number": 5,
        "window_text": "| Nimenrix는 임신 중에는 꼭 필요 | 할 때만, 그리고 가능한 이점이 태 | 아에 대한 잠재적 위험보다 많을 | 것으로 여겨질 때만 사용해야 합 | 니다.  | 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다.  모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다.  | 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다.  | 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다.  | 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05.  (EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A. ",
        "original_sentence": "| 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "| 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 88,
        "word_count": 25,
        "page_number": 15,
        "window_text": "| 수유 | Nimenrix가 모유에 포함되는지 여 | 부는 알려지지 않았습니다.  모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다.  | 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다.  | 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다.  | 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05.  (EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A.  | 허가일 | 2006.2.21. ",
        "original_sentence": "| 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "| 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 524,
        "word_count": 140,
        "page_number": 24,
        "window_text": "모유 | 수유 중에는 가능한 이점이 잠재 | 적인 위험보다 많은 경우에만 | Nimenrix를 사용해야 합니다.  | 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다.  | 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다.  | 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05.  (EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A.  | 허가일 | 2006.2.21.  (EU) | 회사명 | GSK | 허가일 | 2007.09.20. ",
        "original_sentence": "| 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05. "
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "(EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 257,
        "word_count": 61,
        "page_number": 5,
        "window_text": "| 최종 CSR: | 2015년 6월 |\n| ZOSTER-041: | 18세 이상의 신장 이식 성인 | 환자를 대상으로 0개월과 1~2 | 개월에 근육 내 투여하였을 | 때 Shingrix의 면역원성과 안 | 전성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 | 중요한 부족 정보 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | (PSUR), 안전성 프로파일 모니터 | 링, 안전성 실마리정보 개발 및 | 탐지) | 다른 여행자 백신으로 Ixiaro와 | 동시접종 시 영향에 대한 새로운 | 임상시험 IC51-316 | 시료 샘플을 제출할 수 있는 | 기회를 제공한다.  | 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다.  | 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05.  (EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A.  | 허가일 | 2006.2.21.  (EU) | 회사명 | GSK | 허가일 | 2007.09.20.  (EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31. ",
        "original_sentence": "(EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A. "
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "| 허가일 | 2006.2.21. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 5,
        "window_text": "| 진 | 행 |\n| 중요한 부족정보 | 9개월 미만의 유아에 대한 M-M-RVAXPRO 사용의 안전성 및 유효성에 대 | 한 자료는 현재 존재하지 않는다.  | 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05.  (EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A.  | 허가일 | 2006.2.21.  (EU) | 회사명 | GSK | 허가일 | 2007.09.20.  (EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31.  (EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28.",
        "original_sentence": "| 허가일 | 2006.2.21. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "(EU) | 회사명 | GSK | 허가일 | 2007.09.20. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 25,
        "window_text": "| 위해성 | 관리 |\n| 제품명 | Vaxelis | 중요한   규명된 위해성 | 50세 이상의 성인에서의 장기 | 면역원성 | 임상시험(Zoster–060, 049) | 없음 |\n| 생후 6주 미만의 영아에 | 대한 투여 |\n| 제품명 | Nimenrix |\n| Nimenrix를 12개월에 1회 접종하거나 9개월 및 12개월에 2회 접종한 | 후 항체 지속성을 평가하고, 백신 접종 후 5년째 추가 접종의 안전성과 | 면역원성을 평가 하는 연구 | 없음 |\n| 제품명 | Gardasil 9 | 중요한 잠재적 위해성 | 제품명 | Zostavax | 일반적인 위해성 최소화   활동 |\n| 회사명 | GSK | 허가일 | 2010.02.19 | (International Birth Date) | 임신 수유 중 백신 안전 | 성 | 기관지염 | Study Rota 036 6) | 없음 | 다른 백신과의 병용 투여 |\n| 번호 | 내용 | 제출일 | 회사명 | Sanofi Pasteur MSD | 허가일 | 2006.05.05.  (EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A.  | 허가일 | 2006.2.21.  (EU) | 회사명 | GSK | 허가일 | 2007.09.20.  (EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31.  (EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28. (EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험. ",
        "original_sentence": "(EU) | 회사명 | GSK | 허가일 | 2007.09.20. "
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "(EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 92,
        "word_count": 22,
        "page_number": 11,
        "window_text": "(EU) | 수막구균 역학/혈청 그룹 | 교체의 변화 | 연구 HPV-039 | 18-25세의 건강한 중국인 여 | 성 시험대상자에서 0, 1, 6개 | 월 일정에 따라 근육 내로 | 투여한 | GlaxoSmithKline |\n| 회사명 | Pfizer Limited | 허가일 | 2009.12.09(EU) | 프리베나의 높은 유효성와 프 | 리베나13의 유효성의 동등 여 | 부 | 회사명 | GlaxoSmithKline Biologicals | S.A.  | 허가일 | 2006.2.21.  (EU) | 회사명 | GSK | 허가일 | 2007.09.20.  (EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31.  (EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28. (EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험.  | (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다. ",
        "original_sentence": "(EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31. "
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "(EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28.",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 372,
        "word_count": 97,
        "page_number": 36,
        "window_text": "| 허가일 | 2006.2.21.  (EU) | 회사명 | GSK | 허가일 | 2007.09.20.  (EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31.  (EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28. (EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험.  | (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다.  혈관내 또는 근육 주사를 하여서는 안된다. ",
        "original_sentence": "(EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28."
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "(EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 1215,
        "word_count": 288,
        "page_number": 24,
        "window_text": "(EU) | 회사명 | GSK | 허가일 | 2007.09.20.  (EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31.  (EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28. (EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험.  | (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다.  혈관내 또는 근육 주사를 하여서는 안된다.  | 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험. ",
        "original_sentence": "(EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험. "
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "| (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 846,
        "word_count": 229,
        "page_number": 30,
        "window_text": "(EU) | 중요한   잠재적 위해성 | 중요한 잠재적 위해성 | 제품명 |\n| 회사명 | Valneva Austria GmbH | 허가일 | 2009.03.31.  (EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28. (EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험.  | (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다.  혈관내 또는 근육 주사를 하여서는 안된다.  | 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험.  (범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다. ",
        "original_sentence": "| (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다. "
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "혈관내 또는 근육 주사를 하여서는 안된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 13,
        "window_text": "(EU) | 백신 동시접종 자 | 첨부문서 및 백신접종을 받은   사람의 가이드에 의한   정보제공 |\n| 주성분 및 함량 | Meningococcal group A, C, W-135 and Y conjugate vaccine | (상세 내용 생략) | MenACWY-TT-059 | (EXT:052 Y1/Y3/Y5); | 주성분   및 함 | 량 | 시판 후 조사 활동(범주 3): | 5개 국가(핀란드, 네덜란드, | 영국, 노르웨이 및 덴마크)의 | 암 등록부로부터 항문암 및 | 기타 HPV 관련 암의 연차 | 보고 모니터링 | 성, 내약성 및 제 | 조일관성을 확인 | 하기 위한 3상 연 | 구 |\n| 회사명 | GSK | 허가일 | 2018.03.28. (EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험.  | (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다.  혈관내 또는 근육 주사를 하여서는 안된다.  | 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험.  (범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다.  | 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다. ",
        "original_sentence": "혈관내 또는 근육 주사를 하여서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "| 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 1324,
        "word_count": 329,
        "page_number": 5,
        "window_text": "(EU) |\n| 제품명 | Menveo | 위해성 관리 계획 | 번호 (버전) | Version 7.2 | Study V59_57 | 추가 위해성 최소화   활동 |\n| 제품명 | 로타릭스 (Rotarix) | 위해성관리계 | 획번호(버전) | 주성분 및 함량 | Varicella-zoster virus (live, attenuated) |\n| 제품명 | Prevenar   13 suspension for injection | 폐렴구균 다당류 접합 백신 (13가 흡착) | 제품명 | M-M-RVaxPro |\n| 제품명 | 가다실 및 가다실9 | 간의 제품 혼동 | 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치   방법 |\n| 면역기능 이상 환자 | 일반 약물감시 | 효능·효과 | Neisseria meningitidis A, C, W135 및 Y 군에 의한 감염 예방 | ZOSTER-064: | ZOSTER-006과 | ZOSTER-022 | EPI-ZOSTER-031: | 미국에서 50세 이상의 시험대 | 상자에게서 백신 유효성을 평 | 가하기 위한 후향적 코호트 | 관찰(비중재) 연구 | 제품명 | Ixiaro | 추가 위해성 최소화   활동의 | 명칭 | 전환점이 되는 예정   시기 | 실시상황 |\n| 제품명 | Shingrix |\n| 아나필락시스 반응을 포 | 함한 과민반응 | 50세 이상의 취약한 성인에서 | 의 Shingrix의 접종 | 임상시험(Zoster–063, 064) |\n| 주성분 및 함량 | MENINGOCOCCAL   GROUP A, C, W135 AND Y CONJUGATE VACCINE | (상세내용 생략) | Study V59_34OB | 11~20세 피험자에게 MenACWY의 안전성 | 을 평가하는 4상 연구 | 효능·효과 | 50세 이상의 성인에서의 대상포진의 예방 | 중요한 잠재적 위해성 |\n| 주성분 및 함량 | 용법·용량 | 근육주사 | (상세 내용 생략) | MenACWY-TT-062 | (EXT:055 Y1/Y3/Y5); | 주성분 및 함량 | 약독 사람 로타 바이러스 (human rotavirus, live attenuated) | 시험/활동 | 유형, 제목 및 | 카테고리 (1-3) | Biologicals의 HPV-16/18 L1 | VLP AS04 백신의 유효성, 면 | 역원성 및 안전성 평가를 위 | 한 제2/3상, 이중 눈가림, 무 | 작위 배정, 대조 임상시험.  | (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다.  혈관내 또는 근육 주사를 하여서는 안된다.  | 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험.  (범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다.  | 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다.  |\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다. ",
        "original_sentence": "| 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "(범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 435,
        "word_count": 108,
        "page_number": 30,
        "window_text": "| (범주 3) | 연구/활동 | 목적 | 안전성 중점검토항 | 목 | 상태 | 중간/최종 보고서 | 제출일(목표 날짜) | V503-004-02 | 27-45세 여성에서 | 9vHPV 백신의 시 | 판 후 면역원성 | 및 안전성 연구 | : 젊은 여성(16-26 | 세)와 비교하였을 | 때 | 성인 | 여성 | ZOSTER-028: | 18세 이상의 함암치료를 받고 | 있는 고형암 성인 환자를 대 | 상으로 0개월과 1~2개월에 근 | 육 내 투여하였을 때 Shingrix | 의 면역원성과 안전성을 평가 | 하기 위한 무작위배정, 관찰자 | 맹검, 위약대조, 다기관, 제 | 2/3상 임상시험 | 주성분 및 | 함량 |\n| 임신, 수유 중 사용 | 자발보고 | PSUR에 보고된 사례 기술 |\n| 효능.효과 | 영아에서 G1, G2, G3, G4, G9P1A 혈청형 로타바이러스에 의한 위장관염 예방 | 주성분 및 함량 | 인유두종바이러스 16형 L1 단백질- 20㎍ | 인유두종바이러스 18형 L1 단백질- 20㎍ | 연구를 참여한 50세 이상의 | 시험대상자를 대상으로 진행 | 한 삶의 질에 대한 설문조사 | 를 코드화하여, 이를 근거로 | 한 취약한 상태와 인구학적 | 특성에 따른 Shingrix의 유효 | 성, 안전성과 면역원성의 기술 | 적 분석 |\n| 의도치 않게 백신에 | 노출된 임신부에서 서 | 바릭스의 영향 | 주성분 및 함량 | 과민/알레르기 반응: | 결막염, 저혈압 |\n| 효능.효과 | 생후 6주-24주의 영아에서 로타바이러스에 의한 위장관염의 예방 | 효과부족 | 용법·용량 | 이 백신은 1회 0.65㎖ 피하주사하며, 상완부(삼각근 부위)에 주사하는 것 | 이 선호된다.  혈관내 또는 근육 주사를 하여서는 안된다.  | 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험.  (범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다.  | 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다.  |\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다.  | 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. ",
        "original_sentence": "(범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다. "
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "| 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 1217,
        "word_count": 322,
        "page_number": 10,
        "window_text": "혈관내 또는 근육 주사를 하여서는 안된다.  | 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험.  (범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다.  | 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다.  |\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다.  | 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 이 백신은 근육주사되어야 한다. ",
        "original_sentence": "| 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "|\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 130,
        "word_count": 38,
        "page_number": 30,
        "window_text": "| 주성분 및 함량 | 불활성화 일본뇌염바이러스 (Vero 세포배양 약독화 SA14-14-2 주) |\n| 주성분 및 함량 | Varicella Zoster Virus glycoprotein E antigen |\n| 주성분 및 함 | 량 | 효능·효과 | 2세 이상의 소아, 청소년 및 성인에서 Neisseria meningitidis A, C, W135 | 및 Y 군에 의한 침습성 수막구균 질환의 예방 |\n| 백신 혈청형의 감소와 연관된 | 非백신 폐렴구균 혈청형의 역 | 학에서의 잠재적 변화 | 전환 (접종) 계획 | (프리베나에서 프리베나13으로) | 면역력이 약화된 영아에서의 | 사용 | Study Rota 022 4) | 시판 직후 조사(소아)에 의한 | 정보제공 |\n| MenACWY-TT-043 | (EXT:036 Y2/Y3/Y4/Y5); |\n| Study V59_54OB | 2~10세 집단에서 MenACWY의 안전성을 | 평가하는 4상 연구 | 면역기능이 | 저하 |\n| 중요한 부족 정보 | 장중첩증(Intussusception) | 용법.용량 | 시판 후 조사 활동(범주 3): | 5년마다 항문암 및 기타 | HPV 관련 암에 대한 경향 | 분석 | 효능·효과 | 2개월 이상의 소아, 청소년 및 성인에서 일본뇌염의 예방 |\n| 효능·효과 | 효능·효과 | 50세 이상의 성인에서의 대상포진 및 대상포진 후 신경통의 예방 | 아나필락시스 |\n| 용법·용량 | 1회 0.5mg   근육주사 | (상세내용 생략) | 임상시험번호 | 연구제목 | 용법.용량 | 된 사람에 대한 | 연구* | Category 3 | 효능 효과 |\n| 출생시 재태기간이 28주 | 미만인 미숙아에 대한 | 투여 |\n| 출혈 장애 환자 | 일반 약물감시 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 임신한 사람에 대 | 한 등록대장 작성 | (범주 3) |\n| 주성분 및 함량 | MenACWY-TT-101 | (EXT:036Y6/Y7/Y8/Y9/Y10); |\n**주성분 및 함량**\n| IC51-324 | 비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 장기 면 | 역원성 및 안전성 평가를 위한 비통제, 제3상 추적관찰 연구 | 연구 HPV-040 | GlaxoSmithKline Biologicals의 | HPV-16/18 L1 VLP AS04 백 | 신두 가지 백신접종 전략으 | 로 12-15세의 건강한 여성 | 및 남성 시험대상자에서 0, | 1, 6개월 일정에 따라 근육 | 투여했을 때 감염 유병률 감 | 소에 대한 유효성 평가를 위 | 한 제3/4상 지역사회 무작위 | 배정, 대조 임상시험.  (범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다.  | 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다.  |\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다.  | 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 이 백신은 근육주사되어야 한다.  상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다. ",
        "original_sentence": "|\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "| 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 610,
        "word_count": 165,
        "page_number": 8,
        "window_text": "(범주 | 3) | 면역력이 저하된 성인에서의 | Shingrix의 접종 | 겸형 적혈구증, 비장결손, 신 | 장 증후군이 있는 어린이에 | 대한 자료 | 만 9세 이상에서 인유두종바이러스에 의한 질병의 예방: | - 백신에 포함된 인유두종바이러스 유형에 의한 자궁경부, 외음부, 질, |\n**중요한 규명된 위해성**\n| 효능효과 | 혈관내, 피내, 피하투여로 | 접종 | 용법·용량 |\n| 장기 백신 유효성 | Study V59P20E1 | 용법·용량 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 시판 직후 조사(고연령층(65 | 세이상의 성인))에 의한 정보 | 제공 |\n| 효능 효과 | MenACWY-TT-048 | (EXT:039 Y2,Y3,Y4,Y5); | * 이 보고서 작성일 기준, 개념   보고서 초안을 아직 확인할 수 없는 상태이다.  | 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다.  |\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다.  | 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 이 백신은 근육주사되어야 한다.  상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다.  |\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다. ",
        "original_sentence": "| 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "| Ÿ | 이 백신은 근육주사되어야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 24,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| 효능·효과 | 열성 경련을 포함한 경 | 련 | 잠재적 면역매개질환(pIMD)를 | 갖고 | 있는 | 성인에서의 |\n| 임부 | 감시계획 | 없음 | 없음 | 없음 | (27-45세)에서 가 | 다실9의 면역원성 | 및 내약성을 확인 | 하기 위한 오픈라 | 벨 3상 연구 |\n| 안전성 중점 검토   항목 | 의약품 감시계획 | 위해성 완화 조치 방법 | 안전성 중점검토항목 | 의약품 감시계획 |\n| Study V59_38 | 여행자 백신과 멘비오를 동시 접종 | 최종 임상시험 결과보고서 | 2013년 2분기 | 가다실 및 가다실9 | 사이의 혼합 요법 | ZOSTER-063: | 50세 | 이상의 | 성인에서의 | ZOSTER-069: | 잠재적 면역매개질환(pIMD)을 | 갖고 있는 성인을 대상으로 0 | 개월과 1~2개월에 근육 내 투 | 여하였을 때 Shingrix의 면역 | 원성과 안전성을 평가하기 위 | 한 무작위배정, 관찰자 맹검, | 위약대조, 다기관, 제 3상 임 | 상시험 | 중요한 규명된 위해성 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 |\n| 고위험 소아 인구군에서의 안 | 전성과 면역원성: | Ÿ | HIV에 감염된 어린이 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | IC51-325 |\n| 중요한 잠재적 위해성 | Shingrix 접종 | 중요한 규명된 위해성 |\n| 중대한 급성, 만성 또는 | 진행성 질환 환자 | 일반 약물감시 | 해당 없음 | 오카/머크(Oka/Merck_ | 백신 |\n| MenACWY-TT-102 | (EXT:039 Y6/Y7/Y8/Y9/Y10); | 없음 | 없음 | 없음 | 신경계 이상반응: | 급성파종성뇌척수염, 급 | 성뇌염, 급성척수염, 중 | 추신경계 염증, 길랑-바 | 레 증후군 | 중요한 규명된 위해성 | 뇌병증/ 뇌염 |\n| 중요한 규명된 위해성 | 대상포진, 대상포진 후 신경 | 통, 대상포진과 관련된 합병 | 증을 예방하는 Shingrix의 유 | 용성 |\n| 장중첩증 (Intussusception) | Shingrix 접종 후 반응원성이 | 삶의 질에 미치는 여향을 평 | 가하기 위한 연구 | 바이러스의 잠재적 전염 | 잠재적인 중추신경 사례 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 접종과오 상황을 확인하고 | 필요에 따라‘적정사용’의 | 알림 문서의 배포 등에 의 | 한 정보제공을 실시한다.  |\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다.  | 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 이 백신은 근육주사되어야 한다.  상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다.  |\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다.  |\n| MenACWY-TT-084. ",
        "original_sentence": "| Ÿ | 이 백신은 근육주사되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 13,
        "window_text": "|\n| 출혈 위험이 있는 혈소판 | 감소증 또는 응고 장애가 | 있는 사람에게 투여 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 열성 경련 |\n| 추가적인 F/U이 필요한 중요 | 한 규명된 위해성은 없다.  | 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 이 백신은 근육주사되어야 한다.  상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다.  |\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다.  |\n| MenACWY-TT-084.  | 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2. ",
        "original_sentence": "상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다. "
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "|\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 217,
        "word_count": 62,
        "page_number": 24,
        "window_text": "| 폐렴 사망 | PASS study (Mexico) | 없음 | 안전성 문제 요약 |\n| 효능효과 | 용법용량 | Ÿ | 37개월 미만 조산아 | 길랑바레증후군의 병력 | 일반 약물감시 | 해당 없음 | 길랑바레 증후군 | 중요한 잠재적 위해성 및 부족정보 | 뉴모박스®NP와의 | 접종과오 |\n| 바이알/프리필드시린지 | (PFS) 내 반투명 입자 | 임신 중 ZOSTAVAXⓇ 접종 | 기관지염 | Study 036 | 추가적인 위해성 완화 조치는 없음 |\n| 중요한 부족정보 | 중요한 규명된 위해성 | - |\n| Ÿ | 이전에 23가 폐렴구균 백 | 신을 접종한 겸형 적혈구 | 증을 가진 어린이 | MenACWY-TT-088 | (EXT: 081 Y2, Y3, Y4, Y5) | 용법·용량 | 중요한 규명된 위해성 | 방지의 활동 | 저긴장성-저반응성 에피소드 |\n**효능효과**\n| HPV 유형 대체 | (substitution) | 저긴장성-저반응성 에피 | 소드 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 만삭 및 조산아의 무호흡증 |\n| 장기 백신 반응 지속성 및 | 추가 접종 필요 | - 가다실9는 3회(0, 2, 6개월) 접종할 수 있다.  | Ÿ | 이 백신은 근육주사되어야 한다.  상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다.  |\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다.  |\n| MenACWY-TT-084.  | 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2.  유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다. ",
        "original_sentence": "|\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "|\n| MenACWY-TT-084. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 20,
        "word_count": 3,
        "page_number": 49,
        "window_text": "| Ÿ | 이 백신은 근육주사되어야 한다.  상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다.  |\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다.  |\n| MenACWY-TT-084.  | 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2.  유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다.  제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n",
        "original_sentence": "|\n| MenACWY-TT-084. "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "| 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 447,
        "word_count": 123,
        "page_number": 24,
        "window_text": "상완의 삼각근이나 대퇴부 전외측 | 상부 부분에 주사하는 것이 선호된다.  |\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다.  |\n| MenACWY-TT-084.  | 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2.  유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다.  제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n <!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다. ",
        "original_sentence": "| 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2. "
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 469,
        "word_count": 78,
        "page_number": 24,
        "window_text": "|\n| 고령자에서의 | 안전성과 | 안전성 중점검토항목 | 의약품 감시계획 | 위해성 완화조치방법 | 백신효과와 혈청형 변경 |\n| 중요한 잠재적 위해성 | 면역원성 자료 | 일반 약물감시 | 중요한 잠재적 위해성 | 없음 | 없음 | 없음 | 중요한 잠재적 위해성 |\n| 접종과오 상황을 확인하고 | 필요에 따라 ‘적정사용’ | 의 알림 문서의 배포 등에 | 의한 정보제공을 실시한다.  |\n| MenACWY-TT-084.  | 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2.  유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다.  제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n <!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다.  백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n",
        "original_sentence": "유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 199,
        "word_count": 37,
        "page_number": 24,
        "window_text": "|\n| MenACWY-TT-084.  | 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2.  유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다.  제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n <!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다.  백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n <!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다. ",
        "original_sentence": "제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "<!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 642,
        "word_count": 107,
        "page_number": 24,
        "window_text": "| 수막구균 백신 GSK134612을 1 세에서 18세 미만에게 | 접종시 면역원성 및 안전성 연구 | 백신효과 | Study (Belgium) | EPI-ZOSTER-030 VS: | 안전성 연구 | 중요한 규명된 위해성 |\n| 항문 병소 및 암에 대 | 한 영향 및 유효성 | 면역기능이 저하된 환자 | 에 대한 투여 |\n| 자색반 | 중요한 규명된 위해성 | 중요한 잠재적 위해성 | 접종대상 및 접종경로 선택에 | 관련된 과오방지의 활동 |\n| 광범위한 | 사지부종/중증 |\n| 길랑바레증후군 | 투약/접종 오류 가능성 | 접종자로부터 밀접 접촉자로의 전파의 | 위험과   새로운 재조합체 출현 가능성 | 수동적 보고 |\n| 중요한 부족 정보 | 임부 |\n| 주사부위 반응 | (없음) | 중요한 부족정보 |\n\n**[표 끝]**\n\n- - 19 -\n<!-- PAGE_24 -->\n#### 2.  유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다.  제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n <!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다.  백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n <!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다.  예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n",
        "original_sentence": "<!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다. "
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 106,
        "word_count": 20,
        "page_number": 24,
        "window_text": "유럽연합\n\n<!-- PAGE_24 -->\n###### 유럽연합의\n\n<!-- PAGE_24 -->\n###### 경우,\n\n<!-- PAGE_24 -->\n###### 이미\n\n<!-- PAGE_24 -->\n###### 2006년\n\n<!-- PAGE_24 -->\n###### 위해성\n\n<!-- PAGE_24 -->\n###### 관리\n\n<!-- PAGE_24 -->\n###### 계획을\n\n<!-- PAGE_24 -->\n###### 도입하였으며\n\n<!-- PAGE_24 -->\n###### 홈페이지(www.ema.europa.eu)에서\n\n<!-- PAGE_24 -->\n###### 디프테리아·파상풍·백일해(DTaP)\n\n<!-- PAGE_24 -->\n###### 기반\n\n<!-- PAGE_24 -->\n###### 혼합백신, 수두바이러스 백신 등 여러 제품의 위해성 관리 계획에 대한 정보를\n\n<!-- PAGE_24 -->\n###### 확인할 수 있다.  제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n <!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다.  백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n <!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다.  예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n <!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다. ",
        "original_sentence": "백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "<!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 93,
        "word_count": 20,
        "page_number": 24,
        "window_text": "제품별로 중요 안전성 검토항목(중요한 규명된 위해성, 중요한\n\n<!-- PAGE_24 -->\n###### 잠재적 위해성,\n\n<!-- PAGE_24 -->\n###### 중요한 부족정보)\n\n<!-- PAGE_24 -->\n###### 및 의약품감시계획, 위해성 완화 조치방법에\n\n<!-- PAGE_24 -->\n###### 대한 개략적인 내용이 공개되어 있다.\n\n <!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다.  백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n <!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다.  예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n <!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다.  자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n",
        "original_sentence": "<!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 306,
        "word_count": 54,
        "page_number": 24,
        "window_text": "<!-- PAGE_24 -->\n###### 본 사례집은 DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신,\n\n<!-- PAGE_24 -->\n###### 폐렴구균 백신,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신,\n\n<!-- PAGE_24 -->\n###### 수두바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 일본뇌염\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 로타바이러스\n\n<!-- PAGE_24 -->\n###### 백신,\n\n<!-- PAGE_24 -->\n###### 홍역·유행성이하선염·풍진(MMR)\n\n<!-- PAGE_24 -->\n###### 혼합백신,\n\n<!-- PAGE_24 -->\n###### 인유두종바이러스 백신의 총 14개\n\n<!-- PAGE_24 -->\n###### 제품별 유럽 공공 평가 보고서(European\n\n<!-- PAGE_24 -->\n###### Public\n\n<!-- PAGE_24 -->\n###### Assessment\n\n<!-- PAGE_24 -->\n###### Report)의 위해성\n\n<!-- PAGE_24 -->\n###### 관리 계획 항목을 기반으로 작성되었다.  백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n <!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다.  예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n <!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다.  자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n - - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n",
        "original_sentence": "예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "<!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 120,
        "word_count": 25,
        "page_number": 24,
        "window_text": "백신의 경우 여러 제품에서 중요한\n\n<!-- PAGE_24 -->\n###### 부족정보는 면역기능이 저하된 사람,\n\n<!-- PAGE_24 -->\n###### 소아대상 백신은 미숙아였다.\n\n <!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다.  예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n <!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다.  자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n - - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n",
        "original_sentence": "<!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 142,
        "word_count": 26,
        "page_number": 24,
        "window_text": "<!-- PAGE_24 -->\n###### 또한,\n\n<!-- PAGE_24 -->\n###### 제제별로 물질의 특성 등에 따라 유사한 위해성 정보를 확인할 수 있다.  예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n <!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다.  자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n - - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n 용법\n\n근육주사(IM) 한다. ",
        "original_sentence": "자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "- - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 200,
        "word_count": 45,
        "page_number": 25,
        "window_text": "예를\n\n<!-- PAGE_24 -->\n###### 들면 로타바이러스 백신의 장중첩증,\n\n<!-- PAGE_24 -->\n###### 수막구균 백신의 길랑바레증후군,\n\n<!-- PAGE_24 -->\n###### 급성파종성 뇌척수염,\n\n<!-- PAGE_24 -->\n###### DTaP\n\n<!-- PAGE_24 -->\n###### 기반 혼합백신의 저긴장성·저반응성 에피소드,\n\n<!-- PAGE_24 -->\n###### 경련, 뇌병증 또는 뇌염이 제품은 상이하나 유사하게 확인된 위해성 정보에\n\n<!-- PAGE_24 -->\n###### 해당된다.\n\n <!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다.  자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n - - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n 용법\n\n근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n",
        "original_sentence": "- - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 49,
        "word_count": 9,
        "page_number": 13,
        "window_text": "<!-- PAGE_24 -->\n###### 일부 백신에서 허가 후 유용성 평가 또는 장기면역원성시험을 수행하는\n\n<!-- PAGE_24 -->\n###### 사례가 있으나 본 사례집에는 간단한 정보만 기술되어 있다.  자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n - - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n 용법\n\n근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n 안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기. ",
        "original_sentence": "추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "용법\n\n근육주사(IM) 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 13,
        "window_text": "자세한 내용은\n\n<!-- PAGE_24 -->\n###### 임상시험정보 사이트(예, clinicaltrials.gov) 등을 이용하면 확인 가능하므로 유용성\n\n<!-- PAGE_24 -->\n###### 평가 등 연구 설계시 도움이 될 것으로 사료된다.\n\n - - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n 용법\n\n근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n 안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기.  주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다. ",
        "original_sentence": "용법\n\n근육주사(IM) 한다. "
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 59,
        "word_count": 12,
        "page_number": 5,
        "window_text": "- - 20 -\n<!-- PAGE_25 -->\n#### <Hexacima>\n\n<!-- PAGE_25 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_25 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법용량\n\n용량\n\n기초접종: 공식 권장 사항에 따라 2회 접종 (최소 8주 간격) 또는 3회 접\n\n종(최소 4주 간격) 스케줄로 투여한다.\n\n 추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n 용법\n\n근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n 안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기.  주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다.  이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다. ",
        "original_sentence": "권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 190,
        "word_count": 44,
        "page_number": 2,
        "window_text": "추가접종: 국가예방접종지침에 해당하는 경우 기초접종 최소 6개월 이후\n\n추가접종한다.\n\n 용법\n\n근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n 안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기.  주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다.  이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다.  이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n",
        "original_sentence": "안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기. "
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 89,
        "word_count": 21,
        "page_number": 26,
        "window_text": "용법\n\n근육주사(IM) 한다.  권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n 안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기.  주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다.  이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다.  이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n - - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n",
        "original_sentence": "주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 92,
        "word_count": 21,
        "page_number": 23,
        "window_text": "권장되는 주사부위는 대퇴부 전외측 또는 보다 높은\n\n연령의 소아(15개월 이상부터)의 경우 삼각근이다.\n\n 안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기.  주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다.  이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다.  이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n - - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n - - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다. ",
        "original_sentence": "이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다. "
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 79,
        "word_count": 23,
        "page_number": 26,
        "window_text": "안전성 문제 요약\n\n중요한 규명된 위해성\n\n표시사항에 기재된 이상사례\n\nŸ\n\n저긴장성-저반응성 에피소드\n\nŸ\n\n광범위한 팔다리 부기\n\n중요한 잠재적 위해성\n\n유사한 백신에서 일반적으로 표시사항에 기재된 이상사례:\n\n- - 21 -\nŸ\n\n경련\n\nSmPC 4.8항 [부작용]:\n\n전신 이상 및 투여 부위 상태\n\n드물게: 광범위한 팔다리 부기.  주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다.  이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다.  이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n - - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n - - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다.  이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n",
        "original_sentence": "이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "- - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 173,
        "word_count": 46,
        "page_number": 11,
        "window_text": "주\n\n사부위에서 확대되어 한쪽 또는\n\n양쪽 관절을 침범하는 광범위한\n\n팔다리 부기를 포함하여 큰 주사\n\n부위 반응(50 mm 초과)이 소아에\n\n서 보고되었다.  이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다.  이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n - - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n - - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다.  이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n - - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n",
        "original_sentence": "- - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "- - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 170,
        "word_count": 38,
        "page_number": 2,
        "window_text": "이러한 반응은 접\n\n종 후 24~72시간 이내에 발생하고,\n\n주사부위의 홍반, 열감, 압통 또는\n\n통증이 관련될 수 있으며, 3~5일\n\n이내에 자연적으로 소실된다.  이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n - - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n - - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다.  이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n - - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n 이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n",
        "original_sentence": "- - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 56,
        "word_count": 12,
        "page_number": 28,
        "window_text": "이러\n\n한 반응은 4차 및 5차 접종 시 위\n\n험이 증가하며, 과거 무세포 백일\n\n해 포함 백신의 접종 횟수에 좌우\n\n되는 것으로 보인다.\n\n - - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n - - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다.  이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n - - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n 이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n - 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n",
        "original_sentence": "이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "- - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 153,
        "word_count": 37,
        "page_number": 27,
        "window_text": "- - 22 -\n중요한 잠재적 위해성\n\n- 4.3항 [금기]:\n백일해 백신은 조절되지 않는 신\n\n경계 장애 또는 조절되지 않는 간\n\n질이 있는 사람의 경우 그러한 상\n\n태에 대한 치료가 확립되고, 상태\n\n가 안정화되고, 백신 접종에 따른\n\n유익성이 위해성을 명백하게 상회\n\n하기 전에는 투여해서는 안 된다.\n\n - - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다.  이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n - - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n 이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n - 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n",
        "original_sentence": "- - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 86,
        "word_count": 21,
        "page_number": 29,
        "window_text": "- - 23 -\n- 4.4항 [사용상의 주의사항]:\n극미숙아(very premature infants)\n\n(출생시 재태기간 28주 이하)와 호\n\n흡계 미성숙 기왕력이 있는 영아\n\n에 대해 기초접종을 실시할 경우\n\n무호흡의 잠재적 위험과 48-72시\n\n간 동안 호흡 모니터링의 필요성\n\n을 고려해야 한다.  이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n - - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n 이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n - 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n **[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다. ",
        "original_sentence": "이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n"
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "- 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 410,
        "word_count": 86,
        "page_number": 30,
        "window_text": "이러한 영아에\n\n서 예방접종의 유익성이 높으므로,\n\n예방접종을 보류하거나 지연해서\n\n는 안 된다.\n\n - - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n 이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n - 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n **[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다.  |\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰). ",
        "original_sentence": "- 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 141,
        "word_count": 31,
        "page_number": 30,
        "window_text": "- - 24 -\n- 4.3항 [금기]:\n백일해 포함 백신(전세포 또는 무\n\n세포 백일해 백신)으로 이전에 예\n\n방접종을 실시한 후 7일 이내에\n\n발생된 병인을 알 수 없는 뇌병증\n\n을 경험한 경우, DTaP-IPV-Hep\n\nB-PRP-T 백신접종을 실시해서는\n\n안 된다.\n\n 이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n - 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n **[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다.  |\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰).  또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사. ",
        "original_sentence": "Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "**[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 827,
        "word_count": 210,
        "page_number": 31,
        "window_text": "이러한 경우 백일해 예방접종을\n\n중단하여야 하며, 디프테리아-파상\n\n풍, B형 간염, 폴리오 및 Hib 백신\n\n을 사용하여 접종을 실시해야 한\n\n- 다.\n - 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n **[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다.  |\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰).  또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사.  | Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군). ",
        "original_sentence": "**[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다. "
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "|\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 600,
        "word_count": 157,
        "page_number": 36,
        "window_text": "- 4.8항 [부작용]:\n잠재적 이상사례 (즉, 헥사심주\n\n(Hexacima)의 구성요소 또는 성분\n\n이 1개 이상 포함된 다른   백신\n\n접종 시 보고되었으나 헥사심주\n\n투여와는 직접적인 관련이 없는\n\n이상사례):\n\n신경계 이상\n\n뇌병증, 뇌염\n\n영아 돌연사 증후군(SIDS) 및 돌연\n\n사(SUD)의 모니터링에 대한 강화\n\n된 약물감시 활동의 일환으로, 사\n\n노피파스퇴르는 가능한 경우 관찰\n\n값:예상값 비율 평가방법을 사용하\n\n여 이러한 이상사례에 대한 정기\n\n분석을 실시하고 결과를 PSUR에\n\n- - 25 -\n<!-- PAGE_30 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nCategory 1은 제품의 유익성/위해성에 있어 중요한 것으로 판단되는 의무적인 활동이다.\n\n Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n **[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다.  |\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰).  또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사.  | Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군).  |\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034. ",
        "original_sentence": "|\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰). "
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 7,
        "window_text": "Category 2는 고유한 의무이다\n\nCategory 3은 (고유한 안전성 문제를 기술하거나 위해성 완화 조치방법의 유용성을 평가하기 위해) 필수\n\n적으로 요구되는 추가 PhV 활동이다\n\n또는 안전성 문제가 확인된 경우\n\n그 전에 제공할 계획이다.\n\n **[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다.  |\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰).  또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사.  | Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군).  |\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034.  | 정기적인 최신 안전성 보고서 | 모니터링. ",
        "original_sentence": "또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사. "
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "| Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 1256,
        "word_count": 338,
        "page_number": 51,
        "window_text": "**[표 시작]**\n\n| 문제 | 진행상황 | 중간 또는 최종 | 보고서 제출일 |\n| --- | --- | --- | --- |\n| Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With | Routine EPI Vaccinations Including OPV in Healthy Infants |\n\n**[표 끝]**\n\n- - 26 -\n<!-- PAGE_31 -->\n#### <Vaxelis>\n\n<!-- PAGE_31 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_31 -->\n###### ☐ 안전성 중점검토항목\n\n**[표 시작]**\n\n| V503-021 북유럽 | 장기 추적관찰 연 | 구(V503-001 시험 | 대상자에서의 10 | 년 연장 연구) (범 | 주 3) | : 자궁경부암 스 | 크리닝에 대한 집 | 중화된 인프라가 | 갖춰진 나라들에 | 서 가다실9을 접 | 종받은 | 16-26세 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| • 일상적인 실마리 정보 평가 | 업무 (위해성 관리 계획 버전 | 3 2.1.1항 참고) | • study 10PN-PD-DIT-043의 | 체계 안에서, 연구에 등록된 | 시험대상자들로부터(신플로릭 | 스를 접종 받은 약 100,000명) | 얻어진 핀란드 입원 데이터베 | 이스 등록 자료는 시판 후 기 | 간 동안 발생한 예기치 않은 | 안전성 실마리 정보를 깊이있 | 게 평가할 수 있게 할 것이 | 다.  |\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰).  또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사.  | Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군).  |\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034.  | 정기적인 최신 안전성 보고서 | 모니터링.  |\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n",
        "original_sentence": "| Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군). "
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "|\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 701,
        "word_count": 180,
        "page_number": 11,
        "window_text": "|\n| 어린이의 비인두 세균총에 있 | 는 비-폐렴구균성 세균 치환 | 을 모니터링하는 것을 포함한 | 비인두 집락에 대한 프리베나 | 13의 영향 |\n| Shingrix 접종 후 잠재적 면역 | 매개질환(potential | Immune |\n| 시판 후 환경에서, 순환 RV | 균주의 다양성 모니터링 | 연구제목 | 목적 | 안전성 중점검토 | 항목 | ZOSTER-062: | 50세 이상의 대상포진 병력이 | 있는 성인을 대상으로 0개월 | 과 1~2개월에 근육 내 투여하 | 였을 때 Shingrix의 면역원성 | 과 안전성을 평가하기 위한 | 무작위배정, 관찰자 맹검, 위 | 약대조, 다기관, 제 3상 임상 | 시험 |\n**중요한 부족정보**\n| 로타바이러스 감염의 장외발현 가능 | 성(향신경작용과 간독성을 포함) |\n| 안전성   중점검토항목 | 의약품   감시계획 | 위해성   완화조치방법 | 중요한 잠재적 위해성 |\n| 안전성 문제 요약 | 혈관염 | 자발보고 | PSUR에 보고된 사례 기술 | EPI-HPV-048 (범주 3) | 2016년까지 영국 여성 중 유 | 형별 HPV 감염에 대한 조사 | 연구(EPI-HPV-033의 추적관 | 찰).  또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사.  | Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군).  |\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034.  | 정기적인 최신 안전성 보고서 | 모니터링.  |\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n - - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n",
        "original_sentence": "|\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "| 정기적인 최신 안전성 보고서 | 모니터링. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 30,
        "window_text": "또한, 30세 미만 여성의 | 자궁경부암에서 유형별 HPV | 조사.  | Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군).  |\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034.  | 정기적인 최신 안전성 보고서 | 모니터링.  |\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n - - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n 3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다. ",
        "original_sentence": "| 정기적인 최신 안전성 보고서 | 모니터링. "
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "|\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 597,
        "word_count": 169,
        "page_number": 43,
        "window_text": "| Mediated Disorders, pIMD)의 | 위험 | ZOSTER-049: | Shingrix의 예방적 유효성, 안 | 전성과 면역원성의 지속성을 | 평가하기 | 위한 | 110390과 | ZOSTER-002: | 자가 조혈 줄기세포 이식 성 | 인 환자를 대상으로 2회 근육 | 내 투여하였을 때 Shingrix의 | 예방적 유효성, 안전성과 면역 | 원성을 평가하기 위한 무작위 | 배정, 관찰자 맹검, 위약 대조, | 다기관, 제 3상 임상시험 |\n| 급성파종성뇌척수염 | 백신바이러스의 유전학적 안 | 정성 | 중요한 부족정보 | 뇌병증/ 뇌염 | 과민/알레르기 반응: | 피부염, 호흡곤란, 홍반, | 눈부위 가려움, 홍조, | 과민성, 가려움증, 발진, | 두드러기 |\n| 용법 용량 | 추가 접종을 포함한 반복 | 용량 접종 | 내용 | 제출일 | 중요한   잠재적 위해성 | 백신접종 후 백신유발 | 자가면역 질환 획득에 | 대한 이론적 위해성 |\n| 대상포진 백신에 의한 일시적 | 인 대상포진-유사 또는 수두- | 유사 발진 |\n| 중요한 규명된 위해성 | 없음 | HIV감염된 영아에 대한 접종: 해당 | 아이들이 백신을 접종받은 다른 영 | 아로부터 백신 바이러스를 우연히 | 전파 받게 될 위험성을 평가할 수 | 있을 것임 |\n| HSA(human | serum | 잠재적 알레르기 반응 |\n| 아나필락시스 반응 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 |\n| 프리베나13 임상시험에서 발 | 견되지 않은 예상하지 못한 | 안전성 실마리 정보 |\n| albumin) | 및 | 안전성 중점검토항 | 목 | 여성들에서의 장 | 기간 유효성, 면 | 역원성, 안전성을 | 평가하기 위한 레 | 지스트리 | 기반 |\n| 생후 | 15개월 | 이후의 |\n| rHA(recombinant human | albumin)의 교체와 관련 | 된 M-M-RTMII의 안전성 | 프로파일에서의 잠재적 | 변화 | 급 성 파 종 성 뇌 척 수 염 | (ADEM) | 중요한 부족정보 |\n| 혈소판 감소증 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | 임신 중 노출 | 113077 | 연구의 | 임부에서의 사용 | 백셀리스(Vaxelis) 투여와 관련된 무호흡 (재태기 | 간이 28주 이하인 미숙아에서)의 잠재적인 가능 | 성은 SmPC에 기술되어 있다 (4.4항 특수 경고 및 | 사용상의 주의사항과 4.8항/d 바람직하지 못한 효 | 과/기타 특수환자군).  |\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034.  | 정기적인 최신 안전성 보고서 | 모니터링.  |\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n - - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n 3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다.  기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다. ",
        "original_sentence": "|\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n"
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "- - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 405,
        "word_count": 96,
        "page_number": 34,
        "window_text": "|\n**유아에 대한 투여**\n| 중요한 잠재적 위해성 | 백신바이러스 전파 | 중요한 규명된 위해성 |\n| 면역 저하 및 면역 결핍 | (무비증 포함) 환자 사용 | 대상포진 병력이 있으며, 면 | 역력이 있는 사람에서의 바이 | 러스 재발현 |\n| 연구/활동 | 목적 | 무호흡 (재태기간이 28 | 주 이하인 미숙아에서) |\n| 가와사키병과 혈관염 | 질문지 사용과 안전관리부서 판정 | 을 통한 추가 약물감시 | 해당 없음 | 연구번호 | 연구제목 | HIV감염 시험대상자 | 또는 면역결핍이 알려 | 진 시험대상자에서 서 | 바릭스의 사용 | 예측하지 못한 안전성 시그날 | 의 검출 |\n| 위식도역류질환의 가능성 | 수동적 보고와 US 시판 후 안전성조사 연구 |\n| ZOSTER-056: | ZOSTER-006과 | ZOSTER-022 |\n| 20,000 Ixiaro 접종자에 대한 강 | 화된 감시활동 |\n| 2세 미만이나 off-label | (허가외) 사용 | 상완 신경염 | 자발보고 | PSUR에 보고된 사례 기술 | 과민반응(1형) | 해당사항 없 | 음 | 과민반응 | 수동적 보고와 US 시판 후 안전성조사 연구 | “Maladministrations (잘못 복용/접 | 종)”과 Preferred Term “Drug | administered | to | patients | of | Study 10PN-PD-DIT-034.  | 정기적인 최신 안전성 보고서 | 모니터링.  |\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n - - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n 3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다.  기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다.  첫번째 접종은 생후 6주에\n\n진행할 수도 있다. ",
        "original_sentence": "- - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 13,
        "window_text": "| 정기적인 최신 안전성 보고서 | 모니터링.  |\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n - - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n 3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다.  기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다.  첫번째 접종은 생후 6주에\n\n진행할 수도 있다.  4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n",
        "original_sentence": "3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다. "
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 75,
        "word_count": 20,
        "page_number": 33,
        "window_text": "|\n| 상완 신경염 | 일반 약물감시 | Studies V59_54 and 34 | 해당 없음 | V503-001 확장연 | 구 | 백일해 항원에 의한 방 | 어면역기간 | 없음 | 없음 | 예방 | 기간 | 및 | 추가접종 | 조산아/저체중아에 대한 임상 | 자료 | 18세 이상의 혈액악 | 성종양 | 환자에서의 |\n| 진 | 행 |\n| Ÿ | 생후 6주 미만의 영아에 대한 투여 |\n| 용법용량 | 중요한 부족 정보 | 면역력이 약화된 사람의 접종 | (booster dose)의 필요성 | 면역원성 | 중 |\n| 면역저하 | 환자에서의 | Ÿ 백신을 접종하지 않은 생후 7개월 이상인 영아 및 어린이 | 중 |\n| 부족 정보 | Ÿ | 출생시 재태기간이 28주 미만인 미숙아에 대한 투여 |\n\n**[표 끝]**\n\nŸ\n\n면역기능이 저하된 환자에 대한 투여\n\n- - 27 -\nŸ\n\n생후 15개월 이후의 유아에 대한 투여\n\n광범위한 팔다리 부종\n\n백셀리스(Vaxelis) 또는 구성성분 투여와 관련된\n\n광범위한 팔다리 부종의 잠재적 가능성은 SmPC\n\n없음\n\n- - 28 -\n에 기술되어 있다 (4.8항/c 바람직하지 못한 효과/\n\n기재된 이상약물반응의 개요).\n\n - - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n 3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다.  기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다.  첫번째 접종은 생후 6주에\n\n진행할 수도 있다.  4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n 2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다. ",
        "original_sentence": "기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "첫번째 접종은 생후 6주에\n\n진행할 수도 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 13,
        "window_text": "- - 29 -\n<!-- PAGE_34 -->\n#### <Prevenar 13>\n\n<!-- PAGE_34 -->\n###### □ 품목 개요\n\n폐렴구균 다당류 혈청형 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1\n\n- 2.2 μg\nCRM197 단백질 접합, 알루미늄 포스페이트에 흡착\n\nŸ\n\n생후 6주부터 만 17세까지의 영아, 어린이 및 청소년에게서 폐렴구균으로\n\n인한 침습적 질환, 폐렴 그리고 급성 중이염에 대한 예방(예방에 대한 능\n\n동 면역)\n\nŸ\n\n만 18세 이상의 성인 및 고령자에게서 폐렴구균으로 인한 침습적 질환 및\n\n폐렴에 대한 예방(예방에 대한 능동 면역)\n\n프리베나13으로 첫 접종을 한 영아는 프리베나13으로 예방 접종 코스를\n\n마치는 것이 권장된다.\n\n 3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다.  기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다.  첫번째 접종은 생후 6주에\n\n진행할 수도 있다.  4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n 2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다.  첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다. ",
        "original_sentence": "첫번째 접종은 생후 6주에\n\n진행할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 5,
        "window_text": "3회 기초접종\n\n권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구성된다.  기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다.  첫번째 접종은 생후 6주에\n\n진행할 수도 있다.  4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n 2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다.  첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다.  세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n",
        "original_sentence": "4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 5,
        "window_text": "기초 접\n\n종은 3회 접종으로 구성되며, 첫번째 접종은 대개 생후 2개월에 하게 되\n\n고, 접종 간격은 최소 1개월 이상이어야 한다.  첫번째 접종은 생후 6주에\n\n진행할 수도 있다.  4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n 2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다.  첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다.  세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n 조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다. ",
        "original_sentence": "2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 55,
        "word_count": 14,
        "page_number": 33,
        "window_text": "첫번째 접종은 생후 6주에\n\n진행할 수도 있다.  4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n 2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다.  첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다.  세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n 조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다.  기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다. ",
        "original_sentence": "첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다. "
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 5,
        "window_text": "4번째 접종(추가 접종)은 생후 11개월에서 생후 15개월\n\n사이에 하는 것이 권장된다.\n\n 2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다.  첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다.  세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n 조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다.  기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다.  첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver. ",
        "original_sentence": "세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 13,
        "window_text": "2회 기초접종\n\n프리베나13이 필수 영아 예방 접종 프로그램으로서 접종될 때, 각 0.5mL의\n\n3회 접종으로 구성될 수 있다.  첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다.  세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n 조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다.  기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다.  첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver.  3.2\n\n하는 것도 가능하다.\n\n",
        "original_sentence": "조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다. "
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 64,
        "word_count": 16,
        "page_number": 33,
        "window_text": "첫번째 접종은 생후 2개월부터 접종이 가능\n\n하며, (첫번째 접종) 2달 후 두번째 접종을 한다.  세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n 조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다.  기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다.  첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver.  3.2\n\n하는 것도 가능하다.\n\n 네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n",
        "original_sentence": "기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 35,
        "window_text": "세번째 접종(추가 접종)은\n\n생후 11개월에서 생후 15개월 사이에 하는 것이 권장된다.\n\n 조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다.  기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다.  첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver.  3.2\n\n하는 것도 가능하다.\n\n 네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n (4.4항 및 5.1항 참고).\n\n",
        "original_sentence": "첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver. "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "3.2\n\n하는 것도 가능하다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 13,
        "window_text": "조산아의 경우, 권장되는 예방 접종 시리즈는 각 0.5mL, 4회 접종으로 구\n\n성된다.  기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다.  첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver.  3.2\n\n하는 것도 가능하다.\n\n 네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n (4.4항 및 5.1항 참고).\n\n 생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다. ",
        "original_sentence": "3.2\n\n하는 것도 가능하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 5,
        "window_text": "기초 접종은 3회 접종으로 구성되며, 첫번째 접종은 생후 2개월에\n\n하고 접종 간격은 최소 1개월 이상으로 한다.  첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver.  3.2\n\n하는 것도 가능하다.\n\n 네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n (4.4항 및 5.1항 참고).\n\n 생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다.  세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n",
        "original_sentence": "네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "(4.4항 및 5.1항 참고).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 35,
        "window_text": "첫번째 접종은 생후 6주에\n\n- - 30 -\n<!-- PAGE_35 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획 – ver.  3.2\n\n하는 것도 가능하다.\n\n 네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n (4.4항 및 5.1항 참고).\n\n 생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다.  세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n 생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n",
        "original_sentence": "(4.4항 및 5.1항 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 76,
        "word_count": 18,
        "page_number": 5,
        "window_text": "3.2\n\n하는 것도 가능하다.\n\n 네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n (4.4항 및 5.1항 참고).\n\n 생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다.  세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n 생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n (SmPC 5.1항 참고).\n\n",
        "original_sentence": "생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다. "
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 13,
        "window_text": "네번째 접종(추가 접종)은 생후 11개월에서 생후 15개월 사이에 하는 것이\n\n권장된다.\n\n (4.4항 및 5.1항 참고).\n\n 생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다.  세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n 생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n (SmPC 5.1항 참고).\n\n 만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n",
        "original_sentence": "세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 71,
        "word_count": 17,
        "page_number": 5,
        "window_text": "(4.4항 및 5.1항 참고).\n\n 생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다.  세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n 생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n (SmPC 5.1항 참고).\n\n 만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n 프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n",
        "original_sentence": "생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "(SmPC 5.1항 참고).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 35,
        "window_text": "생후 7개월에서 생후 11개월 사이의 영아\n\n(먼저) 각 0.5mL씩 2회   접종을 하며, 접종 간격은 최소 1개월 이상으로\n\n한다.  세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n 생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n (SmPC 5.1항 참고).\n\n 만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n 프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n 이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다. ",
        "original_sentence": "(SmPC 5.1항 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 5,
        "window_text": "세번째 접종은 그 다음 해에 하는 것이 권장된다.\n\n 생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n (SmPC 5.1항 참고).\n\n 만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n 프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n 이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다.  아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n",
        "original_sentence": "만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n"
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 92,
        "word_count": 20,
        "page_number": 5,
        "window_text": "생후 12개월에서 생후 23개월 사이의 어린이\n\n각 0.5mL씩 2회 접종을 하며, 접종 간격은 최소 2개월 이상으로 한다.\n\n (SmPC 5.1항 참고).\n\n 만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n 프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n 이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다.  아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n - - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n",
        "original_sentence": "프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n"
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 109,
        "word_count": 28,
        "page_number": 35,
        "window_text": "(SmPC 5.1항 참고).\n\n 만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n 프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n 이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다.  아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n - - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n 혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n",
        "original_sentence": "이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다. "
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 10,
        "window_text": "만2세에서 만17세까지의 어린이 및 청소년\n\n- 0.5mL을 1회 접종한다.\n 프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n 이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다.  아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n - - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n 혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n - - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n",
        "original_sentence": "아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "- - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 37,
        "word_count": 12,
        "page_number": 5,
        "window_text": "프리베나13의 안전성 프로파일\n\n을 모니터링하기 위해 프리베\n\n나13을 접종한 최소 43,000\n\n명의 어린이에서 실시되는 시\n\n판후 안전성 관찰 연구 4002.\n\n 이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다.  아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n - - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n 혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n - - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n 앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno.",
        "original_sentence": "- - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n"
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 423,
        "word_count": 98,
        "page_number": 30,
        "window_text": "이 연구는 병원 및 응급실 환\n\n경에서 일어나는 모든 의학적\n\n사례와 병원, 응급실 및 외래\n\n클리닉 환경에서 일어나는 사\n\n전에 정해놓은 안전성 정보의\n\n비율을 평가하기 위해 디자인\n\n되었다.  아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n - - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n 혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n - - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n 앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno. (체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다. ",
        "original_sentence": "혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "- - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 401,
        "word_count": 89,
        "page_number": 5,
        "window_text": "아나필락시스, 과민증,\n\n발작, 경련, 천명, 무호흡과 같\n\n은 사례가 이 연구에서 사전\n\n에 정해놓은 평가변수이다.\n\n - - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n 혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n - - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n 앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno. (체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다.  기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다. ",
        "original_sentence": "- - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno.",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 74,
        "word_count": 19,
        "page_number": 26,
        "window_text": "- - 31 -\n백신 실패에 대한 시판 후 이\n\n상사례 보고서.\n\n 혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n - - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n 앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno. (체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다.  기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다.  첫번째\n\n접종은 생후 6주에도 할 수 있다. ",
        "original_sentence": "앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno."
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "(체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 150,
        "word_count": 32,
        "page_number": 38,
        "window_text": "혈청형 정보가 수집되었는지\n\n확인하기 위한 백신 실패 보\n\n고서의 F/U 질문지\n\n다른 백신과 마찬가지로 프\n\n리베나13이 접종 받는 모두\n\n에게 효과가 있지는 않다는\n\n내용을 SmPC의 사용상의 주\n\n의사항에 기재\n\n면역 반응 장애가 있는 어린\n\n이에서 항체 반응이 감소할\n\n수 있다는 내용을 SmPC의\n\n사용상의 주의사항에 기재\n\n이전에 프리베나로 기초접종\n\n을 한 어린이에서 6개의 추가\n\n혈청형에 대한 예방을 위해\n\n프리베나13이 접종되었을 때\n\nCRM 기반 폐렴구균 접합 백\n\n신의 4회 이상 접종에 대한\n\n안전성\n\n2개의 연구(미국에서의 Study\n\n3011과 알라스카에서의 Study\n\n3010)에서 (추가 혈청형의 면\n\n역원성 획득에 대한) 격차 해\n\n소 프로그램 고려를 위한 프\n\n리베나13의 4회 이상 접종의\n\n안전성을 평가할 것이다.\n\n - - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n 앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno. (체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다.  기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다.  첫번째\n\n접종은 생후 6주에도 할 수 있다.  추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. ",
        "original_sentence": "(체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다. "
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 33,
        "window_text": "- - 32 -\n프리베나로 기초 접종 3회를\n\n받은 어린이에게 프리베나13\n\n으로 추가 접종을 하면 6개의\n\n추가 혈청형에 대해 적절한\n\n면역원성을   보인다는 Study\n\n008의 결과를 확증하기 위한\n\nStudy   3011 catch-up study\n\n약용량\n\n항목(posology\n\nsection)에 기술된 것처럼 6\n\n개의 새로운 혈청형에 대한\n\n방어 면역을 얻기 위해서는\n\n연령에 맞는 접종이 필요하\n\n다고 SmPC 항목 4.2에서 기\n\n재\n\n허가권자는 의약전문인에게\n\na) 프리베나13과 프리베나의\n\n차별점, 예를 들어 포장, 제\n\n품 라벨과 시린지 및 바늘\n\n덮개의 색상 차이와 b) 프리\n\n베나로 백신 접종을 시작하\n\n는 어린이들에게 프리베나13\n\n으로 전환하는 방법에 대한\n\n정보를 알릴 것이다.\n\n 앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno. (체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다.  기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다.  첫번째\n\n접종은 생후 6주에도 할 수 있다.  추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다. ",
        "original_sentence": "기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다. "
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "첫번째\n\n접종은 생후 6주에도 할 수 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 13,
        "window_text": "앞으로 수집될 이상사례 보\n\n고서가 접종된 백신의 종류\n\n와 명확하게 연결될 수 있도\n\n록 허가권자는 두 백신이\n\nbatch\n\nno. (체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다.  기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다.  첫번째\n\n접종은 생후 6주에도 할 수 있다.  추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다.  첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다. ",
        "original_sentence": "첫번째\n\n접종은 생후 6주에도 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 62,
        "word_count": 15,
        "page_number": 33,
        "window_text": "(체계),\n\n시린지\n\n- - 33 -\n<!-- PAGE_38 -->\n#### <Sinflorix>\n\n<!-- PAGE_38 -->\n###### □ 품목 개요\n\n3회 기초접종\n\n권장되는 접종 시리즈는 최적의 예방 효과를 위해 각 0.5mL씩 4회의\n\n접종으로 구성된다.  기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다.  첫번째\n\n접종은 생후 6주에도 할 수 있다.  추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다.  첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다.  추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. ",
        "original_sentence": "추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. "
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "(생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 109,
        "word_count": 24,
        "page_number": 5,
        "window_text": "기초 접종은 3회 접종으로 구성되고, 첫번째 접종은\n\n대개 생후 2개월에 이루어지며 접종 간격은 최소 1개월로 한다.  첫번째\n\n접종은 생후 6주에도 할 수 있다.  추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다.  첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다.  추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n",
        "original_sentence": "(생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다. "
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 13,
        "window_text": "첫번째\n\n접종은 생후 6주에도 할 수 있다.  추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다.  첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다.  추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n 최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n",
        "original_sentence": "첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다. "
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 33,
        "window_text": "추가(4번째) 접종은 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다.  첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다.  추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n 최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n 기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다. ",
        "original_sentence": "추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다. "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "(생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 39,
        "word_count": 8,
        "page_number": 5,
        "window_text": "(생후\n\n12개월에서 생후 15개월 사이가 좋다) (4.4항과 5.1항 참고)\n\n2회 기초접종\n\n신플로릭스가 필수 영아 예방 접종 프로그램으로서 접종될 때, 각\n\n- 0.5mL씩 3회 접종된다.  첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다.  추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n 최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n 기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다.  추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다. ",
        "original_sentence": "(생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 38,
        "window_text": "첫번째 접종은 생후 6주에도 가능하며, 접종 2개월\n후 두번째 접종을 한다.  추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n 최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n 기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다.  추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다.  (4.4항과 5.1항 참고).\n\n",
        "original_sentence": "최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 59,
        "word_count": 14,
        "page_number": 33,
        "window_text": "추가(세번째) 접종은 최소한 마지막 기초 접종\n\n이후 최소 6개월 이후, 생후 9개월을 넘겨 진행하는 것이 권장된다.  (생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n 최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n 기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다.  추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다.  (4.4항과 5.1항 참고).\n\n - - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다. ",
        "original_sentence": "기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다. "
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 13,
        "window_text": "(생후\n\n12개월에서 생후 5개월 사이가 좋다) (5.1항 참고).\n\n 최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n 기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다.  추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다.  (4.4항과 5.1항 참고).\n\n - - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다.  추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n",
        "original_sentence": "추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다. "
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "(4.4항과 5.1항 참고).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 18,
        "word_count": 3,
        "page_number": 5,
        "window_text": "최소 임신 27주 이후의 조산아의 경우, 각 0.5mL씩 4회 접종이 권장된다.\n\n 기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다.  추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다.  (4.4항과 5.1항 참고).\n\n - - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다.  추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n - - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n",
        "original_sentence": "(4.4항과 5.1항 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "- - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 126,
        "word_count": 34,
        "page_number": 39,
        "window_text": "기초 접종은 3회로 구성되며, 첫번째 접종은 생후 2개월에 이루어지며\n\n접종 간격은 최소 1개월로 한다.  추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다.  (4.4항과 5.1항 참고).\n\n - - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다.  추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n - - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n 열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다. ",
        "original_sentence": "- - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다. "
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 65,
        "word_count": 16,
        "page_number": 47,
        "window_text": "추가(4번째) 접종은 기초 접종 이후 최소\n\n6개월 이후에 하는 것이 권장된다.  (4.4항과 5.1항 참고).\n\n - - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다.  추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n - - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n 열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다.  의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다. ",
        "original_sentence": "추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "- - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 68,
        "word_count": 17,
        "page_number": 5,
        "window_text": "(4.4항과 5.1항 참고).\n\n - - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다.  추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n - - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n 열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다.  의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다.  열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n",
        "original_sentence": "- - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 10,
        "window_text": "- - 생후 7-11개월 영아: 접종 스케줄은 각 0.5mL씩 기초 접종 2회로\n- - 34 -\n<!-- PAGE_39 -->\n###### □ 안전성 중점 검토 항목 및 조치 계획\n\n구성되며 접종 간격은 최소 1개월로 한다.  추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n - - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n 열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다.  의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다.  열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n",
        "original_sentence": "열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 53,
        "word_count": 15,
        "page_number": 10,
        "window_text": "추가(세번째) 접종은 그 다음\n\n해에 하는 것이 권장되며, 마지막 기초 접종 이후 최소 2개월 이후에\n\n진행한다.\n\n - - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n 열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다.  의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다.  열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n 해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n",
        "original_sentence": "의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 10,
        "window_text": "- - 생후 12개월-만 5세 어린이: 접종 스케줄은 각 0.5mL씩 2회로 구성되며\n접종 간격은 최소 2개월로 한다.\n\n 열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다.  의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다.  열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n 해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n 염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다. ",
        "original_sentence": "열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 175,
        "word_count": 42,
        "page_number": 39,
        "window_text": "열성 경련에 대한 내용은 EU\n\n에 제출한 SmPC의 4.8항에\n\n있다.  의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다.  열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n 해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n 염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다.  연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다. ",
        "original_sentence": "EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 13,
        "window_text": "의약전문인은 신플로릭\n\n스 접종 후 열성 경련이 일어\n\n날 수 있다는 정보를 얻을 수\n\n있다.  열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n 해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n 염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다.  연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다.  회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n",
        "original_sentence": "해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 73,
        "word_count": 16,
        "page_number": 39,
        "window_text": "열성 경련은 고위험군\n\n으로 확인된 일부 인구집단에\n\n서 발생하는 매우 드문 이상\n\n사례이다.\n\n EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n 해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n 염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다.  연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다.  회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n 10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n",
        "original_sentence": "염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 2,
        "window_text": "EU에 제출된 SmPC의 4.4항에\n\n서 다음과 같이 기술하고 있\n\n다:\n\n“백일해 균이 포함된 백신과\n\n신플로릭스를 동시에 접종 받\n\n는 모든 어린이와 이전에 열\n\n성 경련 경험이 있거나 경련\n\n성 질환을 가진 어린이에게는\n\n열반응이 나타날 가능성이 높\n\n으므로 예방적 해열제가 권장\n\n된다(4.8항 참고).\n\n 해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n 염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다.  연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다.  회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n 10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n - - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다. ",
        "original_sentence": "연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다. "
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 383,
        "word_count": 94,
        "page_number": 40,
        "window_text": "해열제 처방은 각국의 지침에\n\n따라 이루어져야 한다.\n\n 염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다.  연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다.  회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n 10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n - - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다.  연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다. ",
        "original_sentence": "회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 172,
        "word_count": 40,
        "page_number": 5,
        "window_text": "염/백신 실패/혈청형 치환\n\n가능성/집단 면역/항생제 내\n\n성 균주를 모니터할 시판후\n\n조사 연구 수행의 타당성을\n\n검토 중이다.  연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다.  회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n 10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n - - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다.  연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다.  회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n",
        "original_sentence": "10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "- - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 81,
        "word_count": 19,
        "page_number": 39,
        "window_text": "연구 기간은\n\n5년이며, 신플로릭스의 연\n\n구가 수행되는 지역에서 사\n\n용 지속 여부에 달렸다.  회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n 10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n - - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다.  연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다.  회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n 게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다. ",
        "original_sentence": "- - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다. "
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 2,
        "window_text": "회\n\n- - 35 -\n사는 다음의 조건들이 충족\n\n될 때 신플로릭스를 사용하\n\n는 국가에서 침습성 질환의\n\n확인과 모니터링을 위한 역\n\n할 조사의 강화를 지원할\n\n것이다:\n\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“기초 접종이 아주 조산아\n\n(28주 이하), 특히 호흡 미숙\n\n에 대한 이력을 가지고 있는\n\n조산아에게 접종되었을 때 무\n\n호흡의\n\n잠재적\n\n위해성과\n\n48-72시간 동안 호흡 모니터\n\n링의 필요성이 고려되어야 한\n\n- 다.이 영아군에서의 접종으로\n인한 이익이 크기 때문에 접\n\n종을 보류하거나 지연해서는\n\n안된다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 취\n\n약한 어린이 집단에서의 무호\n\n흡 위험을 관리할 수 있다.\n\n 10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n - - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다.  연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다.  회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n 게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다.  (5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n",
        "original_sentence": "연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다. "
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 159,
        "word_count": 39,
        "page_number": 41,
        "window_text": "10PN-PD-DIT-043\n\n- • GSK는 침습성 질환/돌발 감\nEU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로,\n\n신플로릭스가 접종한 모든 사\n\n람에게 백신이 포함한 혈청형\n\n에 의한 침습성 질환 또는 중\n\n이염에 대한 면역 효과가 있\n\n는 것은 아니다.\n\n - - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다.  연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다.  회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n 게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다.  (5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n",
        "original_sentence": "회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 80,
        "word_count": 18,
        "page_number": 30,
        "window_text": "- - 36 -\n염/백신 실패/혈청형 치환 가\n\n능성/집단 면역/항생제 내성\n\n균주를 모니터할 시판후조사\n\n연구 수행의 타당성을 검토\n\n중이다.  연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다.  회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n 게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다.  (5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n",
        "original_sentence": "게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다. "
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "(5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 75,
        "word_count": 19,
        "page_number": 5,
        "window_text": "연구 기간은 5년이며,\n\n신플로릭스의 연구가 수행되\n\n는 지역에서 사용 지속 여부\n\n에 달렸다.  회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n 게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다.  (5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n 이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n",
        "original_sentence": "(5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 302,
        "word_count": 80,
        "page_number": 39,
        "window_text": "회사는 다음의 조\n\n건들이 충족될 때 신플로릭스\n\n를 사용하는 국가에서 침습성\n\n질환의 확인과 모니터링을 위\n\n한 역할 조사의 강화를 지원\n\n할 것이다:\n\n백신의 폐렴구균 혈청형으로\n\n인한 중이염에 대한 예방은\n\n침습적 질환에 대한 예방 효\n\n과보다 대체로 낮을 것으로\n\n예상된다.\n\n 게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다.  (5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n 이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n - - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음. ",
        "original_sentence": "EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 149,
        "word_count": 36,
        "page_number": 39,
        "window_text": "게다가 중이염은 백신에 있는\n\n폐렴구균 혈청형들보다 많은\n\n미생물에 의해 발생하기 때문\n\n에 중이염에 대한 전반적인\n\n예방 효과는 제한적이다.  (5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n 이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n - - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음.  이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.  ",
        "original_sentence": "EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n"
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 61,
        "word_count": 16,
        "page_number": 40,
        "window_text": "(5.1\n\n항 참고)”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n 이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n - - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음.  이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.   이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다. ",
        "original_sentence": "이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "- - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 271,
        "word_count": 65,
        "page_number": 43,
        "window_text": "EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“면역 억제 치료, 유전적 결\n\n함, HIV 감염 또는 다른 이유\n\n- - 37 -\n에 의해 면역 반응 장애가 있\n\n는 어린이들은 접종에 의한\n\n항체 반응이 감소될 수 있\n\n- 다.”\nEU에 제출한 SmPC의 4.5항에\n\n다음과 같이 기술하고 있다:\n\n“다른 백신과 마찬가지로 면\n\n역 억제 치료를 받는 환자에\n\n서 저절한 반응이 유도되지\n\n않을 수도 있다.”\n\n이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n 이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n - - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음.  이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.   이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다.  이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다.",
        "original_sentence": "- - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음. "
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.  ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 124,
        "word_count": 36,
        "page_number": 30,
        "window_text": "EU에 제출한 SmPC의 4.4항에\n\n다음과 같이 기술하고 있다:\n\n“폐렴구균성 감염 위험이 높\n\n은 어린이(겸형 적혈구증, 선\n\n천성 또는 후천성 비장 기능\n\n장애, HIV 감염, 악성 종양,\n\n신장 증후군)의 이용 가능한\n\n안전성과 면역원성 자료는 없\n\n- 다.\n 이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n - - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음.  이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.   이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다.  이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다. \"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다. ",
        "original_sentence": "이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.  "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 114,
        "word_count": 29,
        "page_number": 49,
        "window_text": "이 내용은 의사에게 적절히\n\n알려질 것이고, 이 내용이 이\n\n러한 환자군에서의 위험을 관\n\n리할 수 있다.\n\n - - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음.  이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.   이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다.  이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다. \"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다.  |\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조). ",
        "original_sentence": "이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다. "
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다.",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 213,
        "word_count": 68,
        "page_number": 30,
        "window_text": "- - 38 -\n<!-- PAGE_43 -->\n#### <Menveo>\n\n<!-- PAGE_43 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_43 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n사지부종\n\n일반 약물감시\n\n해당 없음\n\n- - 39 -\n주사부위 반응(중증)\n\n일반 약물감시\n\n해당 없음\n\n**[표 시작]**\n\n| 일반적인 의약품 감시 활동 | 판매가 되면 대상포진-유사 | 또는 수두-유사 발진을 포함 | 하는 이상사례 보고서가 수집 | 될 수 있음.  이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.   이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다.  이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다. \"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다.  |\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조).  면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다. ",
        "original_sentence": "이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다."
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "\"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 352,
        "word_count": 108,
        "page_number": 30,
        "window_text": "이들이 시간적으 | 로 조스타박스 투여와 관련성 | 이 있을 수는 있지만, 이들이 | 야생형 수두 대상포진 바이러 | 스와 관련되어 있거나 또는 | 수두 대상포진 바이러스와 전 | 혀 관련되어 있지 않을 수도 | 있다.   이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다.  이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다. \"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다.  |\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조).  면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다.  | 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다. ",
        "original_sentence": "\"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "|\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 217,
        "word_count": 57,
        "page_number": 52,
        "window_text": "이 발진이 오카/머크 | (Oka/Merck) 바이러스 또는 | 야생형 수두 대상포진 바이러 | 스의 발현과 관련성이 있을지 | 여부는 임상적으로나 혈청학 | 적으로나 구별하는 것이 가능 | 하지 않다.  이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다. \"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다.  |\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조).  면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다.  | 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다.  |\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
        "original_sentence": "|\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조). "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 115,
        "word_count": 30,
        "page_number": 30,
        "window_text": "이런 문제의 해결 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| EU SmPC 4.4항에 다음 내용 기술: | \"면역 억제 치료를 받는 환자나 | 면역 결핍 환자에게 적절한 면역 | 반응이 유도되지 않을 수도 있습 | 니다. \"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다.  |\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조).  면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다.  | 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다.  |\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n",
        "original_sentence": "면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "| 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 5,
        "window_text": "\"및 \"말초의 보체 결핍 및 해 | 부학적 또는 기능적 무증상과 같 | 은 증상으로 인해 수막구균 감염 | 에 대한 감수성이 증가된 환자에 | 서 안전성과 면역원성이 평가되지 |\n| 일반적인 의약품 감시 활동 | 허 가 조 건 ( r e g u l a t o r y | commitment)으로써 3개의 시험 | 시판 후, 위약대조 일반 안전 | 성 시험 | 허가 후, 대규모 (백신 접종한 | 20,000명의 시험대상자) 안전 | 성 관찰 연구 |\n| 4.4 경고 및 주의사항: | 백신접종자와 접촉한 항체음성 | 인 자에게, 배출된 백신 바이 | 러스가 전이된 경우 임상적 증 | 상을 야기하지 않는 것으로 관 | 찰되었다.  |\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조).  면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다.  | 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다.  |\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n - - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다.",
        "original_sentence": "| 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "|\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 101,
        "word_count": 29,
        "page_number": 20,
        "window_text": "|\n| (ZOSTER-006/022) 장기 추적 | 연구(ZOE-LTFU)와 50세 이상 | 의 성인에서의 0 또는 0, 2 개 | 월에 1회 또는 2회 추가접종 | 을 하는 2개의 군에 대한 평 | 가를 위한 공개, 다국가, 다기 | [일반적 조치] SmPC 문구(경고 및 사용상 주 | 의사항)추가: | “데이터가 부족한 무증상 HIV 감염 환자는 | 제외(“약력학적 영향” 참조).  면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다.  | 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다.  |\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n - - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다. \"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1. ",
        "original_sentence": "|\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음. "
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 1063,
        "word_count": 259,
        "page_number": 45,
        "window_text": "면역억제치료 | 를 받는 환자와 같이 면역반응성이 저하된 시 | 험대상자에서 서바릭스 사용에 대한 자료는 |\n| SmPC 4.2: 멘비오는 2세 미 | 만에서의 안전성과 유효성이 | 아직 확립되지 않았다.  | 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다.  |\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n - - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다. \"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1.  연구목록\n\n않았습니다. ",
        "original_sentence": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "- - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다.",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 258,
        "word_count": 62,
        "page_number": 46,
        "window_text": "| 현재까지의 자료는 5.1항에 | 기술되어 있으나 추천 용량 | 은 확립되지 않았다.  |\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n - - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다. \"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1.  연구목록\n\n않았습니다.  이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여. ",
        "original_sentence": "- - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다."
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "\"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 150,
        "word_count": 31,
        "page_number": 25,
        "window_text": "|\n| 유효성 임상시험 Protocol 004 | 에서 백신 접종을 받았던 시 | 험대상자를 대상으로 장기 유 | 효성 연구 완료 | 현재는 위해성 완화조치가 필요하 | 지 않음.  | Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n - - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다. \"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1.  연구목록\n\n않았습니다.  이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여.  불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n",
        "original_sentence": "\"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1. "
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "연구목록\n\n않았습니다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 13,
        "word_count": 2,
        "page_number": 13,
        "window_text": "| Safety signal이 탐지되는 경우 위 | 해성 완화조치 필요여부 재평가 |\n| MenACWY-TT-016/017/018/019/020 | (EXT:015Y1/Y2/Y3/Y4/Y5) | MenACWY-TT-099 | (EXT:015Y6/Y7/Y8/Y9/Y10); |\n| ZOSTER-039: | 18세 이상의 혈액악성종양 성 | 인 환자를 대상으로 2회 근육 | 일반적인 의약품 감시 활동 | 계획된 안전성과 면역원성 임 | 상시험 | 면역력이 저하된 | 성 인 에 서 의 | Shingrix 접종 |\n| 연구 HPV-019 | 18-25세의 사람 면역결핍 바 | 이러스(HIV) 감염 여성 시험 | HIV 양성 여성 | 에서의 안전성 | 및 면역원성 | 부족 정보 | HIV 양성 | 시 험 대 상 | 2014년 6월까지 24 | 개월 연구 결과를 이 | 용할 수 있을 것으로 |\n| 연구에서 위약군이었던 시험 | 대상자를 대상으로 Shingrix | 경구 폴리오백신과의 병용접 | 종   후 추가적인 효능 | Study 024 5) | 접종 이전에 대상포 | 진의 병력이 있는 시 | 이 있는 시험대 | 상자에서의 바이 | 연구 시 | 작 |\n| 신경계 이상반응: | 경련 | 일반적인 의약품 감시(개별이상 | 사례보고(ICSR), 정기안전성보고 | 건강한 청소년 및 성인에게 접종시 MenACWY-TT 백 | 신 (GSK134612) 대 Mencevax ACWY의 장기 면역원성 | 연구 시 | 작 | 2016년 9월 |\n| 미숙아에서의 사용 | Study Rota 054 3) | SPC: | 사용 | Shingrix의 안전성, 반 | - SPC 4.3: |\n| 장기 유효성 및 면 | 아래‘의약품 없음 |\n**inappropriate age (부적절한 연령**\n\n**[표 끝]**\n\n- - 40 -\n<!-- PAGE_45 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n환자의 약물 복용/접종)”, “Off\n\nlabel use (허가외 사용)”로 보고\n\n된 증례 수 모니터링 – 정기안전\n\n성보고서로 보건당국에 보고 될\n\n것이다.\n\n - - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다. \"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1.  연구목록\n\n않았습니다.  이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여.  불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n",
        "original_sentence": "연구목록\n\n않았습니다. "
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 921,
        "word_count": 135,
        "page_number": 49,
        "window_text": "- - 41 -\n<!-- PAGE_46 -->\n#### <Nimenrix>\n\n<!-- PAGE_46 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_46 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 42 -\nEU SmPC에 다음 내용 기술\n\n- 4.3:“활성 물질 또는 부형제에 대\n한 과민성\"은 금기 사항으로 기재\n\n- 4.4: \"백신 접종 후 드물게 발생하\n는 아나필락시스를 대비하여 적절\n\n한 치료와 감독이 항상 가능해야\n\n합니다. \"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1.  연구목록\n\n않았습니다.  이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여.  불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n",
        "original_sentence": "이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여. "
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 46,
        "word_count": 13,
        "page_number": 13,
        "window_text": "\"라고 명시\n\n- - 43 -\nŸ\n\nPSUR: Periodic Safety Update Report 정기 안전성 보고서\n\nŸ\n\nECDC: European Centre for Disease Prevention and Control 유럽 질병 예방 관리 센터\n\n참고 1.  연구목록\n\n않았습니다.  이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여.  불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n",
        "original_sentence": "불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 115,
        "word_count": 24,
        "page_number": 5,
        "window_text": "연구목록\n\n않았습니다.  이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여.  불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n",
        "original_sentence": "SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 138,
        "word_count": 30,
        "page_number": 52,
        "window_text": "이러한 사람에서는 적\n\n절한 면역 반응이 유도되지 않을\n\n수 있습니다.”\n\n- - 44 -\n<!-- PAGE_49 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n평가 및 1차 백신 접종 후 10년 후 MenACWY-TT 백\n\n신 추가 접종 반응 연구\n\n장기 항체 지속성 및 추가 접종 필요 연구:\n\nMenACWY-TT-016/017/018/019/020   (EXT:015Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-099   (EXT:015Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-028/29/030/031/032   (EXT:027 Y1/Y2/Y3/Y4/Y5)\n\nMenACWY-TT-100  (EXT:027Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-059  (EXT:052 Y1/Y3/Y5)\n\nMenACWY-TT-062  (EXT:055 Y1/Y3/Y5)\n\nMenACWY-TT-043  (EXT:036 Y2/Y3/Y4/Y5)\n\nMenACWY-TT-101  (EXT:036 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-048  (EXT:039 Y2,Y3,Y4,Y5)\n\n- - 45 -\nMenACWY-TT-102  (EXT:039 Y6/Y7/Y8/Y9/Y10)\n\nMenACWY-TT-088  (EXT:081 Y2,Y3,Y4,Y5)\n\n위험이 있는 (무비증 아동 또는 보체 결핍 아동) 피험자에서 Nimenrix\n\n1회\n\n접종\n\n및\n\n2회\n\n접종의\n\n면역원성\n\n평가를\n\n위한\n\n연구:\n\n- - 46 -\n<!-- PAGE_51 -->\n#### <Shingrix>\n\n<!-- PAGE_51 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_51 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n용법·용량\n\n- 0.5mL 2개월 간격으로 2회 근육 내 투여.  불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n **[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다. ",
        "original_sentence": "따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 115,
        "word_count": 24,
        "page_number": 5,
        "window_text": "불가피한 경우 2번째 접종은\n첫 번째 접종 이후 6개월 이내에 투여할 수 있다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n **[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다.  비임상 연구는 생식독성 | 을 확인하기에는 불충분하다. ",
        "original_sentence": "SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n"
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 62,
        "word_count": 15,
        "page_number": 44,
        "window_text": "SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n **[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다.  비임상 연구는 생식독성 | 을 확인하기에는 불충분하다.  | 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다. ",
        "original_sentence": "따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "**[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 90,
        "word_count": 27,
        "page_number": 44,
        "window_text": "따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n- - 47 -\n<!-- PAGE_52 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n해성을 판단하여야 한다.\n\n SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n **[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다.  비임상 연구는 생식독성 | 을 확인하기에는 불충분하다.  | 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다.  조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다. ",
        "original_sentence": "**[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다. "
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "비임상 연구는 생식독성 | 을 확인하기에는 불충분하다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 13,
        "window_text": "SmPC 4.4, 5.1 항목에 기재\n\n함\n\nSmPC 4.4: 대상포진 병력\n\n및 다중 공존이환질환을 가\n\n진\n\n취약한\n\n사람들에서의\n\nShingrix의 투여에 대한 자\n\n료는 제한적이다(5.1 참고).\n\n 따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n **[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다.  비임상 연구는 생식독성 | 을 확인하기에는 불충분하다.  | 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다.  조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다.  백신 투여 후 1 | 개월은 임신을 피해야 한다. ",
        "original_sentence": "비임상 연구는 생식독성 | 을 확인하기에는 불충분하다. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "| 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 51,
        "window_text": "따라서 의료진이 개별적인\n\n근거에 따라 대상포진 백신\n\n접종에 대한 유익성 및 위\n\n해성을 판단하여야 한다.\n\n **[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다.  비임상 연구는 생식독성 | 을 확인하기에는 불충분하다.  | 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다.  조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다.  백신 투여 후 1 | 개월은 임신을 피해야 한다.  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c. ",
        "original_sentence": "| 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 32,
        "word_count": 9,
        "page_number": 13,
        "window_text": "**[표 시작]**\n\n| SPC 4.6 수태능, 임신 및 수 | 유 항에 기술: | - SPC 4.6: 임산부의 조스타 | 박스 투여에 대한 자료는 없 | 다.  비임상 연구는 생식독성 | 을 확인하기에는 불충분하다.  | 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다.  조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다.  백신 투여 후 1 | 개월은 임신을 피해야 한다.  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c.  바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨. ",
        "original_sentence": "조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "백신 투여 후 1 | 개월은 임신을 피해야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 28,
        "word_count": 9,
        "page_number": 5,
        "window_text": "비임상 연구는 생식독성 | 을 확인하기에는 불충분하다.  | 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다.  조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다.  백신 투여 후 1 | 개월은 임신을 피해야 한다.  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c.  바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨.  |\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. ",
        "original_sentence": "백신 투여 후 1 | 개월은 임신을 피해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "|\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 461,
        "word_count": 136,
        "page_number": 70,
        "window_text": "| 하지만 자연적으로 발생하는 | 대상포진 바이러스의 감염은 | 때로는 태아에 해를 가하는 | 것으로 알려져 있다.  조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다.  백신 투여 후 1 | 개월은 임신을 피해야 한다.  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c.  바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨.  |\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | 프로타민황산염)에 대한 과민반 | 응. ",
        "original_sentence": "|\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c. "
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 37,
        "window_text": "조스타 | 박스는 임산부의 투여를 권장 | 하지 않는다.  백신 투여 후 1 | 개월은 임신을 피해야 한다.  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c.  바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨.  |\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | 프로타민황산염)에 대한 과민반 | 응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. ",
        "original_sentence": "바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨. "
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "|\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 2,
        "window_text": "백신 투여 후 1 | 개월은 임신을 피해야 한다.  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c.  바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨.  |\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | 프로타민황산염)에 대한 과민반 | 응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다. ",
        "original_sentence": "|\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. "
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "| 프로타민황산염)에 대한 과민반 | 응. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 44,
        "window_text": "|\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 일본뇌염 유행 국가의 소아에서 일본뇌염백신 Ixiaro 기초접종 후 추가접종 | 유·무에 따른 장기 면역원성 및 안전성 평가를 위한 공개, 무작위배정 제3 | 상 임상시험 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase | 보 고 서 : | 2019.12.31 | 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.06.30 |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 보 고 서 : | 2025.03.30 |\n| SPC 4.8, c.  바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨.  |\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | 프로타민황산염)에 대한 과민반 | 응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다.  | 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다. ",
        "original_sentence": "| 프로타민황산염)에 대한 과민반 | 응. "
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "| 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 51,
        "word_count": 17,
        "page_number": 5,
        "window_text": "바람직하지 못한 | 효과, 기재된 이상약물반응의 | 개요에 대상포진-유사 및 수 | 두-유사 발진 포함됨.  |\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | 프로타민황산염)에 대한 과민반 | 응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다.  | 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다.  | 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다. ",
        "original_sentence": "| 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "|\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 193,
        "word_count": 53,
        "page_number": 45,
        "window_text": "|\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | 프로타민황산염)에 대한 과민반 | 응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다.  | 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다.  | 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다.  | 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다. ",
        "original_sentence": "|\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "| 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 128,
        "word_count": 34,
        "page_number": 30,
        "window_text": "| 프로타민황산염)에 대한 과민반 | 응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다.  | 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다.  | 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다.  | 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다.  따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다. ",
        "original_sentence": "| 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "| 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 518,
        "word_count": 130,
        "page_number": 30,
        "window_text": "| 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다.  | 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다.  | 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다.  | 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다.  따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다.  |\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다. ",
        "original_sentence": "| 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "| 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 72,
        "word_count": 18,
        "page_number": 30,
        "window_text": "|\n| 최종 | 임상 |\n| 시험 | 결과 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 최종 | 임상 |\n| 중간보고서: | 2021.03.31 | 최종 | 임상 |\n| SPC Section 4.6 임부 및 수유부: | 예방책으로써, 임신 또는 수유기 | 동안에는 Ixiaro의 사용을 피해야 | 한다.  | 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다.  | 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다.  | 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다.  따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다.  |\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다.  그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다. ",
        "original_sentence": "| 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다. "
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 65,
        "word_count": 21,
        "page_number": 24,
        "window_text": "| 보 고 서 : | 2022.06.30 |\n| 수두 대상포진 바이러스 확인 | 프로그램(Varicella | Zoster | 반응의 가능성에 대해 적절한 | 의료처치 및 감독이 언제든 | 이뤄질 수 있도록 준비되어야 | 한다.  | 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다.  | 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다.  따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다.  |\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다.  그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다.  또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다. ",
        "original_sentence": "따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "|\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 143,
        "word_count": 46,
        "page_number": 5,
        "window_text": "| 시험 | 결과 |\n| Virus | Identification | 보 고 서 : | 2019.03.31 |\n| Virus | Identification |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| 시험 | 결과 |\n\n**[표 끝]**\n\n보 고 서 :\n\n- 2024.10.31\n- - 48 -\n관, 제 3b상 임상시험\n\nZOSTER-060:\n\n백신 접종 후 108개월과 120\n\n개월에 Shingrix의 면역 반응\n\n의 지속성과 안전성을 평가하\n\n고   ZOSTER-003에 참여하였\n\n던 60세 이상의 건강한 시험\n\n대상자의 초기접종 10년 후, 2\n\n회 추가접종에 대하여 평가하\n\n기 위한 공개, 제 3b상, 장기\n\n확장 연구\n\n**[표 시작]**\n\n| 중간보고서: | 2019.04.30 | 최종 | 임상 |\n| --- | --- | --- | --- |\n| - SPC 4.5: 조스타박스는 불 | 활화 인플루엔자 백신과 다른 | 투여부위에 병용투여가 가능 | 하다.  | 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다.  따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다.  |\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다.  그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다.  또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다.  이는 조스터박스 투여 | 에 대한 이론적인 위험이다. ",
        "original_sentence": "|\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다. "
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 145,
        "word_count": 42,
        "page_number": 30,
        "window_text": "| 조스타박스와 23가 폐렴구균 | 백신과의 병용투여는 | 조스타박스의 면역원성을 감 | 소시키므로 병용투여 하지 않 | 는다.  따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다.  |\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다.  그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다.  또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다.  이는 조스터박스 투여 | 에 대한 이론적인 위험이다.  | 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다. ",
        "original_sentence": "그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다. "
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 67,
        "word_count": 19,
        "page_number": 36,
        "window_text": "따라서 두 백신의 접종 | 이 필요할 경우, 최소 4주 이 | 상의 간격을 두고 접종할 것 | 을 고려하여야 한다.  |\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다.  그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다.  또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다.  이는 조스터박스 투여 | 에 대한 이론적인 위험이다.  | 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다.  | 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다. ",
        "original_sentence": "또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "이는 조스터박스 투여 | 에 대한 이론적인 위험이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 13,
        "window_text": "|\n| 시험 | 결과 |\n| 보 고 서 : | 2020.03.31 | 최종 | 임상 |\n| 추가적인 위해성 완화 조치는 없 | 음 | 시험 | 결과 |\n| SPC 4.4: | 조스타박스에 대한 임상시험 | 에서 백신 바이러스의 전염은 | 보고되지 않았다.  그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다.  또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다.  이는 조스터박스 투여 | 에 대한 이론적인 위험이다.  | 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다.  | 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다.  이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. ",
        "original_sentence": "이는 조스터박스 투여 | 에 대한 이론적인 위험이다. "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "| 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 138,
        "word_count": 38,
        "page_number": 36,
        "window_text": "그러나, 수 | 두백신의 시판 후 경험은 수 | 두-유사 발진 증상을 보인 사 | 람들과 접촉에 민감한 사람들 | (예를 들면, 수두대상포진 바 | 이러스에 민감한 유아) 사이 | 에서 백신 바이러스의 전염이 | 드물지만 발생할 수 있다는 | 것을 말해준다.  또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다.  이는 조스터박스 투여 | 에 대한 이론적인 위험이다.  | 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다.  | 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다.  이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | Protamin Sulphate)에 대한 과민 | 반응. ",
        "original_sentence": "| 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "| 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 77,
        "word_count": 19,
        "page_number": 5,
        "window_text": "또한 수두-유 | 사 증상이 발생하지 않은 수 | 두백신 접종자로부터도 백신 | 바이러스의 전염이 보고된 바 | 있다.  이는 조스터박스 투여 | 에 대한 이론적인 위험이다.  | 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다.  | 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다.  이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | Protamin Sulphate)에 대한 과민 | 반응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. ",
        "original_sentence": "| 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다. "
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 2,
        "window_text": "이는 조스터박스 투여 | 에 대한 이론적인 위험이다.  | 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다.  | 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다.  이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | Protamin Sulphate)에 대한 과민 | 반응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신. ",
        "original_sentence": "이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예. "
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "| Protamin Sulphate)에 대한 과민 | 반응. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 44,
        "window_text": "| 백신 접종자로부터 접촉에 민 | 감한 사람들에게로 약독화 백 | 신 바이러스가 전염될 위험은 | 자연적인 대상포진의 발생 및 | 접촉에 민감한 사람들로의 야 | 생형 대상포진 바이러스의 잠 | 재적 전염의 위험과 비교하여 | 평가되어야 한다.  | 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다.  이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | Protamin Sulphate)에 대한 과민 | 반응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신.  백신 접종 | 후 1개월은 임신을 피해야 한 | 다. ",
        "original_sentence": "| Protamin Sulphate)에 대한 과민 | 반응. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "| 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 51,
        "word_count": 17,
        "page_number": 5,
        "window_text": "| 보 고 사 : | 2019.03.31 |\n**위약군 6,900명)의 추적 기간을 확장하여 진행한 장기 유효성 연구를 완료할 예정이다.  이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | Protamin Sulphate)에 대한 과민 | 반응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신.  백신 접종 | 후 1개월은 임신을 피해야 한 | 다.  |\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다. ",
        "original_sentence": "| 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "|\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 93,
        "word_count": 34,
        "page_number": 45,
        "window_text": "이**\n| SPC Section 4.3 금기사항: | 주성분 또는 부형제나 불순물(예.  | Protamin Sulphate)에 대한 과민 | 반응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신.  백신 접종 | 후 1개월은 임신을 피해야 한 | 다.  |\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다.  | “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조). ",
        "original_sentence": "|\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신. "
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "백신 접종 | 후 1개월은 임신을 피해야 한 | 다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 30,
        "word_count": 10,
        "page_number": 5,
        "window_text": "| Protamin Sulphate)에 대한 과민 | 반응.  | 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신.  백신 접종 | 후 1개월은 임신을 피해야 한 | 다.  |\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다.  | “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조).  동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조). ",
        "original_sentence": "백신 접종 | 후 1개월은 임신을 피해야 한 | 다. "
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "|\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 166,
        "word_count": 50,
        "page_number": 30,
        "window_text": "| 본 백신을 1회 접종 후 과민반응 | 을 보인 자는 2차 접종을 하지 | 않아야 한다.  |\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신.  백신 접종 | 후 1개월은 임신을 피해야 한 | 다.  |\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다.  | “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조).  동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조).  하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다. ",
        "original_sentence": "|\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "| “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 91,
        "word_count": 22,
        "page_number": 5,
        "window_text": "|\n| 최종 | 임상 | 최종 | 임상 |\n| 시험 | 결과 | 최종 | 임상 | 시험 | 결과 |\n| SPC 4.3 금기 항에 기술: | - SPC 4.3: 임신.  백신 접종 | 후 1개월은 임신을 피해야 한 | 다.  |\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다.  | “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조).  동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조).  하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다.  따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다. ",
        "original_sentence": "| “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조). "
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 36,
        "word_count": 7,
        "page_number": 44,
        "window_text": "백신 접종 | 후 1개월은 임신을 피해야 한 | 다.  |\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다.  | “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조).  동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조).  하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다.  따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다.  만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다. ",
        "original_sentence": "동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조). "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 30,
        "window_text": "|\n| 보 고 서 : | 2020.09.30 | 시험 | 결과 | 보 고 서 : | 2033.08.01 |\n| 보 고 서 : | 2019.03.31 |\n| [일반적 조치] SmPC 4.6항 수태능, 임신 및 수유 항에 | 가다실 9는 임신 중 사용이 권장되지 않음을 명시하는 | 내용을 포함한다.  | “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조).  동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조).  하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다.  따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다.  만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다.  |\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n",
        "original_sentence": "하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다. "
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 145,
        "word_count": 33,
        "page_number": 5,
        "window_text": "| “임신한 여성에 대한 많은 양의 자료(1000 건 이상의 | 임신 결과)는 가다실9의 최기형성 또는 태아/신생아 독 | 성을 나타내지 않았다(5.1항 참조).  동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조).  하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다.  따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다.  만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다.  |\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n - - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n",
        "original_sentence": "따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 73,
        "word_count": 22,
        "page_number": 36,
        "window_text": "동물연구에서도 생 | 식독성을 나타내지 않았다(5.3항 참조).  하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다.  따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다.  만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다.  |\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n - - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n - - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n",
        "original_sentence": "만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "|\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 629,
        "word_count": 154,
        "page_number": 56,
        "window_text": "하지만, 이러한 | 자료들은 가다실9을 임신 중에 사용할 수 있다고 권장 | 하기에는 부족하다고 여겨진다.  따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다.  만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다.  |\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n - - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n - - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n - - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4. ",
        "original_sentence": "|\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n"
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "- - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 122,
        "word_count": 27,
        "page_number": 51,
        "window_text": "따라서 백신 접종은 임 | 신이 종료될 때까지 연기되어야 한다(5.1항 참조).” | [추가적조치] 없음 |\n| Programme)을 통하여 종합효 | 소 | 연쇄반응(Poly | merase |\n| M-M-RVAXPRO가 주어져야 하는지 결정해야 | 한다.  만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다.  |\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n - - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n - - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n - - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4.  경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n",
        "original_sentence": "- - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "- - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 5,
        "window_text": "만약 당신이 임신부나 수유부 또는 임 | 신 가능성이 있다면, 의사 또는 약사에게 백 | 신 투여를 받기 전 조언을 구해야 한다.  |\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n - - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n - - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n - - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4.  경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n - - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행). ",
        "original_sentence": "- - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "- - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 1739,
        "word_count": 323,
        "page_number": 60,
        "window_text": "|\n| 최종 | 임상 |\n| 최종 | 임상 | 시험 | 결과 |\n| 시험 | 결과 |\n**보 고 서 :**\n\n**[표 끝]**\n\n- - 49 -\n내 투여하였을 때 Shingrix의\n\n안전성과 면역원성을 평가하\n\n기 위한 무작위배정, 관찰자\n\n맹검, 위약 대조, 다기관, 제 3\n\n상 임상시험\n\n**[표 시작]**\n\n| 보 고 서 : | 2020.07.31 |\n| --- | --- |\n\n**[표 끝]**\n\n- - 50 -\n험대상자\n\n포함)에서\n\n실행가능성\n\n(Feasibility)\n\n평가보고서:\n\n- 2018.07.31\n- - 51 -\n<!-- PAGE_56 -->\n#### <Zostavax>\n\n<!-- PAGE_56 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_56 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n- - 52 -\n을 돕기 위하여 이상사례를\n\n보고하는 의료진에게 수두 대\n\n상포진 바이러스 확인프로그\n\n램(Varicella\n\nZoster\n\nVirus\n\n- - 53 -\n원발성 및 다음의 조건으로\n\n인한 후천성 면역결핍 상태에\n\n있는 환자: 급성 및 만성 백\n\n혈병, 림프종 또는 골수/림프\n\n계에 영향을 미치는 기타 상\n\n황, HIV/AIDS에 의한 면역억\n\n제, 세포성 면역결핍.\n\n - - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n - - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n - - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4.  경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n - - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행).  이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다. ",
        "original_sentence": "- - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4. "
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 112,
        "word_count": 30,
        "page_number": 2,
        "window_text": "- - SPC 4.4:\n조스타박스는 약독화된 대상\n\n포진생바이러스 백신으로 면\n\n역억제환자 또는 면역결핍환\n\n자에게 투여시 치명적인 결과\n\n를 포함하여 수두-대상포진\n\n바이러스 관련 산재성 질환이\n\n나타날 수 있다.\n\n - - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n - - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4.  경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n - - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행).  이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다.  홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n",
        "original_sentence": "경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "- - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행). ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 2028,
        "word_count": 255,
        "page_number": 68,
        "window_text": "- - SPC 5.1:\n이 백신은 면역기능이 손상된\n\n시험대상자를 대상으로 연구\n\n된 바가 없다.\n\n - - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4.  경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n - - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행).  이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다.  홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n 일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver. ",
        "original_sentence": "- - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행). "
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 93,
        "word_count": 23,
        "page_number": 70,
        "window_text": "- - 54 -\nSPC 4.5 다른 의약품과의 상\n\n호작용 및 기타 상호작용 항\n\n에 기술:\n\n- - 55 -\n<!-- PAGE_60 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\nŸ\n\nProtocol 004:  유효성을 평가하기 위한 임상시험인 Protocol 004(백신 접종군 약 7,000명 및\n\nŸ\n\nProtocol 013: 장기 유효성을 연구하기 위하여 백신 접종 후 10년을 추적하는 Protocol 013\n\n유효성\n\n임상시험,\n\nProtocol\n\n- - 56 -\n<!-- PAGE_61 -->\n#### <Ixiaro>\n\n<!-- PAGE_61 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_61 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n일반적인 의약품 감시(개별이상\n\n사례보고(ICSR), 정기안전성보고\n\n(PSUR), 안전성 프로파일 모니터\n\n추가적인 위해성 완화 조치는 없\n\n음\n\n- - 57 -\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n임상시험:\n\nOngoing\n\nfollow-up\n\nSPC Section 4.5 다른 의약품과의\n\n상호작용 및 기타 상호작용: 면\n\n- - 58 -\n<!-- PAGE_63 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(PSUR), 안전성 프로파일 모니터\n\n링, 안전성 실마리정보 개발 및\n\n탐지)\n\n개별 증례 분석, PSUR에 보고된\n\n결과\n\n역억제요법으로 치료 중이거나\n\n면역결핍 환자에서는 적절한 면\n\n역반응이 나타나지 않을 수 있\n\n- 다.\nIC51-322\n\n비유행(non-endemic) 국가의 소아에서 일본뇌염백신 Ixiaro 접종 후 면역원\n\n성 및 안전성 평가를 위한 비통제, 공개, 제3상 임상시험\n\nIC51-401\n\n미국 군인을 대상으로 Ixiaro 접종 후 이상사례에 대한 능동적 감시(active\n\nsurveillance)\n\n- - 59 -\n<!-- PAGE_64 -->\n#### <Rotarix>\n\n<!-- PAGE_64 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_64 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n1) 최초 제출(2006) (lyophilized formulation)\n\n- - 60 -\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성완화조치 필요 없음\n\n2) RMP 변경 제출(2008) (liquid formulation 추가)\n\n- - 61 -\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n[Study Title]\n\n1) PASS:\n\nPost-Authorization\n\nSafety\n\nStudy\n\n(PASS)\n\nof\n\nPost-Marketing\n\nSurveillance\n\nfor\n\nIntussusception following Rotarix™ introduction into the Instituto Mexicano del Seguro Social\n\n(IMSS) in Mexico\n\n(https://clinicaltrials.gov/ct2/show/NCT00595205)\n\n2) 052: Phase IIIb, randomized, double-blinded, placebo-controlled study to explore the existence\n\n- 4.4.  경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n - - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행).  이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다.  홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n 일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver.  17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n",
        "original_sentence": "이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 50,
        "word_count": 13,
        "page_number": 2,
        "window_text": "경고 및 주의사항:\n조산아 140명에서의 제한된 자\n\n료에 따르면, 이 백신은 조산\n\n아에게 투여될 수 있으나, 더\n\n낮은 면역반응이 관찰될 수 있\n\n으며 임상적 방어 수준이 알려\n\n져 있지 않다.\n\n - - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행).  이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다.  홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n 일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver.  17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n - - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n",
        "original_sentence": "홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 207,
        "word_count": 45,
        "page_number": 72,
        "window_text": "- - 62 -\nof horizontal transmission of the RIX4414 vaccine strain between within a family\n\n(https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133580.pdf)\n\n(https://www.gsk-clinicalstudyregister.com/files2/d8529f6e-d475-44f6-9f35-cc2e7d7e4b13)\n\n3) 054: Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to\n\nAssess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live\n\nAttenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants\n\n(https://clinicaltrials.gov/ct2/show/study/NCT00420745)\n\n4) 022: Phase II, double blind, randomised (1:1), placebo controlled study to assess the safety,\n\nreactogenicity and immunogenicity of three doses of GSK Biologicals’ oral live attenuated\n\nhuman rotavirus vaccine administered to human immunodeficiency virus (HIV) infected infants at\n\n6, 10 and 14 weeks of age\n\nhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/hu\n\nman/000639/WC500143025.pdf)\n\n5) 024: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of\n\n(https://clinicaltrials.gov/ct2/show/NCT00139347)\n\n6) 036: Phase 3b, double-blind, randomized, placebo-controlled, multi-country and multi-center\n\nstudy to assess efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live\n\nattenuatd human rotavirus (HRV) vaccine in healthy infants in co-administration with specific\n\nchildhood vaccinations\n\n(https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm)\n\n- - 63 -\n<!-- PAGE_68 -->\n#### <RotaTeq>\n\n<!-- PAGE_68 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_68 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(*: 중요한 규명된 위해성/중요한 잠재적 위해성/중요한 부족정보에 대한 구분 없음)\n\nCHMP 의견: 제출된 허가서류 검토결과, 제품설명서에 포함된 내용 외에 추가적인 위해성 완화 조치 필요 없음\n\n- - 64 -\n<!-- PAGE_69 -->\n#### <M-M-RVaxPro>\n\n<!-- PAGE_69 -->\n###### ☐ 품목 개요\n\n면역원성 및 안전성 자료들에 의하면 공식적인 권고사항에 따라\n\nM-M-RVAXPRO는 9개월에서 12개월 사이의 유아에게 또는 초기예방이 필\n\n요하다고 인정될 때 투여될 수 있다 (예를 들어, 주간돌봄 (day-care), 발\n\n병 또는 홍역 유병율이 높은 지역으로의 여행).  이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다.  홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n 일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver.  17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n - - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n 없다. ",
        "original_sentence": "일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver. "
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 78,
        "word_count": 9,
        "page_number": 5,
        "window_text": "이러한 유아들은 12~15개\n\n- - 65 -\n<!-- PAGE_70 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n월 때 다시 백신 투여를 받아야 한다.  홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n 일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver.  17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n - - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n 없다.  다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. ",
        "original_sentence": "17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "- - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 184,
        "word_count": 29,
        "page_number": 73,
        "window_text": "홍역 바이러스가 포함된 백신의 추\n\n가 투여량은 권고 사항에 따라 고려 되어져야 한다.\n\n 일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver.  17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n - - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n 없다.  다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n",
        "original_sentence": "- - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "없다. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 13,
        "window_text": "일반적인\n\n의약품 환자 및 전문가용 사용설명서를 통한 위해성\n\n- - 66 -\n완화\n\n- - 67 -\n<!-- PAGE_72 -->\n#### <Cervarix>\n\n<!-- PAGE_72 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_72 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2016.06.23 버전에서 최종 변경(RMP Ver.  17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n - - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n 없다.  다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n [일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n",
        "original_sentence": "없다. "
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 669,
        "word_count": 179,
        "page_number": 76,
        "window_text": "17)되어, 해당 version의 assessment\n\nreport인 EMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n - - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n 없다.  다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n [일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n “본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우. ",
        "original_sentence": "다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. "
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 67,
        "word_count": 8,
        "page_number": 5,
        "window_text": "- - 68 -\n<!-- PAGE_73 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항은 2016.06.23 assessment report에서 최종 변경되어, 해당 assessment report인\n\nEMA/CHMP/668339/2015를 기준으로 작성 되었습니다.)\n\n 없다.  다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n [일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n “본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우.  이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n",
        "original_sentence": "1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "[일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 61,
        "word_count": 13,
        "page_number": 44,
        "window_text": "없다.  다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n [일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n “본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우.  이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n “면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. ",
        "original_sentence": "[일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "“본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 44,
        "word_count": 10,
        "page_number": 5,
        "window_text": "다른 백신과 마찬가지로 이러한 개인에\n\n서는 적절한 면역 반응이 도출되지 않을 수도\n\n있다.”\n\n[추가적 조치] 없음\n\n- - 69 -\n대상자에서 3회 투여 일정(0,\n\n1, 6개월)에 따라 근육 내로\n\n투여한\n\nGlaxoSmithKline\n\n**[표 시작]**\n\n| EPI-HPV-069 (범주 3) | 회사의 연구 및 외부에서 수 | 행된 출판된 연구로부터 이 | 서바릭스 백신 | 접종 후 자가 | 면역 갑상선염 | 잠재적 위 | 해성 | 자 가 면 역 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| V503-002-20 대상 | 청소년에 대한 장 | 9가 HPV 백신의 장기 | 유효성 및 면역원성 | 중요부족정보 | 장기적 효과 및 면 | 계획 | 중간 72개월 보고 | 서: |\n\n**[표 끝]**\n\n- - 70 -\n의 상대 위험\n\n도에 대한 전\n\n반적인 평가를\n\n제 공 함 으 로 써\n\n서바릭스 백신\n\n접종과 자가면\n\n역\n\n갑상선염\n\n- - 71 -\n<!-- PAGE_76 -->\n#### <Gardasil 9>\n\n<!-- PAGE_76 -->\n###### ☐ 품목 개요\n\n<!-- PAGE_76 -->\n###### ☐ 안전성 중점검토항목 및 조치계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n [일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n “본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우.  이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n “면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n",
        "original_sentence": "“본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우. "
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 147,
        "word_count": 33,
        "page_number": 47,
        "window_text": "1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n [일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n “본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우.  이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n “면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n 역원성\n\n감 시 계 획 ’\n\n표 참조\n\n- - 74 -\n기추적관찰 연구\n\n(3차 접종 후 10\n\n년 연장 연구) (범\n\n주 3)\n\n: 젊은 여성(16-26\n\n세)와 비교하였을\n\n때 소아 및 청소\n\n년(9-15세)에서 가\n\n다실9의\n\n면역원\n\n- - 75 -",
        "original_sentence": "이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "“면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. ",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 181,
        "word_count": 34,
        "page_number": 78,
        "window_text": "[일반적 조치] 가다실 또는 가다실9 백신 성분에 대한\n\n과민반응이 SmPC 4.3항에 금기로 포함되었다.\n\n “본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우.  이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n “면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n 역원성\n\n감 시 계 획 ’\n\n표 참조\n\n- - 74 -\n기추적관찰 연구\n\n(3차 접종 후 10\n\n년 연장 연구) (범\n\n주 3)\n\n: 젊은 여성(16-26\n\n세)와 비교하였을\n\n때 소아 및 청소\n\n년(9-15세)에서 가\n\n다실9의\n\n면역원\n\n- - 75 -",
        "original_sentence": "“면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver. "
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 67,
        "word_count": 8,
        "page_number": 5,
        "window_text": "“본제 주성분 또는 6.1항에 기술된 부형제들에 대한\n\n과민반응이 있을 경우.  이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n “면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n 역원성\n\n감 시 계 획 ’\n\n표 참조\n\n- - 74 -\n기추적관찰 연구\n\n(3차 접종 후 10\n\n년 연장 연구) (범\n\n주 3)\n\n: 젊은 여성(16-26\n\n세)와 비교하였을\n\n때 소아 및 청소\n\n년(9-15세)에서 가\n\n다실9의\n\n면역원\n\n- - 75 -",
        "original_sentence": "1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "역원성\n\n감 시 계 획 ’\n\n표 참조\n\n- - 74 -\n기추적관찰 연구\n\n(3차 접종 후 10\n\n년 연장 연구) (범\n\n주 3)\n\n: 젊은 여성(16-26\n\n세)와 비교하였을\n\n때 소아 및 청소\n\n년(9-15세)에서 가\n\n다실9의\n\n면역원\n\n- - 75 -",
      "metadata": {
        "source": "백신+위해성+관리+계획+사례집.pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 143,
        "word_count": 41,
        "page_number": 44,
        "window_text": "이전에 가다실9 또는 가다실을\n\n접종받은 후에 과민반응을 경험한 환자는 가다실9을\n\n- - 72 -\n접종받지 말아야 한다.”\n\n아나필락시스/아나필락시스양 반응 역시 SmPC의 4.8항\n\n에 4가백신의 시판 후 사용 중 보고된 약물 이상반응\n\n으로서 포함되었다.\n\n “면역계장애: 아나필락시스/아나필락시스양 반응을 포\n\n함한 과민반응, 기관지경련 및 두드러기”\n\n[추가적 조치] 없음\n\n- - 73 -\n<!-- PAGE_78 -->\n###### ☐ 진행중 또는 계획된 의약품 감시(pharmacovigilance) 계획\n\n(본 항목은 2015.03.26 버전에서 최종 변경(RMP Ver.  1)되어, 해당 assessment report인\n\nEMA/CHMP/76591/2015를 기준으로 작성 되었습니다.)\n\n 역원성\n\n감 시 계 획 ’\n\n표 참조\n\n- - 74 -\n기추적관찰 연구\n\n(3차 접종 후 10\n\n년 연장 연구) (범\n\n주 3)\n\n: 젊은 여성(16-26\n\n세)와 비교하였을\n\n때 소아 및 청소\n\n년(9-15세)에서 가\n\n다실9의\n\n면역원\n\n- - 75 -",
        "original_sentence": "역원성\n\n감 시 계 획 ’\n\n표 참조\n\n- - 74 -\n기추적관찰 연구\n\n(3차 접종 후 10\n\n년 연장 연구) (범\n\n주 3)\n\n: 젊은 여성(16-26\n\n세)와 비교하였을\n\n때 소아 및 청소\n\n년(9-15세)에서 가\n\n다실9의\n\n면역원\n\n- - 75 -"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 539,
    "avg_chunk_length": 160.30612244897958,
    "min_chunk_length": 4,
    "max_chunk_length": 2028,
    "total_characters": 86405,
    "total_words": 20788,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 4418,
    "heading_count": 176,
    "paragraph_count": 1074,
    "list_item_count": 153,
    "table_cell_count": 3015,
    "tables_detected": 18,
    "chunks_generated": 539
  }
}